sentence	label
reactions reported regimens containing dose @DRUG$ , , cis-platinum , @DRUG$ interferon-alfa	DDI-false
Anticoagulants: Potentiation of warfarin-type (@DRUG$ and @DRUG$ substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ Methylxanthines and : with derivatives , , @DRUG$ may hypokalemic effect of   beta2-agonists	DDI-false
Both ibogaine and 18-MC block @DRUG$-induced and @DRUG$-induced dopamine release in the nucleus accumbens;	DDI-false
Lithium Lithium toxicity has been patients receiving @DRUG$ with drugs which cause elimination of sodium , including @DRUG$.	DDI-effect
Concurrent administration of quinolone , ciprofloxacin with multivalent cation-containing products @DRUG$ or aluminum sucralfate , VIDEX chewable/buffered or pediatric , containing , iron zinc may substantially decrease the @DRUG$ serum and urine levels lower than .	DDI-false
Other concomitant In , the safety in treated concomitantly with @DRUG$ and @DRUG$ benzodiazepines ) or analgesics similar to that of taking placebo with	DDI-false
Although specific interaction not performed in studies cerivastatin sodium used angiotensin- ACE ) inhibitors , @DRUG$ @DRUG$ , diuretics nonsteroidal anti-inflammatory drugs NSAIDs without of interactions .	DDI-false
Coadministration of @DRUG$ with 40 mg @DRUG$ epileptic the plasma undetectable levels	DDI-mechanism
Fenfluramine the effect @DRUG$ , e.g. @DRUG$ .	DDI-false
@DRUG$ IV concomitantly with beta adrenergic-blocking agents , methyldopa nitrates calcium-blocking agents , hydralazine @DRUG$ and without of significant .	DDI-false
lidocaine/quinidine , phenobarbital/valproic acid quinidine/@DRUG$ theophylline/acetaminophen ,	DDI-false
the impact of plus on the clinical of patients HIV-related systemic , lymphoma ( HIV-NHL , authors of patients with were with the @DRUG$ , vincristine prednisone chemotherapy plus a who with chemotherapy or ( i.e. , cyclophosphamide doxorubicin , and with vincristine plus bleomycin without receiving @DRUG$ therapy .	DDI-false
Drug Interactions Flupenthixol interact with some drugs Monoamine inhibitors MAOI ): MAOI could affect @DRUG$ pharmacodynamics - - Flupenthixol additive CNS - antidepressants : Flupenthixol increases the effect of @DRUG$	DDI-false
in second study , hour before the 0.3 hours meal in decrease in @DRUG$ AUC of less 8 % and a 30 % compared dosing @DRUG$ alone	DDI-false
The effect of rifampin on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after @DRUG$ withdrawal.	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Both @DRUG$ and @DRUG$ have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
Co-medications that induce CYP3A4 (e.g., @DRUG$, @DRUG$, carbamazepine, rifampin, phenobarbital or St.	DDI-false
with theophylline , phenobarbital with @DRUG$ , and valproic @DRUG$ toxic decreases the binding of target drug .	DDI-false
Drug/Laboratory Test Interactions @DRUG$, including @DRUG$, are known to occasionally induce a positive direct Coombs test.	DDI-false
Other substances: Grapefruit juice given to healthy volunteers increased @DRUG$ AUC by 50% and Cmax by 84%, resulting in increased plasma levels of @DRUG$.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
However the , of cholestyramine 1 before the evening 0.3 @DRUG$ 4 hours the same evening a decrease @DRUG$ less than and decrease in about 30 % compared to	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, haloperidol, phenothiazines, @DRUG$, tricyclic antidepressants or some antihistamines.	DDI-false
@DRUG$, such as @DRUG$, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
studies have not performed , that are mainly CYP3A4 calcium channel blockers dapsone , , tacrolimus @DRUG$ ergot derivatives , , carbamazepine fentanyl , may plasma @DRUG$	DDI-mechanism
specific studies have been , coadministration that are ( blockers @DRUG$ , quinine , @DRUG$ , quinidine , warfarin tacrolimus cyclosporine ergot derivatives pimozide , alprazolam and triazolam ) may plasma when coadministered ;	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as @DRUG$ and procainamide, @DRUG$ and tricyclic anti-depressants.	DDI-false
Colestipol-Concomitant intake of @DRUG$ and @DRUG$ may reduce the absorption of vitamin K.	DDI-mechanism
Nephrotoxicity has @DRUG$ with aminoglycoside antibiotics or potent @DRUG$ furosemide	DDI-effect
@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (@DRUG$), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding @DRUG$ (@DRUG$)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
Caution should be exercised if an @DRUG$ is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and @DRUG$.	DDI-advise
Oxidase Inhibitors and Tricyclic FORADIL be patients being treated with @DRUG$ or because action of @DRUG$ system may be by these agents .	DDI-false
Anticoagulants: Potentiation of warfarin-type (CYP2C9 and @DRUG$ substrate) @DRUG$ response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
, coadministration with that are metabolized by CYP3A4 ( , calcium channel blockers , dapsone disopyramide quinine , , , warfarin , cyclosporine @DRUG$ pimozide , carbamazepine , @DRUG$ , alfentanyl , , and triazolam ) have plasma concentrations when saquinavir ;	DDI-false
Higher @DRUG$ ) - 10(-6 M or @DRUG$ ) enhance of EGF .	DDI-false
Other Cardiovascular Enalapril and @DRUG$ IV used concomitantly with @DRUG$ , methyldopa , , agents , hydralazine , prazosin and digoxin evidence of interactions .	DDI-false
: Pharmacokinetic drug-drug interactions demonstrated Argatroban @DRUG$ 162.5 26 and 2 hours to of @DRUG$ . over hours or acetaminophen ( mg given 12 , 6 and 0 hours prior , hours , of 1.5   g/kg/min over 18 ) .	DDI-false
is necessary be well acquainted the and of @DRUG$ deficit to deficiency due to magnesium intake which requires oral physiological supplementation @DRUG$ depletion to a of the status which requires or less specific regulation its causal dysregulation .	DDI-false
Interaction on the antinociceptive effect between @DRUG$ and @DRUG$ or tuftsin.	DDI-effect
Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, @DRUG$, @DRUG$, phenobarbital or St.	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: @DRUG$, cyclosporine, @DRUG$, nicardipine, and nifedipine.	DDI-false
In addition to the interactions noted above, chronic (  2 weeks) oral Cordarone administration impairs metabolism of @DRUG$, dextromethorphan, and @DRUG$.	DDI-false
The risk during drugs of is concurrent administration of @DRUG$ fibric , nicotinic , , @DRUG$.	DDI-false
Cardiac In receiving digoxin @DRUG$ regularly increase in @DRUG$ concentration reach with resultant toxicity	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
, @DRUG$ Concomitant treatment , @DRUG$ possible hypokalemic effect   beta2-agonists .	DDI-false
treatment with ( such as ketoconazole , intraconazole ritonavir @DRUG$ , , @DRUG$ is reduction of dose should considered .	DDI-false
@DRUG$ and @DRUG$ can additive properties on and ocular	DDI-false
neither dexamethasone @DRUG$ the proliferation prostatic in transferrin , the mitogenic effect @DRUG$.	DDI-effect
In receiving @DRUG$ , a CYP3A4 inhibitor at 200 mg daily 7 , ( AUC ) @DRUG$ was increased to approximately 3.6-fold of control and half-life increased 1.7-fold control .	DDI-mechanism
Sedatives/@DRUG$: triazolam, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
and @DRUG$ could exaggerate the	DDI-effect
evaluate of chemotherapy on the clinical course of patients with , systemic lymphoma HIV-NHL , retrospectively group of HIV-NHL were the doxorubicin , ) chemotherapy regimen HAART with group patients who treated with CHOP or CHOP-like regimen ( i.e. cyclophosphamide doxorubicin , teniposide , with plus @DRUG$ without receiving @DRUG$ therapy .	DDI-false
In to interactions , chronic 2 weeks @DRUG$ administration impairs @DRUG$ , , and .	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, @DRUG$, and @DRUG$.	DDI-false
Hypersensitivity reactions in patients combination regimens containing sequential PROLEUKIN antineoplastic , specifically , @DRUG$ , @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
derivatives , and @DRUG$ nonsteroidal drugs ( NSAIDs ) , and aspirin may risk of bleeding concomitantly with @DRUG$.	DDI-effect
Drug : may interact with drugs Monoamine ( MAOI ): MAOI theoretically flupenthixol pharmacodynamics Eproxindine Ethanol : @DRUG$ and Ethanol additive CNS depression - antidepressants Flupenthixol increases effect @DRUG$	DDI-false
The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-effect
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data.	DDI-false
: rifampin the coadministration of product with saquinavir in @DRUG$ reduces the of	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of , , with multivalent or antacids sucralfate , @DRUG$ tablets pediatric powder , or containing , or @DRUG$ may substantially decrease the of ciprofloxacin serum and considerably lower than desired	DDI-false
Drug Interactions @DRUG$ may interact with some drugs Monoamine oxidase ( @DRUG$ MAOI could affect flupenthixol Ethanol and Ethanol cause additive depression antidepressants Flupenthixol the of Tricyclic antidepressants	DDI-int
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ and EGF- prostatic	DDI-effect
Possible drug interactions of @DRUG$ with @DRUG$ or with other anticholinesterase agents.	DDI-int
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
DIGOXIN Plasma @DRUG$ levels and digoxin clearance at steady-state were not affected by of @DRUG$.	DDI-false
There have case reports of steady-state , @DRUG$ , and during concomitant therapy @DRUG$.	DDI-false
have demonstrated significant reduction in oral bioavailability of and ciprofloxacin when administered concomitantly intravenous @DRUG$ such as @DRUG$.	DDI-false
Drug Interactions may interact with some Monoamine inhibitors ( MAOI theoretically affect pharmacodynamics Arecoline - Eproxindine @DRUG$ @DRUG$ CNS Tricyclic antidepressants the of	DDI-false
The aim of this paper was to study the interaction between @DRUG$ and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or @DRUG$, on the antinonciceptive effect of these peptides in mice after intracisternal injection.	DDI-false
the of @DRUG$ value of @DRUG$ be rationalized at the by following ) polyene cells ;	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
studies have not been performed coadministration with are mainly ( eg disopyramide , @DRUG$ amiodarone , quinidine , , cyclosporine , , pimozide , @DRUG$ fentanyl , alprazolam , ) have saquinavir	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$ disposition @DRUG$ and in HIV-infected patients .	DDI-false
Corticosteroids, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-false
clinical with @DRUG$ , the use oral , inhibitors ) , ( , and @DRUG$ did not significantly pharmacokinetics/pharmacodynamics of fondaparinux sodium	DDI-false
Therefore , interactions could occur following concomitant of @DRUG$ , @DRUG$ analgesics , antiemetics , tranquilizers )	DDI-false
Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an @DRUG$ regimen reduces the plasma concentrations of @DRUG$.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, @DRUG$, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
The possibility of hypotensive effects with @DRUG$ or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or @DRUG$.	DDI-false
Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, @DRUG$, certain @DRUG$, etc.).	DDI-false
In , indomethacin @DRUG$ was administered hypertensive patients @DRUG$.	DDI-false
Aspirin normal in was when multiple doses of @DRUG$ @DRUG$ were administered	DDI-mechanism
is well with and pattern and to between @DRUG$ deficiency an magnesium intake only requires and @DRUG$ depletion dysregulation mechanisms status more regulation of causal	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-effect
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, erythromycin, @DRUG$).	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$, lidocaine, phenobarbital, quinidine, @DRUG$, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
with theophylline @DRUG$ with acetaminophen and acid with @DRUG$ at concentrations the .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Anticoagulants: Potentiation of @DRUG$-type (CYP2C9 and CYP3A4 substrate) @DRUG$ response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
Drug : Flupenthixol drugs like Monoamine oxidase @DRUG$ ): could flupenthixol pharmacodynamics - @DRUG$ Ethanol additive - antidepressants	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In performed with Fondaparinux , of @DRUG$ ) , platelet acetylsalicylic acid ) , @DRUG$ ( , digoxin significantly affect of fondaparinux sodium .	DDI-false
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., narcotics, @DRUG$, antiemetics, sedatives, tranquilizers).	DDI-false
Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of @DRUG$ and @DRUG$, including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.	DDI-effect
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).	DDI-false
To evaluate on the clinical with , lymphoma ) , authors compared a group of 24 patients with were treated with the cyclophosphamide @DRUG$ and prednisone ( ) who were CHOP chemotherapy or a CHOP-like ( i.e. , cyclophosphamide @DRUG$ , prednisone vincristine without receiving .	DDI-false
data the coadministration INVIRASE/ritonavir or @DRUG$/@DRUG$ and	DDI-false
of @DRUG$ @DRUG$ may be by personality characteristics in impulsivity	DDI-false
@DRUG$: In controlled studies in healthy volunteers, bepridil hydrochloride either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum @DRUG$ concentrations.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, @DRUG$ and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, @DRUG$ and @DRUG$ (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
@DRUG$, lidocaine, phenobarbital, quinidine, theophylline, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
@DRUG$ , phenelzine sulfate , HC1 : Concomitant use @DRUG$ MAO inhibitors may cause hypertension	DDI-false
@DRUG$ @DRUG$ , use of L-tyrosine and non-selective inhibitors cause .	DDI-false
In addition to the interactions noted above, chronic (  2 weeks) oral @DRUG$ administration impairs metabolism of phenytoin, @DRUG$, and methotrexate.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Coingestion of acetaminophen with @DRUG$, @DRUG$ with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
evaluate the impact of plus the with HIV-related , lymphoma ( HIV-NHL , authors retrospectively a group 24 with who treated with the cyclophosphamide @DRUG$ , prednisone CHOP plus with of patients who were with CHOP a CHOP-like ( i.e. cyclophosphamide , @DRUG$ , , with vincristine plus ) receiving antiretroviral therapy	DDI-false
of @DRUG$ possible interaction @DRUG$ the : sertraline and paroxetine .	DDI-false
addition , neither the pharmacodynamics @DRUG$ acid piroxicam , and @DRUG$ , pharmacokinetics digoxin at steady	DDI-false
Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, @DRUG$, and nifedipine.	DDI-int
@DRUG$: Plasma digoxin levels and @DRUG$ clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.	DDI-false
Warfarin to the effects of the @DRUG$ @DRUG$ or its	DDI-false
( ; were to treatment with synthetic solutions containing @DRUG$ @DRUG$ higher alcohols proportions found in most and alcoholic beverages ;	DDI-false
Additive adverse effects resulting from cholinergic occur LEVSIN is administered concomitantly @DRUG$ , phenothiazines , monoamine ( MAO ) @DRUG$ antihistamines	DDI-false
determine injection @DRUG$ permit larger to a 9.9-g/m2 dose @DRUG$ intravenously over concurrently doses .	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Although studies have not been coadministration that are , @DRUG$ , quinine , , quinidine warfarin , , ergot derivatives pimozide carbamazepine , fentanyl , alprazolam , and have concentrations coadministered with @DRUG$	DDI-mechanism
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics, @DRUG$ and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
@DRUG$ been reduce , renal insufficiency , , and dyspnea administration of PROLEUKIN reduce antitumor of and thus be . 12 @DRUG$ other antihypertensives may the .	DDI-false
In the present study, the @DRUG$ @DRUG$ was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures.	DDI-false
Amiodarone taken concomitantly with @DRUG$ for less than seven days increases plasma concentrations of @DRUG$ and n-acetyl procainamide by 55% and 33%, respectively.	DDI-false
@DRUG$ : of atorvastatin an oral @DRUG$ increased AUC values ethinyl approximately % 20 % .	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
@DRUG$ the of @DRUG$ deficiency first of	DDI-false
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, @DRUG$ or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-false
Nephrotoxicity has concomitant of cephalosporins with @DRUG$ diuretics such as @DRUG$.	DDI-false
Oral @DRUG$: Coadministration of atorvastatin and an oral contraceptive increased AUC values for @DRUG$ and ethinyl estradiol by approximately 30% and 20%.	DDI-false
Other such @DRUG$ , disopyramide procainamide , @DRUG$ , antihistamines , and with prolongation and of ventricular arrhythmia .	DDI-false
Cholestyramine-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of @DRUG$.	DDI-false
Non-selective inhibitors including sulfate @DRUG$ and @DRUG$ : use of L-tyrosine and may .	DDI-false
The effects of ruthenium red (@DRUG$) on @DRUG$ (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
, the @DRUG$ @DRUG$ avoided .	DDI-advise
BACKGROUND : The effects of combined administration and hydrochloride @DRUG$ calcium channel blocker , on of by azoxymethane ( @DRUG$ ) and the labeling of intestinal cancers were investigated male Wistar rats .	DDI-false
administration of local anesthetic @DRUG$ to @DRUG$ , tricyclic antidepressants phenothiazines may produce severe prolonged hypotension hypertension .	DDI-effect
acetaminophen/theophylline , , , phenobarbital/valproic acid quinidine/lidocaine theophylline/acetaminophen , valproic acid/@DRUG$.	DDI-false
Concomitant cyclophosphamide, doxorubicin, @DRUG$, and prednisone chemotherapy plus @DRUG$ therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
Since @DRUG$ substrate CYP3A4 CYP2C8 , inhibit may the metabolism increase serum	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ (caution is recommended during coadministration with @DRUG$): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Acetaminophen lidocaine @DRUG$ quinidine , @DRUG$ , and acid were added human serum at therapeutic concentrations .	DDI-false
@DRUG$ In diflunisal and tolbutamide significant were @DRUG$ levels or glucose .	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ aminoglycosides or with transmission ( @DRUG$ ) with caution of may potentiated .	DDI-advise
@DRUG$: In normal volunteers, concomitant administration of diflunisal and @DRUG$ resulted in significantly increased plasma levels of hydrochlorothiazide.	DDI-false
second study , of 12 g @DRUG$ 1 hour before mg cerivastatin sodium 4 after evening meal resulted decrease AUC of 8 % , in of about 30 % when compared to dosing @DRUG$	DDI-false
@DRUG$: In healthy subjects receiving @DRUG$, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.	DDI-false
Co-administration of naltrexone with @DRUG$ produced a 25% increase in AUC and a 33% increase in the Cmax of @DRUG$.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents, specifically, dacarbazine, @DRUG$, tamoxifen and interferon-alfa.	DDI-effect
The aim this paper was to the interaction between both @DRUG$ synthetic , or @DRUG$ , on antinonciceptive of intracisternal .	DDI-false
@DRUG$ is the first @DRUG$ to be approved for clinical use, and has been studied extensively in humans since 1986.	DDI-false
, if @DRUG$ is to be initiated of @DRUG$ therapy effect on the aPTT to prior initiation of .	DDI-false
aim paper was neurotensin and @DRUG$ @DRUG$ , or on the antinonciceptive of mice intracisternal .	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Antipyrine : @DRUG$ not affect the pharmacokinetics of @DRUG$ , drugs cytochrome	DDI-false
Sulindac: The concomitant administration of @DRUG$ and @DRUG$ in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.	DDI-mechanism
Monitoring for @DRUG$ toxicity and serial measurement of amiodarone serum concentration during concomitant @DRUG$ therapy should be considered.	DDI-false
and Diuretics : treatment xanthine steroids , @DRUG$ may potentiate possible effect @DRUG$	DDI-effect
@DRUG$ as potent @DRUG$ of glucocorticoid-induced mouse mammary tumor virus gene expression.	DDI-false
@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
@DRUG$ : @DRUG$ ( substrate combination with amiodarone bradycardia , and cardiac	DDI-false
Chloral @DRUG$ interact pharmacologically with @DRUG$ effect significant .	DDI-int
Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by @DRUG$ that cause renin release (e.g., @DRUG$).	DDI-false
However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the @DRUG$ AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing @DRUG$ alone.	DDI-false
Cardiovasculars @DRUG$ In receiving digoxin therapy of oral @DRUG$ regularly results in in concentration that may toxic levels with toxicity .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
is significant in exposure to @DRUG$ @DRUG$ CYP3A4 inhibitor	DDI-false
Antihypertensives Amiodarone used with caution receiving   -receptor blocking , , CYP3A4 or calcium ( , @DRUG$ , a CYP3A4 substrate , and @DRUG$ inhibitor because of possible potentiation bradycardia , arrest , and block	DDI-false
The anesthetic epinephrine @DRUG$ to patients receiving @DRUG$ antidepressants or phenothiazines produce severe , prolonged hypertension	DDI-effect
Interaction on the antinociceptive effect between neurotensin and @DRUG$ or @DRUG$.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	DDI-false
Accordingly @DRUG$ administered with oral @DRUG$ , prothrombin be monitored during and for several concomitant administration	DDI-advise
on antinociceptive between @DRUG$ or	DDI-effect
Although designed to examine have not done it noted @DRUG$ @DRUG$ treatment relapses for 28 days to ( N=180 receiving Betaseron	DDI-false
Digoxin: In controlled studies in healthy volunteers, @DRUG$ either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum @DRUG$ concentrations.	DDI-mechanism
: @DRUG$ flecainide , @DRUG$ serious life-threatening .	DDI-false
@DRUG$/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Orlistat-@DRUG$ may decrease the absorption of @DRUG$.	DDI-mechanism
@DRUG$ Methylxanthines and @DRUG$ : Concomitant steroids diuretics a possible .	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and @DRUG$, have been used concurrently with @DRUG$.	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
, these have activities @DRUG$ , including anti-arrhythmic quinidine @DRUG$ and tricyclic anti-depressants .	DDI-false
If treatment with of ( such @DRUG$ , intraconazole , @DRUG$ , etc is , dose be .	DDI-false
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: @DRUG$, cyclosporine, amiodarone, nicardipine, and nifedipine.	DDI-int
To evaluate the impact of HAART clinical with HIV-related , systemic lymphoma ( ) , the authors retrospectively 24 with who were , vincristine and chemotherapy regimen plus a group of 80 patients were with chemotherapy a CHOP-like ( i.e. cyclophosphamide doxorubicin teniposide , @DRUG$ @DRUG$ ) therapy .	DDI-false
the impact of clinical patients systemic non-Hodgkin ( HIV-NHL ) , retrospectively group of 24 with who were the cyclophosphamide , doxorubicin , vincristine @DRUG$ ( chemotherapy regimen with a group patients who CHOP chemotherapy regimen ( , cyclophosphamide doxorubicin and @DRUG$ bleomycin without receiving .	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
The pharmacokinetics of @DRUG$ and its major metabolite @DRUG$ were unaffected following co-administration with Acamprosate.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
However @DRUG$ stimulated did significantly inhibit proliferation the	DDI-effect
Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of ethanol and nicotine in rats;	DDI-false
Co-administration of @DRUG$ and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.	DDI-advise
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
@DRUG$ diminished the binding of @DRUG$ to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L.	DDI-mechanism
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
: effects combined administration bombesin and @DRUG$ ( ) , a @DRUG$ , on the incidence of peritoneal metastasis intestinal adenocarcinomas induced ( AOM ) labeling index of cancers investigated male .	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, ritonavir, indinavir, @DRUG$, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
However, the absolute number of @DRUG$-related deaths is far greater than the number of deaths in @DRUG$ or heroin users.	DDI-false
In studies with Fondaparinux , the concomitant use of oral @DRUG$ ( @DRUG$ , inhibitors ( , NSAIDs ( ) , digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of sodium .	DDI-false
The naltrexone and major @DRUG$ were co-administration	DDI-false
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Sedatives/Hypnotics: @DRUG$, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
have been mainly by CYP3A4 eg calcium blockers , @DRUG$ quinine amiodarone , , , , derivatives , pimozide carbamazepine @DRUG$ , , alprazolam and triazolam ) elevated plasma concentrations coadministered with	DDI-false
Acetaminophen, lidocaine, phenobarbital, @DRUG$, theophylline, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
diuretics e.g. @DRUG$ , triamterene or ) @DRUG$ or to significant in serum potassium .	DDI-false
@DRUG$ ('@DRUG$') is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia.	DDI-false
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of @DRUG$ (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of @DRUG$ (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45.	DDI-false
Since amiodarone is a substrate for @DRUG$, there is the potential that the use of St. John s Wort in patients receiving @DRUG$ could result in reduced amiodarone levels.	DDI-false
of @DRUG$ other agents neuromuscular transmission ( e.g. , @DRUG$ ) should performed with caution as effect of may	DDI-false
acetaminophen/theophylline , lidocaine/@DRUG$ phenobarbital/@DRUG$ , , , and valproic .	DDI-false
@DRUG$: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when @DRUG$ was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	DDI-false
will plasmaconcentration of other drugs ( triazolo-benzodiazepines , @DRUG$ @DRUG$ , . ) .	DDI-false
@DRUG$: As with some other quinolones, concurrent administration of @DRUG$ with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	DDI-false
Interaction on the antinociceptive effect between @DRUG$ and enkephalins or @DRUG$.	DDI-effect
It is assumed that increased interaction between @DRUG$ and high affinity binding sites for @DRUG$ on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
have not been coadministration that by CYP3A4 ( , dapsone disopyramide , quinine @DRUG$ quinidine , warfarin , ergot derivatives , , fentanyl , , @DRUG$ , and triazolam ) may plasma concentrations coadministered saquinavir	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, procainamide, @DRUG$, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
: Monoamine MAOI ): could theoretically affect - - @DRUG$ and Ethanol cause depression - : @DRUG$ effect of	DDI-false
@DRUG$ In volunteers , a small @DRUG$ observed of and administered	DDI-false
Drug Interactions Flupenthixol , inhibitors ( ): MAOI theoretically affect @DRUG$ pharmacodynamics - Flupenthixol @DRUG$ CNS depression - Tricyclic Flupenthixol effect Tricyclic antidepressants	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient @DRUG$ intake which only requires oral physiological supplementation and @DRUG$ depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
have shown to @DRUG$-induced side renal insufficiency , and dyspnea , administration @DRUG$ may antitumor of PROLEUKIN and be may potentiate hypotension PROLEUKIN	DDI-false
To evaluate the impact of chemotherapy plus on the with HIV-related , , non-Hodgkin lymphoma ) , the authors compared retrospectively 24 the doxorubicin @DRUG$ ( regimen a group of who were treated chemotherapy a regimen i.e. , cyclophosphamide , @DRUG$ teniposide , with bleomycin ) without therapy .	DDI-false
@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
@DRUG$: Other @DRUG$ drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Enalapril and enalapril IV have been concomitantly adrenergic-blocking agents , methyldopa , , @DRUG$ @DRUG$ , prazosin digoxin without evidence of adverse .	DDI-false
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, @DRUG$, amiodarone, nicardipine, and nifedipine.	DDI-int
@DRUG$ vincristine chemotherapy @DRUG$ patients with human immunodeficiency ,	DDI-false
The blood pressure effect of @DRUG$ tended to be greater in patients on @DRUG$ than in patients on no other antihypertensive therapy.	DDI-effect
naltrexone with @DRUG$ a 25 % AUC % in Cmax of	DDI-false
Limited comparative data in patients with high viral loads treated with @DRUG$- or @DRUG$-based regimens currently exist.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including anti-arrhythmic agents such as quinidine and @DRUG$, cardiac glycosides and tricyclic anti-depressants.	DDI-false
Nephrotoxicity has been reported following concomitant administration of @DRUG$ with @DRUG$ or potent diuretics such as furosemide.	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Plasma concentrations decreased approximately % when @DRUG$ @DRUG$ were	DDI-mechanism
@DRUG$ , Methylxanthines : xanthine steroids may a @DRUG$	DDI-false
Although been , coadministration with are mainly metabolized by ( channel blockers dapsone , disopyramide , quinine , amiodarone , , tacrolimus , , fentanyl , @DRUG$ and triazolam elevated concentrations @DRUG$ ;	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Cyclosporine of nonsteroial drugs @DRUG$ has with possibly synthesis renal prostacyclin	DDI-false
@DRUG$ been shown to be antagonistic to @DRUG$ , on in studies kill with gram-negative	DDI-effect
Although specific have , with that metabolized CYP3A4 channel , @DRUG$ , , quinidine , tacrolimus , @DRUG$ , pimozide alfentanyl ) concentrations coadministered ;	DDI-false
Demonstrated be 3A Inhibitors Possible Significance Basis Studies Involving Alprazolam ( @DRUG$ ): of fluoxetine with @DRUG$ increased the of alprazolam 46 , decreased by 21 , increased half-life by % , decreased psychomotor .	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Coadministration @DRUG$ the @DRUG$ by % by 38 , increased by %	DDI-mechanism
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Agents a study , of @DRUG$ with @DRUG$ not meaningfully alter the pharmacokinetics either )	DDI-false
@DRUG$ @DRUG$ antagonism	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, @DRUG$, amiodarone, nicardipine, and @DRUG$.	DDI-false
@DRUG$ procainamide , phenothiazines , , @DRUG$ be associated prolongation an increased risk of ventricular arrhythmia	DDI-false
studies with Fondaparinux , concomitant oral @DRUG$ ( warfarin , platelet @DRUG$ ) , NSAIDs piroxicam ) , and affect the pharmacokinetics/pharmacodynamics of fondaparinux	DDI-false
BACKGROUND of and ( ) , channel , on incidence peritoneal metastasis intestinal induced by @DRUG$ @DRUG$ ) cancers were rats	DDI-false
Dexamethasone and retinyl acetate similarly inhibit and stimulate @DRUG$- or @DRUG$-induced proliferation of prostatic epithelium.	DDI-false
@DRUG$ is inhibited by @DRUG$.	DDI-mechanism
administration drugs nephrotoxic e.g. aminoglycosides , @DRUG$ , , doxorubicin ) hepatotoxic ( e.g. , methotrexate , ) effects @DRUG$ may increase toxicity these	DDI-effect
acetaminophen/theophylline , , phenobarbital/@DRUG$ , acid , , and valproic .	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	DDI-false
In some patients combined @DRUG$ @DRUG$ has been associated with gastrointestinal hemorrhage .	DDI-effect
evaluate the of the clinical of , systemic ) , the compared group of HIV-NHL were with cyclophosphamide , doxorubicin and prednisone chemotherapy regimen HAART a who were CHOP-like , doxorubicin , prednisone @DRUG$ ) receiving @DRUG$ therapy	DDI-false
administration of ( e.g. , indomethacin , myelotoxic ( , chemotherapy ) ( @DRUG$ ( , @DRUG$ , ) with PROLEUKIN toxicity in .	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
block and dopamine release accumbens ;	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
- ingestion of may @DRUG$ response to @DRUG$ treatment poisoning	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
treatment with inhibitors CYP3A4 activity such @DRUG$ , , ritonavir indinavir @DRUG$ is reduction of dose should be considered .	DDI-false
Test @DRUG$ , @DRUG$ , are known occasionally positive direct Coombs	DDI-false
Here we show that a combination of @DRUG$ or 3,7-dihydroxyflavone with @DRUG$ may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus faecium to the level of vancomycin-sensitive strains.	DDI-false
Drug @DRUG$ may interact drugs Monoamine oxidase inhibitors ( MAOI could theoretically @DRUG$ Arecoline Eproxindine Ethanol : and CNS Tricyclic Flupenthixol	DDI-false
Concomitant @DRUG$ @DRUG$ prednisone chemotherapy plus highly active antiretroviral therapy in virus-related , non-Hodgkin	DDI-false
acetaminophen/@DRUG$ phenobarbital/acetaminophen , , , .	DDI-false
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-false
Other : such , disopyramide procainamide @DRUG$ , @DRUG$ and with QT-interval risk of arrhythmia	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
that may alter plasma increase plasma Caution recommended when administering Gleevec with inhibitors the family , @DRUG$ , @DRUG$ , ) .	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, @DRUG$, glutethimide, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Although been shown including fever insufficiency hyperbilirubinemia confusion and of these agents with PROLEUKIN reduce antitumor effectiveness of @DRUG$ and thus should be avoided Beta-blockers other antihypertensives potentiate seen with .	DDI-false
@DRUG$ is a neutralizing agent for @DRUG$ protects renal damage .	DDI-effect
Azithromycin no Cmax @DRUG$ significantly decreased @DRUG$ tmax 44 % and exposure phosphorylated by %	DDI-false
@DRUG$ be in receiving blocking agents ( e.g. , @DRUG$ CYP3A4 ) or calcium e.g. , substrate , and , ) of the possible potentiation of , sinus arrest AV ;	DDI-false
not ( ) in AUC 48.59 vs. + ) Cmax ( + /- 2.6 vs. 6.6 + ) and ( + vs. 1.6 + for levofloxacin @DRUG$/@DRUG$ regimens .	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Other Drugs:Drugs such as quinidine, @DRUG$, @DRUG$, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, erythromycin, clarithromycin).	DDI-false
@DRUG$: Caution should be used if @DRUG$ is administered concomitantly with methotrexate.	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of @DRUG$, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of @DRUG$ at steady state.	DDI-false
Although studies to examine been done , it was corticosteroid @DRUG$ treatment relapses periods of to has receiving	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Both @DRUG$ and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with @DRUG$ regimens and superiority observed with efavirenz.	DDI-false
neither influenced warfarin @DRUG$ piroxicam digoxin , @DRUG$ state .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drugs may alter imatinib plasma concentrations may imatinib : Caution when @DRUG$ with the family ( e.g. , itraconazole , @DRUG$ ) .	DDI-advise
@DRUG$ inhibited by	DDI-mechanism
Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine (@DRUG$ substrate) given for local @DRUG$.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, @DRUG$, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
clinical studies performed with @DRUG$ the oral , platelet inhibitors acid ) @DRUG$ , digoxin did not affect pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
Cardiovascular Agents : Enalapril @DRUG$ been beta , @DRUG$ , hydralazine prazosin and evidence clinically significant interactions .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Concurrent , @DRUG$ , multivalent cation-containing such as aluminum sucralfate VIDEX chewable/buffered tablets or products containing calcium , @DRUG$ , or zinc the absorption of ciprofloxacin resulting serum and urine lower than	DDI-mechanism
Antiarrhythmics: Other antiarrhythmic drugs, such as @DRUG$, procainamide, disopyramide, and phenytoin, have been used concurrently with @DRUG$.	DDI-false
Hypotension Patients and especially those in therapy recently instituted , experience reduction of blood pressure of therapy @DRUG$ @DRUG$.	DDI-false
administration of nephrotoxic e.g. , aminoglycosides , @DRUG$ ) , ( e.g. , chemotherapy , cardiotoxic e.g. doxorubicin ) or e.g. , @DRUG$ asparaginase ) with PROLEUKIN increase toxicity these	DDI-false
@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
shown to effects including fever , confusion , and of these may reduce effectiveness PROLEUKIN should be . 12 Beta-blockers other @DRUG$ potentiate with @DRUG$.	DDI-effect
@DRUG$ : and not changes in prothrombin time or VII compared of @DRUG$ placebo .	DDI-false
No significant interactions were found between nisoldipine and @DRUG$ or @DRUG$.	DDI-false
Sinus bradycardia has been amiodarone with @DRUG$ ( @DRUG$ given for local	DDI-false
Although have not coadministration with mainly ( eg , calcium , , @DRUG$ quinine quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide carbamazepine , , , and ) plasma coadministered with @DRUG$ ;	DDI-mechanism
acetaminophen/theophylline lidocaine/quinidine , phenobarbital/valproic acid @DRUG$/lidocaine theophylline/@DRUG$ and valproic .	DDI-false
@DRUG$ including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	DDI-effect
Although specific have been coadministration that metabolized by calcium , quinine , warfarin , @DRUG$ @DRUG$ , carbamazepine , alfentanyl , alprazolam ) plasma with ;	DDI-false
Although specific not performed drugs are metabolized by CYP3A4 eg , calcium blockers , @DRUG$ , @DRUG$ quinine tacrolimus , derivatives , pimozide , , fentanyl alfentanyl alprazolam , and triazolam have plasma coadministered saquinavir	DDI-false
Oral Contraceptives: Coadministration of @DRUG$ and an oral contraceptive increased AUC values for @DRUG$ and ethinyl estradiol by approximately 30% and 20%.	DDI-mechanism
Although specific been , drugs that mainly CYP3A4 ( eg , calcium channel , @DRUG$ , quinine , amiodarone warfarin , tacrolimus , derivatives , carbamazepine @DRUG$ alprazolam elevated plasma concentrations when coadministered ;	DDI-false
plasma concentrations @DRUG$ concentrations : Caution when administering inhibitors of @DRUG$ , itraconazole , erythromycin .	DDI-false
Although specific studies have not performed , coadministration that are mainly CYP3A4 , blockers , , , @DRUG$ , , tacrolimus ergot , , fentanyl , , @DRUG$ and may elevated plasma when with	DDI-false
These results suggest that both @DRUG$ and retinyl acetate, and possibly other glucocorticoids and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of @DRUG$, but significantly decreased the urinary excretion of @DRUG$ and its glucuronide metabolite.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving @DRUG$ therapy.	DDI-false
In EM individuals treated with @DRUG$ or fluoxetine, the AUC of @DRUG$ is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.	DDI-mechanism
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of @DRUG$ and @DRUG$ in rats;	DDI-false
Warfarin: @DRUG$ enhances the effect of @DRUG$.	DDI-false
To evaluate impact chemotherapy the clinical patients HIV-related , systemic non-Hodgkin HIV-NHL ) authors compared a group HIV-NHL who were the vincristine , ( plus HAART with group 80 were treated chemotherapy or a ( i.e. , , , , and @DRUG$ @DRUG$ without receiving therapy .	DDI-false
To evaluate the impact of chemotherapy plus course of HIV-related systemic , lymphoma ( HIV-NHL , the authors a of 24 treated the @DRUG$ , and @DRUG$ CHOP ) chemotherapy plus with group of patients who were treated with a CHOP-like regimen , doxorubicin , , with bleomycin receiving antiretroviral therapy	DDI-false
Mineral Oil-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of @DRUG$.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, @DRUG$, cis-platinum, @DRUG$ and interferon-alfa.	DDI-false
@DRUG$/theophylline lidocaine/quinidine , phenobarbital/acetaminophen @DRUG$/valproic acid ,	DDI-false
@DRUG$: @DRUG$ appear to have no significant effect on the bioavailability of ciprofloxacin.	DDI-false
Acetaminophen: In normal volunteers, concomitant administration of @DRUG$ and acetaminophen resulted in an approximate 50% increase in plasma levels of @DRUG$.	DDI-false
It is therefore necessary to acquainted the clinical and paraclinical pattern deficit to discriminate between @DRUG$ deficiency magnesium intake oral supplementation depletion of the of @DRUG$ status which more or less specific regulation causal	DDI-false
Other Drugs:Drugs such as @DRUG$, disopyramide, @DRUG$, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Concurrent of possessing nephrotoxic ( e.g. , @DRUG$ , ) ( cardiotoxic , or e.g. , @DRUG$ , effects PROLEUKIN organ .	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and @DRUG$ (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Methotrexate if @DRUG$ administered with @DRUG$.	DDI-advise
on @DRUG$ patient maximal 5 days the initiation @DRUG$ and time rifampin .	DDI-false
@DRUG$ has been shown to be antagonistic to beta-lactam antibiotics, including @DRUG$, based on in vitro studies and time kill curves with enteric gram-negative bacilli.	DDI-effect
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/@DRUG$.	DDI-false
@DRUG$ derivatives indandione , inhibitors such as @DRUG$ , aspirin may increase the risk of concomitantly .	DDI-false
Drug with some drugs Monoamine oxidase inhibitors MAOI ): could flupenthixol pharmacodynamics @DRUG$ - Eproxindine - Flupenthixol and Ethanol cause : @DRUG$	DDI-false
If treatment of CYP3A4 ( such ketoconazole @DRUG$ , @DRUG$ , . ) indicated of dose should considered	DDI-false
@DRUG$/Hypnotics : triazolam , @DRUG$ CONTRAINDICATED potential for reactions such as prolonged increased respiratory .	DDI-false
@DRUG$ not affect the pharmacokinetics of interactions other @DRUG$ same cytochrome are not expected .	DDI-false
: Amiodarone @DRUG$ , flecainide @DRUG$ , quinidine CONTRAINDICATED due to and/or life-threatening .	DDI-false
@DRUG$: Co- administration of @DRUG$ and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.	DDI-false
While @DRUG$ and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, @DRUG$ has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	DDI-advise
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Oral Contraceptives: Coadministration of @DRUG$ and an oral @DRUG$ increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
: a , including , products such as magnesium aluminum antacids , @DRUG$ chewable/buffered tablets powder or products @DRUG$ , iron , may absorption resulting in urine considerably than desired .	DDI-false
Monoamine Oxidase @DRUG$ : be administered caution treated with oxidase inhibitors or @DRUG$ the of formoterol on cardiovascular system agents .	DDI-false
@DRUG$ The use Bepridil with long- @DRUG$ tolerated with stable	DDI-false
The effects of @DRUG$ were very strong and completely depressed the @DRUG$-induced hyperlocomotion.	DDI-effect
specific performed coadministration with drugs that are mainly by , calcium channel , @DRUG$ , quinidine warfarin , cyclosporine , pimozide , @DRUG$ , fentanyl , alprazolam triazolam ) elevated coadministered with saquinavir	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and @DRUG$.	DDI-false
( e.g. spironolactone , @DRUG$ ) , potassium supplements salt substitutes significant increases in	DDI-false
Although specific not been performed coadministration mainly metabolized CYP3A4 eg calcium dapsone disopyramide , amiodarone quinidine , , @DRUG$ , ergot , carbamazepine , alfentanyl alprazolam , triazolam ) have elevated @DRUG$ ;	DDI-mechanism
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ may slightly the effect antihypertensive , e.g. guanethidine ,	DDI-effect
administration of local @DRUG$ or to inhibitors tricyclic antidepressants or @DRUG$ produce prolonged or hypertension	DDI-effect
symptoms should be treated   @DRUG$ @DRUG$ ( physician should the such medication instruct in how should used .	DDI-false
In studies Fondaparinux concomitant use warfarin ) , @DRUG$ ( @DRUG$ ( piroxicam , and not significantly sodium .	DDI-false
Although specific studies have not performed with that are metabolized ( , calcium channel , @DRUG$ , , @DRUG$ , , , pimozide , carbamazepine , fentanyl , , alprazolam triazolam may have elevated when coadministered	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as @DRUG$, procainamide, disopyramide, and @DRUG$, have been used concurrently with amiodarone.	DDI-false
In addition to this pharmacological interaction, this report describes a novel chemical reaction between @DRUG$ (a benzodiazepine) and @DRUG$ under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.	DDI-mechanism
Other reported interactions with amiodarone: @DRUG$ (@DRUG$ substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including anti-arrhythmic agents such as quinidine and procainamide, @DRUG$ and tricyclic anti-depressants.	DDI-false
@DRUG$: The administration of @DRUG$ to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.	DDI-false
Concurrent @DRUG$ and may result levels of @DRUG$.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
If with inhibitors ( @DRUG$ , saquinavir , etc . ) of @DRUG$ dose should be considered	DDI-advise
Amiodarone should caution blocking agents @DRUG$ @DRUG$ or channel , verapamil a CYP3A4 diltiazem , a CYP3A4 inhibitor possible potentiation sinus arrest	DDI-false
first study , concomitant of @DRUG$ g @DRUG$ of more than % for AUC and for Cmax to alone .	DDI-mechanism
lidocaine/quinidine , phenobarbital/@DRUG$ , quinidine/lidocaine , and .	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	DDI-false
Drug : Flupenthixol may interact like @DRUG$ ( MAOI ): MAOI affect flupenthixol - Eproxindine Flupenthixol and additive CNS depression @DRUG$ Flupenthixol the of antidepressants	DDI-false
, no effects on either @DRUG$ or prothrombin were in @DRUG$.	DDI-false
Haemodynamic effects of @DRUG$ and insulin were additive when @DRUG$ was co-administered but not under basal conditions.	DDI-false
evaluate the of chemotherapy HAART on course of with lymphoma ( HIV-NHL ) , authors compared retrospectively group of patients HIV-NHL who with the , doxorubicin @DRUG$ @DRUG$ chemotherapy with a group 80 treated with i.e. , , doxorubicin teniposide prednisone vincristine plus without receiving antiretroviral therapy .	DDI-false
Interactions Flupenthixol may interact with , @DRUG$ @DRUG$ ): could theoretically affect - - Ethanol Ethanol cause additive depression - antidepressants Flupenthixol the effect antidepressants	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In addition, @DRUG$ neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of @DRUG$ at steady state.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$ @DRUG$ enhances of	DDI-effect
@DRUG$/theophylline , @DRUG$/quinidine phenobarbital/acetaminophen , phenobarbital/valproic , quinidine/lidocaine , theophylline/acetaminophen .	DDI-false
Lithium @DRUG$ toxicity has in concomitantly with drugs elimination of sodium including @DRUG$.	DDI-false
There have been reports of QTc prolongation, with or without TdP, in patients taking amiodarone when @DRUG$, @DRUG$, or azoles were administered concomitantly.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Interactions Flupenthixol may interact , oxidase inhibitors MAOI ): @DRUG$ theoretically flupenthixol pharmacodynamics - Arecoline Ethanol Flupenthixol and cause Tricyclic antidepressants Flupenthixol @DRUG$	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, @DRUG$, clarithromycin).	DDI-false
Although not coadministration with drugs are metabolized by CYP3A4 , channel blockers @DRUG$ disopyramide , @DRUG$ amiodarone quinidine , warfarin , , cyclosporine pimozide , carbamazepine fentanyl , and triazolam may have plasma concentrations coadministered with ;	DDI-false
Barbiturates and @DRUG$ should not be administered to patients receiving @DRUG$.	DDI-advise
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
@DRUG$: Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and @DRUG$, have been used concurrently with amiodarone.	DDI-false
Moreover, additional interaction studies with @DRUG$ and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
Coingestion of acetaminophen with @DRUG$, phenobarbital with acetaminophen, and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Aspirin/Acetaminophen Pharmacokinetic demonstrated concomitantly aspirin 162.5 mg orally and 2 prior to initiation Argatroban g/kg/min . over 4 hours @DRUG$ ( 1000 mg orally given 12 hours to , initiation of @DRUG$ 1.5   g/kg/min over )	DDI-false
Oral @DRUG$: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and @DRUG$ by approximately 30% and 20%.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
BACKGROUND: The effects of combined administration of bombesin and @DRUG$ (@DRUG$), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Limited clinical data in angina receiving concomitant @DRUG$ @DRUG$ indicate no changes levels	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, @DRUG$, and pargyline HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.	DDI-false
is concluded and @DRUG$ may safely monitoring oral @DRUG$ .	DDI-false
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Therefore , it would be dosing schedule of @DRUG$ at bedtime @DRUG$ before would result in a in sodium	DDI-false
@DRUG$ and Tricyclic : FORADIL should administered caution with oxidase inhibitors @DRUG$ because the of on cardiovascular may potentiated by	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with @DRUG$): Coadministration of fluoxetine with @DRUG$ increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
To determine whether injection of @DRUG$ would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of @DRUG$ was given intravenously over three hours concurrently with escalating doses of cisplatin.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
@DRUG$ : and digoxin at steady-state affected 0.2	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Oral @DRUG$: Coadministration of @DRUG$ and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, clarithromycin).	DDI-advise
@DRUG$ Caution should used if @DRUG$ is concomitantly with methotrexate .	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
effects of @DRUG$ on the pharmacokinetics @DRUG$.	DDI-false
Data in vitro of other suggest possible : , @DRUG$ @DRUG$ nicardipine .	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Aspirin/Acetaminophen or drug-drug interactions not demonstrated between @DRUG$ and concomitantly @DRUG$ ( 162.5 mg orally 26 2 hours to   g/kg/min over ( orally given , 6 and 0 hours prior to , 6 and hours initiation of 1.5   g/kg/min )	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The intensity course of @DRUG$ interference , secobarbital , hydrate were investigated @DRUG$	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
@DRUG$: Altered serum levels of @DRUG$ (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.	DDI-false
Cardiovasculars: Cardiac glycosides: In patients receiving digoxin therapy, administration of oral @DRUG$ regularly results in an increase in serum @DRUG$ concentration that may reach toxic levels with resultant clinical toxicity.	DDI-false
@DRUG$: The concomitant use of Bepridil with long- and short-acting @DRUG$ has been safely tolerated in patients with stable angina pectoris.	DDI-false
Although specific have , coadministration with drugs by CYP3A4 calcium channel dapsone disopyramide , quinine , , @DRUG$ warfarin , tacrolimus , cyclosporine , ergot , carbamazepine , fentanyl , @DRUG$ and have concentrations saquinavir ;	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
from studies of alprazolam suggest possible interaction alprazolam for : @DRUG$ @DRUG$.	DDI-false
If with CYP3A4 such @DRUG$ , @DRUG$ saquinavir erythromycin etc . the be	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$-@DRUG$ sterilize the bowel and vitamin K contribution to the body by the intestinal microflora	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
with , administration of @DRUG$ with may lead @DRUG$ prolongation its elimination .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ produced distinctive effects in each task: it substituted for the training dose in @DRUG$ discrimination and it increased the number of responses with short (<3 s) interresponse times as well as increasing overall response rates in the DRL schedule.	DDI-false
In clinical studies performed , the concomitant of oral ( @DRUG$ , @DRUG$ NSAIDs ) , and digoxin did the of .	DDI-false
@DRUG$ significantly incidence of lymphatic invasion adenocarcinomas @DRUG$.	DDI-effect
The administration local @DRUG$ epinephrine or to receiving @DRUG$ tricyclic antidepressants or phenothiazines severe hypotension	DDI-false
dialyzed were @DRUG$ , quinidine , and theophylline , both at concentrations in serum @DRUG$ three concentrations serum .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
@DRUG$, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Monoamine Inhibitors and @DRUG$ : be with treated with inhibitors or tricyclic because action of @DRUG$ the cardiovascular by .	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., @DRUG$, analgesics, antiemetics, @DRUG$, tranquilizers).	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Monoamine and : @DRUG$ should with extreme being treated oxidase inhibitors or @DRUG$ action may by	DDI-advise
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Effect of @DRUG$ on the pharmacokinetics of @DRUG$.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Interactions : interact ( @DRUG$ could flupenthixol - Ethanol : Flupenthixol additive @DRUG$ of antidepressants	DDI-false
@DRUG$ @DRUG$ psychotomimetic humans that resemble	DDI-false
acetaminophen/theophylline , phenobarbital/@DRUG$ , acid , , theophylline/acetaminophen @DRUG$/phenobarbital	DDI-false
@DRUG$ (e.g., spironolactone, triamterene, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
evaluate the chemotherapy of with HIV-related , systemic non-Hodgkin lymphoma ( , the retrospectively of 24 who treated with , doxorubicin and prednisone ( with a of were treated with CHOP a CHOP-like regimen ( , , @DRUG$ @DRUG$ , plus ) without antiretroviral therapy .	DDI-false
There have been case reports of increased steady-state levels of @DRUG$, procainamide, and @DRUG$ during concomitant therapy with amiodarone.	DDI-false
@DRUG$ the	DDI-mechanism
@DRUG$ with administered @DRUG$ , but is not clinically significant	DDI-int
@DRUG$ : of antacids may levels @DRUG$.	DDI-false
@DRUG$-Broad-spectrum antibiotics may sterilize the bowel and decrease the @DRUG$ contribution to the body by the intestinal microflora.	DDI-false
Physiological oral @DRUG$ load constitutes the best tool for diagnosis of @DRUG$ deficiency and the first step of its treatment.	DDI-false
@DRUG$ ( @DRUG$ ): Cerivastatin plasma were not by antacid	DDI-false
: may with some Monoamine ( ): theoretically affect - @DRUG$ - @DRUG$ and Ethanol cause additive depression antidepressants Flupenthixol effect	DDI-false
To determine whether injection of thiosulfate would permit larger doses of @DRUG$ to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of @DRUG$.	DDI-false
Anticoagulants : Potentiation ) is patients receiving @DRUG$ and can result in serious bleeding .	DDI-false
@DRUG$/Hypnotics: @DRUG$, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
The aim of this paper was to study the interaction between neurotensin and both @DRUG$ or its synthetic analogue @DRUG$, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection.	DDI-false
Dosage STRATTERA may CYP2D6 inhibitors , e.g. , , @DRUG$ @DRUG$.	DDI-false
If treatment inhibitors activity ( , intraconazole , indinavir @DRUG$ , erythromycin , is reduction of @DRUG$ be considered	DDI-advise
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
[Quantitative approach to treatment with incisive @DRUG$ by therapeutic monitoring]; The problems encountered during the longterm treatment of psychotic patients with @DRUG$ are illustrated by six typical case reports.	DDI-false
Potential differences in @DRUG$ dosing and pharmacokinetics at different levels of @DRUG$ exposure were assessed in the context of ANOVA.	DDI-false
effect of @DRUG$ the @DRUG$ requirement of our patient to to days after of similar of rifampin .	DDI-effect
comparative patients with high loads treated @DRUG$- currently	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$: The concomitant administration of diflunisal and @DRUG$ in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	DDI-false
Reactions to @DRUG$ A of the literature that 12.6 % 28 % ) 501 treated with interleukin-2 who subsequently administered @DRUG$ experienced acute , atypical adverse reactions .	DDI-false
@DRUG$ - prior ingestion of diphenidol may decrease the @DRUG$ response to apomorphine in the treatment of poisoning.	DDI-false
Co- of and @DRUG$ to healthy volunteers not result time or factor when @DRUG$ and placebo	DDI-false
Drugs Drugs such as , , @DRUG$ , , antihistamines , @DRUG$ prolongation	DDI-false
@DRUG$-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of @DRUG$.	DDI-false
Garlic capsules should be @DRUG$ ( @DRUG$ ) sole inhibitor due saquinavir plasma concentrations .	DDI-false
Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with @DRUG$, the co-administration of @DRUG$ may result in a further deterioration of renal function.	DDI-effect
The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$ or @DRUG$.	DDI-false
Although have not been performed , with drugs are mainly metabolized by ( eg blockers disopyramide , , amiodarone , , warfarin , pimozide , , alfentanyl , @DRUG$ ) may elevated plasma when coadministered @DRUG$ ;	DDI-mechanism
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
derivatives , indandione inhibitors anti-inflammatory ( @DRUG$ , and @DRUG$ increase the administered concomitantly ardeparin	DDI-false
@DRUG$ had no on plasma levels @DRUG$.	DDI-false
@DRUG$: In controlled studies in healthy volunteers, @DRUG$ either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum digoxin concentrations.	DDI-false
Theophylline : other quinolones concurrent administration @DRUG$ with @DRUG$ to serum concentrations and prolongation of its elimination half-life .	DDI-mechanism
If @DRUG$ is administered with drugs that inhibit Pgp, increased concentrations of @DRUG$ are likely, and caution should be exercised.	DDI-false
@DRUG$-Concomitant intake of mineral oil and vitamin K may reduce the absorption of @DRUG$.	DDI-false
Coingestion acetaminophen with , @DRUG$ with @DRUG$ acid phenobarbital at toxic decreases the target	DDI-effect
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Both @DRUG$ levels the nucleus accumbens , but @DRUG$ increases of serotonin the nucleus accumbens	DDI-false
Co-medications that induce CYP3A4 (e.g., @DRUG$, phenytoin, @DRUG$, rifampin, phenobarbital or St.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
@DRUG$ : drug-drug interactions between Argatroban and @DRUG$ ( 7.5 ) been .	DDI-false
In @DRUG$ influenced the of warfarin acid @DRUG$ digoxin , pharmacokinetics steady .	DDI-false
is interaction @DRUG$ affinity for @DRUG$ on and the action of prolonged .	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with @DRUG$, hypnotics and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
The @DRUG$ are a	DDI-false
additional studies with niacin @DRUG$ have not demonstrated effect on fluvastatin plasma levels and administration to a patient population chronically digoxin difference in of bioavailability of @DRUG$ relative to control data	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
BACKGROUND of combined administration of @DRUG$ and verapamil hydrochloride ( verapamil , a channel blocker , on the incidence of peritoneal adenocarcinomas induced by @DRUG$ and the index cancers investigated male rats .	DDI-false
METHODS the of the , rats were given injections of @DRUG$ weight ) and injections of bombesin ( body ) other day and from , injections @DRUG$ mg/kg body ) day until the end week 45 .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Antipyrine: Because @DRUG$ does not affect the pharmacokinetics of @DRUG$, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics, hypnotics and sedatives (including benzodiazepines), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
These suggest that both @DRUG$ retinyl , @DRUG$ and , of epithelium a dose-dependent of the activity of and .	DDI-false
Co-medications that induce CYP3A4 @DRUG$ phenytoin , @DRUG$ , , phenobarbital St.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, @DRUG$, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Data in vitro studies of benzodiazepines other suggest a possible drug for the : @DRUG$ , @DRUG$ , and nifedipine	DDI-false
Although nor retinyl of prostatic epithelium in RPMI1640 containing @DRUG$ , the mitogenic effect of @DRUG$	DDI-false
Moreover, additional interaction studies with @DRUG$ and propranolol have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
@DRUG$ : Plasma @DRUG$ levels at steady-state were not affected co-administration of cerivastatin sodium	DDI-false
oral administration of @DRUG$ a known inhibitor activity and in the intestinal caused an eight-fold the systemic @DRUG$.	DDI-mechanism
chains ( , @DRUG$ , cefamandole latamoxef ) cefazolin ) can vitamin K and hypoprothrombinemia .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
In the present study, the @DRUG$ clozapine was tested in combination with an active dose of @DRUG$ in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures.	DDI-false
Co-administration of @DRUG$ and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the @DRUG$ may be potentiated.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
@DRUG$ will other metabolized ( , triazolo-benzodiazepines dihydropyridine calcium certain @DRUG$ etc . .	DDI-mechanism
The conversion of @DRUG$ to @DRUG$ is catalyzed by aldehyde oxidase.	DDI-false
Co- administration @DRUG$ cerivastatin to volunteers any in time clotting factor compared to @DRUG$	DDI-false
Both and nevirapine have been compared to triple with the PI indinavir weeks as therapy with observed with @DRUG$ and observed with @DRUG$.	DDI-false
Fondaparinux concomitant use oral ( warfarin ) , platelet ( NSAIDs @DRUG$ did the	DDI-false
effects metabotropic glutamate receptor ( mGluR agonists , @DRUG$ @DRUG$ , on above changes by PCP	DDI-false
The blood pressure effect of @DRUG$ tended to be greater in patients on atenolol than in patients on no other @DRUG$ therapy.	DDI-false
Cholestyramine-Concomitant intake of cholestyramine and @DRUG$ may reduce the absorption of @DRUG$.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), @DRUG$ supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Drug-drug interactions have not been observed between @DRUG$ and @DRUG$ or erythromycin.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$-@DRUG$ may sterilize the bowel and decrease the vitamin K contribution to the body by the intestinal microflora.	DDI-false
Therefore, patients under @DRUG$ therapy should be carefully monitored when concomitant @DRUG$ therapy is indicated.	DDI-advise
Nephrotoxicity has been reported concomitant of @DRUG$ with @DRUG$ diuretics as .	DDI-effect
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, @DRUG$, diuretics, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, @DRUG$, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
The effect of @DRUG$ on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after @DRUG$ withdrawal.	DDI-false
The intensity and time @DRUG$ secobarbital @DRUG$ , chloral hydrate and were systematically 16 receiving therapy .	DDI-false
are known to accelerate the stimulating the synthesis of @DRUG$ enzyme )	DDI-false
Based on the results of these studies, it is concluded that azithromycin may be safely coadministered with both @DRUG$ and @DRUG$.	DDI-false
Histamine H2-receptor antagonists: @DRUG$ appear to have no significant effect on the bioavailability of @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
@DRUG$ and extent of absorption of Proquin given alone when @DRUG$ given hours after omeprazole at the maximally gastric acid secretion .	DDI-false
@DRUG$ When digoxin , steady-state plasma @DRUG$ concentrations increased by approximately 20 .	DDI-false
use @DRUG$ and other @DRUG$ not due the gastrointestinal , no increase .	DDI-effect
Other Drugs Drugs as quinidine , @DRUG$ , @DRUG$ phenothiazines antihistamines tricyclic antidepressants associated QT-interval prolongation risk ventricular arrhythmia	DDI-false
The of SULAR tended on @DRUG$ than patients on other @DRUG$	DDI-false
The intensity , uniformity and time course of anticoagulant interference by , , @DRUG$ and @DRUG$ were systematically investigated patients receiving coumarin	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
studies performed Fondaparinux , concomitant of oral @DRUG$ ( warfarin inhibitors acetylsalicylic ) , piroxicam ) , did not significantly	DDI-false
If treatment with inhibitors of CYP3A4 activity ( such @DRUG$ , intraconazole @DRUG$ indinavir , erythromycin etc ) is indicated of should considered .	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: @DRUG$, cyclosporine, amiodarone, nicardipine, and @DRUG$.	DDI-false
Like @DRUG$ ( ) 40 mg/kg the of morphine and @DRUG$ the of and rats ;	DDI-false
Hydrochlorothiazide: In normal volunteers, concomitant administration of @DRUG$ and hydrochlorothiazide resulted in significantly increased plasma levels of @DRUG$.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
OBJECTIVE : Our was to the @DRUG$ INN , @DRUG$ when de allograft during first	DDI-false
To determine whether injection @DRUG$ would @DRUG$ to administered fixed over three hours escalating doses of cisplatin .	DDI-false
@DRUG$, an anionic-binding resin, has a considerable effect in lowering the rate and extent of @DRUG$ bioavailability.	DDI-mechanism
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, @DRUG$, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
@DRUG$: In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs, the co-administration of @DRUG$ may result in a further deterioration of renal function.	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
risk of during with concurrent cyclosporine acid derivatives , @DRUG$ ( @DRUG$ ) azole antifungals .	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
Nitrates : The concomitant use @DRUG$ with short-acting @DRUG$ has been safely tolerated angina .	DDI-false
Data from of benzodiazepines than @DRUG$ suggest possible interaction for the , cyclosporine , @DRUG$ , and .	DDI-int
may suppress certain CYP450 enzymes , including @DRUG$ , CYP2C9	DDI-false
Antimycobacterial Agents the coadministration product with @DRUG$ an plasma concentrations	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
BACKGROUND: The effects of combined administration of bombesin and @DRUG$ (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
The effects of @DRUG$ and L-CCG-1 upon phencyclidine (@DRUG$)-induced locomotion and behavioral changes in mice.	DDI-false
This study demonstrated that the potent cytochrome P450 enzyme-inducer @DRUG$ did indeed have a marked effect on the metabolism of @DRUG$, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder.	DDI-mechanism
Both @DRUG$ and @DRUG$ decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens.	DDI-false
Non-selective MAO inhibitors including @DRUG$, @DRUG$, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
the impact chemotherapy plus HAART clinical course with HIV-related ( HIV-NHL , authors a 24 patients with HIV-NHL @DRUG$ , vincristine , and CHOP chemotherapy regimen HAART with a group 80 who treated chemotherapy or a regimen ( i.e. , doxorubicin , teniposide , @DRUG$ ) without receiving .	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
This cytochrome @DRUG$ did have a the metabolism of @DRUG$ , increase in clearance administered patients with , schizoaffective disorder .	DDI-mechanism
Although neither dexamethasone nor @DRUG$ affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of @DRUG$ and insulin.	DDI-effect
CYP2D6 inhibitors - @DRUG$ primarily by the CYP2D6 pathway @DRUG$.	DDI-false
induce , @DRUG$ , , @DRUG$ , phenobarbital or St.	DDI-false
Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with @DRUG$ or @DRUG$.	DDI-false
specific studies have not been performed coadministration with drugs that are mainly by ( eg channel , , disopyramide quinine , amiodarone quinidine warfarin tacrolimus ergot pimozide , , @DRUG$ @DRUG$ , and triazolam ) have plasma with saquinavir ;	DDI-false
These results that both @DRUG$ and @DRUG$ and glucocorticoids retinoids may epithelium by a activity insulin and EGF .	DDI-false
Other Cardiovascular Agents : enalapril IV have been used concomitantly with beta adrenergic-blocking agents @DRUG$ , calcium-blocking @DRUG$ clinically significant adverse .	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
In the first study, concomitant administration of 0.2 mg @DRUG$ and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing @DRUG$ alone.	DDI-false
because @DRUG$ displaces @DRUG$ from binding	DDI-mechanism
Ergot Derivatives: Dihydroergotamine, ergonovine, ergotamine, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, @DRUG$, @DRUG$ and interferon-alfa.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
, @DRUG$ and @DRUG$ : with steroids , or diuretics may effect  	DDI-false
Higher concentrations of @DRUG$ (10(-8) - 10(-6) M) or @DRUG$ (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF.	DDI-false
@DRUG$ with produced a 25 increase in a 33 of	DDI-false
Antihistamines : @DRUG$ , @DRUG$ * CONTRAINDICATED due serious and/or life-threatening .	DDI-false
therefore, the use of @DRUG$ does not necessitate an adjustment in @DRUG$ dose to maintain therapeutic digoxin levels.	DDI-false
Aspirin : @DRUG$ may lower @DRUG$ plasma possibly for .	DDI-mechanism
Antiarrhythmics: @DRUG$, bepridil, flecainide, propafenone, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
, phenobarbital/valproic , quinidine/lidocaine , @DRUG$/@DRUG$ and acid/phenobarbital	DDI-false
@DRUG$/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
These results and @DRUG$ , and retinoids proliferation of by a of activity of and @DRUG$.	DDI-effect
was significant change in test the of @DRUG$ @DRUG$.	DDI-false
@DRUG$: Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Other Drugs:Drugs such as @DRUG$, disopyramide, procainamide, phenothiazines, @DRUG$, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
@DRUG$ Plasma concentrations atorvastatin 25 when @DRUG$	DDI-false
@DRUG$ and : be administered extreme caution treated with @DRUG$ antidepressants the of on cardiovascular potentiated these agents	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ (caution is recommended during coadministration with alprazolam): Coadministration of @DRUG$ with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
effects of @DRUG$ ( ) on inositol responses were bone marrow megakaryocytes the patch-clamp whole-cell technique in fura-2 .	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, @DRUG$ (nicotinic acid), @DRUG$, azole antifungals.	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Anticoagulant inhibition observed administration of @DRUG$ @DRUG$ and	DDI-false
Co-medications that induce CYP3A4 (e.g., dexamethasone, @DRUG$, carbamazepine, rifampin, @DRUG$ or St.	DDI-false
and have been compared to triple therapy with the @DRUG$ over 48 weeks as initial being observed with regimens and with	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
alter plasma Drugs may concentrations Caution is recommended when inhibitors of the family ( e.g. , , @DRUG$ @DRUG$ ) .	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, @DRUG$, glutethimide, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
@DRUG$ - prior of @DRUG$ may decrease to apomorphine the of poisoning	DDI-false
Aspirin/Acetaminophen Pharmacokinetic or drug-drug interactions not been demonstrated between @DRUG$ concomitantly ( 162.5 mg orally 26 to @DRUG$ . over 4 ) or acetaminophen mg orally 12 6 and 0 hours , and hours to ,   over 18 )	DDI-false
OTHER studies , clinical cerivastatin used concomitantly with @DRUG$ @DRUG$ , blockers diuretics , nonsteroidal anti-inflammatory drugs ( NSAIDs of clinically significant .	DDI-false
@DRUG$  may interact with drugs known to interact with the conventional formulation of @DRUG$.	DDI-false
have performed , with drugs are mainly CYP3A4 eg , @DRUG$ dapsone , disopyramide , , amiodarone , quinidine , , ergot derivatives , pimozide carbamazepine fentanyl , alfentanyl , @DRUG$ , and triazolam may plasma when coadministered ;	DDI-false
: Plasma @DRUG$ % @DRUG$ atorvastatin coadministered .	DDI-false
of @DRUG$ regimens for antiretroviral therapy and regarding protease (PI)-related metabolic disturbances have to significant shifts in treatment practices infection .	DDI-false
ERYTHROMYCIN In steady-state @DRUG$ AUC and 50 and after 10 with co-administration of @DRUG$ of cytochrome 3A4 .	DDI-mechanism
Therefore concomitant administration of psychotropic drugs ( , narcotics , analgesics , antiemetics @DRUG$ , @DRUG$	DDI-false
@DRUG$: @DRUG$, bepridil, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
The family of @DRUG$	DDI-false
WARFARIN : administration @DRUG$ @DRUG$ to result in any changes in prothrombin time when compared co-administration of warfarin and placebo .	DDI-false
efavirenz and @DRUG$ have with PI over 48 therapy with similar being observed with @DRUG$ regimens superiority	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The raise possibility the reaction stomach of who consume @DRUG$ @DRUG$ on basis .	DDI-mechanism
Concomitant use with @DRUG$s may result in the reduced absorption of @DRUG$.	DDI-false
@DRUG$ increases bioavailability by @DRUG$ , and valproates .	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, ritonavir, indinavir, @DRUG$, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
@DRUG$ and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
The @DRUG$ are a family of anxiolytic and @DRUG$.	DDI-false
The data that @DRUG$ narrower and will a greater index than @DRUG$.	DDI-false
on warfarin levels times a concomitant @DRUG$ @DRUG$.	DDI-false
In addition to the noted , ) oral @DRUG$ impairs phenytoin , dextromethorphan	DDI-false
@DRUG$-@DRUG$ decrease vitamin	DDI-false
Methotrexate Renal of @DRUG$ concomitant administration of ciprofloxacin , to increased plasma of @DRUG$.	DDI-false
addition to the interactions above ,   2 weeks Cordarone impairs metabolism of @DRUG$ , and @DRUG$.	DDI-false
@DRUG$: Other antiarrhythmic drugs, such as quinidine, procainamide, @DRUG$, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Theophylline : As with some other , concurrent administration ciprofloxacin with @DRUG$ may lead to elevated serum of @DRUG$ prolongation of elimination	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Sinus bradycardia has been reported with oral @DRUG$ in combination with lidocaine (CYP3A4 substrate) given for local @DRUG$.	DDI-false
In general these are drugs one or more activities similar hydrochloride , agents such quinidine @DRUG$ cardiac and	DDI-false
Administration @DRUG$ concomitantly with amiodarone has shown to result in serum of @DRUG$ desethylamiodarone .	DDI-false
To the of chemotherapy on HIV-related , , non-Hodgkin ( HIV-NHL ) authors retrospectively 24 HIV-NHL were treated cyclophosphamide @DRUG$ , , prednisone ( CHOP chemotherapy HAART a 80 were treated with CHOP a ( i.e. @DRUG$ , doxorubicin , , prednisone with bleomycin receiving antiretroviral	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, fibric acid derivatives, niacin (@DRUG$), erythromycin, azole antifungals.	DDI-false
Cation-Containing : Concurrent of ciprofloxacin , multivalent cation-containing such as antacids sucralfate @DRUG$ pediatric powder or products @DRUG$ iron or substantially decrease the absorption , resulting in serum and lower than .	DDI-false
The effects with @DRUG$ enalaprilat be discontinuing the increasing the intake prior to treatment @DRUG$.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
, , phenobarbital/acetaminophen , phenobarbital/valproic , quinidine/lidocaine theophylline/acetaminophen valproic acid/@DRUG$.	DDI-false
for CYP3A4 there is the that of St. John s patients receiving @DRUG$ result in @DRUG$ levels	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of @DRUG$ by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Acetaminophen normal volunteers of @DRUG$ 50 plasma	DDI-false
Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of @DRUG$, potentially leading to increased plasma levels of @DRUG$.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin (nicotinic acid), @DRUG$, @DRUG$.	DDI-false
@DRUG$ , @DRUG$ Concomitant derivatives , diuretics potentiate of .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ increases enterohepatic elimination of amiodarone and may reduce its serum levels and @DRUG$/2.	DDI-false
Anticoagulants Potentiation of warfarin-type ( @DRUG$ substrate ) @DRUG$ response almost always seen in receiving and can result or fatal .	DDI-false
Antipyrine: Because @DRUG$ does not affect the pharmacokinetics of antipyrine, interactions with other @DRUG$ metabolized via the same cytochrome isozymes are not expected.	DDI-false
The hypotensive @DRUG$ or enalaprilat by discontinuing the diuretic or increasing the intake to with @DRUG$ or enalaprilat	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Non-selective MAO inhibitors including @DRUG$, phenelzine sulfate, and pargyline HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.	DDI-false
@DRUG$ neither influenced @DRUG$ acid , piroxicam digoxin , nor the pharmacokinetics of at steady .	DDI-false
@DRUG$ including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
There are 3 types of indications: specific (for the treatment of some forms of @DRUG$ deficit i.e. acute), pharmacological (i.e. without alterations of @DRUG$ status) and mixed--pharmacological and aetiopathogenic--(for example complications of chronic alcoholism).	DDI-false
The concomitant intake of @DRUG$ and @DRUG$ does not affect the pharmacokinetics of either alcohol or acamprosate.	DDI-false
Antimycobacterial Agents: @DRUG$ CONTRAINDICATED since the coadministration of this product with saquinavir in an @DRUG$ regimen reduces the plasma concentrations of saquinavir.	DDI-false
Mineral @DRUG$ @DRUG$ the absorption vitamin	DDI-mechanism
( , @DRUG$ 40 mg/kg ) the morphine and and oral of @DRUG$ ;	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ plasma concentrations reduction not altered coadministration	DDI-false
@DRUG$: Dihydroergotamine, ergonovine, ergotamine, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Drug Interactions : drugs like Monoamine inhibitors ( MAOI MAOI could theoretically @DRUG$ pharmacodynamics - : and Ethanol additive CNS depression antidepressants @DRUG$ effect Tricyclic	DDI-false
@DRUG$: In normal volunteers, concomitant administration of diflunisal and @DRUG$ resulted in an approximate 50% increase in plasma levels of acetaminophen.	DDI-false
@DRUG$ with has associated with an in , due to	DDI-false
Antiarrhythmics : Other , such as , , and @DRUG$ , have been used with	DDI-false
Acetaminophen, lidocaine, phenobarbital, quinidine, @DRUG$, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
of drugs possessing nephrotoxic e.g. indomethacin ) ( e.g. cytotoxic ( , doxorubicin hepatotoxic e.g. , methotrexate , @DRUG$ ) with @DRUG$ in systems .	DDI-effect
Pretreatment of megakaryocytes with extracellular @DRUG$ (50 microM) also inhibited @DRUG$-induced responses.	DDI-effect
colestipol may the of	DDI-false
increase the antihypertensive , e.g. , @DRUG$ methyldopa @DRUG$.	DDI-false
Coingestion @DRUG$ phenobarbital with acetaminophen @DRUG$ concentrations decreases binding of drug	DDI-false
Although been performed , with drugs mainly CYP3A4 ( eg channel , , quinine , quinidine warfarin tacrolimus @DRUG$ , pimozide , @DRUG$ alfentanyl , alprazolam triazolam ) have elevated plasma when ;	DDI-false
OTHER THERAPY Although specific interaction performed , in , cerivastatin sodium was with angiotensin- converting ( inhibitors calcium-channel blockers , diuretics and @DRUG$ ( @DRUG$ of clinically significant interactions .	DDI-false
not been performed coadministration drugs that CYP3A4 eg blockers dapsone disopyramide , amiodarone , warfarin , derivatives , pimozide , @DRUG$ alfentanyl @DRUG$ , and may when coadministered saquinavir ;	DDI-false
: Flupenthixol may with some , like Monoamine ( ): could theoretically - @DRUG$ - Ethanol : Ethanol depression - Tricyclic antidepressants @DRUG$ effect of Tricyclic	DDI-false
@DRUG$ : Histamine antagonists appear significant on of @DRUG$.	DDI-false
@DRUG$ (Magnesium-Aluminum Hydroxide): Cerivastatin plasma concentrations were not affected by co-administration of @DRUG$.	DDI-false
@DRUG$ : Other antiarrhythmic drugs as quinidine , procainamide @DRUG$ , phenytoin , have used with .	DDI-false
specific studies have , coadministration drugs mainly CYP3A4 eg calcium channel blockers , , quinine @DRUG$ warfarin , tacrolimus , cyclosporine , ergot derivatives , @DRUG$ , alfentanyl , alprazolam , and triazolam have elevated plasma concentrations when with	DDI-false
: The effects of combined of @DRUG$ verapamil , @DRUG$ on incidence of of intestinal induced by azoxymethane ( the index intestinal were in Wistar rats	DDI-false
interaction @DRUG$ not demonstrated effect @DRUG$ levels , to a patient population chronically receiving resulted no difference in the extent of bioavailability relative	DDI-false
The of anesthetic solutions @DRUG$ patients monoamine @DRUG$ or severe prolonged or	DDI-effect
the : @DRUG$ @DRUG$ are known to CYP3A4 to .	DDI-false
Potassium-sparing diuretics (e.g., @DRUG$, @DRUG$, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
The @DRUG$ are a family of @DRUG$ and hypnotic drugs.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, @DRUG$, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg @DRUG$ approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing @DRUG$ alone.	DDI-false
containing chains of @DRUG$ cefoperazone , cefotetan cefamandole , @DRUG$ ) or methylthiadiazole cefazolin .	DDI-false
Dextromethorphan is a substrate for both @DRUG$ and @DRUG$.	DDI-false
In studies performed with concomitant anticoagulants @DRUG$ acetylsalicylic acid , @DRUG$ ( piroxicam ) digoxin did not the pharmacokinetics/pharmacodynamics of fondaparinux sodium	DDI-false
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, @DRUG$ and @DRUG$, on the above behavioral changes induced by PCP were found.	DDI-false
alter imatinib concentrations @DRUG$ Caution recommended when administering Gleevec with family ( e.g. , @DRUG$	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (@DRUG$), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
There have been case reports of increased steady-state levels of quinidine, @DRUG$, and phenytoin during concomitant therapy with @DRUG$.	DDI-false
Corticosteroids @DRUG$ and : with @DRUG$ , , diuretics may a possible effect beta2-agonists	DDI-false
administration @DRUG$ and naproxen in normal no on levels of @DRUG$ significantly urinary excretion naproxen and metabolite	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, betablockers, @DRUG$, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Aspirin/Acetaminophen or pharmacodynamic have demonstrated between concomitantly administered mg given 26 and 2 to initiation @DRUG$ 1   hours ( 1000 mg given and hours to and and 12 hours subsequent to initiation of @DRUG$   g/kg/min )	DDI-false
@DRUG$/Hypnotics : @DRUG$ CONTRAINDICATED due to for life-threatening reactions such increased	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , acid , quinidine/lidocaine , acid/@DRUG$.	DDI-false
additional @DRUG$ and not demonstrated effect on fluvastatin plasma and administration to chronically @DRUG$ resulted no the bioavailability to data .	DDI-false
@DRUG$ @DRUG$ enhance the	DDI-false
@DRUG$ : Concurrent @DRUG$ may lower sodium levels possibly by competing for protein-binding sites	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
transport @DRUG$ inhibited concomitant @DRUG$ , potentially leading to increased plasma levels of methotrexate	DDI-mechanism
Lithium: Lithium toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including @DRUG$.	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
@DRUG$ should not be used as a substitute for oral or inhaled @DRUG$.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
OTHER studies performed in , sodium was used angiotensin- converting enzyme ( ACE inhibitors betablockers @DRUG$ @DRUG$ , drugs ( NSAIDs ) without evidence of significant adverse interactions	DDI-false
It therefore necessary to be well clinical and paraclinical pattern @DRUG$ deficiency due to an insufficient @DRUG$ oral physiological supplementation and to a of the control of requires regulation of dysregulation	DDI-false
The hypoglycemic effect of @DRUG$ has been reported to increase when @DRUG$ is given concurrently.	DDI-effect
Oral Contraceptives : of atorvastatin an oral AUC @DRUG$ @DRUG$ 30 % and 20 % .	DDI-false
@DRUG$ (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Other Agents : and enalapril IV have used @DRUG$ , @DRUG$ , digoxin without evidence clinically .	DDI-false
Cyclosporine: Administration of @DRUG$ concomitantly with @DRUG$ has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	DDI-mechanism
@DRUG$: Histamine H2-receptor antagonists appear to have no significant effect on the bioavailability of @DRUG$.	DDI-false
Amiodarone taken concomitantly with @DRUG$ increases @DRUG$ serum concentration by 33% after two days.	DDI-false
To the plus HAART on course HIV-related systemic lymphoma ( HIV-NHL authors compared group 24 with HIV-NHL cyclophosphamide doxorubicin , vincristine , and ) chemotherapy HAART of with chemotherapy CHOP-like i.e. @DRUG$ , , and @DRUG$ with bleomycin without receiving antiretroviral therapy	DDI-false
Interactions : interact drugs oxidase inhibitors ( @DRUG$ ): theoretically affect Arecoline - @DRUG$ depression - antidepressants : Flupenthixol increases effect of antidepressants	DDI-false
Broad-Spectrum Antibiotics-@DRUG$ may sterilize the bowel and decrease the @DRUG$ contribution to the body by the intestinal microflora.	DDI-false
effects of @DRUG$ on @DRUG$ ( InsP(3))-induced responses were studied in marrow with whole-cell recording technique in microfluorometry .	DDI-false
specific studies not been with drugs are mainly by CYP3A4 , blockers , quinine , amiodarone , @DRUG$ , , @DRUG$ , pimozide , , alfentanyl alprazolam , and elevated plasma when coadministered saquinavir ;	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with @DRUG$ increased the maximum plasma concentration of @DRUG$ by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
Antimycobacterial Agents: @DRUG$ CONTRAINDICATED since the coadministration of this product with @DRUG$ in an antiretroviral regimen reduces the plasma concentrations of saquinavir.	DDI-false
: interact like Monoamine oxidase inhibitors MAOI ): MAOI theoretically affect pharmacodynamics - - @DRUG$ @DRUG$ and CNS - Tricyclic antidepressants : the of Tricyclic antidepressants	DDI-false
These results suggest that both dexamethasone and @DRUG$, and possibly other glucocorticoids and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
No are available the garlic capsules	DDI-false
@DRUG$ may enhance the of alcohol , @DRUG$ , and CNS .	DDI-effect
@DRUG$ does not affect serum @DRUG$ levels.	DDI-false
Concurrent of quinolone , including with products magnesium or aluminum , , @DRUG$ tablets or pediatric powder or products containing @DRUG$ , or substantially of , resulting serum levels lower .	DDI-false
Coingestion of acetaminophen with @DRUG$, phenobarbital with @DRUG$, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
@DRUG$: The concomitant administration of @DRUG$ and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	DDI-false
@DRUG$ such @DRUG$ , diltiazem nifedipine , inhibit in decrease adhesion .	DDI-false
Other : , the safety treated @DRUG$ @DRUG$ and including benzodiazepines ) , or analgesics was to that placebo	DDI-false
@DRUG$ suppress certain @DRUG$ CYP2D6 CYP3A4 .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
In addition, @DRUG$ neither influenced the pharmacodynamics of warfarin, @DRUG$, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state.	DDI-false
@DRUG$ (@DRUG$): Cerivastatin plasma concentrations were not affected by co-administration of antacid.	DDI-false
@DRUG$: @DRUG$ have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.	DDI-false
- prior ingestion @DRUG$ decrease the @DRUG$ response to apomorphine the treatment poisoning .	DDI-false
@DRUG$: In healthy subjects receiving the CYP3A4 inducer, @DRUG$, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Since the concomitant administration of @DRUG$ with @DRUG$ increases the prothrombin time by 100% after 3 to 4 days, the dose of the anticoagulant should be reduced by one-third to one-half, and prothrombin times should be monitored closely.	DDI-false
Coingestion of @DRUG$ with theophylline , @DRUG$ acetaminophen acid at high to the of drug .	DDI-false
The possibility of hypotensive effects with @DRUG$ or enalaprilat can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.	DDI-effect
Potassium-sparing diuretics amiloride ) , @DRUG$ , or salt substitutes may lead significant in serum .	DDI-false
Theophylline: As with some other quinolones, concurrent administration of @DRUG$ with theophylline may lead to elevated serum concentrations of @DRUG$ and prolongation of its elimination half-life.	DDI-false
@DRUG$-Concomitant intake of and reduce the @DRUG$.	DDI-false
Multivalent Cation-Containing Products @DRUG$ including , with cation-containing such @DRUG$ , , VIDEX tablets or powder , calcium , or substantially decrease absorption , resulting urine considerably	DDI-mechanism
Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or @DRUG$ (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of @DRUG$.	DDI-effect
was significant 0.05 AUC + 8.52 vs. /- 9.93 ) , ( + /- 6.6 tmax ( 1.1 + /- 0.6 vs. 1.6 + /- 1.1 @DRUG$ versus @DRUG$/oxycodone .	DDI-false
@DRUG$ @DRUG$ chemotherapy plus active antiretroviral in with virus-related , lymphoma	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
CONCOMITANT : specific interaction studies were in studies cerivastatin sodium was used concomitantly @DRUG$ betablockers calcium-channel blockers diuretics and @DRUG$ ( NSAIDs ) without clinically adverse	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (@DRUG$), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
specific been performed , coadministration drugs are by eg calcium channel blockers disopyramide , , amiodarone , , @DRUG$ , , derivatives , @DRUG$ , , alfentanyl alprazolam and ) have plasma concentrations when coadministered	DDI-false
In vitro studies have shown that precipitation occurs when eye drops containing @DRUG$ are mixed with @DRUG$.	DDI-false
In clinical studies performed Fondaparinux the oral ( warfarin ) , platelet inhibitors @DRUG$ ) @DRUG$ piroxicam ) digoxin not the pharmacokinetics/pharmacodynamics sodium	DDI-false
@DRUG$: As with some other quinolones, concurrent administration of ciprofloxacin with @DRUG$ may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, dacarbazine, cis-platinum, tamoxifen and @DRUG$.	DDI-false
Like ibogaine ( 40 , 18-MC ( 40 ) the intravenous @DRUG$ and cocaine of ethanol and @DRUG$ rats	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or @DRUG$ to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
Drug Interactions with like Monoamine MAOI ): MAOI could - - @DRUG$ cause additive depression - Tricyclic antidepressants : of @DRUG$	DDI-false
performed Fondaparinux , concomitant oral anticoagulants @DRUG$ acid @DRUG$ ) and did not fondaparinux sodium	DDI-false
@DRUG$ may block the antihypertensive action of @DRUG$ and similarly acting compounds.	DDI-effect
, , phenobarbital/acetaminophen , phenobarbital/valproic ,	DDI-false
Since @DRUG$ is a substrate for CYP3A4 and CYP2C8, drugs/substances that inhibit these isoenzymes may decrease the metabolism and increase serum concentration of @DRUG$.	DDI-false
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and @DRUG$ (INN, @DRUG$) when coadministered in de novo kidney allograft recipients during the first year after transplantation.	DDI-false
Cephalosporins-Cephalosporins containing side N-methylthiotetrazole ( cefoperazone cefamandole @DRUG$ @DRUG$ cause K and hypoprothrombinemia .	DDI-false
Cation-Containing administration a including with cation-containing such as @DRUG$ , @DRUG$ VIDEX chewable/buffered tablets , containing or zinc the absorption of ciprofloxacin resulting in serum and levels than .	DDI-false
: other @DRUG$ , concurrent administration ciprofloxacin with may to of @DRUG$ its elimination half-life	DDI-false
these drugs activities , including anti-arrhythmic such as @DRUG$ and procainamide and	DDI-false
@DRUG$ decreased the hyperuricemic effect of @DRUG$.	DDI-effect
However, the absolute number of @DRUG$-related deaths is far greater than the number of deaths in amphetamine or @DRUG$ users.	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
@DRUG$: Potentiation of @DRUG$-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and @DRUG$ with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-effect
Other Drugs:Drugs such as @DRUG$, disopyramide, procainamide, @DRUG$, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
administration containing to patients receiving @DRUG$ @DRUG$ may produce severe , prolonged or hypertension .	DDI-false
Similarly dialyzed were @DRUG$, quinidine, and @DRUG$, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum.	DDI-false
Therefore, it would be expected that a dosing schedule of @DRUG$ given at bedtime and cholestyramine given before the evening meal would not result in a significant decrease in the clinical effect of @DRUG$.	DDI-false
Since amiodarone is substrate @DRUG$ , there is the of John s @DRUG$ could result in reduced .	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, calcium-channel blockers, diuretics, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
: be caution in patients receiving agents e.g. , propranolol a CYP3A4 inhibitor ) calcium channel verapamil a @DRUG$ substrate , diltiazem , a ) of of , arrest and ;	DDI-false
studies been coadministration are mainly by CYP3A4 channel , dapsone , quinine , , @DRUG$ , cyclosporine , pimozide , , alprazolam , and triazolam ) have elevated plasma coadministered with @DRUG$	DDI-mechanism
of this study between @DRUG$ and enkephalins or synthetic or @DRUG$ , the of peptides in mice	DDI-false
Cephalosporins-Cephalosporins side of N-methylthiotetrazole ( @DRUG$ , @DRUG$ , ) ) vitamin K deficiency and hypoprothrombinemia .	DDI-false
@DRUG$ may displace acidic drugs such as @DRUG$ or tolbutamide from their binding sites.	DDI-mechanism
LDL-C was @DRUG$ @DRUG$ were than when drug was .	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drug Flupenthixol interact some , Monoamine oxidase inhibitors ): MAOI flupenthixol - Arecoline - : Flupenthixol @DRUG$ cause depression @DRUG$ effect	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
No significant interactions were found between @DRUG$ and @DRUG$ or digoxin.	DDI-false
@DRUG$ had a effect in presence of	DDI-false
Hypotension: Patients on Diuretic Therapy: Patients on @DRUG$ and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or @DRUG$.	DDI-effect
The effect of @DRUG$ on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ and extended a similar length of time after rifampin withdrawal.	DDI-false
addition to this interaction , report novel chemical between @DRUG$ ) and @DRUG$ found vivo resulting in a 3-ethoxylated product .	DDI-false
Both efavirenz and @DRUG$ have been compared to triple therapy with the PI @DRUG$ over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
from in @DRUG$ a drug interaction with alprazolam following sertraline and @DRUG$.	DDI-false
@DRUG$ 150 mg twice daily did not interact significantly with @DRUG$ (AUC was decreased by 15-20 %).	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, secobarbital, glutethimide, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, @DRUG$, and pargyline HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.	DDI-false
doxorubicin , @DRUG$ , and prednisone plus @DRUG$ patients human immunodeficiency virus-related lymphoma .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
The administration of @DRUG$ @DRUG$ to oxidase inhibitors tricyclic or phenothiazines may produce severe , hypotension or hypertension .	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, @DRUG$, tricyclic antidepressants or some antihistamines.	DDI-effect
@DRUG$/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and @DRUG$.	DDI-effect
@DRUG$: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of @DRUG$.	DDI-false
Potassium-sparing diuretics (e.g., @DRUG$, triamterene, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Antihypertensives : Amiodarone should be used caution ( propranolol , CYP3A4 ) calcium antagonists a CYP3A4 , @DRUG$ a ) because of the potentiation arrest , block	DDI-false
Although specific studies have not performed coadministration with metabolized by CYP3A4 , , , , , warfarin , cyclosporine , derivatives , @DRUG$ fentanyl alfentanyl @DRUG$ ) have concentrations when	DDI-false
@DRUG$/@DRUG$: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
Erythromycin: In healthy individuals, plasma concentrations of @DRUG$ increased approximately 40% with coadministration of atorvastatin and @DRUG$, a known inhibitor of cytochrome P450 3A4.	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of @DRUG$, acetylsalicylic acid, piroxicam, and @DRUG$, nor the pharmacokinetics of digoxin at steady state.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with @DRUG$.	DDI-effect
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, @DRUG$, @DRUG$, and phenytoin, have been used concurrently with amiodarone.	DDI-false
@DRUG$ should be with caution to patients Antabuse @DRUG$ , .	DDI-advise
In in vitro in liver inhibition of CYP2A6 @DRUG$ by @DRUG$ 200 m m M , 350 mg/L ) .	DDI-mechanism
interactions occur following administration psychotropic drugs ( narcotics , @DRUG$ antiemetics , , @DRUG$	DDI-false
Cation-Containing : administration @DRUG$ including ciprofloxacin products such as or aluminum , @DRUG$ chewable/buffered or or products calcium , may substantially the of ciprofloxacin and urine considerably than	DDI-mechanism
Coingestion of @DRUG$ with theophylline, @DRUG$ with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Co-medications induce CYP3A4 ( e.g. , , @DRUG$ , @DRUG$ or St.	DDI-false
@DRUG$ @DRUG$ flecainide CONTRAINDICATED due to potential reactions	DDI-false
Multivalent : Concurrent of a , including @DRUG$ such as , VIDEX tablets products @DRUG$ , , or zinc substantially decrease the ciprofloxacin resulting in serum and urine considerably desired .	DDI-mechanism
In @DRUG$ or @DRUG$ AUC of is 6- to Css is about to greater than .	DDI-false
@DRUG$ including tranylcypromine sulfate, phenelzine sulfate, and @DRUG$ HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
In a pharmacology , @DRUG$ or to patients @DRUG$.	DDI-false
of chemotherapy HAART on the clinical patients with HIV-related , , non-Hodgkin ( , authors retrospectively a group 24 patients with with the cyclophosphamide , , vincristine and prednisone CHOP chemotherapy regimen plus HAART with group patients who were treated CHOP chemotherapy regimen i.e. @DRUG$ , doxorubicin , and prednisone vincristine plus ) receiving @DRUG$ .	DDI-false
Other @DRUG$ , , procainamide disopyramide , and @DRUG$ , been with amiodarone .	DDI-false
Tolbutamide : In receiving diflunisal @DRUG$ , were seen @DRUG$ levels fasting .	DDI-false
administration of oral @DRUG$ @DRUG$ be reviewed and reduced by 50 % discontinued .	DDI-advise
is distinct from the other currently available @DRUG$ ( @DRUG$ and ) leading properties relative the other this .	DDI-false
Both @DRUG$ and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with @DRUG$.	DDI-false
apomorphine - prior ingestion of diphenidol may decrease the @DRUG$ response to @DRUG$ in the treatment of poisoning.	DDI-false
Other @DRUG$ and enalapril IV used concomitantly beta , methyldopa @DRUG$ , , prazosin evidence of significant interactions	DDI-false
@DRUG$: Because atorvastatin does not affect the pharmacokinetics of @DRUG$, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.	DDI-false
Tolbutamide: In diabetic patients receiving @DRUG$ and @DRUG$, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.	DDI-false
Glyburide The concomitant administration @DRUG$ with the @DRUG$ glyburide on rare resulted severe .	DDI-effect
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, @DRUG$, piroxicam, and digoxin, nor the pharmacokinetics of @DRUG$ at steady state.	DDI-false
is assumed that increased interaction between @DRUG$ affinity binding for apomorphine dopamine2- serotonin2-receptors the action @DRUG$ after prolonged	DDI-false
@DRUG$ lidocaine , quinidine theophylline , @DRUG$ were added to therapeutic	DDI-false
of @DRUG$ and @DRUG$ (PCP)-induced and .	DDI-false
@DRUG$ (NNRTI)-based for antiretroviral @DRUG$ metabolic led to in treatment practices HIV infection	DDI-false
@DRUG$: Because atorvastatin does not affect the pharmacokinetics of antipyrine, interactions with other @DRUG$ metabolized via the same cytochrome isozymes are not expected.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
Aspirin: In normal volunteers, a small decrease in @DRUG$ levels was observed when multiple doses of diflunisal and @DRUG$ were administered concomitantly.	DDI-false
The pharmacokinetics of @DRUG$ and its major metabolite 6-beta-naltrexol were unaffected following co-administration with @DRUG$.	DDI-false
@DRUG$-@DRUG$ containing side chains N-methylthiotetrazole ( cefmenoxime , latamoxef ) or ( cefazolin can cause deficiency hypoprothrombinemia .	DDI-false
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ , Methylxanthines with @DRUG$ , , diuretics potentiate a	DDI-false
Other Cardiovascular : and enalapril have been agents methyldopa , @DRUG$ , , @DRUG$ , significant	DDI-false
clinical studies with Fondaparinux concomitant @DRUG$ , inhibitors acetylsalicylic piroxicam and @DRUG$ did not significantly pharmacokinetics/pharmacodynamics of .	DDI-false
, lidocaine/quinidine phenobarbital/valproic , theophylline/@DRUG$ , and .	DDI-false
The availability of potent @DRUG$ (NNRTI)-based regimens for @DRUG$ therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
Tolbutamide: In diabetic patients receiving @DRUG$ and tolbutamide, no significant effects were seen on @DRUG$ plasma levels or fasting blood glucose.	DDI-false
in @DRUG$ dosing and at levels @DRUG$ in the context .	DDI-false
@DRUG$ : @DRUG$ be with   -receptor blocking ( e.g. , propranolol , a inhibitor or channel , CYP3A4 substrate , and diltiazem , CYP3A4 inhibitor ) because of possible potentiation of bradycardia and block	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
Acute symptoms should be treated with a short-acting, inhaled  @DRUG$ such as @DRUG$ (the physician should provide the patient with such medication and instruct the patient in how it should be used).	DDI-false
Derivatives @DRUG$ , @DRUG$ , methylergonovine CONTRAINDICATED to for and reactions as toxicity characterized by and ischemia the extremities and other tissues	DDI-false
@DRUG$ may suppress certain CYP450 enzymes, including CYP1A2, @DRUG$, CYP2D6, and CYP3A4.	DDI-false
administration three patients a range of 0.025 2.2 mg to a inhibition @DRUG$ effect of @DRUG$ on drug metabolism in patients is .	DDI-false
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of @DRUG$ and cyclosporine (INN, @DRUG$) when coadministered in de novo kidney allograft recipients during the first year after transplantation.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
have performed that are by eg calcium blockers , dapsone disopyramide , quinine , @DRUG$ , tacrolimus cyclosporine ergot derivatives , , @DRUG$ triazolam may plasma concentrations when coadministered with saquinavir ;	DDI-false
Hypersensitivity been containing sequential dose @DRUG$ antineoplastic , , dacarbazine @DRUG$ and	DDI-effect
lidocaine/quinidine phenobarbital/acetaminophen @DRUG$/lidocaine theophylline/acetaminophen , and acid/phenobarbital .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
: Drugs as @DRUG$ , @DRUG$ procainamide , phenothiazines , antihistamines , tricyclic may with QT-interval increased of ventricular arrhythmia .	DDI-false
Both the toxicity of filipin and the therapeutic value of @DRUG$ can be rationalized at the cellular and molecular level by the following observations: (i) these @DRUG$ showed differential effects on cells;	DDI-false
acetaminophen/theophylline phenobarbital/acetaminophen phenobarbital/@DRUG$ quinidine/lidocaine theophylline/@DRUG$ , and	DDI-false
It is assumed that increased interaction between @DRUG$ and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of @DRUG$ after their prolonged administration.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
nephrotoxic ( e.g. , , indomethacin ) e.g. @DRUG$ ) ( , or ( e.g. , @DRUG$ PROLEUKIN may organ systems	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and @DRUG$.	DDI-effect
Other concomitant therapies : In safety subjects Acamprosate concomitantly with , @DRUG$ including @DRUG$ , to that of taking these .	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, @DRUG$, and @DRUG$, nor the pharmacokinetics of digoxin at steady state.	DDI-false
@DRUG$ : and @DRUG$ at were affected mg cerivastatin sodium .	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, @DRUG$, tamoxifen and @DRUG$.	DDI-false
@DRUG$ , such as verapamil diltiazem and @DRUG$ activation in vitro , and decrease platelet .	DDI-false
@DRUG$ diminished binding of @DRUG$ by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L.	DDI-mechanism
WARFARIN: Co- administration of @DRUG$ and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of @DRUG$ and placebo.	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of @DRUG$, acetylsalicylic acid, @DRUG$, and digoxin, nor the pharmacokinetics of digoxin at steady state.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
However, in the second study, administration of 12 g @DRUG$ 1 hour before the evening meal and 0.3 mg @DRUG$ approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.	DDI-mechanism
Moreover, additional interaction studies with @DRUG$ and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
groups ( ) were submitted daily with hydroalcoholic @DRUG$ and @DRUG$ the proportions as found common distilled and fermented alcoholic beverages ;	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Corticosteroids , @DRUG$ Concomitant with derivatives or diuretics a hypokalemic effect of @DRUG$	DDI-false
specific have performed coadministration drugs are mainly metabolized CYP3A4 ( calcium channel blockers , dapsone , , quinine , @DRUG$ @DRUG$ , derivatives , fentanyl alprazolam , and triazolam ) concentrations	DDI-false
Other concomitant therapies clinical the in with Acamprosate @DRUG$ and sedatives ( @DRUG$ non-opioid analgesics to of placebo with medications	DDI-false
@DRUG$ to increase @DRUG$ in these agents .	DDI-mechanism
injection of @DRUG$ (@DRUG$) were observed by measuring locomotor activity and stereotyped behavior.	DDI-false
specific have not drugs are mainly channel blockers dapsone , disopyramide , , , warfarin , @DRUG$ , cyclosporine ergot , @DRUG$ carbamazepine fentanyl , alfentanyl , triazolam ) elevated plasma concentrations coadministered with saquinavir ;	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, @DRUG$, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
The steady state plasma concentrations of @DRUG$ and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of @DRUG$ tablets in doses up to 4 mg/day.	DDI-mechanism
@DRUG$ subjects receiving ketoconazole inhibitor 200 twice days , exposure AUC ) @DRUG$ increased 3.6-fold of half-life 1.7-fold control .	DDI-false
@DRUG$ and stimulate @DRUG$- or insulin-induced of epithelium	DDI-effect
Renin Release effect @DRUG$ enalapril is antihypertensive agents that cause renin release ( e.g. , @DRUG$ ) .	DDI-effect
Drugs Inhibit or P450 Enzymes @DRUG$ extensive CYP3A4 concomitant strong inhibitors inducers of alter @DRUG$ concentrations significantly .	DDI-false
epithelium a defined of basal RPMI1640 containing @DRUG$ ( ) , EGF @DRUG$ ( 3.7 0.1 IU/ml )	DDI-false
Chloramphenicol has been shown to be antagonistic to @DRUG$, including @DRUG$, based on in vitro studies and time kill curves with enteric gram-negative bacilli.	DDI-false
individuals with @DRUG$ or fluoxetine , the AUC of @DRUG$ is 6- and , max 3- 4-fold	DDI-mechanism
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (@DRUG$), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (@DRUG$) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
treatment with inhibitors of CYP3A4 such as ketoconazole @DRUG$ ritonavir , @DRUG$ erythromycin , etc indicated dose should be .	DDI-false
inhibition was during the of , @DRUG$ and @DRUG$ ;	DDI-false
Acetaminophen, lidocaine, @DRUG$, quinidine, theophylline, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
Anticoagulants including derivatives , , @DRUG$ as anti-inflammatory drugs and @DRUG$ increase the administered ardeparin	DDI-false
Other reported interactions with amiodarone: Fentanyl (@DRUG$ substrate) in combination with @DRUG$ may cause hypotension, bradycardia, and decreased cardiac output.	DDI-false
@DRUG$: Plasma concentrations of atorvastatin decreased approximately 25% when colestipol and @DRUG$ were coadministered.	DDI-false
The aim of this paper was to study the interaction between neurotensin and both @DRUG$ or its synthetic analogue D-Ala2-metenkephalinamide, or @DRUG$, on the antinonciceptive effect of these peptides in mice after intracisternal injection.	DDI-false
Clinical of @DRUG$ interactions @DRUG$.	DDI-int
phenobarbital/acetaminophen , quinidine/lidocaine theophylline/acetaminophen , and valproic acid/@DRUG$.	DDI-false
Both ibogaine and @DRUG$ block @DRUG$-induced and nicotine-induced dopamine release in the nucleus accumbens;	DDI-effect
The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving @DRUG$, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
Caution should if HMG-CoA reductase is administered concomitantly may decrease the levels or of steroid , such as @DRUG$ , @DRUG$	DDI-false
To evaluate the impact of plus HAART clinical of patients HIV-related , systemic , ( ) compared group of 24 patients HIV-NHL treated cyclophosphamide doxorubicin , @DRUG$ prednisone ( CHOP plus HAART of who treated with CHOP or a regimen i.e. cyclophosphamide , doxorubicin , , prednisone plus @DRUG$ receiving therapy	DDI-false
Data from in vitro studies of @DRUG$ suggest a possible drug interaction with @DRUG$ for the following: sertraline and paroxetine.	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
It is concluded that @DRUG$ and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral @DRUG$ therapy.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Since a substrate @DRUG$ , there the that use St. John s patients amiodarone result in reduced @DRUG$	DDI-false
In this report novel chemical between @DRUG$ a @DRUG$ and under acidic conditions to found in vivo , resulting in a .	DDI-false
Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes @DRUG$ undergoes extensive metabolism by CYP3A4, and concomitant administration of strong inhibitors or inducers of CYP3A4 alter @DRUG$ concentrations significantly.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
In clinical studies Fondaparinux , the of oral @DRUG$ ( warfarin ) acid ) , @DRUG$ ) , did significantly the fondaparinux sodium .	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Interactions : Flupenthixol may interact some drugs , like oxidase inhibitors ( ): @DRUG$ could pharmacodynamics @DRUG$ - Eproxindine Ethanol : Ethanol cause additive depression - Tricyclic the effect of	DDI-false
of hypotensive effects with or @DRUG$ either discontinuing diuretic or increasing the salt initiation with @DRUG$ or enalaprilat	DDI-false
treatment with ( such as ketoconazole , intraconazole , ritonavir , @DRUG$ , saquinavir , etc indicated , of @DRUG$ should be considered	DDI-advise
Co-administration: Concomitant use of Argatroban with @DRUG$, thrombolytics, and other @DRUG$ may increase the risk of bleeding.	DDI-false
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ alone, they modify the mitogenic effect of EGF and @DRUG$.	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic @DRUG$.It is not known whether the concurrent use of these agents with @DRUG$ in humans can lead to resulting interference with the IOP lowering effect.	DDI-false
To evaluate the of course patients , lymphoma ( ) , the authors compared retrospectively treated the , doxorubicin , vincristine , ( CHOP regimen plus HAART of who treated CHOP or CHOP-like i.e. , cyclophosphamide , @DRUG$ , plus @DRUG$ therapy .	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-int
@DRUG$ affected the proliferation prostatic epithelium in RPMI1640 transferrin , they the of @DRUG$ and insulin .	DDI-effect
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Cardiovascular Agents : and IV concomitantly with , @DRUG$ , @DRUG$ calcium-blocking and digoxin evidence of clinically significant adverse .	DDI-false
The availability transcriptase therapy and @DRUG$ (PI)-related metabolic have led to in treatment in HIV .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Like @DRUG$ ( intravenous self-administration morphine cocaine the self-administration ethanol @DRUG$ in ;	DDI-false
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
THERAPY specific studies were not performed , @DRUG$ was used with inhibitors , calcium-channel , @DRUG$ and drugs NSAIDs evidence of clinically significant	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, erythromycin, clarithromycin).	DDI-advise
Hypersensitivity have been combination regimens containing high dose @DRUG$ and @DRUG$ , specifically dacarbazine , tamoxifen	DDI-effect
The bioavailability of the capsule formulation of @DRUG$ was not affected when administered 5 minutes following an @DRUG$.	DDI-false
BACKGROUND : combined administration of @DRUG$ and ( @DRUG$ a channel blocker on incidence of peritoneal of intestinal adenocarcinomas by azoxymethane ( AOM ) investigated Wistar rats .	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and @DRUG$ when administered concomitantly with an intravenous @DRUG$ such as morphine.	DDI-mechanism
Drug may interact with , oxidase MAOI theoretically affect @DRUG$ pharmacodynamics - Eproxindine - Ethanol : Flupenthixol Ethanol additive CNS depression - @DRUG$ : the	DDI-false
concomitant of @DRUG$ increased levels of @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
when meclofenamate to @DRUG$ dosage of @DRUG$ should be time	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and @DRUG$, cardiac glycosides and @DRUG$.	DDI-false
Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when @DRUG$ was given alone or when @DRUG$ was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	DDI-false
use with @DRUG$s result in reduced @DRUG$.	DDI-false
Nephrotoxicity has been reported following concomitant administration of cephalosporins with @DRUG$ or potent @DRUG$ such as furosemide.	DDI-false
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a @DRUG$, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (@DRUG$) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Concomitant @DRUG$, doxorubicin, @DRUG$, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
@DRUG$ taken concomitantly with quinidine increases @DRUG$ serum concentration by 33% after two days.	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-effect
Cation-Containing : of quinolone , , with such as magnesium or , , VIDEX powder or , @DRUG$ may substantially decrease absorption @DRUG$ and urine levels considerably than .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
@DRUG$ should be administered with caution to patients receiving @DRUG$ (disulfiram, Wyeth-Ayerst Laboratories).	DDI-advise
cefmenoxime , @DRUG$ , cefamandole latamoxef or vitamin K deficiency hypoprothrombinemia	DDI-false
Based on the results of these studies, it is concluded that @DRUG$ may be safely coadministered with both @DRUG$ and dideoxyinosine.	DDI-false
aim was to study the between @DRUG$ and @DRUG$ or its D-Ala2-metenkephalinamide the effect of these in injection	DDI-false
There have been case reports of increased steady-state levels of quinidine, @DRUG$, and @DRUG$ during concomitant therapy with amiodarone.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Although have performed coadministration drugs that are CYP3A4 , , , @DRUG$ tacrolimus , @DRUG$ , , , , alfentanyl , alprazolam and triazolam ) elevated plasma when coadministered with	DDI-false
Although neither dexamethasone nor @DRUG$ affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ alone, they modify the mitogenic effect of EGF and insulin.	DDI-false
Administration of rifampin concomitantly with oral @DRUG$ has been shown to result in decreases in serum concentrations of @DRUG$ and desethylamiodarone.	DDI-false
To impact of course HIV-related lymphoma HIV-NHL ) , authors compared of were @DRUG$ , and prednisone ( CHOP ) regimen 80 treated with CHOP-like ( , , teniposide , and @DRUG$ with vincristine therapy .	DDI-false
@DRUG$ may slightly effect of e.g. , @DRUG$ , methyldopa .	DDI-effect
@DRUG$ : Amiodarone should used with in receiving   -receptor blocking e.g. propranolol a @DRUG$ ) or channel antagonists ( e.g. , verapamil , a CYP3A4 , inhibitor of the bradycardia , sinus arrest and	DDI-false
@DRUG$ concomitantly @DRUG$ for than of and 55 % 33 % , respectively .	DDI-false
glucocorticoids have been shown to reduce PROLEUKIN-induced side including insufficiency , , concomitant administration agents @DRUG$ may reduce the antitumor effectiveness thus should avoided . 12 @DRUG$ and other antihypertensives hypotension with	DDI-false
acetaminophen/theophylline @DRUG$/quinidine phenobarbital/acetaminophen , acid quinidine/lidocaine , , and acid/phenobarbital .	DDI-false
Drug Interactions Flupenthixol with drugs like oxidase ( MAOI theoretically affect - Eproxindine Ethanol and @DRUG$ additive - the effect of @DRUG$	DDI-false
Oxidase and Tricyclic Antidepressants be administered with extreme caution patients with inhibitors or @DRUG$ because @DRUG$ on these	DDI-false
Ergot : , @DRUG$ , , @DRUG$ due to for serious and life-threatening acute characterized vasospasm and other .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
side chains of N-methylthiotetrazole cefmenoxime cefoperazone cefamandole , or @DRUG$ ) can cause K and hypoprothrombinemia .	DDI-false
FLEXERIL may the effects of @DRUG$ , @DRUG$.	DDI-false
Since amiodarone is a substrate for @DRUG$, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced @DRUG$ levels.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Both @DRUG$ and @DRUG$ decrease extracellular levels the accumbens , only increases in nucleus .	DDI-false
Nephrotoxicity has concomitant administration with antibiotics @DRUG$	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, @DRUG$, and @DRUG$.	DDI-false
@DRUG$ decrease diflunisal was when of diflunisal and @DRUG$ were administered .	DDI-false
Moreover, additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data.	DDI-false
of epinephrine or to @DRUG$ , tricyclic @DRUG$ produce severe , or	DDI-false
To evaluate the of chemotherapy plus HAART course , non-Hodgkin HIV-NHL ) , authors compared retrospectively a group of were with cyclophosphamide doxorubicin vincristine CHOP ) chemotherapy HAART group patients were treated with CHOP or CHOP-like regimen ( i.e. doxorubicin , , @DRUG$ bleomycin without @DRUG$ therapy	DDI-false
@DRUG$ bepridil , @DRUG$ serious and/or .	DDI-false
Data from in vitro studies benzodiazepines other than @DRUG$ suggest possible following @DRUG$ amiodarone and .	DDI-int
Drug Interactions @DRUG$ may interact with some like Monoamine oxidase inhibitors ( MAOI affect flupenthixol pharmacodynamics - Ethanol @DRUG$ and Ethanol cause additive - Tricyclic antidepressants : Flupenthixol of Tricyclic antidepressants	DDI-false
Similarly dialyzed were phenobarbital, @DRUG$, and @DRUG$, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum.	DDI-false
To determine whether injection of thiosulfate would permit larger doses of @DRUG$ to be administered, a fixed 9.9-g/m2 dose of @DRUG$ was given intravenously over three hours concurrently with escalating doses of cisplatin.	DDI-false
lidocaine/quinidine phenobarbital/acetaminophen , , , @DRUG$/acetaminophen and valproic acid/@DRUG$.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, @DRUG$, tricyclic antidepressants or some @DRUG$.	DDI-false
@DRUG$ had a similar effect in the presence of @DRUG$.	DDI-false
Naproxen: The concomitant administration of diflunisal and @DRUG$ in normal volunteers had no effect on the plasma levels of @DRUG$, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	DDI-false
@DRUG$ : receiving -receptor agents e.g. CYP3A4 ( , a @DRUG$ , and diltiazem a CYP3A4 of the possible of sinus arrest block ;	DDI-false
should be consideration patients taking @DRUG$ concomitantly	DDI-advise
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Garlic Capsules Garlic capsules should not be used while taking @DRUG$ (FORTOVASE) as the sole @DRUG$ due to the risk of decreased saquinavir plasma concentrations.	DDI-false
@DRUG$ : Potentiation ( @DRUG$ anticoagulant response is almost seen in patients amiodarone result serious fatal .	DDI-false
OTHER CONCOMITANT THERAPY : Although specific interaction studies were not , , sodium used concomitantly with enzyme ACE ) betablockers blockers , @DRUG$ and @DRUG$ ) without of clinically significant	DDI-false
@DRUG$ is substrate for @DRUG$ , the potential the Wort in patients in amiodarone levels	DDI-false
concomitant administration with the @DRUG$ @DRUG$ on rare occasions resulted in .	DDI-false
Like @DRUG$ (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;	DDI-false
@DRUG$ : volunteers , bepridil hydrochloride either had effect ( one or increases about 30 % ( in steady-state @DRUG$ concentrations .	DDI-false
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue @DRUG$, or @DRUG$, on the antinonciceptive effect of these peptides in mice after intracisternal injection.	DDI-false
@DRUG$ or medications - anticholinergic effects may be potentiated when these are used with @DRUG$	DDI-false
@DRUG$: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in @DRUG$-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	DDI-false
@DRUG$ As other @DRUG$ , administration of with theophylline elevated serum concentrations of theophylline and of its half-life .	DDI-false
administration drugs ( , @DRUG$ ) , myelotoxic ( e.g. @DRUG$ chemotherapy , cardiotoxic ( , ) or hepatotoxic ( , methotrexate , effects increase in organ .	DDI-false
Additive effects cholinergic blockade LEVSIN is administered with @DRUG$ amantadine @DRUG$ oxidase ( ) tricyclic or	DDI-false
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (@DRUG$, simvastatin, and @DRUG$), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
rhabdomyolysis has seen weeks after therapy with another @DRUG$ and @DRUG$ but be seen after .	DDI-effect
Hemodynamic electrophysiologic been after concomitant with , @DRUG$ and @DRUG$.	DDI-false
Coingestion of acetaminophen with @DRUG$, phenobarbital with acetaminophen, and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
effects DCG-IV @DRUG$ locomotion and in	DDI-false
@DRUG$ @DRUG$ , ergonovine , ergotamine , CONTRAINDICATED to and life-threatening such toxicity peripheral vasospasm and and other .	DDI-false
chronic is required for therapeutic of @DRUG$ , future studies should focus investigation effects of drugs in with	DDI-false
drugs possessing ( , @DRUG$ indomethacin myelotoxic ( e.g. cytotoxic ) , ( e.g. , ) or ( e.g. methotrexate @DRUG$ effects may toxicity in these organ	DDI-false
@DRUG$ is metabolized to @DRUG$ enzyme group specifically cytochromes P450 ( CYP3A4 ) CYP2C8 .	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
time phenobarbital , , glutethimide , hydrate and @DRUG$ were in patients receiving @DRUG$ .	DDI-false
THERAPY Although specific interaction were performed , clinical studies , cerivastatin was used concomitantly with @DRUG$ , betablockers , calcium-channel blockers , @DRUG$ and anti-inflammatory ( ) without evidence significant interactions .	DDI-false
Methotrexate Renal tubular transport of @DRUG$ may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of @DRUG$.	DDI-false
Effects of @DRUG$ Enzymes and Transport @DRUG$ CYP3A4 CYP2C8 in vitro clinically relevant .	DDI-false
interactions have not between Argatroban @DRUG$ @DRUG$.	DDI-false
Other reported interactions with amiodarone: @DRUG$ (CYP3A4 substrate) in combination with @DRUG$ may cause hypotension, bradycardia, and decreased cardiac output.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-effect
Nonsteroidal Drugs The @DRUG$ to normal decreased the renal clearance and significantly increased plasma levels @DRUG$.	DDI-false
The of effects with or can be by discontinuing the @DRUG$ intake to enalapril	DDI-false
Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, @DRUG$, @DRUG$.	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitor (@DRUG$)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (@DRUG$)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
@DRUG$ CYP2C9 CYP3A4 is patients receiving @DRUG$ can or	DDI-false
Withdrawal of @DRUG$ decreased the @DRUG$ requirement by 50%.	DDI-mechanism
Data from in vitro studies of alprazolam suggest a possible drug interaction with @DRUG$ for the following: sertraline and @DRUG$.	DDI-int
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing @DRUG$ (1 microgram/ml), @DRUG$ (10 ng/ml), and insulin (3.7 micrograms/ml or 0.1 IU/ml).	DDI-false
Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as @DRUG$, @DRUG$, and cimetidine.	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, @DRUG$, @DRUG$) may result in decreased plasma levels of saquinavir.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
been case reports of steady-state levels of quinidine procainamide , and @DRUG$ during	DDI-false
Data from in vitro studies of @DRUG$ suggest a possible drug interaction with alprazolam for the following: @DRUG$ and paroxetine.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
of @DRUG$ for antiretroviral therapy and concerns have to significant in treatment practices HIV	DDI-false
Potassium-sparing diuretics (e.g., @DRUG$, triamterene, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Erythromycin : individuals , concentrations of atorvastatin increased approximately @DRUG$ @DRUG$ a known inhibitor of cytochrome P450 3A4	DDI-mechanism
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, @DRUG$, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	DDI-advise
@DRUG$: @DRUG$ had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.	DDI-false
Interactions may drugs , Monoamine could flupenthixol pharmacodynamics - Eproxindine : depression - @DRUG$ : Flupenthixol the @DRUG$	DDI-false
@DRUG$ diflunisal @DRUG$ normal volunteers resulted lowering the plasma metabolite by approximately one-third	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, procainamide, phenothiazines, @DRUG$, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, @DRUG$, and @DRUG$ HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
Corticosteroids, Methylxanthines and @DRUG$: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
performed coadministration with mainly ( eg , calcium channel blockers , dapsone , disopyramide , , amiodarone , warfarin , , derivatives , @DRUG$ , fentanyl alfentanyl , @DRUG$ ) have plasma coadministered saquinavir ;	DDI-false
Both efavirenz and nevirapine have been compared to triple therapy with the @DRUG$ @DRUG$ over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ ( ' Seroquel is a introduced @DRUG$ with efficacy positive and negative of .	DDI-false
There have been reports of QTc prolongation without , @DRUG$ fluoroquinolones , @DRUG$ were administered .	DDI-false
@DRUG$: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of @DRUG$, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	DDI-false
@DRUG$ some compromised function treated with @DRUG$ , the co-administration may further	DDI-false
Anticoagulants coumarin derivatives indandione derivatives and platelet inhibitors such @DRUG$ ( , aspirin increase bleeding concomitantly with @DRUG$.	DDI-effect
@DRUG$ @DRUG$ been compared with over 48 as therapy , responses observed with nevirapine superiority	DDI-false
Products : of quinolone with multivalent cation-containing such magnesium or @DRUG$ , , VIDEX tablets or @DRUG$ , may substantially decrease the absorption ciprofloxacin resulting in serum and considerably than desired .	DDI-false
@DRUG$ : have been reported to enhance the @DRUG$ warfarin or	DDI-false
@DRUG$-Concomitant intake of cholestyramine and @DRUG$ may reduce the absorption of vitamin K.	DDI-false
For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with @DRUG$ and a @DRUG$ do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure.	DDI-effect
and @DRUG$ K.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ increase slightly effect @DRUG$ , guanethidine methyldopa , reserpine	DDI-effect
In addition, @DRUG$ neither influenced the pharmacodynamics of @DRUG$, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
and Cmax both the ( R ) ( S of @DRUG$ by concurrent dosing of	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Since @DRUG$ is there is the that the use St. John s @DRUG$ could	DDI-false
Acetaminophen: In normal volunteers, concomitant administration of @DRUG$ and @DRUG$ resulted in an approximate 50% increase in plasma levels of acetaminophen.	DDI-mechanism
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, @DRUG$, higher @DRUG$ and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
@DRUG$ may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, @DRUG$, reserpine.	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including @DRUG$ such as quinidine and procainamide, cardiac glycosides and @DRUG$.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, ritonavir, @DRUG$, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
@DRUG$ may enhance the effects of alcohol, @DRUG$, and other CNS depressants.	DDI-effect
Cardiovascular Agents Enalapril enalapril IV have been used concomitantly adrenergic-blocking , , @DRUG$ @DRUG$ hydralazine and digoxin evidence of clinically adverse .	DDI-false
The of transcriptase regimens antiretroviral and concerns @DRUG$ metabolic shifts in infection .	DDI-false
@DRUG$ ( plasma concentrations were not affected	DDI-false
Anticoagulants: Potentiation of @DRUG$-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	DDI-false
Both ibogaine and @DRUG$ block @DRUG$-induced dopamine in nucleus accumbens	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
general , these are hydrochloride , including @DRUG$ as @DRUG$ and and .	DDI-false
to @DRUG$ may enhanced by @DRUG$.	DDI-effect
@DRUG$ : When @DRUG$ were coadministered , plasma increased approximately %	DDI-false
@DRUG$ does not affect pharmacokinetics of interactions @DRUG$ metabolized isozymes	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-effect
Non-selective MAO inhibitors including @DRUG$, phenelzine sulfate, and @DRUG$ HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
Concomitant @DRUG$, @DRUG$, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
Coadministration of phenytoin with 40 mg @DRUG$ tablets in epileptic patients lowered the @DRUG$ plasma concentrations to undetectable levels.	DDI-false
@DRUG$ may sensitivity to the	DDI-effect
acetaminophen/@DRUG$, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Concomitant cyclophosphamide, doxorubicin, @DRUG$, and @DRUG$ chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
interaction studies were , in studies , was used with @DRUG$ , betablockers @DRUG$ nonsteroidal drugs of significant adverse interactions .	DDI-false
: The concomitant and @DRUG$ volunteers no the plasma levels of , significantly decreased the excretion @DRUG$ metabolite	DDI-false
the present study , @DRUG$ clozapine was in combination with active of @DRUG$ and signalled-unsignalled DRL ) procedures .	DDI-false
@DRUG$, lidocaine, @DRUG$, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
clinical performed with , the warfarin ) , inhibitors ( acid @DRUG$ @DRUG$ ) digoxin affect pharmacokinetics/pharmacodynamics fondaparinux .	DDI-false
Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with @DRUG$, @DRUG$, and verapamil.	DDI-false
cholestyramine @DRUG$ may the absorption vitamin	DDI-false
@DRUG$ have been reported to blunt the hypotensive effect of systemic @DRUG$.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.	DDI-effect
The possibility of hypotensive effects enalapril @DRUG$ can be by either discontinuing the diuretic increasing the intake prior to of treatment @DRUG$.	DDI-false
Concurrent administration of drugs nephrotoxic e.g. @DRUG$ , myelotoxic e.g. , , cardiotoxic ( e.g. , doxorubicin hepatotoxic ( e.g. @DRUG$ increase toxicity in these	DDI-effect
Co-administration of BOTOX and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the @DRUG$ may be potentiated.	DDI-false
specific studies have been performed , coadministration with are mainly metabolized CYP3A4 ( , calcium channel blockers , dapsone , @DRUG$ , warfarin , tacrolimus , cyclosporine , ergot derivatives pimozide , @DRUG$ , alfentanyl , alprazolam , have elevated concentrations when with	DDI-false
Administration of @DRUG$ concomitantly with oral @DRUG$ has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
@DRUG$ as , @DRUG$ nifedipine decrease adhesion .	DDI-false
@DRUG$ : , steady-state cerivastatin AUC and 50 and 24 % of @DRUG$ , known of cytochrome P450 .	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, @DRUG$, erythromycin, clarithromycin).	DDI-false
Although specific studies not coadministration drugs are mainly CYP3A4 ( eg , calcium blockers , , disopyramide @DRUG$ amiodarone , tacrolimus @DRUG$ ergot , carbamazepine , , have elevated coadministered with ;	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
results suggest that both @DRUG$ and possibly other @DRUG$ retinoids the of prostate epithelium by dose-dependent modification of the activity insulin and EGF .	DDI-false
Hydrochlorothiazide: In normal volunteers, concomitant administration of @DRUG$ and @DRUG$ resulted in significantly increased plasma levels of hydrochlorothiazide.	DDI-mechanism
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, calcium-channel blockers, @DRUG$, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide, @DRUG$, and phenytoin, have been used concurrently with @DRUG$.	DDI-false
from cholinergic when is administered with @DRUG$ , , oxidase inhibitors antidepressants or @DRUG$.	DDI-false
Although have not with that are mainly metabolized ( eg , blockers dapsone , quinine , amiodarone @DRUG$ , , tacrolimus @DRUG$ , derivatives carbamazepine , alfentanyl , alprazolam , and triazolam ) elevated plasma coadministered saquinavir ;	DDI-false
@DRUG$: Administration of @DRUG$ concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	DDI-false
@DRUG$ and @DRUG$ should not be administered to patients receiving coumarin drugs.	DDI-false
Drugs Demonstrated to be CYP Inhibitors Possible Significance on the @DRUG$ ( caution recommended coadministration with ): of with @DRUG$ increased maximum plasma concentration of % , clearance 21 % increased half-life 17 and decreased measured psychomotor .	DDI-false
Oral anticoagulant agents: Pharmacokinetic drug-drug interactions between @DRUG$ and @DRUG$ (7.5 mg single oral dose) have not been demonstrated.	DDI-false
To of chemotherapy plus HAART clinical with , systemic ( HIV-NHL ) , the compared of with with the @DRUG$ vincristine and CHOP ) HAART of 80 with chemotherapy or , cyclophosphamide , doxorubicin teniposide @DRUG$ bleomycin without receiving antiretroviral therapy	DDI-false
@DRUG$ become @DRUG$ .	DDI-mechanism
@DRUG$-Concomitant of @DRUG$ and vitamin may the K.	DDI-false
Although @DRUG$ have reduce side effects fever , insufficiency , , confusion , and , concomitant of these @DRUG$ antitumor effectiveness of PROLEUKIN thus should be . 12 Beta-blockers antihypertensives may potentiate hypotension .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Two groups SH/DA ) to treatment with hydroalcoholic solutions ethanol @DRUG$ higher and @DRUG$ in proportions in most and alcoholic beverages	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
@DRUG$ taken concomitantly with quinidine increases @DRUG$ concentration by 33 % after two .	DDI-false
from of benzodiazepines other suggest drug the following : @DRUG$ , @DRUG$ , and nifedipine	DDI-false
Other concomitant therapies In clinical in with with @DRUG$ hypnotics @DRUG$ ( or non-opioid analgesics was to that subjects these concomitant medications .	DDI-false
Other Agents : Enalapril and enalapril IV have been with , , nitrates , @DRUG$ hydralazine prazosin @DRUG$ without adverse .	DDI-false
These results suggest that acute dosing with @DRUG$ would not affect behaviors most closely associated with @DRUG$ intoxication.	DDI-false
Both the filipin and of @DRUG$ at the molecular level the following : ( i ) @DRUG$ effects	DDI-false
Combination of @DRUG$ antiarrhythmic should be for patients life-threatening are incompletely to single incompletely responsive @DRUG$.	DDI-false
In clinical studies performed with concomitant use of ( , ( acid ) @DRUG$ ) digoxin did not significantly pharmacokinetics/pharmacodynamics	DDI-false
It is structurally distinct from the other currently available @DRUG$ (lovastatin, simvastatin, and @DRUG$), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
The availability of reverse inhibitor (@DRUG$)-based for concerns (@DRUG$)-related disturbances have led shifts in treatment practices in .	DDI-false
@DRUG$ @DRUG$ interact pharmacologically with orally administered , but effect clinically	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$: In normal volunteers, concomitant administration of @DRUG$ and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.	DDI-false
In a clinical pharmacology study, indomethacin or @DRUG$ was administered to hypertensive patients receiving @DRUG$.	DDI-false
have not been , with mainly by , blockers , quinine , quinidine , cyclosporine , @DRUG$ triazolam ) elevated plasma concentrations when @DRUG$ ;	DDI-mechanism
@DRUG$ produced : it dose @DRUG$ and number short interresponse well as overall response in schedule	DDI-false
apomorphine - prior ingestion of @DRUG$ may decrease the emetic response to @DRUG$ in the treatment of poisoning.	DDI-effect
Therefore , could following of psychotropic e.g. narcotics @DRUG$ , antiemetics @DRUG$	DDI-false
Further no effects either @DRUG$ levels prothrombin were observed a involving @DRUG$	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, @DRUG$, saquinavir, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	DDI-advise
results dexamethasone and acetate , and other and @DRUG$ , regulate proliferation of prostate epithelium by a of insulin	DDI-effect
Because @DRUG$ is metabolized by CYP2C9 and CYP3A4, patients who require anticoagulation should receive low-molecular weight or standard @DRUG$.	DDI-false
@DRUG$ administration of diflunisal receiving indomethacin decreased renal clearance levels of @DRUG$.	DDI-false
studies performed @DRUG$ , ( , @DRUG$ ( piroxicam ) , and digoxin not affect pharmacokinetics/pharmacodynamics sodium	DDI-false
Although , with are by CYP3A4 ( eg , calcium channel blockers , dapsone , , quinine amiodarone , quinidine , @DRUG$ derivatives @DRUG$ carbamazepine , fentanyl , alprazolam ) may have concentrations coadministered ;	DDI-false
The AUC and Cmax of both the (R) and (S) isomers of @DRUG$ were unaffected by concurrent dosing of 0.3 mg @DRUG$.	DDI-false
@DRUG$ taken concomitantly for less than concentrations of and n-acetyl @DRUG$ by 55 33 ,	DDI-false
during of this class increased administration , fibric acid derivatives , @DRUG$ nicotinic , erythromycin ,	DDI-false
The effects of administration bombesin verapamil verapamil ) , @DRUG$ on the intestinal by azoxymethane @DRUG$	DDI-false
@DRUG$ concomitantly @DRUG$ increases quinidine serum 33 % after two days .	DDI-false
effects of ( @DRUG$ ) on @DRUG$ responses bone megakaryocytes with whole-cell recording technique with .	DDI-false
Interactions Flupenthixol may with drugs , @DRUG$ ): flupenthixol - @DRUG$ - - Ethanol : additive CNS depression antidepressants of Tricyclic antidepressants	DDI-false
decrease the absorption of	DDI-false
@DRUG$ CONTRAINDICATED the coadministration this saquinavir an @DRUG$ regimen reduces plasma of .	DDI-false
@DRUG$: Quinolones have been reported to enhance the effects of the oral @DRUG$ warfarin or its derivatives.	DDI-false
@DRUG$ : In healthy receiving @DRUG$ a CYP3A4 inhibitor at 200 daily for days , systemic ) to was approximately 3.6-fold control half-life increased to 1.7-fold of .	DDI-false
In addition Fondaparinux neither pharmacodynamics of warfarin @DRUG$ @DRUG$ , digoxin , pharmacokinetics of digoxin state	DDI-false
Ergot Derivatives: @DRUG$, ergonovine, @DRUG$, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Dosage adjustment of @DRUG$ may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, @DRUG$, and quinidine.	DDI-advise
specific not been performed coadministration are mainly CYP3A4 ( eg , calcium channel blockers , dapsone , , @DRUG$ , , cyclosporine , ergot , @DRUG$ , alprazolam , triazolam may have elevated plasma concentrations when saquinavir	DDI-false
: concomitant administration diflunisal @DRUG$ in had effect levels @DRUG$ , significantly decreased the excretion of its	DDI-false
The @DRUG$ study dosed subjects with 1200 mg/day of @DRUG$ (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
interactions following psychotropic drugs ( @DRUG$ , antiemetics sedatives @DRUG$ )	DDI-false
@DRUG$ (but not @DRUG$): These drugs in combination with very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies.	DDI-false
@DRUG$ rate @DRUG$ was when Proquin XR was when Proquin was omeprazole at dose maximally gastric .	DDI-false
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., @DRUG$, analgesics, antiemetics, sedatives, tranquilizers).	DDI-false
@DRUG$ , such , @DRUG$ , and , amiodarone	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$ has been have blocking properties may the action of @DRUG$.	DDI-effect
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
neither affected proliferation prostatic epithelium RPMI1640 , modify mitogenic effect @DRUG$ and	DDI-false
@DRUG$ have reported the tubular of @DRUG$ and to its .	DDI-mechanism
@DRUG$ : In inducer at 100 daily for 3 mg daily 17 exposure ) to @DRUG$ was approximately 72 .	DDI-false
Although studies designed to examine drug interactions have not been done, it was noted that corticosteroid or @DRUG$ treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving @DRUG$.	DDI-false
, phenobarbital/acetaminophen , quinidine/lidocaine , valproic .	DDI-false
Limited clinical data in angina patients receiving concomitant @DRUG$ and @DRUG$ therapy indicate no discernible changes in serum digoxin levels.	DDI-false
@DRUG$ metabolized CYP2C9 , patients anticoagulation should weight standard @DRUG$.	DDI-false
controlled in healthy volunteers @DRUG$ had no effect one study or was associated , 30 ( serum @DRUG$ concentrations .	DDI-mechanism
Although @DRUG$ administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by @DRUG$ or on the location, histologic type, depth of involvement, labeling index, apoptotic index or tumor vascularity of intestinal cancers, it significantly decreased the incidence of cancer metastasis.	DDI-false
Additive adverse blockade @DRUG$ is administered concomitantly other antimuscarinics , oxidase ( tricyclic antidepressants or	DDI-effect
Patients taking @DRUG$ @DRUG$ more gain and weight loss compared taking either alone	DDI-effect
therefore the use @DRUG$ does not necessitate @DRUG$ dose to maintain therapeutic	DDI-false
specific not been drugs that metabolized by ( eg calcium channel @DRUG$ , , amiodarone , quinidine , tacrolimus , @DRUG$ , derivatives , pimozide alfentanyl , alprazolam and elevated plasma when saquinavir ;	DDI-false
Co-administration of @DRUG$ and @DRUG$ did not alter the pharmacokinetics of cerivastatin sodium.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
ibogaine 40 mg/kg ( decreases the of @DRUG$ and cocaine and the oral @DRUG$ and	DDI-false
@DRUG$ in de novo renal transplant recipients the first year , influence	DDI-false
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, secobarbital, glutethimide, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
@DRUG$, such as verapamil, diltiazem and @DRUG$, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
The administration of local @DRUG$ containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, @DRUG$, @DRUG$ or some antihistamines.	DDI-false
Sulindac : The @DRUG$ @DRUG$ in normal resulted lowering the plasma the active by	DDI-mechanism
@DRUG$ elimination of @DRUG$ and and	DDI-false
Since @DRUG$ does not markedly inhibit CYP450s (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4) in vitro, @DRUG$ is not expected to significantly interact with other drugs in vivo by inhibition of metabolism mediated by these isozymes.	DDI-false
Although not performed with that are mainly metabolized by CYP3A4 , @DRUG$ dapsone quinine , amiodarone quinidine , warfarin , cyclosporine , derivatives , , @DRUG$ , , alprazolam and triazolam concentrations when coadministered ;	DDI-false
specific been , coadministration with drugs that metabolized CYP3A4 ( @DRUG$ dapsone , disopyramide , quinine , amiodarone quinidine , @DRUG$ , cyclosporine , ergot derivatives , fentanyl , alfentanyl , alprazolam , and ) may have concentrations when coadministered	DDI-false
Mineral oil and @DRUG$ may reduce the absorption of	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-false
@DRUG$: Plasma @DRUG$ levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.	DDI-false
It concluded @DRUG$ administered safely without additional caution test during @DRUG$ therapy .	DDI-false
No significant interactions were found between @DRUG$ and warfarin or @DRUG$.	DDI-false
@DRUG$/theophylline lidocaine/quinidine phenobarbital/valproic acid , , theophylline/acetaminophen , valproic	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
@DRUG$ may certain CYP450 , CYP2C9 CYP2D6 , and	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of @DRUG$	DDI-false
Patients taking @DRUG$ concomitantly with @DRUG$ more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.	DDI-effect
Lithium: @DRUG$ toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.	DDI-false
have been , coadministration with are mainly ( calcium channel , disopyramide amiodarone quinidine , , , ergot pimozide , carbamazepine , @DRUG$ , and @DRUG$ ) may have when coadministered with ;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
caution recommended when administering @DRUG$ with narrow window , @DRUG$ )	DDI-advise
Multivalent Products : Concurrent administration of quinolone including @DRUG$ products such magnesium or aluminum @DRUG$ , sucralfate VIDEX , or containing , , or may substantially decrease absorption of resulting in and urine than desired .	DDI-mechanism
The uniformity and time course interference phenobarbital secobarbital , @DRUG$ chloral hydrate methaqualone were investigated in 16 receiving @DRUG$	DDI-false
@DRUG$: Concomitant administration of antacids may reduce plasma levels of @DRUG$.	DDI-false
Mineral Oil-Concomitant intake of @DRUG$ and @DRUG$ may reduce the absorption of vitamin K.	DDI-mechanism
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Particular CYP3A4 that have window ( e.g. , @DRUG$ @DRUG$	DDI-false
Carbamazepine : In receiving the inducer @DRUG$ , at 100 mg twice daily 3 days days , systemic ( AUC to @DRUG$ % .	DDI-mechanism
METHODS the of rats given injections @DRUG$ ( 7.4 weight and subcutaneous injections @DRUG$ ( body weight ) other day 16 verapamil ( ) day until the experiment in week 45 .	DDI-false
@DRUG$: Amiodarone, bepridil, flecainide, @DRUG$, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, @DRUG$).	DDI-advise
Other Drugs:Drugs such as quinidine, disopyramide, @DRUG$, @DRUG$, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$-Cephalosporins chains of , , cefotetan cefamandole ) or @DRUG$ can vitamin K deficiency and hypoprothrombinemia	DDI-false
In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g @DRUG$ resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing @DRUG$ alone.	DDI-false
: @DRUG$ interact drugs , @DRUG$ ( MAOI affect - Ethanol : and Ethanol additive CNS Tricyclic antidepressants Flupenthixol increases effect antidepressants	DDI-int
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, @DRUG$ and sedatives (including benzodiazepines), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Dexamethasone and @DRUG$ similarly and @DRUG$- of	DDI-effect
Both efavirenz and nevirapine have been compared to triple therapy with the PI @DRUG$ over 48 weeks as initial therapy, with similar responses being observed with @DRUG$ regimens and superiority observed with efavirenz.	DDI-false
The study subjects 1200 of @DRUG$ ( = 7 ) ( changed to mg/day [ ] ) Days 8 to of course of , five @DRUG$.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, erythromycin, @DRUG$).	DDI-false
: @DRUG$ used in patients   -@DRUG$ agents e.g. propranolol CYP3A4 inhibitor or ( e.g. , substrate , and diltiazem , a CYP3A4 ) potentiation , and AV block ;	DDI-false
Anticoagulants including coumarin , derivatives , @DRUG$ @DRUG$ NSAIDs , and aspirin the of bleeding concomitantly with	DDI-false
@DRUG$ : Plasma % when @DRUG$ and atorvastatin coadministered	DDI-false
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Anti-Inflammatory : The @DRUG$ to volunteers receiving @DRUG$ decreased the clearance and significantly increased the of indomethacin .	DDI-mechanism
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of ethanol and @DRUG$ in rats;	DDI-false
Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and @DRUG$ in rats;	DDI-false
Therefore, @DRUG$ and @DRUG$ should not be used concomitantly.	DDI-advise
@DRUG$: @DRUG$ enhances the effect of warfarin.	DDI-effect
Agents Causing Release The effect of @DRUG$ IV is augmented @DRUG$ that cause ( e.g. ) .	DDI-effect
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
In , neither influenced @DRUG$ , acetylsalicylic @DRUG$ and digoxin , nor the pharmacokinetics digoxin at	DDI-false
, phenobarbital/valproic acid , quinidine/@DRUG$ theophylline/acetaminophen , .	DDI-false
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
@DRUG$ (increases bioavailability by 50%), @DRUG$, and valproates.	DDI-false
@DRUG$: astemizole*, @DRUG$* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias.	DDI-false
Aspirin: Concurrent administration of @DRUG$ may lower @DRUG$ plasma levels, possibly by competing for protein-binding sites.	DDI-mechanism
Administration rifampin with oral @DRUG$ has shown to in decreases serum @DRUG$ and	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$: @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, erythromycin, clarithromycin).	DDI-false
@DRUG$ (but not aspirin): These drugs in combination with very high doses of @DRUG$ have been shown to provoke convulsions in pre-clinical studies.	DDI-false
To evaluate impact of clinical course patients with HIV-related , non-Hodgkin lymphoma HIV-NHL the authors compared a of 24 with HIV-NHL treated the @DRUG$ , and ( CHOP ) chemotherapy regimen plus with patients who were chemotherapy or a CHOP-like regimen , prednisone with @DRUG$ plus bleomycin antiretroviral therapy .	DDI-false
have reported in combination sequential high PROLEUKIN agents , specifically @DRUG$ , and @DRUG$.	DDI-false
@DRUG$ : rifampin since of this product with @DRUG$ antiretroviral regimen concentrations .	DDI-false
Amiodarone CYP450 enzymes , CYP1A2 @DRUG$ and	DDI-false
Drugs may imatinib plasma concentrations may increase : Caution when @DRUG$ with inhibitors CYP3A4 ( e.g. @DRUG$ itraconazole , .	DDI-advise
@DRUG$ : Amiodarone used caution in patients receiving -receptor agents ( , CYP3A4 @DRUG$ antagonists e.g. , a CYP3A4 substrate , and diltiazem , a CYP3A4 the possible sinus arrest , AV block ;	DDI-false
clinical studies with use of anticoagulants ( warfarin ) platelet acid @DRUG$ piroxicam , @DRUG$ not pharmacokinetics/pharmacodynamics fondaparinux .	DDI-false
These selecting an @DRUG$ a taking @DRUG$.	DDI-advise
Other reported with : @DRUG$ @DRUG$ substrate ) in with amiodarone may hypotension , , and output	DDI-false
Coadministration of @DRUG$ with 40 mg @DRUG$ tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.	DDI-mechanism
@DRUG$ ( , @DRUG$ , triamterene , ) , potassium potassium-containing to significant in serum potassium .	DDI-false
@DRUG$ have been reported to of systemic clonidine . known whether the concurrent of @DRUG$ humans lead resulting the lowering effect .	DDI-false
Isocarboxazid should be administered with caution to patients receiving @DRUG$ (@DRUG$, Wyeth-Ayerst Laboratories).	DDI-false
To determine whether injection of @DRUG$ would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of @DRUG$.	DDI-false
Lack of an effect of @DRUG$ on the disposition of @DRUG$ and dideoxyinosine in HIV-infected patients.	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for @DRUG$ therapy and concerns regarding protease inhibitor (@DRUG$)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of @DRUG$ (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of @DRUG$ (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45.	DDI-false
3 specific for the of forms of @DRUG$ acute pharmacological ( i.e. @DRUG$ status ) and example chronic	DDI-false
of and @DRUG$ absorption @DRUG$.	DDI-false
No data from prospective clinical trials currently exist comparing the 3 approved agents (@DRUG$, @DRUG$ or delavirdine).	DDI-false
@DRUG$ had no significant impact on the Cmax and AUC of @DRUG$, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.	DDI-false
Non-selective @DRUG$ phenelzine sulfate , and : non-selective @DRUG$ hypertension .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Drug : interact with drugs inhibitors ( ): MAOI could theoretically affect @DRUG$ Arecoline - @DRUG$ : and Ethanol cause Tricyclic antidepressants : Flupenthixol effect of antidepressants	DDI-false
containing of N-methylthiotetrazole , @DRUG$ , , , ) methylthiadiazole ( cefazolin ) can cause K and	DDI-false
of and other agents interfering transmission ( @DRUG$ ) only be caution as of @DRUG$ may be potentiated .	DDI-false
blockade may occur other @DRUG$ , , phenothiazines , @DRUG$ , tricyclic antidepressants .	DDI-false
The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors, @DRUG$ or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
In EM individuals treated with paroxetine or @DRUG$, the AUC of @DRUG$ is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.	DDI-mechanism
@DRUG$: The concomitant administration of ciprofloxacin with the @DRUG$ glyburide has, on rare occasions, resulted in severe hypoglycemia.	DDI-false
addition @DRUG$ of acetylsalicylic acid , and , the pharmacokinetics of @DRUG$ at	DDI-false
specific have not been , coadministration with are metabolized channel , quinine , quinidine , , tacrolimus , cyclosporine , ergot derivatives , @DRUG$ , @DRUG$ alprazolam , and ) may elevated when	DDI-false
specific been , that are mainly CYP3A4 ( calcium dapsone disopyramide , , quinidine , cyclosporine derivatives pimozide , carbamazepine , @DRUG$ @DRUG$ alprazolam and triazolam ) may have elevated concentrations ;	DDI-false
@DRUG$ @DRUG$ been to the effects of the anticoagulant warfarin or its .	DDI-false
with @DRUG$ , with @DRUG$ phenobarbital toxic concentrations the binding of .	DDI-false
Corticosteroids, @DRUG$ and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$ transport may be of @DRUG$ to increased plasma levels	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and @DRUG$ HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, @DRUG$, niacin (@DRUG$), erythromycin, azole antifungals.	DDI-false
studies performed coadministration that are mainly metabolized CYP3A4 ( eg @DRUG$ , dapsone , disopyramide quinine , @DRUG$ quinidine , cyclosporine , ergot , carbamazepine , alfentanyl , triazolam ) may have plasma concentrations when coadministered ;	DDI-false
Monitoring @DRUG$ toxicity and serial measurement @DRUG$ serum during concomitant protease inhibitor should be considered .	DDI-false
Slow-channel calcium blockers, such as verapamil, @DRUG$ and @DRUG$, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
for @DRUG$ toxicity measurement amiodarone serum during concomitant @DRUG$ should be .	DDI-false
Dexamethasone and acetate similarly and stimulate @DRUG$- proliferation .	DDI-false
induce ( dexamethasone @DRUG$ , @DRUG$ rifampin phenobarbital or	DDI-false
of @DRUG$ therapy should be for life-threatening who a incompletely responsive @DRUG$.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Acetaminophen , , quinidine @DRUG$ , and @DRUG$ were to pooled human at concentrations .	DDI-false
@DRUG$ interferes tubular secretion of @DRUG$ and produces an level of ciprofloxacin in	DDI-false
@DRUG$ Simvastatin ( @DRUG$ ) with amiodarone	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Although glucocorticoids have been shown PROLEUKIN-induced effects renal , dyspnea administration agents with @DRUG$ reduce the antitumor effectiveness and avoided . 12 and antihypertensives seen @DRUG$.	DDI-false
efavirenz nevirapine been to therapy with the @DRUG$ 48 weeks therapy , with responses being observed with and superiority observed @DRUG$.	DDI-false
: Patients on Diuretic Patients @DRUG$ and especially in was instituted may experience an therapy enalapril @DRUG$.	DDI-effect
The blood pressure effect of SULAR tended to be greater in patients on @DRUG$ than in patients on no other @DRUG$ therapy.	DDI-false
studies have been performed with that metabolized by CYP3A4 ( eg , calcium channel blockers @DRUG$ disopyramide , amiodarone , quinidine warfarin @DRUG$ , cyclosporine , derivatives , pimozide , carbamazepine , fentanyl alfentanyl , alprazolam , triazolam ) may concentrations	DDI-false
with @DRUG$ for days increases concentrations @DRUG$ procainamide by 55 % and 33 %	DDI-false
In addition noted chronic   2 ) @DRUG$ administration , @DRUG$ ,	DDI-false
, suggest @DRUG$ antihypertensive effect of	DDI-effect
@DRUG$: In diabetic patients receiving @DRUG$ and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.	DDI-false
To the impact of chemotherapy plus HAART the clinical of patients with HIV-related , systemic non-Hodgkin lymphoma ( HIV-NHL authors compared retrospectively group HIV-NHL who were the cyclophosphamide doxorubicin , @DRUG$ and prednisone ( ) with group patients who with CHOP chemotherapy or a ( i.e. cyclophosphamide , doxorubicin , teniposide prednisone @DRUG$ plus bleomycin without receiving antiretroviral therapy .	DDI-false
@DRUG$ , @DRUG$ flecainide , , serious and/or .	DDI-false
specific have been coadministration are by ( eg , blockers , dapsone , disopyramide @DRUG$ amiodarone @DRUG$ , cyclosporine , ergot , , , alfentanyl triazolam ) may have when with saquinavir	DDI-false
@DRUG$: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Acetaminophen, lidocaine, @DRUG$, @DRUG$, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Although specific performed that mainly by ( eg calcium channel blockers dapsone , quinine , amiodarone , , tacrolimus , @DRUG$ , carbamazepine , , , @DRUG$ have plasma coadministered with saquinavir ;	DDI-false
diuretics , spironolactone , @DRUG$ amiloride , @DRUG$-containing salt substitutes may lead to increases serum .	DDI-false
Oral Contraceptives: Coadministration of atorvastatin and an oral @DRUG$ increased AUC values for @DRUG$ and ethinyl estradiol by approximately 30% and 20%.	DDI-false
Antiarrhythmics: Other @DRUG$ drugs, such as quinidine, procainamide, @DRUG$, and phenytoin, have been used concurrently with amiodarone.	DDI-false
in suggest a drug following ergotamine @DRUG$ , @DRUG$ , .	DDI-false
Drugs That Inhibit @DRUG$ Metabolism Via Cytochrome P450 3A: The initial step in @DRUG$ metabolism is hydroxylation catalyzed by cytochrome P450 3A (CYP 3A).	DDI-false
Administering @DRUG$ together with @DRUG$ (100-500 microM) inhibited InsP(3)-induced responses (both Ca(2+) and current responses) in a dose-dependent fashion.	DDI-effect
is a for both @DRUG$ @DRUG$.	DDI-false
@DRUG$ had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the @DRUG$ tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.	DDI-mechanism
acid quinidine/@DRUG$ theophylline/acetaminophen valproic	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ deficit and to discriminate between @DRUG$ deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Interactions Flupenthixol with some , like @DRUG$ MAOI theoretically flupenthixol - Arecoline Eproxindine and @DRUG$ cause depression - Tricyclic antidepressants : increases the antidepressants	DDI-false
Corticosteroids , Methylxanthines Diuretics with @DRUG$ steroids diuretics potentiate hypokalemic effect   @DRUG$	DDI-effect
Coadministration phenytoin with @DRUG$ tablets in lowered the @DRUG$ plasma concentrations to undetectable .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
@DRUG$ including coumarin derivatives indandione aggregation inhibitors such as nonsteroidal anti-inflammatory drugs ) and @DRUG$ may the bleeding when concomitantly	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
@DRUG$/Hypnotics: triazolam, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
Drug : may with some inhibitors ( MAOI @DRUG$ theoretically affect flupenthixol pharmacodynamics - Eproxindine - cause depression - @DRUG$ : Flupenthixol the effect	DDI-false
Tricyclic antidepressants have blunt the effect @DRUG$.It known whether the of agents with @DRUG$ resulting with lowering effect .	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
specific have not been coadministration with drugs are mainly metabolized by eg , calcium channel blockers , , quinine , amiodarone quinidine warfarin , , , @DRUG$ , carbamazepine , fentanyl , @DRUG$ ) elevated plasma concentrations coadministered with saquinavir ;	DDI-false
@DRUG$ showed the most potent inhibition (66% inhibition at 10 microM), which was far more potent than that of crude @DRUG$.	DDI-false
@DRUG$ taken less than increases plasma @DRUG$ and by % and , respectively .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and @DRUG$/phenobarbital.	DDI-false
Cephalosporins-Cephalosporins ( cefmenoxime cefoperazone @DRUG$ @DRUG$ latamoxef ) or methylthiadiazole cefazolin ) can deficiency hypoprothrombinemia .	DDI-false
: @DRUG$ , to potential for serious and/or reactions such as or sedation	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Garlic Capsules Garlic capsules should not be used while taking saquinavir (@DRUG$) as the sole protease inhibitor due to the risk of decreased @DRUG$ plasma concentrations.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
specific that metabolized CYP3A4 , @DRUG$ , , quinine amiodarone warfarin , tacrolimus , ergot pimozide , carbamazepine , , @DRUG$ alprazolam , and triazolam ) may concentrations with ;	DDI-false
To evaluate the impact of chemotherapy HAART on the clinical course of patients HIV-related non-Hodgkin ( , the authors compared 24 HIV-NHL treated with the cyclophosphamide vincristine , and prednisone ( regimen plus HAART with of with CHOP or , @DRUG$ , prednisone @DRUG$ receiving .	DDI-false
Corticosteroids, @DRUG$ and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
These results suggest that both dexamethasone and @DRUG$, and possibly other @DRUG$ and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
, , phenobarbital/acetaminophen , @DRUG$/@DRUG$ , , acid/phenobarbital	DDI-false
@DRUG$: The concomitant use of @DRUG$ with long- and short-acting nitrates has been safely tolerated in patients with stable angina pectoris.	DDI-false
The availability of potent @DRUG$ (NNRTI)-based regimens for antiretroviral therapy and concerns regarding @DRUG$ (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
, @DRUG$ treatment , @DRUG$ , or diuretics may potentiate a   beta2-agonists	DDI-false
Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, @DRUG$, @DRUG$, and CYP3A4.	DDI-false
@DRUG$: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of @DRUG$.	DDI-false
Ergot Derivatives @DRUG$ , CONTRAINDICATED potential serious as acute @DRUG$ toxicity peripheral and ischemia of extremities and other tissues .	DDI-false
: In , of @DRUG$ increased approximately 40 with coadministration of atorvastatin and @DRUG$ inhibitor of	DDI-false
To of chemotherapy plus the clinical course of patients HIV-related , , non-Hodgkin HIV-NHL , authors retrospectively a group HIV-NHL treated with cyclophosphamide , @DRUG$ , , and prednisone CHOP ) chemotherapy regimen with of 80 patients were treated with CHOP chemotherapy or CHOP-like ( cyclophosphamide , teniposide , and prednisone vincristine ) without receiving @DRUG$ .	DDI-false
Antihypertensives : be in receiving   -receptor agents propranolol inhibitor ) ( , @DRUG$ @DRUG$ substrate , a inhibitor because possible of , , and ;	DDI-false
in studies of @DRUG$ alprazolam suggest possible for the following : cyclosporine amiodarone , ,	DDI-int
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
@DRUG$ of aspirin @DRUG$ plasma levels competing .	DDI-false
Based on the results of these studies, it is concluded that @DRUG$ may be safely coadministered with both zidovudine and @DRUG$.	DDI-false
@DRUG$: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to @DRUG$ was decreased approximately 72%.	DDI-false
addition influenced , @DRUG$ , , and @DRUG$ , nor at steady state	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-effect
Several drug interaction studies have been completed with both @DRUG$ and @DRUG$.	DDI-false
In EM individuals treated with @DRUG$ or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than @DRUG$ alone.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ may enhance the effects of @DRUG$, barbiturates, and other CNS depressants.	DDI-effect
acetaminophen/theophylline lidocaine/quinidine , quinidine/lidocaine , theophylline/acetaminophen , and valproic	DDI-false
@DRUG$ @DRUG$ been average 31 % concomitant of to	DDI-false
specific not , mainly metabolized CYP3A4 ( eg calcium , disopyramide , , , warfarin tacrolimus , @DRUG$ , ergot , pimozide carbamazepine , fentanyl @DRUG$ , alprazolam may plasma ;	DDI-false
Co-administration of @DRUG$ with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of @DRUG$.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, @DRUG$, @DRUG$, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Demonstrated to be CYP 3A Possible Significance the Basis Clinical Studies @DRUG$ recommended with alprazolam ): Coadministration of @DRUG$ alprazolam plasma of by 46 % by increased half-life by 17 , performance .	DDI-false
@DRUG$ decreased the hyperuricemic of	DDI-effect
Gleevec will plasmaconcentration of CYP3A4 e.g. , @DRUG$ reductase inhibitors etc	DDI-false
: Concomitant use of @DRUG$ , and @DRUG$ bleeding .	DDI-false
In present , @DRUG$ @DRUG$ was tested in combination an dose PCP in and ( ) procedures	DDI-false
@DRUG$ : Other @DRUG$ , quinidine procainamide disopyramide , , have concurrently amiodarone	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
that @DRUG$ Drugs that imatinib concentrations recommended when of CYP3A4 ( , , @DRUG$ .	DDI-false
studies with niacin and not any effect @DRUG$ , administration to population chronically @DRUG$ no extent digoxin relative to control	DDI-false
@DRUG$: @DRUG$ toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.	DDI-false
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$: In hypercholesterolemic patients, steady-state @DRUG$ AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.	DDI-false
Multivalent Cation-Containing Products Concurrent a quinolone , with multivalent cation-containing products as @DRUG$ or pediatric or @DRUG$ , , may substantially of , serum and urine levels considerably lower than desired	DDI-false
Additive adverse effects from cholinergic blockade LEVSIN is administered other antimuscarinics amantadine , phenothiazines , monoamine MAO ) , @DRUG$ @DRUG$.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
@DRUG$: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and @DRUG$ were administered concomitantly.	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
If with activity ( such ketoconazole intraconazole , @DRUG$ , indinavir , @DRUG$ . reduction of budesonide should be	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as @DRUG$ (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
@DRUG$ will of other CYP3A4 ( e.g. , @DRUG$ certain HMG-CoA reductase inhibitors )	DDI-mechanism
phenobarbital/acetaminophen phenobarbital/valproic quinidine/lidocaine	DDI-false
@DRUG$ ('Seroquel') is a newly introduced @DRUG$ with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia.	DDI-false
@DRUG$ and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
Previous have a reduction the bioavailability @DRUG$ and @DRUG$ when with an intravenous such as morphine .	DDI-false
: or pharmacodynamic drug-drug interactions between and concomitantly aspirin mg given 26 2 hours prior to Argatroban 1 g/kg/min over 4 hours ) or @DRUG$ ( mg given 12 , 6 and hours prior to , 6 12 to , initiation   . over 18 hours	DDI-false
Digoxin : When doses @DRUG$ and , steady-state @DRUG$ increased by approximately .	DDI-false
The uniformity course anticoagulant @DRUG$ , secobarbital glutethimide @DRUG$ and methaqualone were systematically 16 patients receiving	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Potentiation ( @DRUG$ substrate anticoagulant is always seen in patients @DRUG$ serious fatal bleeding .	DDI-false
@DRUG$ twice daily did with @DRUG$ ( AUC 20 % )	DDI-false
is @DRUG$ CYP3A4 substrates a therapeutic window ( e.g. , @DRUG$ pimozide .	DDI-advise
@DRUG$: Meclofenamate sodium enhances the effect of @DRUG$.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including @DRUG$ such as quinidine and @DRUG$, cardiac glycosides and tricyclic anti-depressants.	DDI-false
It is therefore necessary to acquainted with the clinical and pattern of @DRUG$ deficit to discriminate between deficiency due to an which only physiological supplementation a dysregulation of control mechanisms @DRUG$ which more or less specific regulation its causal .	DDI-false
acetaminophen/theophylline , @DRUG$/quinidine , phenobarbital/acetaminophen @DRUG$/lidocaine , theophylline/acetaminophen valproic .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Cardiovascular : Enalapril and enalapril IV have used with @DRUG$ , , @DRUG$ , hydralazine prazosin and digoxin of significant	DDI-false
Plasma levels of @DRUG$ may become subtherapeutic during @DRUG$ therapy.	DDI-mechanism
Coadministration with compounds that are potent inducers of CYP3A4 (eg, @DRUG$, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of @DRUG$.	DDI-mechanism
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher @DRUG$ and @DRUG$ in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
Co-administration of @DRUG$ antiplatelet , , and @DRUG$ risk bleeding .	DDI-effect
@DRUG$ , @DRUG$ and CYP3A4	DDI-false
@DRUG$ : atorvastatin an increased AUC for and @DRUG$ % .	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, @DRUG$ and @DRUG$.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
This is with occasional of @DRUG$ , but significant @DRUG$ used on a continuous .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Colestipol: Plasma concentrations of @DRUG$ decreased approximately 25% when colestipol and @DRUG$ were coadministered.	DDI-false
of STRATTERA be coadministered with inhibitors e.g. , @DRUG$ @DRUG$ and quinidine	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, @DRUG$, @DRUG$, sedatives, tranquilizers).	DDI-false
For these , is in most subjects who unsatisfactory either alone , the of combined with @DRUG$ and @DRUG$ not outweigh risks of , acute failure	DDI-effect
@DRUG$ will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, @DRUG$, certain HMG-CoA reductase inhibitors, etc.).	DDI-mechanism
Although specific been performed , drugs that by ( calcium channel , dapsone disopyramide , @DRUG$ amiodarone , @DRUG$ , tacrolimus , , pimozide , alfentanyl , , may elevated plasma concentrations coadministered	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Nonsteroidal Anti-Inflammatory Drugs: The administration of @DRUG$ to normal volunteers receiving @DRUG$ decreased the renal clearance and significantly increased the plasma levels of indomethacin.	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ but @DRUG$ , rate .	DDI-false
Beta-blocking Agents: The concomitant use of @DRUG$ and @DRUG$ has been well tolerated in patients with stable angina.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other @DRUG$, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-effect
of @DRUG$ and depressed the @DRUG$-induced	DDI-effect
@DRUG$ a of @DRUG$ and drugs	DDI-false
acetaminophen/theophylline , , phenobarbital/valproic , , and	DDI-false
Coadministration of @DRUG$ decreased the maximum plasma concentration of @DRUG$ by 6%, decreased clearance by 38%, and increased half-life by 58%.	DDI-mechanism
with potent eg , @DRUG$ , , , carbamazepine may result in decreased of @DRUG$.	DDI-mechanism
@DRUG$ including , phenelzine and @DRUG$ Concomitant use L-tyrosine and non-selective inhibitors cause hypertension .	DDI-false
@DRUG$ Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of @DRUG$.	DDI-false
Although @DRUG$ been shown to side effects including , , hyperbilirubinemia and administration these may reduce the and thus be avoided potentiate the hypotension seen @DRUG$.	DDI-false
Methylxanthines @DRUG$ : with derivatives steroids or @DRUG$ potentiate possible hypokalemic of   .	DDI-false
Agents Causing Renin Release: The antihypertensive effect of enalapril and @DRUG$ IV is augmented by @DRUG$ that cause renin release (e.g., diuretics).	DDI-effect
administration of @DRUG$ potentiate undesirable of	DDI-effect
risk of myopathy with class is administration @DRUG$ , @DRUG$ ) , erythromycin	DDI-false
clinical studies with use of anticoagulants ( @DRUG$ ) , @DRUG$ acid ( , and did significantly affect of fondaparinux	DDI-false
@DRUG$/theophylline , lidocaine/quinidine , , phenobarbital/valproic acid , @DRUG$/lidocaine and acid/phenobarbital .	DDI-false
of this to the @DRUG$ and enkephalins or synthetic analogue @DRUG$ , antinonciceptive effect of peptides in intracisternal injection	DDI-false
Although have not been performed , with that are metabolized CYP3A4 ( channel dapsone disopyramide , @DRUG$ , , @DRUG$ , pimozide carbamazepine , , triazolam elevated when coadministered with	DDI-false
Digoxin: When multiple doses of atorvastatin and @DRUG$ were coadministered, steady-state plasma @DRUG$ concentrations increased by approximately 20%.	DDI-false
@DRUG$ : The administration of volunteers no effect on plasma levels , significantly excretion of @DRUG$ and glucuronide .	DDI-false
@DRUG$/Acetaminophen Pharmacokinetic or interactions have demonstrated between Argatroban concomitantly administered @DRUG$ ( 162.5 orally given hours of g/kg/min . over hours ) or acetaminophen 1000 mg orally given , 0 prior to and 6 and 12 hours subsequent Argatroban 1.5 g/kg/min over 18 hours	DDI-false
acetaminophen/theophylline @DRUG$/@DRUG$ phenobarbital/acetaminophen valproic .	DDI-false
: and enalapril IV have been used beta agents , @DRUG$ , nitrates , calcium-blocking agents @DRUG$ without evidence of clinically interactions	DDI-false
CONCOMITANT THERAPY : Although interaction performed clinical studies @DRUG$ enzyme ACE ) @DRUG$ , calcium-channel blockers diuretics , nonsteroidal ( evidence of significant adverse	DDI-false
Antiarrhythmics: @DRUG$, bepridil, @DRUG$, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
@DRUG$ had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated @DRUG$ by 110%.	DDI-mechanism
Dexamethasone and @DRUG$ similarly inhibit and stimulate EGF- or @DRUG$-induced proliferation of prostatic epithelium.	DDI-effect
The concomitant of @DRUG$ does of @DRUG$	DDI-false
Sinus bradycardia has been reported with oral amiodarone in combination with @DRUG$ (CYP3A4 substrate) given for local @DRUG$.	DDI-false
Cardiovascular Agents been @DRUG$ , methyldopa , calcium-blocking agents , hydralazine prazosin and @DRUG$ without evidence interactions	DDI-false
Hypersensitivity in patients receiving regimens containing dose PROLEUKIN agents specifically , @DRUG$ , @DRUG$ .	DDI-false
@DRUG$: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of @DRUG$.	DDI-false
Other reported interactions with @DRUG$: Fentanyl (@DRUG$ substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.	DDI-false
: normal volunteers , of @DRUG$ and @DRUG$ in plasma levels of hydrochlorothiazide .	DDI-mechanism
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Colestipol-Concomitant intake of colestipol and @DRUG$ may reduce the absorption of @DRUG$.	DDI-false
Drugs that alter concentrations Drugs that @DRUG$ plasma : Caution is administering Gleevec of CYP3A4 , ketoconazole @DRUG$ , clarithromycin	DDI-false
@DRUG$-@DRUG$ the	DDI-false
In addition to this pharmacological interaction, this report describes a novel chemical reaction between @DRUG$ (a @DRUG$) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.	DDI-false
with compounds CYP3A4 ( eg , @DRUG$ , phenytoin , @DRUG$ , carbamazepine may result in levels of saquinavir	DDI-false
The of anesthetic solutions containing @DRUG$ norepinephrine receiving oxidase , or @DRUG$ produce severe or hypertension .	DDI-effect
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (@DRUG$, @DRUG$, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
In addition to the interactions noted above, chronic (  2 weeks) oral Cordarone administration impairs metabolism of phenytoin, @DRUG$, and @DRUG$.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
In general are that have or pharmacologic activities similar agents such @DRUG$ procainamide @DRUG$	DDI-false
would be a dosing schedule @DRUG$ given at bedtime given before evening would result a significant decrease in effect @DRUG$.	DDI-false
Oral @DRUG$: Coadministration of atorvastatin and an oral @DRUG$ increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.	DDI-false
@DRUG$ Antidepressants : @DRUG$ administered with extreme patients being treated oxidase the of the cardiovascular be potentiated by these agents	DDI-false
WARFARIN: Co- administration of @DRUG$ and @DRUG$ to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.	DDI-false
Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with @DRUG$ may lead to elevated serum concentrations of @DRUG$ and prolongation of its elimination half-life.	DDI-false
specific studies not , coadministration that metabolized CYP3A4 eg , calcium blockers , dapsone quinine @DRUG$ , , , tacrolimus @DRUG$ , , pimozide , fentanyl , alfentanyl alprazolam , and triazolam ) may have concentrations coadministered ;	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Co-administration: Concomitant use of Argatroban with @DRUG$, @DRUG$, and other anticoagulants may increase the risk of bleeding.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
The effects of ruthenium red (@DRUG$) on inositol 1,4,5-trisphosphate (@DRUG$)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
Anticoagulants: Potentiation of @DRUG$-type (@DRUG$ and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, @DRUG$, phenytoin, dexamethasone, @DRUG$) may result in decreased plasma levels of saquinavir.	DDI-false
The extent absorption @DRUG$ was bioequivalent @DRUG$ given or XR was omeprazole at the that gastric acid .	DDI-false
@DRUG$ have been to triple the @DRUG$ indinavir initial therapy , with responses observed nevirapine and observed with efavirenz	DDI-false
@DRUG$ had impact the Cmax AUC of zidovudine although it significantly decreased @DRUG$ tmax and the intracellular exposure zidovudine %	DDI-mechanism
@DRUG$: In some patients with compromised renal function who are being treated with @DRUG$, the co-administration of enalapril may result in a further deterioration of renal function.	DDI-false
Multivalent : of a quinolone , multivalent such as @DRUG$ @DRUG$ sucralfate , VIDEX chewable/buffered powder , or products containing calcium , or the of ciprofloxacin resulting serum urine levels considerably desired	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Lack of an effect @DRUG$ on the zidovudine @DRUG$ patients	DDI-false
In addition, we have shown that @DRUG$ is a useful pharmacological tool with which to examine the @DRUG$-mediated responses of megakaryocytes.	DDI-false
Naproxen: The concomitant administration of @DRUG$ and @DRUG$ in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	DDI-mechanism
@DRUG$     @DRUG$ antagonism	DDI-false
The concomitant intake of @DRUG$ and Acamprosate does not affect the pharmacokinetics of either @DRUG$ or acamprosate.	DDI-false
Corticosteroids, @DRUG$ and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
The following eight target drug/added drug combinations were studied: @DRUG$/@DRUG$.	DDI-false
It is structurally distinct from the other currently available @DRUG$ (lovastatin, @DRUG$, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
Mineral Oil-Concomitant intake of mineral oil and @DRUG$ may reduce the absorption of @DRUG$.	DDI-false
Primary and secondary @DRUG$ deficiencies constitute the sole indication of physiological oral @DRUG$ therapy.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, @DRUG$, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
could @DRUG$ ( , narcotics analgesics , , sedatives @DRUG$ ) .	DDI-false
These results suggest that both @DRUG$ and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF.	DDI-effect
@DRUG$ and tricyclic anti-depressants could of interval with	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
@DRUG$ , @DRUG$ and to cause QTc .	DDI-false
Methotrexate: Caution should be used if @DRUG$ is administered concomitantly with @DRUG$.	DDI-advise
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by @DRUG$, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitor (@DRUG$)-based regimens for @DRUG$ therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
The availability of potent @DRUG$ (@DRUG$)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
Drugs may alter imatinib may increase @DRUG$ plasma : Caution administering @DRUG$ inhibitors of CYP3A4 ( , itraconazole , erythromycin , )	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
FLEXERIL enhance the effects @DRUG$	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, @DRUG$, indinavir, @DRUG$, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
These dexamethasone acetate glucocorticoids may proliferation by a the @DRUG$ and	DDI-false
Lack of an effect of azithromycin on the disposition of @DRUG$ and @DRUG$ in HIV-infected patients.	DDI-false
@DRUG$ concomitantly oral has shown to result amiodarone and @DRUG$.	DDI-false
While 18-MC @DRUG$ similar affinities nicotinic , @DRUG$ lower affinities than ibogaine sigma-2 receptors sodium the	DDI-false
Amiodarone with patients   agents a CYP3A4 ) @DRUG$ , a @DRUG$ substrate , and diltiazem , a CYP3A4 ) because of bradycardia , sinus arrest , and AV	DDI-false
The effects of @DRUG$ (@DRUG$) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
( 40 18-MC ( 40 mg/kg ) decreases intravenous self-administration of @DRUG$ @DRUG$ and the self-administration nicotine in rats ;	DDI-false
However, in the second study, administration of 12 g @DRUG$ 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing @DRUG$ alone.	DDI-false
@DRUG$ : with caution patients receiving -receptor blocking ( e.g. propranolol a inhibitor ) or calcium antagonists ( , @DRUG$ , a , and diltiazem CYP3A4 inhibitor because of of bradycardia sinus and AV block ;	DDI-false
structurally distinct from inhibitors ( @DRUG$ , @DRUG$ pravastatin ) , unique relative to other agents this class	DDI-false
However, if @DRUG$ is to be initiated after cessation of heparin therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of @DRUG$ therapy.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
treatment with drugs of this is with concurrent administration cyclosporine fibric derivatives , niacin @DRUG$ ) , erythromycin	DDI-false
@DRUG$ also significantly decreased the incidence of lymphatic invasion of adenocarcinomas, which was enhanced by @DRUG$.	DDI-effect
Coingestion of acetaminophen with theophylline, phenobarbital with @DRUG$, and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
state plasma concentrations of @DRUG$ been to be increased an respectively by concomitant of @DRUG$ tablets in doses to	DDI-mechanism
These results that both dexamethasone and acetate possibly other @DRUG$ and the of by a modification the activity @DRUG$.	DDI-effect
There have reports levels of @DRUG$ @DRUG$ , and phenytoin during	DDI-false
of @DRUG$ coadministered with CYP2D6 inhibitors , e.g. paroxetine , fluoxetine , and	DDI-advise
@DRUG$ Quinolones been reported enhance the anticoagulant @DRUG$ or its .	DDI-false
The concentrations of imipramine and @DRUG$ have reported to increased an 20 % respectively by concomitant @DRUG$ tablets 4 mg/day .	DDI-mechanism
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of @DRUG$ (7.4 mg/kg body weight) and subcutaneous injections of @DRUG$ (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45.	DDI-false
studies performed drugs mainly metabolized by CYP3A4 channel , quinine quinidine , , tacrolimus cyclosporine , derivatives , @DRUG$ fentanyl , @DRUG$ , and triazolam may have plasma when with saquinavir ;	DDI-false
@DRUG$-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of vitamin K.	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of @DRUG$, @DRUG$, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Both efavirenz and @DRUG$ have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with @DRUG$ regimens and superiority observed with efavirenz.	DDI-false
Omeprazole: The rate and extent of absorption of @DRUG$ was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion.	DDI-false
Non-selective sulfate , phenelzine , @DRUG$ Concomitant @DRUG$ MAO may	DDI-false
Multivalent Products quinolone , @DRUG$ , with multivalent cation-containing products such magnesium or antacids , VIDEX chewable/buffered or pediatric or products iron or may substantially decrease the @DRUG$ , in and considerably	DDI-mechanism
While 18-MC and @DRUG$ have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
@DRUG$ and @DRUG$ other agents ( e.g. , curare-like compounds the effect of toxin be potentiated	DDI-advise
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
The of during drugs of this increased of cyclosporine , , acid @DRUG$ ,	DDI-false
Antimycobacterial Agents: @DRUG$ CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of @DRUG$.	DDI-false
Multivalent Cation-Containing : Concurrent administration of a quinolone , ciprofloxacin , with multivalent cation-containing such or @DRUG$ @DRUG$ , VIDEX tablets , or containing calcium or zinc decrease absorption of ciprofloxacin resulting considerably desired .	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).	DDI-false
sampling @DRUG$ and @DRUG$ on 1 , on , 3 , 4 , , , 6 9 and 12 .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
There have been reports of QTc prolongation, with or without TdP, in patients taking @DRUG$ when fluoroquinolones, @DRUG$, or azoles were administered concomitantly.	DDI-false
and @DRUG$ not the pharmacokinetics	DDI-false
when @DRUG$ to receiving @DRUG$ dosage warfarin reduced prolongation of prothrombin .	DDI-advise
Concomitant administration of other @DRUG$ may potentiate the undesirable effects of @DRUG$.	DDI-effect
Since @DRUG$ a substrate for CYP3A4 , is the potential use John s Wort patients amiodarone could in reduced @DRUG$ .	DDI-false
@DRUG$ and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
Multivalent Cation-Containing : ciprofloxacin magnesium or aluminum antacids , sucralfate @DRUG$ chewable/buffered or pediatric or iron , or zinc substantially decrease @DRUG$ , resulting levels considerably lower than .	DDI-false
Moreover, additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
of @DRUG$ its @DRUG$ were following co-administration with .	DDI-false
Like @DRUG$ mg/kg ) , 40 mg/kg decreases the intravenous self-administration morphine cocaine @DRUG$ nicotine in	DDI-false
The @DRUG$ study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of @DRUG$.	DDI-false
a increase in to @DRUG$ when @DRUG$ is coadministered with ketoconazole ( CYP3A4 inhibitor	DDI-false
Like @DRUG$ ( 40 mg/kg ) 18-MC 40 mg/kg decreases the intravenous @DRUG$ and and oral nicotine rats ;	DDI-false
that recommended for with @DRUG$ @DRUG$	DDI-false
of , cefoperazone , , @DRUG$ , ) or methylthiadiazole cefazolin can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
On administration of oral @DRUG$, the need for @DRUG$ therapy should be reviewed and the dose reduced by approximately 50% or discontinued.	DDI-advise
@DRUG$ may suppress certain CYP450 enzymes, including @DRUG$, CYP2C9, CYP2D6, and CYP3A4.	DDI-false
Ergot Derivatives: @DRUG$, @DRUG$, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
HMG-CoA Reductase Inhibitors: @DRUG$ (CYP3A4 substrate) in combination with @DRUG$ has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
@DRUG$ plasma and were coadministration of	DDI-false
It is concluded that chloral hydrate and @DRUG$ may be administered safely without additional caution in prothrombin test monitoring during oral @DRUG$ therapy.	DDI-false
However, reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$.	DDI-effect
these have one pharmacologic @DRUG$ , including such quinidine @DRUG$ and .	DDI-false
These suggest and acetate and possibly @DRUG$ and @DRUG$ , the prostate epithelium of the insulin EGF	DDI-false
@DRUG$ coumarin derivatives @DRUG$ anti-inflammatory drugs aspirin risk bleeding ardeparin .	DDI-false
@DRUG$ is metabolized to @DRUG$ by the cytochrome P450 (CYP450) enzyme group, specifically cytochromes P450 3A4 (CYP3A4) and CYP2C8.	DDI-false
chemotherapy HAART on the patients HIV-related systemic non-Hodgkin lymphoma HIV-NHL a of 24 patients HIV-NHL who were , @DRUG$ and prednisone CHOP ) regimen plus with a group of patients who were treated CHOP ( i.e. doxorubicin @DRUG$ , and prednisone with plus ) without receiving antiretroviral therapy .	DDI-false
, @DRUG$ , phenobarbital @DRUG$ were added to pooled serum at .	DDI-false
To evaluate impact on with HIV-related HIV-NHL ) a of 24 with HIV-NHL were treated with cyclophosphamide , vincristine and prednisone ( CHOP chemotherapy plus HAART a of 80 who were with CHOP chemotherapy cyclophosphamide doxorubicin @DRUG$ with @DRUG$ bleomycin ) without therapy	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-false
acetaminophen/theophylline lidocaine/quinidine , phenobarbital/acetaminophen phenobarbital/@DRUG$ , and valproic acid/phenobarbital	DDI-false
In clinical @DRUG$ concomitant of oral ( @DRUG$ , platelet ( ) ( piroxicam and not of .	DDI-false
Other Drugs:Drugs such as quinidine, @DRUG$, procainamide, @DRUG$, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
evaluate of HAART on clinical of with HIV-related , systemic , ( the authors compared retrospectively 24 patients who were treated with @DRUG$ , , vincristine , ( ) chemotherapy HAART a group of were treated chemotherapy or a ( , @DRUG$ bleomycin )	DDI-false
acetaminophen/theophylline lidocaine/quinidine , , and	DDI-false
: @DRUG$ should be with caution in   -receptor blocking agents , propranolol , a @DRUG$ inhibitor ) calcium channel ( e.g. verapamil , a substrate , diltiazem a ) the potentiation bradycardia , arrest ,	DDI-false
the of clinical HIV-related non-Hodgkin lymphoma HIV-NHL , authors retrospectively a of HIV-NHL who with the cyclophosphamide doxorubicin , vincristine prednisone CHOP ) chemotherapy plus HAART a of patients treated chemotherapy or a CHOP-like regimen ( i.e. , @DRUG$ , doxorubicin @DRUG$ , plus bleomycin ) without antiretroviral therapy .	DDI-false
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and @DRUG$, on the above behavioral changes induced by @DRUG$ were found.	DDI-false
@DRUG$: @DRUG$ plasma concentrations and LDL-C reduction were not altered by coadministration of cimetidine.	DDI-false
No from clinical trials exist ( @DRUG$ @DRUG$ ) .	DDI-false
The effect of @DRUG$ on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal.	DDI-effect
Therefore , @DRUG$ receiving warfarin dosage of @DRUG$ reduced of .	DDI-false
@DRUG$: The concomitant administration of ciprofloxacin with the sulfonylurea @DRUG$ has, on rare occasions, resulted in severe hypoglycemia.	DDI-false
may acidic such as @DRUG$ or @DRUG$ from sites	DDI-false
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (@DRUG$), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
In clinical performed Fondaparinux , use of ( warfarin ) , @DRUG$ acetylsalicylic acid ) NSAIDs ( , @DRUG$ affect the pharmacokinetics/pharmacodynamics	DDI-false
Antagonism between @DRUG$ and @DRUG$ in vitro has been demonstrated.	DDI-effect
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Cephalosporins-@DRUG$ of N-methylthiotetrazole ( , cefotetan cefamandole , @DRUG$ methylthiadiazole cefazolin can cause vitamin deficiency	DDI-false
Antiarrhythmics: @DRUG$, bepridil, flecainide, @DRUG$, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Therefore, it would be expected that a dosing schedule of cerivastatin sodium given at bedtime and @DRUG$ given before the evening meal would not result in a significant decrease in the clinical effect of @DRUG$.	DDI-false
, Methylxanthines and Diuretics : treatment with @DRUG$ @DRUG$ , a effect of   beta2-agonists	DDI-false
@DRUG$ The administration diflunisal to receiving @DRUG$ renal the plasma levels	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
To evaluate the chemotherapy plus HAART the clinical of patients with , non-Hodgkin lymphoma authors compared retrospectively group 24 patients the cyclophosphamide , , and CHOP chemotherapy plus HAART a patients were treated with CHOP or a CHOP-like , @DRUG$ teniposide and prednisone vincristine plus bleomycin without receiving @DRUG$ .	DDI-false
BACKGROUND: The effects of combined administration of @DRUG$ and @DRUG$ (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, @DRUG$, @DRUG$, tranquilizers).	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Theophylline: As with some other @DRUG$, concurrent administration of ciprofloxacin with @DRUG$ may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	DDI-mechanism
@DRUG$ lidocaine @DRUG$ , theophylline and added to pooled serum at .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Lack of of on @DRUG$ and @DRUG$ in HIV-infected	DDI-false
Non-selective MAO inhibitors @DRUG$ @DRUG$ , and L-tyrosine and non-selective may .	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including @DRUG$ such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants.	DDI-false
Co-medications CYP3A4 ( , , @DRUG$ , carbamazepine rifampin @DRUG$ or	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., @DRUG$, @DRUG$, and quinidine.	DDI-false
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing @DRUG$ (1 microgram/ml), EGF (10 ng/ml), and @DRUG$ (3.7 micrograms/ml or 0.1 IU/ml).	DDI-false
Drug @DRUG$ may with drugs , oxidase inhibitors MAOI ): affect - Ethanol Flupenthixol and @DRUG$ cause CNS - Tricyclic antidepressants : increases the effect Tricyclic	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: @DRUG$, cyclosporine, amiodarone, nicardipine, and nifedipine.	DDI-int
Although specific studies not performed , with drugs that by ( eg , blockers dapsone , disopyramide amiodarone quinidine warfarin tacrolimus cyclosporine ergot , @DRUG$ and ) have plasma @DRUG$ ;	DDI-mechanism
@DRUG$: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of @DRUG$ and prolongation of its elimination half-life.	DDI-false
Warfarin: @DRUG$ have been reported to enhance the effects of the oral anticoagulant @DRUG$ or its derivatives.	DDI-effect
It necessary well acquainted with the magnesium deficit and discriminate due to insufficient magnesium only physiological supplementation @DRUG$ to a of @DRUG$ requires less specific regulation of causal dysregulation	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$: Potentiation of warfarin-type (CYP2C9 and @DRUG$ substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
Observations from drug interaction studies with @DRUG$ may not be predictive for @DRUG$.	DDI-false
To evaluate chemotherapy plus HAART the with , systemic lymphoma ( HIV-NHL ) authors compared retrospectively a 24 patients treated cyclophosphamide doxorubicin , prednisone ) plus with group patients who were treated with chemotherapy or regimen ( i.e. @DRUG$ , @DRUG$ , and prednisone with bleomycin ) antiretroviral therapy .	DDI-false
@DRUG$: When multiple doses of atorvastatin and @DRUG$ were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, @DRUG$, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to @DRUG$ was decreased approximately 72%.	DDI-mechanism
that are potent inducers CYP3A4 eg , , @DRUG$ , @DRUG$ carbamazepine ) in decreased levels of saquinavir	DDI-false
Amiodarone taken concomitantly with @DRUG$ for less than seven days increases plasma concentrations of procainamide and n-acetyl @DRUG$ by 55% and 33%, respectively.	DDI-false
In general these drugs that or more activities similar hydrochloride including @DRUG$ as quinidine and @DRUG$ , glycosides tricyclic anti-depressants	DDI-false
studies not been performed with drugs mainly metabolized by ( , @DRUG$ , quinine , amiodarone quinidine , cyclosporine ergot fentanyl , , alprazolam , @DRUG$ ) may elevated concentrations with	DDI-false
administration of drugs e.g. , aminoglycosides myelotoxic e.g. @DRUG$ ) hepatotoxic ( e.g. , methotrexate , @DRUG$ PROLEUKIN increase these .	DDI-false
Other antiarrhythmic procainamide , @DRUG$ , and @DRUG$ been used amiodarone	DDI-false
The myopathy during with drugs of class is with @DRUG$ , niacin ) @DRUG$ azole antifungals	DDI-false
@DRUG$ and @DRUG$ should not be .	DDI-false
Multivalent Cation-Containing Concurrent administration , including @DRUG$ , cation-containing products such as @DRUG$ aluminum , tablets pediatric products containing , , zinc of ciprofloxacin , and levels considerably desired	DDI-mechanism
( @DRUG$ or @DRUG$ , supplements or potassium-containing salt lead in potassium .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ alone, they modify the mitogenic effect of @DRUG$ and insulin.	DDI-false
bradycardia has been reported @DRUG$ in with @DRUG$ substrate given anesthesia .	DDI-false
Therefore , patients @DRUG$ should monitored @DRUG$ therapy is indicated .	DDI-advise
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
studies performed with Fondaparinux concomitant use oral warfarin platelet @DRUG$ , NSAIDs ( piroxicam , and @DRUG$ did not significantly the pharmacokinetics/pharmacodynamics of sodium	DDI-false
Cardiovasculars: @DRUG$: In patients receiving digoxin therapy, administration of oral @DRUG$ regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.	DDI-false
BACKGROUND administration of verapamil hydrochloride ( a @DRUG$ the incidence of by @DRUG$ ( AOM ) of intestinal were male Wistar rats	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
However , study administration of @DRUG$ hour before meal and mg cerivastatin the evening meal a decrease in the @DRUG$ of less than and of 30 % compared sodium .	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other @DRUG$ and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF.	DDI-effect
@DRUG$ may enhance the seizure risk in patients taking @DRUG$	DDI-effect
@DRUG$ : As with , administration of ciprofloxacin with @DRUG$ may theophylline its half-life	DDI-false
Potassium-sparing diuretics ( @DRUG$ amiloride @DRUG$ supplements potassium-containing salt substitutes may in serum .	DDI-false
Since of @DRUG$ with increases by 100 % after 3 to 4 of the @DRUG$ should by one-third , and times	DDI-false
OTHER CONCOMITANT : Although specific interaction in clinical studies , @DRUG$ used converting enzyme ACE inhibitors , , calcium-channel blockers diuretics , and @DRUG$ ( evidence of significant adverse .	DDI-false
Therefore , interactions could occur following concomitant @DRUG$ @DRUG$ tranquilizers .	DDI-false
in vitro studies benzodiazepines other than alprazolam a drug the @DRUG$ cyclosporine amiodarone ,	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, @DRUG$).	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$: Other antiarrhythmic drugs, such as @DRUG$, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.	DDI-false
@DRUG$: Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$ at little intestinal carcinogenesis by @DRUG$ or on histologic type depth of labeling index , tumor vascularity of intestinal cancers decreased the incidence of .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
of does affect of @DRUG$ or	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate @DRUG$ , and Concomitant use of L-tyrosine non-selective @DRUG$ may cause hypertension .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
studies have , with drugs that are mainly CYP3A4 eg , disopyramide , quinine , amiodarone @DRUG$ , , cyclosporine ergot derivatives , pimozide , carbamazepine , @DRUG$ , alprazolam , and may have elevated plasma when coadministered with saquinavir ;	DDI-false
@DRUG$ inhibits @DRUG$.	DDI-false
Ketoconazole: In healthy subjects receiving @DRUG$, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to @DRUG$ was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ : @DRUG$ and were coadministered plasma concentrations increased %	DDI-false
Antihypertensives : @DRUG$ used caution -receptor blocking agents ( e.g. propranolol a inhibitor ) or @DRUG$ ( e.g. , CYP3A4 substrate CYP3A4 inhibitor and AV block	DDI-false
@DRUG$ and compared to triple with weeks initial therapy with responses observed with @DRUG$ regimens observed efavirenz	DDI-false
@DRUG$ : Administration nonsteroial drugs concomitantly with with increase in @DRUG$-induced toxicity , due to decreased synthesis of renal prostacyclin .	DDI-false
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and @DRUG$ and the oral self-administration of ethanol and nicotine in rats;	DDI-false
Probenecid: @DRUG$ interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of @DRUG$ in serum.	DDI-mechanism
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, erythromycin, clarithromycin).	DDI-false
@DRUG$, such as verapamil, @DRUG$ and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
To evaluate impact of chemotherapy HAART clinical patients with , systemic , non-Hodgkin ( HIV-NHL authors compared retrospectively a of patients with HIV-NHL who @DRUG$ @DRUG$ vincristine , prednisone CHOP chemotherapy plus with a 80 patients treated with CHOP chemotherapy or a CHOP-like , doxorubicin teniposide prednisone with bleomycin without receiving therapy .	DDI-false
Although not performed , that mainly by ( eg , calcium blockers , dapsone disopyramide , , quinidine , , pimozide , @DRUG$ , @DRUG$ , alprazolam and may have elevated when coadministered with saquinavir	DDI-false
a pharmacology study , @DRUG$ @DRUG$ administered hypertensive patients receiving	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, @DRUG$, sedatives, @DRUG$).	DDI-false
Guardians of children who have been prescribed @DRUG$ should be alerted to the general concern regarding asthma therapy compliance, especially neglect of anti-inflammatory therapy and overuse of @DRUG$.	DDI-false
glucocorticoids have been PROLEUKIN-induced side effects including fever , insufficiency hyperbilirubinemia , and of these with PROLEUKIN reduce the antitumor effectiveness of should be . @DRUG$ and other @DRUG$ may potentiate seen PROLEUKIN	DDI-false
Caution be @DRUG$ administered drugs that may decrease the or activity endogenous steroid ketoconazole , and	DDI-advise
Drug Interactions Flupenthixol may interact with some @DRUG$ ): could theoretically flupenthixol pharmacodynamics - Arecoline - : Flupenthixol and Ethanol CNS depression - Tricyclic : Flupenthixol the @DRUG$	DDI-false
: Plasma @DRUG$ clearance at steady-state were not co-administration of	DDI-false
is structurally distinct the other currently available HMGCoA reductase inhibitors ( lovastatin @DRUG$ , and @DRUG$ , leading biopharmaceutical relative the this .	DDI-false
Data from in studies of other than suggest a possible drug interaction the following : ergotamine cyclosporine @DRUG$ nicardipine	DDI-false
@DRUG$ as @DRUG$ glucocorticoid-induced mouse gene expression .	DDI-false
Coingestion of acetaminophen with theophylline @DRUG$ with , and @DRUG$ with at high to concentrations decreases	DDI-false
Myocardial injury infarction , myocarditis , ventricular severe rhabdomyolysis to be increased in @DRUG$ @DRUG$ concurrently .	DDI-effect
@DRUG$ may increase sensitivity to the @DRUG$.	DDI-effect
, phenobarbital/acetaminophen , phenobarbital/valproic acid , @DRUG$/lidocaine , @DRUG$/acetaminophen valproic acid/phenobarbital	DDI-false
Cephalosporins-Cephalosporins chains , @DRUG$ , cefamandole @DRUG$ or methylthiadiazole ( can cause vitamin and hypoprothrombinemia .	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, @DRUG$, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
, phenobarbital/acetaminophen , acid , quinidine/lidocaine , , and	DDI-false
CONCLUSIONS/INTERPRETATION: @DRUG$ and @DRUG$ can exert additive vasodilator properties on renal and ocular circulation.	DDI-false
There is a significant increase in exposure to imatinib when @DRUG$ is coadministered with @DRUG$ (CYP3A4 inhibitor).	DDI-mechanism
There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for @DRUG$ versus @DRUG$/oxycodone regimens.	DDI-false
neither @DRUG$ nor @DRUG$ the RPMI1640 containing transferrin alone , they modify effect of EGF and insulin .	DDI-false
@DRUG$ : @DRUG$ plasma LDL-C were altered coadministration cimetidine	DDI-false
Co-administration of @DRUG$ and cerivastatin did not alter the pharmacokinetics of @DRUG$.	DDI-false
@DRUG$: Plasma concentrations of atorvastatin decreased approximately 25% when @DRUG$ and atorvastatin were coadministered.	DDI-false
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
However , @DRUG$ is be after cessation of , allow time for on aPTT to decrease prior to initiation of @DRUG$ .	DDI-false
Concomitant @DRUG$ , doxorubicin @DRUG$ prednisone chemotherapy plus highly active antiretroviral with human virus-related non-Hodgkin lymphoma	DDI-false
: @DRUG$ decreased 25 and @DRUG$ were .	DDI-false
Although specific that are metabolized , @DRUG$ dapsone , quinine amiodarone , , , cyclosporine @DRUG$ , pimozide , alfentanyl , and may have coadministered	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Although studies have , with are mainly eg , , dapsone , disopyramide , , warfarin , @DRUG$ , cyclosporine ergot derivatives , , , , , @DRUG$ have concentrations when coadministered with	DDI-false
@DRUG$ coumarin derivatives derivatives , aggregation as @DRUG$ , and aspirin the of bleeding ardeparin .	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
@DRUG$ and not the of alcohol	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
@DRUG$	DDI-false
@DRUG$ The concomitant administration @DRUG$ has rare , resulted in	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, secobarbital, @DRUG$, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Although this @DRUG$ given 4 hours prior @DRUG$ , not result in diminished	DDI-effect
@DRUG$ : healthy subjects inducer @DRUG$ at mg for days and twice AUC to approximately .	DDI-false
Both efavirenz and nevirapine have been compared to triple therapy with the @DRUG$ indinavir over 48 weeks as initial therapy, with similar responses being observed with @DRUG$ regimens and superiority observed with efavirenz.	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ including @DRUG$, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
@DRUG$ : some patients with compromised function who are treated nonsteroidal anti-inflammatory drugs the co-administration of @DRUG$ may result in a deterioration of renal .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, @DRUG$, indinavir, saquinavir, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
the concomitant warfarin with @DRUG$ prothrombin time by % after 3 to 4 days , @DRUG$ should be reduced by one-third , and prothrombin times should closely .	DDI-false
Although neither @DRUG$ nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ alone, they modify the mitogenic effect of EGF and insulin.	DDI-false
Antiarrhythmics : antiarrhythmic such as @DRUG$ , procainamide disopyramide , been used with @DRUG$.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine @DRUG$/acetaminophen , acid quinidine/lidocaine , , and valproic acid/phenobarbital	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ suppress CYP450 , including @DRUG$ , CYP2C9 , .	DDI-false
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics, hypnotics and @DRUG$ (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
shown that @DRUG$ antagonized evidently the antinociceptive effect of @DRUG$ analogue .	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to @DRUG$ was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.	DDI-false
@DRUG$ have triple therapy the PI @DRUG$ over 48 weeks as initial therapy , with similar responses observed regimens observed	DDI-false
18-MC @DRUG$ similar nicotinic receptors than @DRUG$ for NMDA sigma-2 receptors sodium and the 5-HT transporter .	DDI-false
Although studies been drugs that are mainly CYP3A4 eg , calcium channel blockers , @DRUG$ , disopyramide , amiodarone warfarin tacrolimus , ergot @DRUG$ , carbamazepine fentanyl alfentanyl and triazolam ) may elevated plasma concentrations coadministered with	DDI-false
glycosides @DRUG$ an @DRUG$ may reach toxic with resultant toxicity .	DDI-false
Cephalosporins-Cephalosporins containing of cefmenoxime , cefoperazone cefotetan @DRUG$ , latamoxef methylthiadiazole @DRUG$ ) can K deficiency hypoprothrombinemia .	DDI-false
The effects @DRUG$ L-CCG-1 upon phencyclidine behavioral changes in mice	DDI-false
acetaminophen/theophylline, @DRUG$/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ with @DRUG$ protection	DDI-effect
Antiarrhythmics : such @DRUG$ , disopyramide , @DRUG$ have been concurrently	DDI-false
Capsules Garlic should ( @DRUG$ ) sole @DRUG$ decreased saquinavir concentrations	DDI-false
Acetaminophen, @DRUG$, phenobarbital, @DRUG$, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
The investigated of a interaction between @DRUG$	DDI-false
DIGOXIN: Plasma @DRUG$ levels and @DRUG$ clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
Inhibitors Simvastatin ( @DRUG$ substrate combination @DRUG$ has been reports of myopathy/rhabdomyolysis .	DDI-false
concomitant : In clinical trials safety treated with @DRUG$ with anxiolytics sedatives ( ) @DRUG$ similar to that of subjects with concomitant .	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Oral @DRUG$ : Coadministration atorvastatin and increased AUC values @DRUG$ ethinyl by 30 .	DDI-false
@DRUG$ subjects mg/day of ( 7 ) ( changed to mg/day [ n = 5 ] for 8 to of a of 100 , times/day of	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, ritonavir, indinavir, saquinavir, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
CYP3A4 ( e.g. , @DRUG$ @DRUG$ , carbamazepine , St.	DDI-false
@DRUG$: When multiple doses of @DRUG$ and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Both ibogaine and @DRUG$ decrease extracellular levels of dopamine in the nucleus accumbens, but only @DRUG$ increases extracellular levels of serotonin in the nucleus accumbens.	DDI-false
@DRUG$ including phenelzine and HC1 : use L-tyrosine and @DRUG$ hypertension .	DDI-false
@DRUG$ and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with @DRUG$.	DDI-effect
risk of treatment of this class is increased with administration @DRUG$ , fibric @DRUG$ ( nicotinic ) , azole .	DDI-false
Non-steroidal anti-inflammatory drugs (but not @DRUG$): These drugs in combination with very high doses of @DRUG$ have been shown to provoke convulsions in pre-clinical studies.	DDI-false
Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of @DRUG$ and @DRUG$.	DDI-false
There have been reports of QTc prolongation, with or without TdP, in patients taking @DRUG$ when @DRUG$, macrolide antibiotics, or azoles were administered concomitantly.	DDI-false
@DRUG$ : In normal volunteers concomitant @DRUG$ significantly levels of .	DDI-false
administration @DRUG$ doubled the AUC for	DDI-mechanism
Although specific studies have been performed coadministration that are CYP3A4 ( eg , calcium disopyramide , , , , , @DRUG$ carbamazepine , alfentanyl @DRUG$ and triazolam plasma when coadministered with saquinavir	DDI-false
Concurrent administration possessing , @DRUG$ @DRUG$ ) , , cytotoxic cardiotoxic ( e.g. , ) or , ) with may toxicity these organ systems .	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, hypnotics and @DRUG$ (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
( to daily treatment hydroalcoholic @DRUG$ , higher @DRUG$ and same proportions those found in common and	DDI-false
intensity uniformity time @DRUG$ interference @DRUG$ , secobarbital , glutethimide chloral methaqualone investigated in receiving coumarin	DDI-false
The @DRUG$ to @DRUG$ by aldehyde	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Like ibogaine 40 ) , 18-MC 40 mg/kg morphine cocaine self-administration @DRUG$ and @DRUG$ in rats ;	DDI-false
impact of chemotherapy plus HAART of with , , authors compared retrospectively with who were treated with the doxorubicin , and prednisone ( of patients who with chemotherapy a ( , cyclophosphamide @DRUG$ prednisone with vincristine plus @DRUG$ without receiving antiretroviral .	DDI-false
To impact on the course of patients with , , non-Hodgkin lymphoma ( HIV-NHL ) a group 24 with HIV-NHL who doxorubicin , , and CHOP HAART with a group 80 patients chemotherapy or a CHOP-like regimen i.e. , , @DRUG$ , @DRUG$ vincristine plus bleomycin ) receiving antiretroviral therapy	DDI-false
Both ibogaine and @DRUG$ block morphine-induced and @DRUG$-induced dopamine release in the nucleus accumbens;	DDI-effect
Other interactions with @DRUG$ ( ) with @DRUG$ , decreased cardiac	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including @DRUG$ such as quinidine and procainamide, @DRUG$ and tricyclic anti-depressants.	DDI-false
Anticoagulants: Potentiation of warfarin-type (@DRUG$ and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	DDI-false
Concomitant cyclophosphamide, @DRUG$, vincristine, and @DRUG$ chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Although specific studies have not , drugs are metabolized , calcium channel blockers , , @DRUG$ , amiodarone , quinidine , warfarin cyclosporine , ergot derivatives , @DRUG$ , fentanyl alfentanyl alprazolam and have plasma concentrations when coadministered with	DDI-false
The possibility of hypotensive effects with enalapril or @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$ or enalaprilat.	DDI-false
Although studies not been performed , coadministration drugs that mainly metabolized by CYP3A4 ( eg channel blockers dapsone @DRUG$ quinidine warfarin tacrolimus ergot , pimozide , @DRUG$ , fentanyl , alprazolam ) have elevated when	DDI-false
Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with @DRUG$, diltiazem, and @DRUG$.	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of @DRUG$ and ciprofloxacin when administered concomitantly with an intravenous opiate such as @DRUG$.	DDI-mechanism
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of @DRUG$ and nicotine in rats;	DDI-false
phenobarbital/acetaminophen , quinidine/lidocaine , and	DDI-false
Like @DRUG$ ( mg/kg ) , @DRUG$ ) the intravenous of morphine and the oral self-administration ethanol nicotine rats	DDI-false
colestipol @DRUG$ reduce @DRUG$.	DDI-false
@DRUG$ : of ( @DRUG$ substrate ) anticoagulant in receiving and or fatal	DDI-false
@DRUG$ may acidic as phenytoin or @DRUG$ their binding sites	DDI-mechanism
Blood sampling for the pharmacokinetics of @DRUG$ and @DRUG$ was performed on day 1, on weeks 1, 2, 3, and 4, and on months 2, 3, 6, 9, and 12.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-int
Amiodarone CYP450 enzymes , CYP1A2 , @DRUG$ , @DRUG$ CYP3A4 .	DDI-false
@DRUG$/substances are accelerate the metabolism @DRUG$ by the CYP3A4 enzyme induction .	DDI-false
@DRUG$ : Co- administration of @DRUG$ to healthy volunteers not result in changes in prothrombin time to co-administration placebo .	DDI-false
@DRUG$ and @DRUG$ could the the QT observed with bepridil	DDI-false
Moreover , additional with @DRUG$ propranolol have any effect @DRUG$ plasma levels patient population chronically digoxin resulted difference in the bioavailability relative to	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
antinociceptive neurotensin and @DRUG$ or @DRUG$.	DDI-false
@DRUG$-based regimens may have several advantages over @DRUG$-based therapy for initial or prolonged therapy, including more convenient administration regimens, lower tablet volume, fewer drug interactions, and central nervous system penetration.	DDI-false
@DRUG$ In patients receiving @DRUG$ of oral amiodarone results an serum concentration that may toxic levels with resultant clinical toxicity .	DDI-false
If treatment with inhibitors activity ( such as ketoconazole @DRUG$ , @DRUG$ , indinavir saquinavir , etc ) indicated the budesonide dose be considered .	DDI-false
Antiarrhythmics Amiodarone bepridil , flecainide , @DRUG$ @DRUG$ CONTRAINDICATED to serious reactions	DDI-false
Primary secondary @DRUG$ constitute indication of @DRUG$ therapy	DDI-false
Although specific have been coadministration drugs are mainly metabolized CYP3A4 eg calcium blockers dapsone , , , quinidine , , tacrolimus , , pimozide , , fentanyl , @DRUG$ and ) elevated plasma concentrations @DRUG$	DDI-mechanism
In EM individuals treated with paroxetine or @DRUG$, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than @DRUG$ alone.	DDI-false
[ Quantitative to with @DRUG$ by ] ; during the longterm treatment of psychotic with @DRUG$ six typical case	DDI-false
Naproxen: The concomitant administration of @DRUG$ and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of @DRUG$ and its glucuronide metabolite.	DDI-false
Although studies been , coadministration with are metabolized eg calcium channel blockers , amiodarone , @DRUG$ , , , pimozide , carbamazepine , fentanyl , alfentanyl alprazolam , and ) have plasma coadministered @DRUG$ ;	DDI-mechanism
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
studies have not been coadministration with drugs metabolized CYP3A4 calcium channel blockers , disopyramide @DRUG$ , amiodarone , , tacrolimus cyclosporine ergot , fentanyl , , , @DRUG$ have elevated when coadministered	DDI-false
The effects of @DRUG$ and @DRUG$ upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.	DDI-false
Other Agents Enalapril enalapril concomitantly with adrenergic-blocking agents , , @DRUG$ , calcium-blocking agents , prazosin @DRUG$ clinically significant interactions .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
During to @DRUG$ , the dose levels previously be reduced 50 % several after of oral @DRUG$.	DDI-false
Both @DRUG$ and 18-MC block morphine-induced and @DRUG$-induced dopamine release in the nucleus accumbens;	DDI-effect
@DRUG$: @DRUG$, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for @DRUG$ and @DRUG$ by approximately 30% and 20%.	DDI-false
Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving @DRUG$ and @DRUG$ concurrently.	DDI-effect
demonstrated the of @DRUG$ administered with @DRUG$ such morphine	DDI-mechanism
Data @DRUG$ other suggest drug for following : , cyclosporine amiodarone @DRUG$ and	DDI-int
This demonstrates that concurrent administration @DRUG$ at least a twofold in and total exposure	DDI-mechanism
@DRUG$: Co- administration of warfarin and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of @DRUG$ and placebo.	DDI-false
groups ( SH/DA ; SH/FA ) were daily treatment with hydroalcoholic ethanol @DRUG$ higher @DRUG$ acetaldehyde in same as those most and alcoholic	DDI-false
Physiological oral @DRUG$ supplementation (5 mg/kg/day) is easy and can be carried out in the diet or with @DRUG$s, with practically only one contra-indication: overt renal failure.	DDI-false
apomorphine - prior ingestion of @DRUG$ may decrease the @DRUG$ response to apomorphine in the treatment of poisoning.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Both @DRUG$ and @DRUG$ enhance the locomotor and/or stereotypic effects of stimulants.	DDI-false
glucocorticoids been to PROLEUKIN-induced side effects of agents reduce antitumor @DRUG$ and thus avoided @DRUG$ hypotension with PROLEUKIN	DDI-false
is structurally other available @DRUG$ ( @DRUG$ , and pravastatin ) , to unique to class .	DDI-false
Theophylline: As with some other @DRUG$, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of @DRUG$ and prolongation of its elimination half-life.	DDI-false
Other : as @DRUG$ disopyramide @DRUG$ , , and tricyclic antidepressants be prolongation risk ventricular .	DDI-false
is therefore necessary to with clinical and pattern of @DRUG$ discriminate between @DRUG$ due insufficient magnesium intake only requires oral supplementation and related a the control magnesium status which requires more or less regulation of its causal	DDI-false
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin (1 microgram/ml), @DRUG$ (10 ng/ml), and @DRUG$ (3.7 micrograms/ml or 0.1 IU/ml).	DDI-false
@DRUG$ and procainamide doses should be reduced by one-third when either is administered with @DRUG$.	DDI-false
Multivalent Products : administration of a including @DRUG$ with multivalent magnesium or antacids , VIDEX or powder , products or @DRUG$ may decrease the of ciprofloxacin urine levels than desired	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-false
Other : @DRUG$ concomitantly beta adrenergic-blocking , nitrates , , hydralazine , prazosin @DRUG$ without clinically interactions	DDI-false
Coingestion of acetaminophen with phenobarbital @DRUG$ , and @DRUG$ high to toxic the of target drug .	DDI-false
Drugs that alter plasma concentrations imatinib recommended when @DRUG$ the CYP3A4 e.g. ketoconazole , @DRUG$ , clarithromycin	DDI-advise
@DRUG$: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) @DRUG$ response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
Drug Interactions : Flupenthixol interact with drugs , like Monoamine inhibitors ( ): affect pharmacodynamics - - Eproxindine @DRUG$ Ethanol additive depression @DRUG$ : the effect	DDI-false
Other reported interactions amiodarone Fentanyl @DRUG$ substrate ) combination @DRUG$ may cause , bradycardia , decreased cardiac	DDI-false
@DRUG$ administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of @DRUG$ elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.	DDI-mechanism
Concomitantly given @DRUG$ did not interfere with the absorption of a tablet of @DRUG$.	DDI-false
Other Drugs Drugs as , , procainamide @DRUG$ , @DRUG$ QT-interval prolongation an increased risk arrhythmia .	DDI-false
Naproxen: The concomitant administration of diflunisal and @DRUG$ in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of @DRUG$ and its glucuronide metabolite.	DDI-false
In clinical studies with Fondaparinux oral @DRUG$ ) , platelet ( acetylsalicylic ) NSAIDs piroxicam and did significantly affect of @DRUG$.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
of @DRUG$	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
@DRUG$ : In individuals concentrations of atorvastatin increased approximately 40 coadministration atorvastatin and @DRUG$ , a known cytochrome P450 .	DDI-false
Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: ergotamine, @DRUG$, amiodarone, nicardipine, and nifedipine.	DDI-int
Drug may with some like oxidase inhibitors MAOI MAOI could theoretically affect @DRUG$ - @DRUG$ - - Ethanol additive depression - Tricyclic antidepressants : the of Tricyclic	DDI-false
OBJECTIVE Our was steady-state @DRUG$ and @DRUG$ , ciclosporin in novo allograft during the year	DDI-false
Coadministration with compounds are ( @DRUG$ , dexamethasone @DRUG$ ) result decreased of saquinavir .	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Like ibogaine ( 40 40 decreases of @DRUG$ the self-administration ethanol and @DRUG$ rats ;	DDI-false
specific have not performed , that mainly metabolized by CYP3A4 ( eg , dapsone , disopyramide , , @DRUG$ , quinidine , @DRUG$ tacrolimus , cyclosporine , , pimozide , carbamazepine fentanyl , , ) may have when with saquinavir ;	DDI-false
Ergot Derivatives: Dihydroergotamine, @DRUG$, ergotamine, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
However, the concomitant use of @DRUG$ and @DRUG$ (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).	DDI-effect
@DRUG$ to three cancer a dose range of 0.025 mg 2.2 mg led to dose-dependent inhibition antipyrine The effect alternate-day administration of mg of @DRUG$ on drug MS patients is unknown .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
of @DRUG$ theophylline , acetaminophen and with @DRUG$ at to toxic concentrations decreases target drug .	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Although studies not performed , coadministration that mainly metabolized ( , channel , , @DRUG$ @DRUG$ tacrolimus ergot pimozide , carbamazepine , alfentanyl , and ) may have plasma coadministered saquinavir	DDI-false
Garlic Capsules Garlic capsules should not be used while taking @DRUG$ (FORTOVASE) as the sole protease inhibitor due to the risk of decreased @DRUG$ plasma concentrations.	DDI-false
@DRUG$: @DRUG$ CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir.	DDI-false
It is concluded that @DRUG$ and @DRUG$ may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.	DDI-false
Co-administration Concomitant of @DRUG$ with @DRUG$ the of bleeding .	DDI-effect
Other concomitant therapies In trials the profile treated concomitantly @DRUG$ and sedatives ( or @DRUG$ that placebo	DDI-false
@DRUG$: Simvastatin (CYP3A4 substrate) in combination with @DRUG$ has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
@DRUG$ : should with patients receiving   -receptor agents , a CYP3A4 inhibitor ) or calcium channel antagonists verapamil , CYP3A4 substrate , diltiazem , a @DRUG$ inhibitor of the potentiation bradycardia , arrest , and ;	DDI-false
diuretics ( , @DRUG$ , @DRUG$ , or amiloride ) , salt substitutes lead potassium	DDI-false
The intensity uniformity time course interference by phenobarbital secobarbital @DRUG$ , @DRUG$ systematically 16 receiving therapy .	DDI-false
@DRUG$ @DRUG$ * terfenadine * CONTRAINDICATED due for serious life-threatening arrhythmias	DDI-false
@DRUG$ and @DRUG$ be administered safely additional caution test monitoring anticoagulant therapy .	DDI-false
Potassium-sparing diuretics (e.g., spironolactone, @DRUG$, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
No data are available for the coadministration of INVIRASE/ritonavir or @DRUG$/@DRUG$ and garlic capsules.	DDI-false
These results suggest that the hepatoxicity of @DRUG$ in alcoholic beverages is enhanced by interaction with its congeners and @DRUG$;	DDI-effect
Oral : Coadministration @DRUG$ oral contraceptive AUC values @DRUG$ approximately 30 and .	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In clinical studies performed with Fondaparinux concomitant of oral anticoagulants ( ) , platelet @DRUG$ piroxicam ) , and digoxin did significantly affect	DDI-false
Cardiovascular Agents : @DRUG$ and have concomitantly with agents , , calcium-blocking agents @DRUG$ prazosin without evidence of significant adverse	DDI-false
@DRUG$ administration to cancer patients range of mg to dose-dependent of @DRUG$ of 0.25 mg of drug metabolism MS	DDI-mechanism
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
OTHER THERAPY : interaction studies were not performed in studies , cerivastatin sodium was concomitantly with @DRUG$ calcium-channel , diuretics and nonsteroidal anti-inflammatory drugs @DRUG$ ) significant adverse interactions .	DDI-false
: should used caution in patients   agents e.g. , @DRUG$ , CYP3A4 inhibitor calcium channel antagonists e.g. verapamil a @DRUG$ , and inhibitor ) possible arrest , AV block ;	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
side chains N-methylthiotetrazole ( @DRUG$ , latamoxef @DRUG$ ) deficiency hypoprothrombinemia .	DDI-false
@DRUG$ ( , spironolactone , @DRUG$ , or amiloride , supplements or potassium-containing salt substitutes lead increases .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
adverse effects resulting from occur when LEVSIN administered concomitantly with antimuscarinics @DRUG$ haloperidol , phenothiazines , monoamine tricyclic antidepressants or	DDI-false
@DRUG$ : Simvastatin ) in with @DRUG$ has been with	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous @DRUG$ such as @DRUG$.	DDI-false
intake vitamin K may the absorption of @DRUG$.	DDI-false
that acute with @DRUG$ behaviors most closely associated with @DRUG$ intoxication .	DDI-false
Antiarrhythmics: @DRUG$, @DRUG$, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Data in studies of than @DRUG$ a possible for the , , @DRUG$ nicardipine and nifedipine .	DDI-int
@DRUG$: Lithium toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.	DDI-false
@DRUG$-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of vitamin K.	DDI-false
METHOD was randomized study of 101 patients who were randomly assigned 1:1:1 @DRUG$ at doses , mg mg daily with cyclosporine and @DRUG$.	DDI-false
@DRUG$/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic , acid/phenobarbital .	DDI-false
Concurrent use with @DRUG$ or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of @DRUG$.	DDI-mechanism
unlike @DRUG$, @DRUG$ does not affect responding for a nondrug reinforcer (water).	DDI-false
, Methylxanthines and : with , @DRUG$ or @DRUG$ potentiate possible	DDI-false
Cation-Containing : administration of a quinolone , including ciprofloxacin , with products , VIDEX chewable/buffered or , or products containing , @DRUG$ , @DRUG$ substantially decrease the absorption , resulting in lower	DDI-false
HMG-CoA Reductase Inhibitors @DRUG$ ( CYP3A4 substrate in combination with @DRUG$ associated with reports .	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, @DRUG$, @DRUG$, tamoxifen and interferon-alfa.	DDI-false
Naproxen : The concomitant administration of diflunisal naproxen volunteers had the plasma levels @DRUG$ the of @DRUG$ metabolite	DDI-false
@DRUG$: The concomitant use of Bepridil and @DRUG$ has been well tolerated in patients with stable angina.	DDI-false
Cation-Containing Products administration a quinolone , including with cation-containing products as or @DRUG$ , @DRUG$ chewable/buffered , containing , iron zinc may substantially decrease absorption ciprofloxacin , resulting serum and lower than desired .	DDI-false
@DRUG$ Hydroxide ): @DRUG$ plasma concentrations were affected of antacid .	DDI-false
@DRUG$: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an @DRUG$ regimen reduces the plasma concentrations of saquinavir.	DDI-false
Additive adverse effects cholinergic may is administered concomitantly with other antimuscarinics @DRUG$ @DRUG$ , monoamine ( ) inhibitors antidepressants or some .	DDI-false
When multiple atorvastatin @DRUG$ were steady-state @DRUG$ approximately .	DDI-false
vitro of than @DRUG$ suggest drug interaction following @DRUG$ , amiodarone , nicardipine and .	DDI-int
Orlistat-@DRUG$ the absorption of @DRUG$.	DDI-mechanism
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and sedatives (including @DRUG$), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Other therapies In clinical safety @DRUG$ with hypnotics and @DRUG$ benzodiazepines ) , or analgesics similar to of subjects taking placebo with these medications	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with @DRUG$ regimens and superiority observed with @DRUG$.	DDI-false
This study demonstrates that concurrent administration of @DRUG$ permits at least a twofold increase in dose and total exposure to @DRUG$.	DDI-mechanism
@DRUG$: Quinolones have been reported to enhance the effects of the oral anticoagulant @DRUG$ or its derivatives.	DDI-false
Potassium-sparing diuretics e.g. , spironolactone , or @DRUG$ ) @DRUG$ to significant in .	DDI-false
Multivalent : administration @DRUG$ , including , with cation-containing products such magnesium or aluminum antacids sucralfate tablets pediatric containing @DRUG$ , iron or decrease absorption resulting in urine levels lower than desired .	DDI-mechanism
Caution be an @DRUG$ drugs may decrease the levels or activity of endogenous steroid hormones , such ketoconazole @DRUG$ ,	DDI-advise
: In volunteers , concomitant administration diflunisal and @DRUG$ levels of @DRUG$.	DDI-false
Antihypertensives : should be in patients   ( e.g. , , CYP3A4 inhibitor calcium ( , , CYP3A4 and diltiazem @DRUG$ inhibitor ) of the possible of , sinus arrest , and AV block ;	DDI-false
Delayed Adverse Reactions to @DRUG$: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered @DRUG$ experienced acute, atypical adverse reactions.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, @DRUG$ (@DRUG$), erythromycin, azole antifungals.	DDI-false
@DRUG$ @DRUG$ use and studied extensively humans	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-false
Both @DRUG$ and nevirapine have been compared to triple therapy with the @DRUG$ indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
In EM individuals treated with paroxetine or fluoxetine, the AUC of @DRUG$ is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than @DRUG$ alone.	DDI-false
structurally from other currently available @DRUG$ , , @DRUG$ , leading to unique biopharmaceutical properties relative to the other agents of class	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
Drug Interactions : @DRUG$ may with like inhibitors ): theoretically affect pharmacodynamics Arecoline Ethanol : Flupenthixol and Ethanol CNS - antidepressants @DRUG$ increases the antidepressants	DDI-false
@DRUG$ @DRUG$ be administered with extreme caution being treated oxidase or tricyclic of on cardiovascular be potentiated agents .	DDI-false
@DRUG$ may suppress CYP450 , including , @DRUG$ and .	DDI-false
The administration local @DRUG$ containing or @DRUG$ patients receiving monoamine tricyclic phenothiazines produce , prolonged hypotension hypertension	DDI-false
Drugs that @DRUG$ plasma concentrations that may imatinib plasma concentrations : is recommended when administering inhibitors the family , ketoconazole itraconazole , erythromycin , @DRUG$ )	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, @DRUG$, and nifedipine.	DDI-int
Therefore, when meclofenamate sodium is given to a patient receiving @DRUG$, the dosage of @DRUG$ should be reduced to prevent excessive prolongation of the prothrombin time.	DDI-false
drug-drug not been demonstrated between @DRUG$ concomitantly aspirin mg orally 26 hours to of 1   g/kg/min . over ) mg orally 12 6 and hours , 6 and 12 subsequent Argatroban 1.5   over hours .	DDI-false
, of anticoagulant interference by phenobarbital @DRUG$ , @DRUG$ were investigated in patients .	DDI-false
Azithromycin had no significant the and AUC @DRUG$ , it the zidovudine by % and increased the intracellular to @DRUG$ by %	DDI-false
Naproxen The @DRUG$ in normal volunteers no on levels but significantly the excretion @DRUG$ glucuronide metabolite .	DDI-false
of @DRUG$ on the our patient be maximal to after a similar length @DRUG$ withdrawal	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Naproxen The concomitant @DRUG$ and @DRUG$ volunteers had no on levels of naproxen , but the urinary of and metabolite	DDI-mechanism
is for other formulations of @DRUG$ , are administered before hours	DDI-advise
Hypotension : Patients Patients on @DRUG$ and in whom was , may occasionally experience excessive blood pressure of therapy @DRUG$ or .	DDI-effect
Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when @DRUG$ was given alone or when Proquin XR was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Co-administration : Concomitant with antiplatelet agents , @DRUG$ , @DRUG$ may increase the	DDI-false
Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., @DRUG$ or @DRUG$).	DDI-false
@DRUG$ has been shown to to , @DRUG$ based on in vitro studies kill with gram-negative bacilli .	DDI-effect
of warfarin-type ( CYP2C9 @DRUG$ ) anticoagulant response seen patients receiving @DRUG$ and can in	DDI-false
@DRUG$ As with some quinolones concurrent @DRUG$ with may lead elevated and prolongation .	DDI-false
There is a increase when @DRUG$ coadministered with @DRUG$ ( CYP3A4 .	DDI-mechanism
@DRUG$: Potentiation of warfarin-type (@DRUG$ and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
with @DRUG$ phenobarbital acetaminophen , and acid @DRUG$ high binding the target	DDI-false
Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of @DRUG$ and @DRUG$, a known inhibitor of cytochrome P450 3A4.	DDI-mechanism
Cephalosporins-Cephalosporins N-methylthiotetrazole cefmenoxime , @DRUG$ , cefamandole , latamoxef or ( @DRUG$ can vitamin K	DDI-false
To evaluate the impact of plus HAART on clinical course of patients with , systemic , non-Hodgkin lymphoma HIV-NHL the retrospectively a 24 with were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone chemotherapy plus HAART group 80 patients were CHOP a CHOP-like i.e. @DRUG$ doxorubicin , @DRUG$ plus bleomycin without receiving antiretroviral therapy	DDI-false
However, the absolute number of alcohol-related deaths is far greater than the number of deaths in @DRUG$ or @DRUG$ users.	DDI-false
Cephalosporins-Cephalosporins side chains N-methylthiotetrazole @DRUG$ , cefoperazone , @DRUG$ cefamandole ) methylthiadiazole ( vitamin deficiency	DDI-false
In EM individuals treated with @DRUG$ or @DRUG$, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.	DDI-false
In addition to the interactions noted above, chronic (  2 weeks) oral @DRUG$ administration impairs metabolism of phenytoin, dextromethorphan, and @DRUG$.	DDI-false
Aspirin: In normal volunteers, a small decrease in @DRUG$ levels was observed when multiple doses of @DRUG$ and aspirin were administered concomitantly.	DDI-false
@DRUG$ retinyl acetate affected proliferation of prostatic epithelium in RPMI1640 they mitogenic of @DRUG$ insulin .	DDI-effect
Both efavirenz and nevirapine have been compared to triple therapy with the PI @DRUG$ over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with @DRUG$.	DDI-false
Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of @DRUG$ and @DRUG$ were administered concomitantly.	DDI-mechanism
Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., @DRUG$, methyldopa, @DRUG$.	DDI-false
acetaminophen @DRUG$ , phenobarbital with @DRUG$ , and valproic phenobarbital to toxic the of target drug .	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
: Other @DRUG$ such quinidine , , phenytoin have been used with @DRUG$.	DDI-false
Administering @DRUG$ @DRUG$ ( 500 ) InsP(3)-induced responses ( both Ca(2 ) and ) a dose-dependent fashion .	DDI-effect
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
of N-methylthiotetrazole ( @DRUG$ cefoperazone , @DRUG$ or methylthiadiazole cefazolin ) cause K deficiency and	DDI-false
To evaluate of on the of HIV-related , non-Hodgkin HIV-NHL the authors compared retrospectively a group of 24 HIV-NHL treated with the cyclophosphamide , doxorubicin , vincristine and @DRUG$ ( chemotherapy regimen plus with a group 80 who with a regimen ( , , @DRUG$ prednisone ) without receiving	DDI-false
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
The intensity uniformity and time course of @DRUG$ interference by phenobarbital , secobarbital glutethimide , @DRUG$ methaqualone systematically investigated in 16 receiving coumarin therapy .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The course of interference @DRUG$ , @DRUG$ and methaqualone investigated receiving coumarin	DDI-false
Anticoagulants derivatives , indandione , and aggregation such as ( NSAIDs ) , @DRUG$ may of concomitantly	DDI-effect
@DRUG$/acetaminophen , valproic acid/phenobarbital	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of @DRUG$ in serum.	DDI-false
is from other HMGCoA @DRUG$ , simvastatin , and @DRUG$ ) , to relative agents this class .	DDI-false
There have been case reports of increased steady-state levels of @DRUG$, @DRUG$, and phenytoin during concomitant therapy with amiodarone.	DDI-false
Although specific studies have , that metabolized CYP3A4 , blockers quinidine , warfarin @DRUG$ , , @DRUG$ , and have elevated ;	DDI-false
data from prospective trials currently comparing the @DRUG$ or @DRUG$	DDI-false
evaluate the impact plus the clinical patients with HIV-related , systemic , ( HIV-NHL ) the authors retrospectively patients HIV-NHL were cyclophosphamide @DRUG$ and prednisone HAART with of were with chemotherapy CHOP-like ( i.e. , cyclophosphamide teniposide @DRUG$ without receiving .	DDI-false
@DRUG$ : Because atorvastatin not affect pharmacokinetics @DRUG$ , interactions with drugs metabolized the same are	DDI-false
In addition to the interactions noted above, chronic (  2 weeks) oral Cordarone administration impairs metabolism of @DRUG$, @DRUG$, and methotrexate.	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (@DRUG$), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
The steady state plasma concentrations of imipramine and @DRUG$ have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of @DRUG$ tablets in doses up to 4 mg/day.	DDI-mechanism
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$-Concomitant intake @DRUG$ and vitamin K reduce the absorption of	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, @DRUG$, nicardipine, and @DRUG$.	DDI-false
Antiarrhythmics @DRUG$ , @DRUG$ , quinidine due to potential for serious and/or	DDI-false
Cardiovascular Agents : @DRUG$ enalapril IV have beta adrenergic-blocking nitrates calcium-blocking , , and @DRUG$ evidence	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents, specifically, @DRUG$, cis-platinum, tamoxifen and interferon-alfa.	DDI-effect
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Data from in vitro studies of alprazolam suggest a possible drug interaction with @DRUG$ for the following: @DRUG$ and paroxetine.	DDI-int
Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of ethanol and nicotine in rats;	DDI-false
general , drugs that @DRUG$ including anti-arrhythmic agents as quinidine procainamide cardiac glycosides	DDI-false
Antihistamines: @DRUG$*, @DRUG$* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias.	DDI-false
There is a significant increase in exposure to @DRUG$ when @DRUG$ is coadministered with ketoconazole (CYP3A4 inhibitor).	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Similarly dialyzed were @DRUG$, @DRUG$, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum.	DDI-false
Potassium-sparing diuretics (e.g., @DRUG$, triamterene, or amiloride), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
@DRUG$ : The administration of diflunisal and volunteers had on the levels of @DRUG$ excretion and its glucuronide	DDI-false
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
acetaminophen/theophylline phenobarbital/acetaminophen phenobarbital/valproic acid @DRUG$/lidocaine , and @DRUG$/phenobarbital	DDI-false
The effects of DCG-IV and @DRUG$ upon @DRUG$ (PCP)-induced locomotion and behavioral changes in mice.	DDI-false
Cephalosporins-Cephalosporins of ( cefmenoxime @DRUG$ , @DRUG$ , cefamandole , or methylthiadiazole ( cefazolin ) cause vitamin K hypoprothrombinemia	DDI-false
efavirenz and @DRUG$ been compared to therapy PI as initial , responses being observed superiority observed	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
@DRUG$: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Concurrent administration of oxyphenbutazone and @DRUG$ may result in elevated serum levels of @DRUG$.	DDI-false
Coingestion of acetaminophen with @DRUG$ @DRUG$ acetaminophen , and with at to concentrations binding the	DDI-false
Oral @DRUG$ : between @DRUG$ warfarin single dose ) have demonstrated	DDI-false
The effects of @DRUG$ (RR) on inositol 1,4,5-trisphosphate (@DRUG$)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
bradycardia been reported with @DRUG$ lidocaine ( substrate ) given for local	DDI-false
Although studies have performed are mainly eg , channel blockers dapsone @DRUG$ quinine , quinidine , tacrolimus @DRUG$ ergot , pimozide , fentanyl , alfentanyl , and ) have plasma coadministered with ;	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, betablockers, calcium-channel blockers, diuretics, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
performed with concomitant use oral @DRUG$ ( warfarin @DRUG$ acid ) NSAIDs ( ) , and digoxin did affect of	DDI-false
Oral Coadministration atorvastatin and oral @DRUG$ values for @DRUG$ and ethinyl estradiol by approximately and %	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
inhibitors @DRUG$ : @DRUG$ non-selective inhibitors may hypertension .	DDI-false
Cation-Containing Concurrent of quinolone , including ciprofloxacin with multivalent cation-containing products as antacids @DRUG$ or powder , or products containing calcium , zinc decrease of @DRUG$ , urine levels considerably	DDI-false
Concurrent administration oxyphenbutazone and @DRUG$ result	DDI-false
treatment with inhibitors CYP3A4 ( such as @DRUG$ , , @DRUG$ saquinavir , . ) indicated , reduction of the should be considered .	DDI-false
The intensity uniformity and course @DRUG$ interference by phenobarbital , @DRUG$ , glutethimide , and methaqualone were 16 patients .	DDI-false
Antihypertensives in patients   -receptor agents ( e.g. @DRUG$ CYP3A4 inhibitor or calcium e.g. @DRUG$ , a and , a ) of the possible potentiation of , , AV block ;	DDI-false
@DRUG$ the most ( 66 % inhibition at 10 microM ) which was far more than that of	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, erythromycin, clarithromycin).	DDI-false
Glyburide: The concomitant administration of ciprofloxacin with the @DRUG$ @DRUG$ has, on rare occasions, resulted in severe hypoglycemia.	DDI-false
@DRUG$	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, @DRUG$, @DRUG$, and digoxin, nor the pharmacokinetics of digoxin at steady state.	DDI-false
suggest both @DRUG$ and retinyl acetate and glucocorticoids , may proliferation of epithelium modification the activity @DRUG$ and EGF .	DDI-effect
The hypoglycemic effect of @DRUG$ been to increase when @DRUG$ given concurrently .	DDI-effect
interactions of @DRUG$	DDI-int
Other reported with @DRUG$ : ( CYP3A4 substrate ) in with @DRUG$ , .	DDI-false
The effects of DCG-IV @DRUG$ upon @DRUG$ (PCP)-induced changes in mice	DDI-false
@DRUG$, but not @DRUG$, decreases heart rate at high doses.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with @DRUG$ in an @DRUG$ regimen reduces the plasma concentrations of saquinavir.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between @DRUG$ deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and @DRUG$ depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen acid quinidine/@DRUG$ , , and .	DDI-false
No and @DRUG$ or	DDI-false
Non-selective MAO inhibitors including @DRUG$, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.	DDI-false
@DRUG$: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of @DRUG$, a known inhibitor of cytochrome P450 3A4.	DDI-false
Although specific have not been performed coadministration drugs that are metabolized by eg , channel blockers , , disopyramide @DRUG$ , @DRUG$ , warfarin , tacrolimus , ergot , pimozide , fentanyl , alfentanyl and triazolam have elevated concentrations coadministered with	DDI-false
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, cyclosporine, @DRUG$, nicardipine, and nifedipine.	DDI-int
The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-effect
reactions have been reported in regimens sequential dose @DRUG$ antineoplastic dacarbazine , @DRUG$ and	DDI-effect
Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of @DRUG$ elimination.14 The effect of alternate-day administration of 0.25 mg of @DRUG$ on drug metabolism in MS patients is unknown.	DDI-false
@DRUG$/@DRUG$ : Pharmacokinetic or drug-drug interactions not demonstrated and administered aspirin orally given 26 initiation 1   g/kg/min over 4 ) acetaminophen mg 12 6 0 hours , and 12 hours , Argatroban 1.5   g/kg/min 18 hours .	DDI-false
ingestion of @DRUG$ decrease emetic response to @DRUG$ in of poisoning	DDI-effect
Other Chemotherapy Agents In a separate study, concomitant administration of @DRUG$ with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of @DRUG$).	DDI-false
@DRUG$ should caution to patients @DRUG$ ( disulfiram Wyeth-Ayerst	DDI-advise
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., narcotics, analgesics, @DRUG$, sedatives, tranquilizers).	DDI-false
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Oral Contraceptives: Coadministration of @DRUG$ and an oral contraceptive increased AUC values for norethindrone and @DRUG$ by approximately 30% and 20%.	DDI-mechanism
In addition , Fondaparinux influenced of warfarin acetylsalicylic acid , @DRUG$ , the pharmacokinetics @DRUG$ state .	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, @DRUG$, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ : Potentiation of ( CYP3A4 @DRUG$ always receiving amiodarone and result or fatal	DDI-false
Since the concomitant administration of warfarin with @DRUG$ increases the prothrombin time by 100% after 3 to 4 days, the dose of the @DRUG$ should be reduced by one-third to one-half, and prothrombin times should be monitored closely.	DDI-false
Additive adverse effects occur when @DRUG$ with antimuscarinics , amantadine , @DRUG$ , phenothiazines , MAO ) , or some .	DDI-effect
@DRUG$ healthy , concentrations @DRUG$ increased approximately 40 % coadministration atorvastatin and erythromycin cytochrome P450 .	DDI-false
: Pharmacokinetic or demonstrated between and administered aspirin orally 26 2 prior of 1   g/kg/min over ) or ( mg orally given 12 and 0 to and 12 hours of @DRUG$ 1.5   over	DDI-false
: @DRUG$ , propafenone @DRUG$ due serious and/or .	DDI-false
@DRUG$: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including @DRUG$.	DDI-false
@DRUG$ used with caution in -@DRUG$ blocking , propranolol CYP3A4 inhibitor ) or , CYP3A4 , CYP3A4 because of potentiation , , and AV ;	DDI-false
@DRUG$ @DRUG$ since the coadministration of with saquinavir in an antiretroviral regimen the plasma concentrations of	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, procainamide, @DRUG$, @DRUG$, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with @DRUG$): Coadministration of @DRUG$ with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
Drug : Flupenthixol with drugs , @DRUG$ ( @DRUG$ affect flupenthixol Arecoline - Eproxindine Ethanol : and Ethanol CNS - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Digoxin: When multiple doses of @DRUG$ and @DRUG$ were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.	DDI-mechanism
Interactions Flupenthixol may interact with some drugs , @DRUG$ ( ): theoretically @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol Flupenthixol and cause additive Tricyclic : Flupenthixol the effect of Tricyclic	DDI-false
Other Cardiovascular Enalapril @DRUG$ have used , @DRUG$ , agents digoxin evidence of clinically .	DDI-false
@DRUG$: Amiodarone, @DRUG$, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, @DRUG$, phenothiazines, @DRUG$, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, fibric acid derivatives, niacin (nicotinic acid), erythromycin, @DRUG$.	DDI-false
The concomitant intake @DRUG$ not affect the pharmacokinetics of either or	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drug Interactions @DRUG$ interact with , ( MAOI could theoretically affect flupenthixol - - Ethanol : and Ethanol cause additive CNS - @DRUG$ : Flupenthixol increases the effect of antidepressants	DDI-false
@DRUG$ The concomitant of the sulfonylurea @DRUG$ has , , resulted in hypoglycemia	DDI-false
Amiodarone may suppress certain CYP450 enzymes, including @DRUG$, @DRUG$, CYP2D6, and CYP3A4.	DDI-false
However, LDL-C reduction was greater when @DRUG$ and @DRUG$ were coadministered than when either drug was given alone.	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Although have been shown to reduce side effects including fever renal , hyperbilirubinemia , dyspnea administration of with the antitumor effectiveness of @DRUG$ thus be avoided 12 @DRUG$ may potentiate hypotension	DDI-false
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, betablockers, calcium-channel blockers, @DRUG$, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Although specific studies have been with drugs are metabolized CYP3A4 eg , calcium channel blockers , , quinine amiodarone , , @DRUG$ cyclosporine ergot , carbamazepine , @DRUG$ alfentanyl , , and triazolam have elevated plasma concentrations saquinavir ;	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-false
Although specific studies have , drugs are by , channel @DRUG$ , , amiodarone @DRUG$ , , ergot , carbamazepine , fentanyl , alprazolam and triazolam ) have elevated when saquinavir ;	DDI-false
This time window is different than for other oral formulations of @DRUG$, which are usually administered 2 hours before or 6 hours after @DRUG$.	DDI-advise
These increases should be considered when selecting an oral @DRUG$ for a woman taking @DRUG$.	DDI-advise
Co-administration: Concomitant use of @DRUG$ with @DRUG$, thrombolytics, and other anticoagulants may increase the risk of bleeding.	DDI-effect
@DRUG$ and @DRUG$ :	DDI-int
There is a significant increase in exposure to @DRUG$ when Gleevec is coadministered with @DRUG$ (CYP3A4 inhibitor).	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, ritonavir, indinavir, saquinavir, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Similarly were phenobarbital quinidine , and @DRUG$ , both alone serum with @DRUG$ at concentrations	DDI-false
specific studies have performed , with that are mainly metabolized by , calcium blockers @DRUG$ @DRUG$ amiodarone quinidine , tacrolimus cyclosporine , ergot , carbamazepine fentanyl , alfentanyl , alprazolam , and triazolam may have elevated concentrations when saquinavir	DDI-false
However, if Argatroban is to be initiated after cessation of @DRUG$ therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of @DRUG$ therapy.	DDI-false
@DRUG$ may increase slightly the effect of @DRUG$, e.g., guanethidine, methyldopa, reserpine.	DDI-effect
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, @DRUG$, niacin (nicotinic acid), erythromycin, @DRUG$.	DDI-false
have been reported in regimens containing sequential dose antineoplastic @DRUG$ @DRUG$ interferon-alfa .	DDI-false
that may plasma concentrations Drugs @DRUG$ of family e.g. , , @DRUG$ , ) .	DDI-advise
Since amiodarone is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving @DRUG$ could result in reduced @DRUG$ levels.	DDI-false
To on the course patients with HIV-related , non-Hodgkin lymphoma authors compared a group of 24 patients who with , doxorubicin @DRUG$ , ( chemotherapy a with or a CHOP-like regimen ( @DRUG$ doxorubicin , with vincristine ) receiving antiretroviral therapy .	DDI-false
Like ibogaine ( mg/kg , @DRUG$ ( intravenous self-administration of @DRUG$ and the self-administration of and nicotine in rats ;	DDI-false
Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., @DRUG$, @DRUG$, reserpine.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, @DRUG$, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
concomitant therapies In clinical , the safety profile concomitantly @DRUG$ @DRUG$ and benzodiazepines or analgesics was similar to of these	DDI-false
, phenobarbital/acetaminophen phenobarbital/valproic , quinidine/lidocaine , theophylline/acetaminophen , @DRUG$/@DRUG$.	DDI-false
No data are available for the coadministration of INVIRASE/@DRUG$ or FORTOVASE/@DRUG$ and garlic capsules.	DDI-false
Aspirin : In volunteers a decrease in @DRUG$ levels observed when and @DRUG$ administered .	DDI-false
CONCOMITANT THERAPY interaction studies were performed , in clinical studies @DRUG$ used angiotensin- ( ACE ) betablockers calcium-channel blockers , nonsteroidal @DRUG$ without significant adverse interactions .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Coingestion of @DRUG$ with theophylline, phenobarbital with acetaminophen, and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Caution should be exercised when @DRUG$ are given in conjunction with @DRUG$.	DDI-advise
Dexamethasone and @DRUG$ similarly inhibit and stimulate @DRUG$- or insulin-induced proliferation of prostatic epithelium.	DDI-effect
Although shown to reduce PROLEUKIN-induced fever , renal hyperbilirubinemia confusion dyspnea , concomitant these with @DRUG$ reduce antitumor effectiveness should be . and @DRUG$ may hypotension with PROLEUKIN .	DDI-false
@DRUG$ prior of the emetic to @DRUG$ in .	DDI-false
acetaminophen/theophylline , phenobarbital/acetaminophen , acid theophylline/acetaminophen .	DDI-false
In @DRUG$ neither influenced the pharmacodynamics , , @DRUG$ , nor the pharmacokinetics digoxin at steady .	DDI-false
of myopathy treatment with drugs class is increased administration @DRUG$ @DRUG$ , niacin ( nicotinic erythromycin azole	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, @DRUG$, phenytoin, @DRUG$, carbamazepine) may result in decreased plasma levels of saquinavir.	DDI-false
Both and @DRUG$ been to therapy with the @DRUG$ indinavir 48 weeks with responses observed with regimens superiority with .	DDI-false
Concurrent use @DRUG$ or drugs significantly eliminated by renal tubular may result increased @DRUG$.	DDI-mechanism
acetaminophen/theophylline , lidocaine/@DRUG$ phenobarbital/valproic acid/phenobarbital	DDI-false
adverse resulting from cholinergic blockade may when @DRUG$ is administered , , phenothiazines , oxidase MAO ) inhibitors , @DRUG$ or antihistamines .	DDI-effect
in vitro benzodiazepines other suggest following ergotamine amiodarone @DRUG$ and @DRUG$.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
of possessing ( e.g. aminoglycosides , ) myelotoxic , cytotoxic chemotherapy ) cardiotoxic e.g. , ) hepatotoxic e.g. , @DRUG$ ) @DRUG$ may increase in these .	DDI-effect
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen acid @DRUG$/lidocaine , and valproic acid/phenobarbital .	DDI-false
The administration of local @DRUG$ containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Acetaminophen: In normal volunteers, concomitant administration of diflunisal and @DRUG$ resulted in an approximate 50% increase in plasma levels of @DRUG$.	DDI-false
Although have not been performed coadministration with metabolized by CYP3A4 ( calcium blockers dapsone disopyramide , @DRUG$ , amiodarone , quinidine , tacrolimus ergot derivatives pimozide alfentanyl alprazolam , ) concentrations coadministered with @DRUG$ ;	DDI-mechanism
Potentiation warfarin-type ( @DRUG$ ) @DRUG$ response almost always seen patients receiving can result or fatal bleeding .	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing @DRUG$, methanol, higher @DRUG$ and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
In addition , neither of warfarin , acid , @DRUG$ @DRUG$ , nor digoxin steady state	DDI-false
, phenobarbital/valproic acid , valproic acid/phenobarbital	DDI-false
containing side chains of @DRUG$ cefotetan , cefamandole , or @DRUG$ vitamin	DDI-false
Coadministration compounds that of eg , , @DRUG$ result in decreased of	DDI-mechanism
@DRUG$: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion.	DDI-false
whether injection thiosulfate permit larger @DRUG$ to administered dose @DRUG$ was given intravenously hours concurrently with cisplatin .	DDI-false
Probenecid: Probenecid interferes with renal tubular secretion of @DRUG$ and produces an increase in the level of @DRUG$ in serum.	DDI-false
Co-administration BOTOX @DRUG$ other neuromuscular ( , curare-like only with the of the @DRUG$	DDI-false
@DRUG$ should be administered with caution to patients receiving Antabuse (@DRUG$, Wyeth-Ayerst Laboratories).	DDI-advise
The , not the coat-core formulation @DRUG$ plasma @DRUG$ about %	DDI-mechanism
@DRUG$ may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, @DRUG$.	DDI-effect
may the effects of @DRUG$ @DRUG$ and other depressants	DDI-false
@DRUG$ will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain @DRUG$, etc.).	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drugs : Drugs such quinidine @DRUG$ , procainamide , @DRUG$ , may be with prolongation and an ventricular arrhythmia .	DDI-false
Seizure , associated increased @DRUG$ concentrations , has reported with concomitant administration	DDI-false
Hypersensitivity have in receiving regimens high dose @DRUG$ and antineoplastic , , dacarbazine , tamoxifen and	DDI-effect
@DRUG$ should be taken as directed and @DRUG$ should be taken with a main meal of the day, preferably the evening meal..	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
@DRUG$ : administration @DRUG$ to did not result in any in clotting factor VII compared co-administration warfarin placebo	DDI-false
@DRUG$: In normal volunteers, concomitant administration of @DRUG$ and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
Although specific studies been performed coadministration drugs that are metabolized by ( @DRUG$ disopyramide , quinidine warfarin , cyclosporine , ergot , carbamazepine , @DRUG$ , , and triazolam ) may elevated plasma concentrations when coadministered ;	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide, @DRUG$, and @DRUG$, have been used concurrently with amiodarone.	DDI-false
Molecular for the selective @DRUG$ for @DRUG$ animal cells .	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
Corticosteroids, @DRUG$ and Diuretics: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
The possibility of hypotensive effects with enalapril or @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or @DRUG$.	DDI-false
children who prescribed @DRUG$ should alerted to general concern regarding asthma therapy compliance , especially and @DRUG$.	DDI-false
@DRUG$ vincristine , and chemotherapy plus @DRUG$ patients with human immunodeficiency virus-related , non-Hodgkin lymphoma .	DDI-false
@DRUG$ @DRUG$ had no significant effect on time when to patients warfarin .	DDI-false
Potassium-sparing e.g. , @DRUG$ , triamterene , or @DRUG$-containing may lead increases in potassium .	DDI-false
The possibility of hypotensive effects with enalapril or @DRUG$ can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.	DDI-effect
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data.	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as @DRUG$, procainamide, @DRUG$, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Co-medications induce CYP3A4 e.g. @DRUG$ , phenytoin , carbamazepine , , @DRUG$ or St.	DDI-false
@DRUG$ CONTRAINDICATED since the this product with @DRUG$ in an antiretroviral regimen plasma of	DDI-false
@DRUG$: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on @DRUG$ plasma levels or fasting blood glucose.	DDI-false
acetaminophen/theophylline @DRUG$/quinidine , phenobarbital/acetaminophen acid , quinidine/lidocaine , and valproic	DDI-false
Coadministration of @DRUG$ with 40 mg SULAR tablets in epileptic patients lowered the @DRUG$ plasma concentrations to undetectable levels.	DDI-false
Then , effects of metabotropic glutamate mGluR @DRUG$ , on behavioral induced by @DRUG$ found .	DDI-false
Oral Contraceptives : atorvastatin oral @DRUG$ norethindrone @DRUG$ by approximately 30 % .	DDI-false
studies designed examine drug interactions not it noted that @DRUG$ or of for periods of days has to patients ( ) @DRUG$.	DDI-false
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of @DRUG$ and @DRUG$.	DDI-false
possessing ( , @DRUG$ , chemotherapy cardiotoxic , doxorubicin hepatotoxic , methotrexate @DRUG$ effects PROLEUKIN these	DDI-false
@DRUG$ but aspirin ): These in combination with very doses @DRUG$ provoke pre-clinical	DDI-false
Both @DRUG$ and nevirapine have been compared to triple therapy with the PI @DRUG$ over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, @DRUG$, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
have not been performed with drugs that ( eg dapsone , , quinine @DRUG$ , quinidine cyclosporine derivatives pimozide , fentanyl , @DRUG$ alprazolam triazolam plasma when coadministered with saquinavir ;	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Other @DRUG$ @DRUG$ IV have been concomitantly , nitrates , digoxin evidence clinically adverse interactions	DDI-false
Cation-Containing : administration quinolone , including ciprofloxacin , multivalent cation-containing magnesium aluminum , VIDEX tablets pediatric products containing @DRUG$ @DRUG$ , zinc substantially ciprofloxacin , resulting than .	DDI-false
Both efavirenz and @DRUG$ have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with @DRUG$.	DDI-false
, @DRUG$/acetaminophen , , quinidine/lidocaine , theophylline/acetaminophen valproic	DDI-false
Concurrent possessing nephrotoxic ( e.g. , aminoglycosides ) , myelotoxic ( cytotoxic chemotherapy ) , doxorubicin hepatotoxic e.g. @DRUG$ , @DRUG$ ) with PROLEUKIN	DDI-false
anticoagulant agents : Pharmacokinetic between @DRUG$ and @DRUG$ ( mg ) demonstrated .	DDI-false
Fenfluramine may increase slightly the effect of @DRUG$, e.g., guanethidine, methyldopa, @DRUG$.	DDI-false
@DRUG$ should administered to patients receiving @DRUG$.	DDI-advise
Multivalent Cation-Containing Products : a , @DRUG$ with such as magnesium aluminum antacids , @DRUG$ VIDEX chewable/buffered or , or products containing zinc may substantially decrease the ciprofloxacin in urine levels lower desired .	DDI-mechanism
If treatment ketoconazole , @DRUG$ indinavir , @DRUG$ , erythromycin etc ) is be .	DDI-false
Combination of @DRUG$ with other @DRUG$ therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone.	DDI-false
Both efavirenz and @DRUG$ have been compared to triple therapy with the @DRUG$ indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
@DRUG$ has used concomitantly @DRUG$ clinically significant .	DDI-false
Antiarrhythmics : antiarrhythmic , such quinidine , @DRUG$ disopyramide , , have been used concurrently with	DDI-false
There have been case reports of increased steady-state levels of quinidine, procainamide, and @DRUG$ during concomitant therapy with @DRUG$.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, clarithromycin).	DDI-false
Seizure, associated with increased @DRUG$ concentrations, has been reported with concomitant administration of intravenous @DRUG$.	DDI-false
Co-administration of @DRUG$ and cerivastatin did the pharmacokinetics of	DDI-false
In with paroxetine @DRUG$ , the AUC of @DRUG$ approximately to 8-fold Css max to 4-fold alone .	DDI-mechanism
WARFARIN: Co- administration of warfarin and @DRUG$ to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of @DRUG$ and placebo.	DDI-false
may be coadministered with e.g. , @DRUG$ , @DRUG$.	DDI-false
@DRUG$ , small in diflunisal levels when doses of @DRUG$ aspirin were concomitantly	DDI-false
The need @DRUG$ agent should after the of @DRUG$ been established ordinarily should be .	DDI-false
Other Drugs:Drugs such as quinidine, @DRUG$, procainamide, phenothiazines, @DRUG$, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive @DRUG$ tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with @DRUG$ and prednisone.	DDI-false
adverse resulting blockade occur @DRUG$ is administered , @DRUG$ , monoamine oxidase ( MAO , tricyclic antidepressants .	DDI-effect
The superiority of @DRUG$ over regimens has been observed in patients with high viral .	DDI-false
Amiodarone may suppress CYP450 enzymes including CYP1A2 @DRUG$ , @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Particular caution is recommended when administering @DRUG$ with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or @DRUG$).	DDI-advise
Although specific studies coadministration drugs are mainly metabolized by ( eg , calcium channel blockers , , quinine , @DRUG$ , , ergot derivatives , , alfentanyl , and @DRUG$ ) saquinavir ;	DDI-false
@DRUG$ and retinyl acetate similarly inhibit and stimulate @DRUG$- or insulin-induced proliferation of prostatic epithelium.	DDI-effect
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Since @DRUG$ is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving @DRUG$ could result in reduced amiodarone levels.	DDI-false
been shown effects including renal , , confusion , dyspnea , concomitant administration of these agents may reduce the @DRUG$ and thus should be avoided Beta-blockers antihypertensives may the	DDI-false
@DRUG$ : , bepridil , , @DRUG$ CONTRAINDICATED to potential life-threatening	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Sinus bradycardia has been reported with oral amiodarone in combination with @DRUG$ (@DRUG$ substrate) given for local anesthesia.	DDI-false
Interactions : Flupenthixol may interact with drugs Monoamine inhibitors ( MAOI MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine Ethanol : @DRUG$ and @DRUG$ additive effect Tricyclic	DDI-effect
Antihypertensives : should patients receiving   @DRUG$ a or @DRUG$ antagonists ( verapamil , CYP3A4 substrate diltiazem , a CYP3A4 inhibitor ) of the of bradycardia sinus arrest block ;	DDI-false
@DRUG$ , , or @DRUG$ ) potassium supplements , or potassium-containing salt may significant in	DDI-false
Antihypertensives should caution in ( , propranolol , a @DRUG$ inhibitor calcium channel antagonists @DRUG$ , a substrate and a ) because of the possible of , arrest , AV block ;	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ deficit and to discriminate between magnesium deficiency due to an insufficient @DRUG$ intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Aspirin/Acetaminophen : drug-drug interactions have demonstrated between Argatroban administered @DRUG$ 2 to initiation of Argatroban   g/kg/min . 4 hours ) or @DRUG$ ( 1000 orally 12 6 and hours to initiation of Argatroban   g/kg/min . over 18 hours ) .	DDI-false
Ergot Dihydroergotamine ergonovine , @DRUG$ @DRUG$ to potential life-threatening reactions as acute ergot by vasospasm ischemia of extremities and .	DDI-false
of chemotherapy plus on the clinical course of with HIV-related systemic , non-Hodgkin HIV-NHL ) the retrospectively a of 24 with HIV-NHL who with the cyclophosphamide @DRUG$ , vincristine and @DRUG$ CHOP ) regimen a group who were or a i.e. cyclophosphamide , doxorubicin , and prednisone with bleomycin receiving therapy .	DDI-false
To evaluate of plus HAART clinical of with HIV-related , , non-Hodgkin ( HIV-NHL ) , the compared retrospectively group who were the cyclophosphamide doxorubicin , vincristine , ) chemotherapy plus group 80 who were CHOP a @DRUG$ , , teniposide , and prednisone with @DRUG$ receiving	DDI-false
Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of @DRUG$ and n-acetyl @DRUG$ by 55% and 33%, respectively.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Since chronic dosing is required for therapeutic efficacy of @DRUG$, future studies should focus on investigation of chronic dosing effects of these drugs in combination with @DRUG$.	DDI-false
@DRUG$ no on the zidovudine it decreased tmax % and increased the to phosphorylated @DRUG$ %	DDI-mechanism
such quinidine , disopyramide @DRUG$ , phenothiazines , @DRUG$ tricyclic antidepressants be associated prolongation and an increased risk ventricular arrhythmia	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors, @DRUG$ or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
@DRUG$ taken @DRUG$ be taken with a meal , preferably evening	DDI-false
Data from in studies of @DRUG$ a drug interaction following ergotamine @DRUG$ , .	DDI-int
Co-administration of @DRUG$ interfering with neuromuscular ( e.g. , curare-like compounds ) should performed with as of the @DRUG$ may be	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
CONCOMITANT THERAPY : Although specific were not , clinical , cerivastatin angiotensin- ACE inhibitors @DRUG$ , , @DRUG$ anti-inflammatory drugs ( without of significant adverse interactions .	DDI-false
BACKGROUND : The effects of administration of @DRUG$ verapamil hydrochloride ) a blocker induced @DRUG$ ) the of investigated rats	DDI-false
acetaminophen/theophylline @DRUG$/quinidine , , phenobarbital/valproic , quinidine/lidocaine , acid/phenobarbital	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, @DRUG$, antiemetics, @DRUG$, tranquilizers).	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, dacarbazine, cis-platinum, @DRUG$ and interferon-alfa.	DDI-false
Some @DRUG$/substances are known to accelerate the metabolism of @DRUG$ by stimulating the synthesis of CYP3A4 (enzyme induction).	DDI-false
@DRUG$ taken concomitantly with @DRUG$ increases quinidine serum concentration by 33% after two days.	DDI-false
The aim of this paper was to study the interaction between @DRUG$ and both enkephalins or its synthetic analogue @DRUG$, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection.	DDI-false
The superiority of @DRUG$ over @DRUG$-based regimens has been observed in comparative data in a subset of patients with high viral loads.	DDI-false
@DRUG$-Concomitant intake of colestipol and vitamin K may reduce the absorption of @DRUG$.	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$ : be with patients treated @DRUG$ or the action on the cardiovascular system be potentiated agents .	DDI-false
Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of @DRUG$ and nicotine in rats;	DDI-false
To the plus HAART on course of patients with ( HIV-NHL , the authors a group patients with HIV-NHL treated with the doxorubicin and @DRUG$ ( CHOP regimen of patients were chemotherapy or a CHOP-like regimen , @DRUG$ , doxorubicin , and prednisone vincristine plus ) without antiretroviral	DDI-false
concentrations dexamethasone ) 10(-6 ) @DRUG$ ( 10(-8 )	DDI-effect
, lidocaine/@DRUG$ phenobarbital/acetaminophen , .	DDI-false
@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-false
METHODS : From the experiment , rats given 10 weekly subcutaneous injections 7.4 mg/kg ) of @DRUG$ microg/kg weight ) day , and from 16 injections of @DRUG$ ( 20 body every other until end the in week 45	DDI-false
been , drugs that are metabolized ( , calcium channel , @DRUG$ , , quinine amiodarone tacrolimus cyclosporine derivatives pimozide , alfentanyl alprazolam , @DRUG$ have plasma saquinavir ;	DDI-false
Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of @DRUG$, increased @DRUG$ oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).	DDI-false
specific have not been performed coadministration drugs are mainly metabolized by eg , @DRUG$ dapsone disopyramide , @DRUG$ , amiodarone , , , tacrolimus , cyclosporine derivatives , , carbamazepine fentanyl alprazolam ) may have plasma concentrations coadministered with saquinavir	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
No data are for the coadministration of or and	DDI-false
@DRUG$: In diabetic patients receiving diflunisal and @DRUG$, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.	DDI-false
Cardiovasculars : : @DRUG$ therapy , of @DRUG$ in concentration reach toxic resultant .	DDI-false
not significant p ( 48.59 + /- 8.52 /- 9.93 2.6 vs. + /- 1.1 /- vs. /- 1.1 @DRUG$ versus levofloxacin/@DRUG$	DDI-false
To evaluate the plus HAART on the clinical of systemic lymphoma ( ) the authors retrospectively a patients HIV-NHL were treated @DRUG$ , doxorubicin vincristine , regimen 80 chemotherapy or a , @DRUG$ , teniposide and prednisone with bleomycin ) without receiving antiretroviral therapy	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
: IV have adrenergic-blocking agents , calcium-blocking agents @DRUG$ @DRUG$ and digoxin without of clinically adverse interactions	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, @DRUG$, cis-platinum, tamoxifen and interferon-alfa.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, @DRUG$, dexamethasone, @DRUG$) may result in decreased plasma levels of saquinavir.	DDI-false
In individuals with or @DRUG$ the AUC is approximately 6- to 8-fold Css is 3- to greater @DRUG$	DDI-false
Antihypertensives : Amiodarone used with   -receptor blocking ( e.g. , a inhibitor ) or calcium antagonists @DRUG$ CYP3A4 substrate , and a @DRUG$ inhibitor of the possible potentiation of , and ;	DDI-false
of @DRUG$ theophylline , with @DRUG$ acid with high toxic concentrations the binding of	DDI-false
Aspirin/@DRUG$ Pharmacokinetic or drug-drug interactions have between and administered ( mg 26 and to 1   . over hours @DRUG$ ( mg orally given 12 0 hours , , 18 )	DDI-false
Dosage adjustment @DRUG$ when CYP2D6 , e.g. , @DRUG$ fluoxetine , quinidine .	DDI-advise
@DRUG$ may displace acidic drugs such as phenytoin or @DRUG$ from their binding sites.	DDI-mechanism
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, @DRUG$, disopyramide, and phenytoin, have been used concurrently with @DRUG$.	DDI-false
have performed , coadministration mainly CYP3A4 ( , calcium channel dapsone quinine , , @DRUG$ , warfarin tacrolimus , cyclosporine @DRUG$ pimozide , fentanyl , , and triazolam elevated concentrations when coadministered saquinavir ;	DDI-false
Drug Interactions : may with , like oxidase ( @DRUG$ could Arecoline - Eproxindine - Ethanol : and cause additive CNS depression Tricyclic : @DRUG$ increases effect Tricyclic antidepressants	DDI-false
Nitrates: The concomitant use of @DRUG$ with long- and short-acting @DRUG$ has been safely tolerated in patients with stable angina pectoris.	DDI-false
BACKGROUND: The effects of combined administration of @DRUG$ and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Drug Interactions interact with some like Monoamine inhibitors @DRUG$ MAOI could - Arecoline - Flupenthixol Ethanol additive Tricyclic antidepressants : @DRUG$ increases Tricyclic	DDI-false
Among the @DRUG$, many, like @DRUG$, cannot be used clinically because they are toxic;	DDI-false
This effect may be by the @DRUG$ induce , thus , catabolism @DRUG$.	DDI-mechanism
Coingestion of acetaminophen with theophylline, @DRUG$ with acetaminophen, and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
@DRUG$ : nonsteroial anti-inflammatory concomitantly @DRUG$ has been cyclosporine-induced toxicity , possibly due to prostacyclin .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Anticoagulants: Potentiation of warfarin-type (@DRUG$ and CYP3A4 substrate) @DRUG$ response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, @DRUG$, niacin (nicotinic acid), @DRUG$, azole antifungals.	DDI-false
@DRUG$ Other drugs such @DRUG$ disopyramide phenytoin concurrently .	DDI-false
treatment with inhibitors of such as , @DRUG$ indinavir , , erythromycin etc . , @DRUG$ dose .	DDI-advise
Data from in vitro studies of @DRUG$ suggest a possible drug interaction with alprazolam for the following: sertraline and @DRUG$.	DDI-false
Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of ethanol and nicotine in rats;	DDI-false
Although neither @DRUG$ nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of @DRUG$ and insulin.	DDI-effect
Antiarrhythmics: Amiodarone, bepridil, @DRUG$, propafenone, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
determine whether @DRUG$ would larger , a fixed given three concurrently with escalating doses of @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drugs Demonstrated CYP 3A Possible on Basis of Involving @DRUG$ during with @DRUG$ of with increased the plasma by 46 % , % , increased half-life by % , and decreased psychomotor	DDI-false
performed with @DRUG$ the use oral anticoagulants ( warfarin , acid ( @DRUG$ and not affect pharmacokinetics/pharmacodynamics of fondaparinux sodium	DDI-false
Like ( 40 mg/kg ) @DRUG$ ( mg/kg morphine and @DRUG$ and oral nicotine in ;	DDI-false
Non-selective MAO inhibitors including @DRUG$ , phenelzine sulfate , @DRUG$ : Concomitant L-tyrosine non-selective may cause hypertension	DDI-false
lidocaine/quinidine , , acid , quinidine/lidocaine , and valproic acid/phenobarbital .	DDI-false
@DRUG$ effect	DDI-false
Ergot Derivatives: Dihydroergotamine, ergonovine, @DRUG$, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Other In a separate study concomitant of @DRUG$ with capecitabine meaningfully alter the pharmacokinetics of either the metabolites of @DRUG$	DDI-false
Concomitant , @DRUG$ , vincristine @DRUG$ plus highly antiretroviral patients with virus-related , lymphoma .	DDI-false
Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, @DRUG$, nicardipine, and nifedipine.	DDI-int
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-false
@DRUG$: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of @DRUG$ and erythromycin, a known inhibitor of cytochrome P450 3A4.	DDI-false
Therefore , interactions could following administration psychotropic @DRUG$ , @DRUG$ , tranquilizers .	DDI-false
Anticoagulants : Potentiation of ( @DRUG$ @DRUG$ substrate almost in patients receiving can result in serious fatal .	DDI-false
Aspirin/Acetaminophen Pharmacokinetic interactions been @DRUG$ aspirin 26 2 hours prior to of Argatroban . over 4 hours 1000 given 12 , 12 to , initiation of @DRUG$ 1.5   g/kg/min . over hours	DDI-false
Co-medications that induce CYP3A4 (e.g., dexamethasone, @DRUG$, carbamazepine, @DRUG$, phenobarbital or St.	DDI-false
increase slightly drugs , @DRUG$ @DRUG$ reserpine .	DDI-false
Response to @DRUG$ may be enhanced by @DRUG$.	DDI-effect
@DRUG$-@DRUG$ in inhibit vitamin K resulting vitamin K deficiency .	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between @DRUG$ deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Dosage adjustment of @DRUG$ may be necessary when coadministered with CYP2D6 inhibitors, e.g., @DRUG$, fluoxetine, and quinidine.	DDI-advise
@DRUG$-Cephalosporins side , , , @DRUG$ ) or methylthiadiazole ( cefazolin ) cause vitamin and hypoprothrombinemia	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
is required when @DRUG$ is administered concurrently @DRUG$.	DDI-advise
Slow-channel calcium blockers, such as @DRUG$, @DRUG$ and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a @DRUG$, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Concomitant cyclophosphamide, @DRUG$, @DRUG$, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
Cardiovascular : @DRUG$ enalapril IV been used concomitantly with , nitrates , calcium-blocking , @DRUG$ and digoxin interactions .	DDI-false
These that @DRUG$ acetate , and other and @DRUG$ regulate by dose-dependent modification of .	DDI-false
Acetaminophen, lidocaine, phenobarbital, @DRUG$, @DRUG$, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
: In clinical trials , in @DRUG$ concomitantly with anxiolytics hypnotics @DRUG$ , or non-opioid analgesics was similar subjects taking these concomitant medications .	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Therefore , interactions could occur following administration of ( e.g. , @DRUG$ @DRUG$ , sedatives , tranquilizers .	DDI-false
The safety and efficacy of @DRUG$ in combination with any @DRUG$ have not been established.	DDI-false
Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another @DRUG$ and @DRUG$ but may be seen after several months.	DDI-effect
Although have not been coadministration drugs that mainly eg , blockers disopyramide , quinine , , , tacrolimus cyclosporine , @DRUG$ pimozide carbamazepine fentanyl @DRUG$ , alprazolam , ) have elevated plasma concentrations ;	DDI-false
Coingestion of acetaminophen with theophylline, @DRUG$ with acetaminophen, and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, @DRUG$, diuretics, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of @DRUG$ and its glucuronide metabolite.	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, @DRUG$, phenothiazines, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
@DRUG$ Renal transport @DRUG$ may be by ciprofloxacin , potentially leading plasma of	DDI-false
@DRUG$ ( , spironolactone , , amiloride , or @DRUG$-containing substitutes may increases serum .	DDI-false
Drug : @DRUG$ may with like oxidase MAOI ): could flupenthixol pharmacodynamics - Eproxindine : CNS depression Tricyclic antidepressants of @DRUG$	DDI-false
@DRUG$ including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.	DDI-false
@DRUG$ taken concomitantly with procainamide for less than seven days increases plasma concentrations of @DRUG$ and n-acetyl procainamide by 55% and 33%, respectively.	DDI-false
Warfarin-@DRUG$ antagonize the @DRUG$	DDI-effect
These results suggest that both @DRUG$ and retinyl acetate, and possibly other @DRUG$ and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
should be caution @DRUG$ ( @DRUG$ Wyeth-Ayerst .	DDI-false
coadministration or @DRUG$/ritonavir and capsules .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
Omeprazole: The rate and extent of absorption of @DRUG$ was bioequivalent when @DRUG$ was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	DDI-false
Multivalent Concurrent administration @DRUG$ , including ciprofloxacin cation-containing or , sucralfate , or powder or products calcium or decrease the absorption of @DRUG$ in serum and urine than desired .	DDI-false
Garlic Capsules Garlic capsules should not be used while taking @DRUG$ (@DRUG$) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations.	DDI-false
: Flupenthixol may with drugs , like ( @DRUG$ ): could flupenthixol pharmacodynamics - Ethanol @DRUG$ cause additive CNS Tricyclic antidepressants Tricyclic	DDI-false
@DRUG$ controlled in volunteers , @DRUG$ either had no effect ( study ) or with modest , about 30 ( steady-state serum	DDI-false
Coingestion of @DRUG$ with theophylline, phenobarbital with @DRUG$, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Omeprazole : The rate absorption of when @DRUG$ given alone was hours @DRUG$ the that gastric acid .	DDI-false
, @DRUG$/quinidine , phenobarbital/acetaminophen ,	DDI-false
@DRUG$ and be reduced by when is	DDI-false
Concurrent administration possessing nephrotoxic aminoglycosides , @DRUG$ , e.g. cytotoxic chemotherapy ) cardiotoxic ( @DRUG$ ) or hepatotoxic ( , ) organ systems	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In , these one or activities similar bepridil , including agents as quinidine and @DRUG$ , @DRUG$ tricyclic	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
The authors investigated the possibility of a similar interaction between @DRUG$ and @DRUG$.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, @DRUG$).	DDI-false
acetaminophen/theophylline phenobarbital/acetaminophen acid , quinidine/@DRUG$ , , valproic	DDI-false
Therefore, the combined use of @DRUG$ with @DRUG$ should generally be avoided.	DDI-advise
@DRUG$ ( @DRUG$ ) on inositol 1,4,5-trisphosphate ( responses were in marrow the patch-clamp whole-cell in with .	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  @DRUG$	DDI-effect
administration @DRUG$ ( the of to blocks ) @DRUG$ may severe , persistent hypertension or cerebrovascular .	DDI-effect
It is structurally distinct from the other currently available @DRUG$ (@DRUG$, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Ergot Derivatives: Dihydroergotamine, @DRUG$, @DRUG$, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, @DRUG$ and sedatives (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing @DRUG$, methanol, higher alcohols and @DRUG$ in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
To evaluate the chemotherapy plus HAART clinical with non-Hodgkin lymphoma ( HIV-NHL the compared a 24 patients with who treated with the @DRUG$ doxorubicin , @DRUG$ and ( CHOP plus HAART group of chemotherapy CHOP-like regimen ( cyclophosphamide bleomycin antiretroviral .	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, @DRUG$, antiemetics, sedatives, @DRUG$).	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-advise
The steady state plasma concentrations of @DRUG$ and @DRUG$ have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.	DDI-false
Both ibogaine @DRUG$ block dopamine release in nucleus accumbens	DDI-effect
Garlic Capsules Garlic while taking @DRUG$ ( ) as inhibitor the of decreased @DRUG$ plasma .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$: The concomitant administration of @DRUG$ with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.	DDI-false
Oral @DRUG$ : Coadministration @DRUG$ an oral for norethindrone ethinyl approximately % %	DDI-false
@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Inhibit @DRUG$ Metabolism Cytochrome The initial step @DRUG$ metabolism catalyzed by cytochrome P450 ( CYP ) .	DDI-false
The blood pressure effect of @DRUG$ tended be greater in patients @DRUG$ in no antihypertensive .	DDI-effect
studies been performed , coadministration drugs by eg , calcium , , disopyramide , quinidine , , @DRUG$ ergot @DRUG$ , carbamazepine alfentanyl and ) may concentrations coadministered saquinavir	DDI-false
The of @DRUG$ or norepinephrine to patients receiving inhibitors , @DRUG$ or phenothiazines may hypotension or hypertension	DDI-effect
Cardiovasculars: Cardiac glycosides: In patients receiving @DRUG$ therapy, administration of oral amiodarone regularly results in an increase in serum @DRUG$ concentration that may reach toxic levels with resultant clinical toxicity.	DDI-false
@DRUG$/Acetaminophen Pharmacokinetic interactions demonstrated between and concomitantly mg orally given 26 and 2 prior to 1   4 or acetaminophen ( mg orally 12 6 and 0 hours prior , 6 hours , initiation of @DRUG$ 1.5 g/kg/min over hours .	DDI-false
The effect of rifampin on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ and extended a similar length of time after rifampin withdrawal.	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of @DRUG$ with @DRUG$ increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-mechanism
have in combination high @DRUG$ antineoplastic , specifically @DRUG$ , cis-platinum ,	DDI-effect
Cardiovasculars: Cardiac glycosides: In patients receiving @DRUG$ therapy, administration of oral @DRUG$ regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.	DDI-false
Ergot Derivatives: @DRUG$, ergonovine, ergotamine, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Non-selective MAO sulfate sulfate and @DRUG$ HC1 and non-selective @DRUG$ may hypertension .	DDI-false
BACKGROUND: The effects of combined administration of bombesin and @DRUG$ (verapamil), a @DRUG$, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Methotrexate Renal tubular transport of @DRUG$ may be inhibited by concomitant administration of @DRUG$, potentially leading to increased plasma levels of methotrexate.	DDI-mechanism
Co-medications that induce CYP3A4 (e.g., @DRUG$, phenytoin, carbamazepine, rifampin, @DRUG$ or St.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In addition, @DRUG$ neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and @DRUG$, nor the pharmacokinetics of digoxin at steady state.	DDI-false
Some @DRUG$/substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of @DRUG$ (enzyme induction).	DDI-false
Although have , with that calcium , , @DRUG$ , quinine , amiodarone quinidine , , , ergot , , , , @DRUG$ triazolam ) may plasma when with	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, @DRUG$ and @DRUG$.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, @DRUG$, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Drugs alter imatinib plasma concentrations may imatinib plasma : Caution is when of the family e.g. ketoconazole @DRUG$ , @DRUG$ clarithromycin .	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and @DRUG$ HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.	DDI-false
Cation-Containing Products administration of quinolone , , with products such as magnesium aluminum , @DRUG$ VIDEX chewable/buffered tablets or products calcium @DRUG$ or zinc decrease absorption resulting in serum urine levels than desired	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
The initiation of @DRUG$ or @DRUG$ use may be precipitated by similar personality characteristics in the user, such as impulsivity and sensation seeking.	DDI-false
Warfarin: @DRUG$ had no clinically significant effect on prothrombin time when administered to patients receiving chronic @DRUG$ treatment.	DDI-false
In EM individuals or @DRUG$ to 8-fold and Css , is 3- greater @DRUG$ alone	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Antihypertensives : Amiodarone with receiving -@DRUG$ blocking agents , CYP3A4 inhibitor ) or channel antagonists , @DRUG$ a CYP3A4 diltiazem a inhibitor because of possible potentiation bradycardia , sinus arrest , AV	DDI-false
This may occur because @DRUG$ competitively displaces @DRUG$ from protein binding sites.	DDI-mechanism
@DRUG$ Renal tubular transport of methotrexate may be inhibited by concomitant administration of @DRUG$, potentially leading to increased plasma levels of methotrexate.	DDI-false
@DRUG$: The rate and extent of absorption of @DRUG$ was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	DDI-false
were between @DRUG$ and @DRUG$	DDI-false
, concomitant administration of @DRUG$ approximate increase levels of @DRUG$.	DDI-false
Acetaminophen, @DRUG$, @DRUG$, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Other Enalapril and @DRUG$ IV used agents methyldopa @DRUG$ , hydralazine , and evidence clinically adverse .	DDI-false
these are drugs that more pharmacologic similar to hydrochloride including agents such as @DRUG$ and @DRUG$ glycosides anti-depressants	DDI-false
view long and variable @DRUG$ , for drug interactions exists with concomitant medication but also with drugs @DRUG$.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, @DRUG$, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
if Argatroban is be after cessation of @DRUG$ therapy , allow sufficient heparins on the aPTT to decrease prior initiation of @DRUG$ .	DDI-false
@DRUG$: Concomitant administration of @DRUG$ may reduce plasma levels of diflunisal.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	DDI-advise
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
@DRUG$: Dihydroergotamine, @DRUG$, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Amiodarone should be with caution   blocking agents ( e.g. , propranolol a @DRUG$ inhibitor antagonists ( , verapamil , a and @DRUG$ , a inhibitor ) of the possible bradycardia sinus block	DDI-false
Based on the results these it is concluded that @DRUG$ may with	DDI-false
In the above , ( 2 ) oral Cordarone metabolism @DRUG$ @DRUG$ , methotrexate .	DDI-false
This effect may be mediated by the ability of @DRUG$ to induce microsomal enzymes and, thus, the catabolism of @DRUG$.	DDI-mechanism
In clinical studies performed with @DRUG$ , the oral @DRUG$ platelet inhibitors acetylsalicylic acid ) , NSAIDs ) , digoxin not affect .	DDI-false
These results both and acetate , and possibly @DRUG$ may proliferation of epithelium by a of @DRUG$ EGF	DDI-effect
: Flupenthixol may interact some drugs like @DRUG$ MAOI theoretically affect pharmacodynamics - - Eproxindine Ethanol : Flupenthixol and Ethanol cause additive depression Tricyclic antidepressants @DRUG$ the effect Tricyclic	DDI-false
@DRUG$ no clinically significant effect on when to patients chronic @DRUG$	DDI-false
Other Chemotherapy Agents In a separate study, concomitant administration of lapatinib with @DRUG$ did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of @DRUG$).	DDI-false
@DRUG$ and @DRUG$ should be concomitantly	DDI-advise
compounds are ( , @DRUG$ , dexamethasone @DRUG$ ) may result levels saquinavir .	DDI-false
: of of @DRUG$ bioequivalent when Proquin was given alone @DRUG$ given at the suppresses gastric acid secretion .	DDI-false
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Other : Enalapril and have concomitantly with @DRUG$ @DRUG$ , calcium-blocking hydralazine and digoxin without of clinically significant adverse	DDI-false
Cholestyramine increases enterohepatic elimination of @DRUG$ and may reduce its serum levels and @DRUG$/2.	DDI-false
studies have a reduction in and @DRUG$ intravenous opiate	DDI-mechanism
studies have performed with that mainly metabolized by CYP3A4 ( eg @DRUG$ , quinine amiodarone , quinidine warfarin , tacrolimus cyclosporine , , @DRUG$ carbamazepine alprazolam , and triazolam ) may with saquinavir ;	DDI-false
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of @DRUG$ and @DRUG$ (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation.	DDI-false
Pretreatment of healthy volunteers with multiple doses of @DRUG$ followed by a single dose of Gleevec, increased @DRUG$ oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).	DDI-false
@DRUG$: @DRUG$*, terfenadine* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias.	DDI-false
specific studies have performed , coadministration drugs are mainly metabolized by ( , calcium blockers , , @DRUG$ , , warfarin , , cyclosporine , derivatives @DRUG$ , , alprazolam and elevated when with saquinavir ;	DDI-false
@DRUG$ may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6, and @DRUG$.	DDI-false
Ergot Derivatives: Dihydroergotamine, ergonovine, @DRUG$, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
@DRUG$: Because @DRUG$ does not affect the pharmacokinetics of antipyrine, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.	DDI-false
In general drugs that have more to including @DRUG$ such quinidine and @DRUG$ anti-depressants	DDI-false
Drug @DRUG$ interact with like Monoamine inhibitors ( MAOI ): MAOI pharmacodynamics - @DRUG$ Eproxindine - Ethanol : and additive Tricyclic antidepressants : Flupenthixol increases the effect of	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., @DRUG$, @DRUG$, antiemetics, sedatives, tranquilizers).	DDI-false
not performed , with drugs are metabolized ( eg , channel , , quinine @DRUG$ , warfarin , tacrolimus , cyclosporine , , @DRUG$ , and triazolam may have elevated with saquinavir ;	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
@DRUG$-Concomitant intake of colestipol and @DRUG$ may reduce the absorption of vitamin K.	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Probenecid : interferes renal of @DRUG$ and the level @DRUG$ in serum	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
These suggest both @DRUG$ , glucocorticoids and @DRUG$ , may regulate the prostate by a dose-dependent modification the activity of and	DDI-false
, ergonovine , ergotamine , @DRUG$ CONTRAINDICATED due to and life-threatening such as acute @DRUG$ toxicity characterized peripheral vasospasm ischemia of the extremities and	DDI-false
Co-administration: Concomitant use of Argatroban with antiplatelet agents, @DRUG$, and other @DRUG$ may increase the risk of bleeding.	DDI-false
Anticoagulant inhibition was observed during the administration of @DRUG$, secobarbital and @DRUG$;	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, antiemetics, @DRUG$, @DRUG$).	DDI-false
@DRUG$: In normal volunteers, a small decrease in @DRUG$ levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.	DDI-false
Antiarrhythmics : @DRUG$ as @DRUG$ , procainamide disopyramide , and used concurrently with	DDI-false
Concomitant administration of @DRUG$ doubled the AUC for @DRUG$.	DDI-mechanism
Other Cardiovascular Agents: @DRUG$ and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ , @DRUG$ theophylline , and valproic added to pooled serum at concentrations .	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of @DRUG$ with alprazolam increased the maximum plasma concentration of @DRUG$ by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
Drug : interact with drugs like oxidase ( MAOI ): theoretically flupenthixol Eproxindine - Ethanol and depression - @DRUG$ : @DRUG$ increases the effect of Tricyclic	DDI-false
and the @DRUG$ were more efficiently inhibited added cholesterol the major membrane , effects @DRUG$ were more the major in	DDI-false
@DRUG$ diminished @DRUG$ a net change of 5.7 % drug FDF ] , 11.0 at 662 micromol/L a change of % ( in FDF , ) micromol/L.	DDI-mechanism
may suppress certain CYP450 enzymes @DRUG$ @DRUG$ CYP3A4	DDI-false
Although interaction studies in , sodium was used with angiotensin- ( ACE ) inhibitors @DRUG$ calcium-channel diuretics , @DRUG$ ( NSAIDs without evidence clinically interactions .	DDI-false
, , , quinidine/@DRUG$ theophylline/acetaminophen , and acid/phenobarbital	DDI-false
Agents Causing Renin Release: The antihypertensive effect of enalapril and @DRUG$ IV is augmented by antihypertensive agents that cause renin release (e.g., @DRUG$).	DDI-effect
Anticoagulant inhibition was observed during the administration of @DRUG$, @DRUG$ and glutethimide;	DDI-false
were @DRUG$ @DRUG$ and theophylline both concentrations in and three different in serum	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and @DRUG$ when administered concomitantly with an intravenous opiate such as @DRUG$.	DDI-mechanism
Data of @DRUG$ other alprazolam suggest possible drug interaction the : ergotamine , cyclosporine , @DRUG$ , nicardipine	DDI-int
should exercised an reductase inhibitor is concomitantly with drugs that decrease the of endogenous steroid , @DRUG$	DDI-false
Interactions : Flupenthixol may interact with , like inhibitors could flupenthixol pharmacodynamics - - Eproxindine - Flupenthixol and @DRUG$ CNS antidepressants : @DRUG$ effect Tricyclic antidepressants	DDI-false
@DRUG$ had no effect on plasma levels of @DRUG$.	DDI-false
The availability of potent @DRUG$ (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (@DRUG$)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
, lidocaine/quinidine , acid quinidine/lidocaine , and .	DDI-false
for amiodarone and serial @DRUG$ concentration concomitant @DRUG$ therapy be	DDI-advise
Antiarrhythmics: Amiodarone, @DRUG$, @DRUG$, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when @DRUG$ was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion.	DDI-false
@DRUG$ : @DRUG$ and beta-blocking agents has well tolerated in patients stable	DDI-false
concentrations of @DRUG$ ( ) - 10(-6 ) M acetate ( 3 10(-8 10(-7 enhance the mitogenic activity of @DRUG$.	DDI-effect
To evaluate HAART on course of with HIV-related , systemic , non-Hodgkin ( , the compared group of 24 HIV-NHL were treated with cyclophosphamide , doxorubicin , , and ( CHOP regimen plus HAART treated CHOP chemotherapy a i.e. cyclophosphamide , @DRUG$ , and prednisone with vincristine plus @DRUG$ without therapy .	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Although specific studies not that CYP3A4 ( eg @DRUG$ , @DRUG$ , , amiodarone quinidine , , , , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , triazolam may elevated concentrations when coadministered ;	DDI-false
CONCOMITANT : interaction were performed in clinical , sodium was used concomitantly with angiotensin- converting ( inhibitors , @DRUG$ , , drugs ( @DRUG$ ) evidence of adverse interactions .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
of ruthenium @DRUG$ ) on inositol were in with recording technique combination fura-2	DDI-false
The zidovudine study dosed subjects with 1200 mg/day of @DRUG$ (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of @DRUG$.	DDI-false
@DRUG$: Amiodarone, bepridil, flecainide, propafenone, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
: @DRUG$ interferes with of @DRUG$ and an increase in the ciprofloxacin serum	DDI-mechanism
@DRUG$ In normal , @DRUG$ and hydrochlorothiazide resulted in significantly increased plasma levels hydrochlorothiazide .	DDI-false
Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with propranolol, @DRUG$, and @DRUG$.	DDI-false
The study the interaction between and both or synthetic analogue @DRUG$ @DRUG$ on the antinonciceptive of these peptides mice	DDI-false
administration possessing nephrotoxic , aminoglycosides , @DRUG$ ) , e.g. @DRUG$ chemotherapy ) cardiotoxic ( , ) e.g. , , ) with may increase .	DDI-false
acetaminophen/theophylline , , , , and @DRUG$/phenobarbital	DDI-false
rifampin CONTRAINDICATED coadministration of this with @DRUG$ @DRUG$ reduces the plasma concentrations of saquinavir	DDI-false
@DRUG$ : Plasma of @DRUG$ approximately and were	DDI-false
Cholestyramine-Concomitant of @DRUG$ and @DRUG$ reduce of vitamin K.	DDI-mechanism
@DRUG$: @DRUG$ interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-advise
: In volunteers , small decrease in @DRUG$ was @DRUG$ concomitantly .	DDI-false
There have reports increased levels quinidine , @DRUG$ , @DRUG$ concomitant therapy with .	DDI-false
During transfer to oral @DRUG$, the dose levels of previously administered agents should be reduced by 30 to 50% several days after the addition of oral @DRUG$.	DDI-false
The of hypotensive effects with enalapril enalaprilat can be either the @DRUG$ the intake to initiation of treatment @DRUG$ .	DDI-false
of potent @DRUG$ (NNRTI)-based regimens @DRUG$ and concerns regarding (PI)-related metabolic HIV infection	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
These results suggest that both @DRUG$ and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and @DRUG$.	DDI-effect
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
: a including , with multivalent products such @DRUG$ sucralfate , VIDEX tablets or powder , or products containing , iron or may substantially decrease @DRUG$ , resulting serum urine considerably lower desired .	DDI-false
@DRUG$ : Administration of @DRUG$ with cyclosporine has been with increase toxicity , due to renal	DDI-false
While 18-MC and @DRUG$ have similar affinities for kappa opioid and possibly nicotinic receptors, @DRUG$ has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
@DRUG$ : use @DRUG$ been well with stable	DDI-false
@DRUG$ should be used @DRUG$ , renal function should be carefully monitored .	DDI-advise
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Since the concomitant @DRUG$ with @DRUG$ the by 100 % 3 to days the be by one-third to prothrombin times should monitored closely .	DDI-false
Interactions Flupenthixol may interact some like oxidase ( MAOI @DRUG$ could theoretically affect pharmacodynamics - Arecoline - - @DRUG$ : and - effect of	DDI-false
Other reported interactions with @DRUG$: Fentanyl (CYP3A4 substrate) in combination with @DRUG$ may cause hypotension, bradycardia, and decreased cardiac output.	DDI-false
Nonsteroidal Anti-Inflammatory administration of @DRUG$ decreased renal and significantly levels	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and @DRUG$, nor the pharmacokinetics of @DRUG$ at steady state.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
has studied effects of the liver interaction @DRUG$ congeners and @DRUG$ coexisting in contents beverages .	DDI-false
In the present study, the atypical antipsychotic @DRUG$ was tested in combination with an active dose of @DRUG$ in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures.	DDI-false
Drug : interact with some drugs inhibitors @DRUG$ could theoretically @DRUG$ pharmacodynamics - Arecoline - Eproxindine Ethanol and cause CNS Tricyclic antidepressants Flupenthixol increases	DDI-effect
Although specific studies have not been performed coadministration that are mainly calcium blockers , @DRUG$ , quinine , amiodarone , warfarin , tacrolimus ergot , , alfentanyl , plasma concentrations when coadministered with @DRUG$ ;	DDI-mechanism
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, @DRUG$, @DRUG$, carbamazepine) may result in decreased plasma levels of saquinavir.	DDI-false
Although @DRUG$ have shown reduce effects , renal insufficiency hyperbilirubinemia , confusion , and dyspnea concomitant these with PROLEUKIN may reduce antitumor effectiveness of and thus should be Beta-blockers and @DRUG$ may with PROLEUKIN	DDI-false
Other Chemotherapy In a separate , concomitant administration @DRUG$ meaningfully the either metabolites of @DRUG$ )	DDI-false
@DRUG$ ( e.g. spironolactone or amiloride ) , @DRUG$ , potassium-containing salt substitutes may lead increases serum	DDI-false
Fenfluramine may increase slightly the effect of @DRUG$, e.g., guanethidine, @DRUG$, reserpine.	DDI-false
, @DRUG$ @DRUG$ , , to potential and/or .	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents, specifically, dacarbazine, cis-platinum, @DRUG$ and interferon-alfa.	DDI-effect
@DRUG$ of @DRUG$ , barbiturates , and .	DDI-effect
the @DRUG$ many , like @DRUG$ be clinically ;	DDI-false
Multivalent Products Concurrent administration of , including , multivalent products @DRUG$ antacids , sucralfate , tablets pediatric powder products , @DRUG$ or zinc substantially the absorption of resulting and lower than	DDI-false
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, @DRUG$, and @DRUG$), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
@DRUG$ (Magnesium-Aluminum Hydroxide): @DRUG$ plasma concentrations were not affected by co-administration of antacid.	DDI-false
specific performed , coadministration with drugs are metabolized ( , , , disopyramide @DRUG$ quinidine warfarin , tacrolimus , , , carbamazepine , alfentanyl , alprazolam , triazolam ) may elevated when coadministered with @DRUG$	DDI-mechanism
BACKGROUND: The effects of combined administration of bombesin and @DRUG$ (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (@DRUG$) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
with are potent ( eg phenobarbital , @DRUG$ , dexamethasone carbamazepine may plasma levels of	DDI-mechanism
Agents Causing Release antihypertensive effect and @DRUG$ IV is augmented by agents renin , @DRUG$	DDI-effect
@DRUG$-Cephalosporins side chains @DRUG$ , cefoperazone cefotetan , , or cefazolin ) can vitamin hypoprothrombinemia	DDI-false
administration of solutions containing epinephrine to patients oxidase inhibitors , @DRUG$ @DRUG$ may prolonged or hypertension	DDI-false
have not performed , coadministration that are by CYP3A4 , channel , disopyramide , @DRUG$ amiodarone , warfarin tacrolimus cyclosporine , @DRUG$ pimozide , , alfentanyl alprazolam , and triazolam ) have elevated plasma coadministered saquinavir ;	DDI-false
Tolbutamide: In diabetic patients receiving diflunisal and @DRUG$, no significant effects were seen on @DRUG$ plasma levels or fasting blood glucose.	DDI-false
Nephrotoxicity has been reported following concomitant administration of @DRUG$ with aminoglycoside antibiotics or potent @DRUG$ such as furosemide.	DDI-effect
Pretreatment of megakaryocytes @DRUG$ 50 )	DDI-effect
Renin : enalapril @DRUG$ is augmented @DRUG$ that renin ( diuretics .	DDI-effect
treatment with as intraconazole , @DRUG$ @DRUG$ , saquinavir , , etc . ) is indicated of budesonide dose should be considered	DDI-false
Caution should be exercised if an @DRUG$ is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, @DRUG$, and cimetidine.	DDI-advise
To thiosulfate would of be , a fixed @DRUG$ given intravenously escalating of	DDI-false
Warfarin @DRUG$ have enhance the effects of the oral @DRUG$ its derivatives .	DDI-false
Other Enalapril enalapril have used concomitantly beta agents , @DRUG$ , , calcium-blocking , , and @DRUG$ without clinically interactions .	DDI-false
studies not been performed coadministration with drugs that mainly by ( calcium channel dapsone , , @DRUG$ , @DRUG$ , cyclosporine , ergot pimozide fentanyl , alfentanyl , alprazolam , triazolam may have plasma when coadministered with saquinavir	DDI-false
Broad-Spectrum sterilize the bowel and @DRUG$ contribution by the intestinal	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
In addition to the interactions noted above, chronic (  2 weeks) oral @DRUG$ administration impairs metabolism of @DRUG$, dextromethorphan, and methotrexate.	DDI-false
@DRUG$ used as a substitute for or @DRUG$.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a @DRUG$) and @DRUG$ under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.	DDI-false
THERAPY studies were performed in , @DRUG$ with angiotensin- ( betablockers , @DRUG$ , and nonsteroidal anti-inflammatory drugs ) without clinically adverse .	DDI-false
Nephrotoxicity has been reported following concomitant administration of cephalosporins with @DRUG$ or potent diuretics such as @DRUG$.	DDI-false
Antiarrhythmics: Amiodarone, @DRUG$, flecainide, @DRUG$, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, @DRUG$ and L-CCG-1, on the above behavioral changes induced by @DRUG$ were found.	DDI-false
acetaminophen/theophylline , phenobarbital/acetaminophen @DRUG$/valproic acid quinidine/@DRUG$ , theophylline/acetaminophen .	DDI-false
Similarly dialyzed were @DRUG$, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with @DRUG$ at three different concentrations in serum.	DDI-false
Drug-drug interactions have not been observed between @DRUG$ and digoxin or @DRUG$.	DDI-false
acetaminophen , phenobarbital with , @DRUG$ @DRUG$ at toxic concentrations the binding of target .	DDI-effect
Coingestion of acetaminophen with theophylline, phenobarbital with @DRUG$, and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Concurrent @DRUG$ and @DRUG$ may result in serum of .	DDI-mechanism
Although studies , coadministration drugs that by ( , calcium channel dapsone , , , @DRUG$ , ergot derivatives carbamazepine , fentanyl alfentanyl , @DRUG$ , ) may have plasma with saquinavir	DDI-false
compounds that are of CYP3A4 , , phenytoin , @DRUG$ @DRUG$ ) result decreased plasma of saquinavir	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$ Renal tubular transport of @DRUG$ may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, clarithromycin).	DDI-false
concomitant : clinical trials the profile in with Acamprosate @DRUG$ , hypnotics and sedatives ( @DRUG$ or non-opioid analgesics was to that subjects placebo these .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
: Altered levels of @DRUG$ ( and have reported in patients receiving concomitant @DRUG$.	DDI-mechanism
of @DRUG$ @DRUG$ : effects on discrimination and rats .	DDI-false
@DRUG$ of @DRUG$-type ( CYP2C9 and ) anticoagulant response is seen amiodarone result or fatal bleeding .	DDI-false
: healthy , plasma concentrations of @DRUG$ increased approximately 40 % of @DRUG$ and , a known cytochrome P450 .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Although studies not been performed , with are mainly by , channel dapsone , quinine , , quinidine @DRUG$ , cyclosporine ergot derivatives , carbamazepine fentanyl , , @DRUG$ have	DDI-false
Anticoagulant inhibition observed during the @DRUG$ secobarbital @DRUG$	DDI-false
Although studies designed to examine drug interactions have not been done, it was noted that @DRUG$ or @DRUG$ treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving Betaseron.	DDI-false
Ergot Derivatives: @DRUG$, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
However absolute number of @DRUG$-related far the deaths in @DRUG$ heroin .	DDI-false
Particular caution is recommended when administering @DRUG$ with CYP3A4 substrates that have a narrow therapeutic window (e.g., @DRUG$ or pimozide).	DDI-advise
DIGOXIN: Plasma @DRUG$ levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg @DRUG$.	DDI-false
Cimetidine: @DRUG$ plasma concentrations and LDL-C reduction were not altered by coadministration of @DRUG$.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Molecular basis for the selective toxicity of @DRUG$ for yeast and @DRUG$ for animal cells.	DDI-false
The of solutions @DRUG$ monoamine oxidase inhibitors , @DRUG$ produce hypotension .	DDI-effect
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
evaluate impact of chemotherapy on clinical patients with HIV-related systemic , non-Hodgkin lymphoma ( HIV-NHL ) the compared a group of 24 with who were the @DRUG$ , doxorubicin , and prednisone ( ) chemotherapy HAART a patients who CHOP or a ( i.e. , @DRUG$ doxorubicin , prednisone plus )	DDI-false
@DRUG$: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of @DRUG$.	DDI-false
@DRUG$ SULAR tablets in @DRUG$ plasma undetectable levels .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
: and enalapril @DRUG$ methyldopa , , calcium-blocking agents , , @DRUG$ digoxin clinically significant interactions	DDI-false
with CYP3A4 activity ( as , @DRUG$ ritonavir saquinavir @DRUG$ . ) reduction the should be .	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-effect
Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the @DRUG$ may be potentiated.	DDI-false
should be patients -receptor agents e.g. , @DRUG$ ) or channel ( e.g. , , and @DRUG$ inhibitor of the potentiation bradycardia , sinus , and ;	DDI-false
@DRUG$-Vitamin K can antagonize the effect of @DRUG$	DDI-false
Additive adverse effects occur is concomitantly other antimuscarinics amantadine , phenothiazines @DRUG$ antidepressants or some @DRUG$.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, @DRUG$, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	DDI-false
, additional interaction studies with @DRUG$ and have demonstrated any effect plasma , and administration to patient population receiving digoxin resulted no difference the extent of of @DRUG$ relative data	DDI-false
If with of ( ketoconazole indinavir saquinavir , @DRUG$ , etc , of @DRUG$ should be .	DDI-advise
Administration @DRUG$ @DRUG$ has an increase synthesis of prostacyclin	DDI-mechanism
Garlic Capsules Garlic capsules should not while taking ( @DRUG$ sole inhibitor due risk decreased @DRUG$ plasma concentrations .	DDI-false
Plasma levels @DRUG$ have oral @DRUG$	DDI-false
Combination of amiodarone with other @DRUG$ therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to @DRUG$.	DDI-false
Antiarrhythmics: Other @DRUG$ drugs, such as @DRUG$, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Antiarrhythmics: Amiodarone, bepridil, @DRUG$, @DRUG$, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Although not coadministration are metabolized CYP3A4 ( , blockers , , quinine quinidine , , , cyclosporine ergot derivatives @DRUG$ @DRUG$ alfentanyl alprazolam , and triazolam have plasma concentrations saquinavir	DDI-false
: should in patients   -receptor blocking ( , a calcium channel e.g. , @DRUG$ substrate , and diltiazem , a @DRUG$ because the bradycardia , sinus , and block	DDI-false
Oral Contraceptives: Coadministration of atorvastatin and an oral @DRUG$ increased AUC values for norethindrone and @DRUG$ by approximately 30% and 20%.	DDI-false
effect of of patient 5 days after the initiation of @DRUG$ extended a after @DRUG$ withdrawal	DDI-false
The bioavailability the capsule formulation of @DRUG$ not affected when administered 5 following @DRUG$.	DDI-false
@DRUG$ ( ) easy and can carried in with @DRUG$s with only contra-indication failure	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Antiarrhythmics: Other @DRUG$ drugs, such as quinidine, procainamide, disopyramide, and @DRUG$, have been used concurrently with amiodarone.	DDI-false
Possible drug interactions of HUMORSOL with @DRUG$ or with other @DRUG$.	DDI-false
Warfarin: Quinolones have been reported to enhance the effects of the oral @DRUG$ @DRUG$ or its derivatives.	DDI-false
@DRUG$ @DRUG$ reported patients receiving lithium concomitantly drugs which cause of including ACE	DDI-false
may alter that : Caution is recommended Gleevec with e.g. @DRUG$ itraconazole @DRUG$ .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
: The extent @DRUG$ was when XR was alone XR 2 @DRUG$ at the that maximally suppresses gastric	DDI-false
Monoamine @DRUG$ be patients @DRUG$ or tricyclic antidepressants of the system may potentiated these	DDI-advise
The , uniformity and time of interference by @DRUG$ , @DRUG$ , , chloral hydrate methaqualone systematically investigated in 16 patients receiving coumarin therapy .	DDI-false
@DRUG$, @DRUG$ and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, hypnotics and sedatives (including benzodiazepines), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
@DRUG$ prothrombin administered @DRUG$ treatment	DDI-false
Sinus bradycardia has been reported with oral @DRUG$ in combination with @DRUG$ (CYP3A4 substrate) given for local anesthesia.	DDI-false
Colestipol-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of @DRUG$.	DDI-false
substances : Grapefruit given to @DRUG$ by and Cmax % resulting in @DRUG$.	DDI-false
@DRUG$ has in patients @DRUG$ concomitantly which cause elimination , ACE inhibitors .	DDI-false
Co-administration : Concomitant @DRUG$ @DRUG$ , and other anticoagulants the risk	DDI-effect
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, @DRUG$, dexamethasone, carbamazepine) may result in decreased plasma levels of @DRUG$.	DDI-mechanism
Reactions to Iodinated Contrast : A the literature revealed that % range - 28 % of patients treated various @DRUG$ containing were administered @DRUG$ experienced adverse .	DDI-effect
been performed , with drugs CYP3A4 ( eg , calcium channel , disopyramide quinine , amiodarone quinidine warfarin tacrolimus cyclosporine , @DRUG$ , carbamazepine , , alfentanyl , @DRUG$ , triazolam ) may coadministered saquinavir ;	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
effects from may is administered concomitantly other , @DRUG$ , @DRUG$ tricyclic antidepressants or some antihistamines	DDI-false
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
The intake of @DRUG$ and @DRUG$ affect of	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
Cation-Containing Products : Concurrent of including @DRUG$ , multivalent cation-containing products @DRUG$ , sucralfate , VIDEX chewable/buffered or powder or products , , or may substantially decrease of resulting in considerably lower desired	DDI-mechanism
, Fondaparinux influenced the pharmacodynamics warfarin acetylsalicylic @DRUG$ , nor the @DRUG$ at state	DDI-false
, these drugs have one or more bepridil , anti-arrhythmic agents such as quinidine and procainamide @DRUG$	DDI-false
It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for @DRUG$ on dopamine2- and serotonin2-receptors underlies the antipsychotic action of @DRUG$ after their prolonged administration.	DDI-false
@DRUG$: The administration of diflunisal to normal volunteers receiving @DRUG$ decreased the renal clearance and significantly increased the plasma levels of indomethacin.	DDI-false
Co-administration of @DRUG$ with @DRUG$ produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.	DDI-mechanism
Probenecid: @DRUG$ interferes with renal tubular secretion of @DRUG$ and produces an increase in the level of ciprofloxacin in serum.	DDI-mechanism
Omeprazole: The rate and extent of absorption of @DRUG$ was bioequivalent when Proquin XR was given alone or when @DRUG$ was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	DDI-false
Interactions like Monoamine @DRUG$ @DRUG$ could theoretically flupenthixol pharmacodynamics Eproxindine - Ethanol : Flupenthixol and CNS antidepressants Flupenthixol the effect of	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	DDI-false
@DRUG$ and @DRUG$: a drug interaction.	DDI-int
@DRUG$ increases enterohepatic elimination of amiodarone reduce and	DDI-false
Since @DRUG$ is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced @DRUG$ levels.	DDI-false
studies not been performed , coadministration drugs are metabolized ( , channel , dapsone , , quinine @DRUG$ quinidine tacrolimus cyclosporine ergot , fentanyl @DRUG$ ) may have plasma when coadministered with saquinavir ;	DDI-false
drug of @DRUG$ with @DRUG$ or with	DDI-int
Sedatives/@DRUG$: @DRUG$, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
Cation-Containing Products administration of a quinolone , including ciprofloxacin or sucralfate , VIDEX chewable/buffered or pediatric powder , calcium @DRUG$ or may decrease of @DRUG$ resulting serum urine levels desired	DDI-false
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of @DRUG$ and nicotine in rats;	DDI-false
in vitro of suggest a drug with @DRUG$ the following : @DRUG$ and paroxetine	DDI-int
@DRUG$ The rate and of ciprofloxacin bioequivalent XR given alone or when after @DRUG$ at the dose maximally acid secretion	DDI-false
There have been case reports of increased steady-state levels of @DRUG$, procainamide, and phenytoin during concomitant therapy with @DRUG$.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
@DRUG$-Concomitant intake of mineral oil and @DRUG$ may reduce the absorption of vitamin K.	DDI-false
@DRUG$ @DRUG$ a newly antipsychotic with in of positive symptoms of	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Antiarrhythmics : Other @DRUG$ drugs such quinidine @DRUG$ disopyramide and been used with amiodarone .	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , , theophylline/acetaminophen , and @DRUG$/phenobarbital .	DDI-false
vitro studies @DRUG$ other than @DRUG$ suggest a drug interaction the ergotamine , ,	DDI-false
Five of @DRUG$ significantly affect pharmacokinetic variables of @DRUG$ compared	DDI-false
Suppression by @DRUG$ of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ in wistar rats.	DDI-false
Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with @DRUG$ has been associated with an increase in @DRUG$-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	DDI-false
@DRUG$ of @DRUG$ to normal the renal clearance increased the of .	DDI-false
alter @DRUG$ plasma concentrations may increase plasma concentrations : Caution when with the CYP3A4 family ( @DRUG$ , , ) .	DDI-false
CONCOMITANT THERAPY Although specific interaction not performed , clinical used ) @DRUG$ blockers diuretics , anti-inflammatory ( @DRUG$ evidence of interactions .	DDI-false
Potassium-sparing diuretics (e.g., spironolactone, @DRUG$, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Quetiapine ' @DRUG$ ' is introduced @DRUG$ efficacy the positive and symptoms	DDI-false
, @DRUG$/acetaminophen , quinidine/@DRUG$ , and valproic acid/phenobarbital	DDI-false
Therefore, it would be expected that a dosing schedule of @DRUG$ given at bedtime and @DRUG$ given before the evening meal would not result in a significant decrease in the clinical effect of cerivastatin sodium.	DDI-false
bowel decrease the @DRUG$ contribution body by .	DDI-false
concomitantly with @DRUG$ less than days increases plasma procainamide n-acetyl @DRUG$ % and , respectively .	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
@DRUG$-Orlistat may decrease the absorption of @DRUG$.	DDI-false
Corticosteroids , Methylxanthines @DRUG$ : treatment with @DRUG$ , steroids , or diuretics hypokalemic effect of beta2-agonists .	DDI-false
FLEXERIL may enhance the effects of @DRUG$, @DRUG$, and other CNS depressants.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and @DRUG$ depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
rifampin amiodarone to result decreases concentrations @DRUG$ and	DDI-false
@DRUG$ , @DRUG$ , quinidine , , valproic pooled at	DDI-false
@DRUG$: The rate and extent of absorption of ciprofloxacin was bioequivalent when @DRUG$ was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	DDI-false
specific have drugs that CYP3A4 ( eg , dapsone disopyramide , amiodarone warfarin , tacrolimus cyclosporine ergot derivatives @DRUG$ , carbamazepine , @DRUG$ , alfentanyl alprazolam ) plasma when coadministered with saquinavir	DDI-false
Antacids administration @DRUG$ levels of @DRUG$.	DDI-mechanism
@DRUG$: Caution should be used if diflunisal is administered concomitantly with @DRUG$.	DDI-false
In addition, @DRUG$ neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, @DRUG$, and digoxin, nor the pharmacokinetics of digoxin at steady state.	DDI-false
Interactions @DRUG$ may interact with drugs , like inhibitors @DRUG$ theoretically affect flupenthixol Ethanol : Ethanol additive depression - antidepressants Flupenthixol increases the effect	DDI-false
Both @DRUG$ 18-MC morphine-induced @DRUG$-induced the nucleus accumbens ;	DDI-effect
Although glucocorticoids been to reduce side effects including fever renal , hyperbilirubinemia , confusion , and administration these agents with PROLEUKIN reduce effectiveness PROLEUKIN @DRUG$ and other may potentiate the hypotension seen with	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as @DRUG$, @DRUG$, disopyramide, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Similarly phenobarbital @DRUG$ , theophylline both in serum and with @DRUG$ three concentrations	DDI-false
clinical studies with , the of warfarin ) platelet ( acetylsalicylic acid ) NSAIDs ( @DRUG$ and @DRUG$ significantly the pharmacokinetics/pharmacodynamics fondaparinux	DDI-false
The effects of @DRUG$ and L-CCG-1 upon @DRUG$ (PCP)-induced locomotion and behavioral changes in mice.	DDI-false
Multivalent Cation-Containing Products Concurrent a , @DRUG$ , cation-containing as magnesium aluminum , @DRUG$ chewable/buffered tablets or , or calcium , iron substantially the resulting serum urine levels lower desired .	DDI-mechanism
Antiarrhythmics , , @DRUG$ , propafenone , @DRUG$ potential for and/or .	DDI-false
@DRUG$ IV has been used concomitantly with @DRUG$ without evidence of clinically significant adverse reactions.	DDI-false
concomitant : trials , safety profile with , hypnotics and @DRUG$ , @DRUG$ was that taking placebo concomitant medications .	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin (@DRUG$), @DRUG$, azole antifungals.	DDI-false
@DRUG$ including tranylcypromine phenelzine and : Concomitant of @DRUG$ inhibitors may .	DDI-false
In studies performed @DRUG$ the of oral anticoagulants ( ) platelet ( @DRUG$ ) , NSAIDs not affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
Antiarrhythmics: Amiodarone, bepridil, flecainide, @DRUG$, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
The continued need for the other @DRUG$ agent should be reviewed after the effects of @DRUG$ have been established, and discontinuation ordinarily should be attempted.	DDI-false
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (@DRUG$), a @DRUG$, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
The possibility effects with or @DRUG$ can minimized either @DRUG$ or the salt initiation with enalapril or	DDI-effect
Anticoagulants : of @DRUG$-type @DRUG$ and CYP3A4 substrate ) anticoagulant response almost always patients receiving and can in serious fatal .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Warfarin: @DRUG$ have been reported to enhance the effects of the oral @DRUG$ warfarin or its derivatives.	DDI-false
@DRUG$ Renal tubular transport methotrexate may be inhibited administration of ciprofloxacin , increased plasma of @DRUG$.	DDI-false
Concurrent administration possessing nephrotoxic , aminoglycosides , indomethacin , @DRUG$ ) ( e.g. ) or hepatotoxic methotrexate @DRUG$ with PROLEUKIN may toxicity in systems	DDI-false
Based results of studies , it is concluded that be with both @DRUG$ @DRUG$.	DDI-false
@DRUG$ Because @DRUG$ not of , interactions drugs the same cytochrome isozymes expected .	DDI-false
It is therefore to be well with the clinical paraclinical deficit due an @DRUG$ only physiological supplementation @DRUG$ depletion a dysregulation of of magnesium more or less specific regulation dysregulation	DDI-false
@DRUG$ , , @DRUG$ and valproic were added to pooled human at therapeutic concentrations	DDI-false
However number of far greater number of deaths @DRUG$ @DRUG$ users .	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, @DRUG$, @DRUG$, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
In clinical studies performed , concomitant ( platelet inhibitors @DRUG$ ) , @DRUG$ did significantly affect of sodium .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and @DRUG$ depletion related to a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation.	DDI-false
The concomitant intake of alcohol and @DRUG$ does not affect the pharmacokinetics of either @DRUG$ or acamprosate.	DDI-false
Histamine H2-receptor antagonists : @DRUG$ appear to have no significant on bioavailability @DRUG$.	DDI-false
Fenfluramine may increase slightly the effect of @DRUG$, e.g., @DRUG$, methyldopa, reserpine.	DDI-false
Moreover , additional with @DRUG$ @DRUG$ any effect on fluvastatin plasma administration patient population chronically resulted no difference extent of digoxin relative to	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
The , uniformity time of anticoagulant interference by @DRUG$ , glutethimide chloral methaqualone were systematically investigated in 16 patients @DRUG$	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, @DRUG$).	DDI-false
Anti-arrhythmics and @DRUG$ could exaggerate the prolongation of the QT interval observed with @DRUG$.	DDI-effect
acetaminophen/theophylline , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen @DRUG$/phenobarbital	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Multivalent Products Concurrent ciprofloxacin with cation-containing products such @DRUG$ or sucralfate , VIDEX or products containing , or @DRUG$ may substantially of ciprofloxacin in serum and urine lower	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
BACKGROUND : effects administration @DRUG$ ( verapamil a incidence of of adenocarcinomas ( @DRUG$ ) the index of intestinal cancers were investigated in .	DDI-false
Erythromycin: In healthy individuals, plasma concentrations of @DRUG$ increased approximately 40% with coadministration of @DRUG$ and erythromycin, a known inhibitor of cytochrome P450 3A4.	DDI-false
Products Concurrent administration of including , with cation-containing products @DRUG$ antacids tablets pediatric , or products , or @DRUG$ the absorption , urine levels considerably lower .	DDI-false
@DRUG$ , CONTRAINDICATED due to serious as @DRUG$ peripheral and ischemia the extremities and other tissues	DDI-false
In an in vitro study in human liver microsomes, inhibition of CYP2A6 hydroxylation of @DRUG$ by @DRUG$ (200 m m M i.e., 350 mg/L) was 17-28%.	DDI-mechanism
specific studies have not been performed , coadministration drugs that mainly ( calcium channel blockers disopyramide quinine amiodarone warfarin tacrolimus , derivatives @DRUG$ , carbamazepine fentanyl , alprazolam and may have when coadministered with @DRUG$ ;	DDI-mechanism
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
Anticoagulants coumarin derivatives derivatives , such @DRUG$ and @DRUG$ may the of administered with .	DDI-false
ERYTHROMYCIN: In hypercholesterolemic patients, steady-state @DRUG$ AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of @DRUG$, a known inhibitor of cytochrome P450 3A4.	DDI-mechanism
Other Drugs:Drugs such as @DRUG$, @DRUG$, procainamide, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
acetaminophen/theophylline , @DRUG$/valproic , quinidine/lidocaine , and	DDI-false
Concomitant @DRUG$ , vincristine , @DRUG$ chemotherapy plus highly active antiretroviral in with immunodeficiency virus-related lymphoma	DDI-false
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving @DRUG$, @DRUG$ or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
Additive adverse from cholinergic blockade may occur LEVSIN is concomitantly with other , @DRUG$ , @DRUG$ , monoamine tricyclic antidepressants some .	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
The concomitant intake of @DRUG$ and Acamprosate does not affect the pharmacokinetics of either alcohol or @DRUG$.	DDI-false
CYP3A4 drugs triazolo-@DRUG$ dihydropyridine calcium , @DRUG$ etc . ) .	DDI-false
Although specific studies have not performed , that are metabolized by , channel blockers , disopyramide quinine @DRUG$ quinidine , warfarin , , , @DRUG$ , carbamazepine , fentanyl , , alprazolam and triazolam ) plasma when	DDI-false
Cardiovascular Agents enalapril have been used with adrenergic-blocking methyldopa nitrates , calcium-blocking , @DRUG$ prazosin @DRUG$ without adverse interactions .	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
There of steady-state levels @DRUG$ , procainamide , and @DRUG$ during with .	DDI-false
Cephalosporins-Cephalosporins of N-methylthiotetrazole cefmenoxime , cefoperazone , @DRUG$ , @DRUG$ cefazolin ) can deficiency and hypoprothrombinemia .	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
have not performed that mainly metabolized by eg , channel blockers , dapsone , quinine amiodarone , warfarin , cyclosporine , @DRUG$ , pimozide , carbamazepine fentanyl and triazolam ) have elevated concentrations when with @DRUG$	DDI-mechanism
of during with drugs of class concurrent administration of fibric acid derivatives , @DRUG$ ( @DRUG$ , azole antifungals .	DDI-false
ANTACID @DRUG$ @DRUG$ were not affected of antacid	DDI-false
Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as @DRUG$, spironolactone, and @DRUG$.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, @DRUG$, @DRUG$, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
to 3A Inhibitors Clinical of Clinical Studies Involving Alprazolam caution is recommended during with @DRUG$ ): @DRUG$ with alprazolam the concentration alprazolam by % , decreased clearance , half-life 17 % , decreased psychomotor .	DDI-false
In the first study, concomitant administration of 0.2 mg @DRUG$ and 12 g @DRUG$ resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.	DDI-mechanism
@DRUG$ and @DRUG$ similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Pretreatment healthy volunteers multiple doses @DRUG$ followed a dose of Gleevec , @DRUG$ oral-dose by significantly ( p 0.05 AUC(0 8) .	DDI-false
Sinus bradycardia has been reported with oral @DRUG$ in combination with lidocaine (@DRUG$ substrate) given for local anesthesia.	DDI-false
@DRUG$ is a substrate for both @DRUG$ and CYP3A4.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Renal of methotrexate of @DRUG$ , leading increased plasma levels @DRUG$.	DDI-false
, as @DRUG$ , and @DRUG$ inhibit vitro , and decrease platelet adhesion .	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Further, no effects on either @DRUG$ levels or prothrombin times were observed in a study involving concomitant administration of @DRUG$ and fluvastatin.	DDI-false
Both @DRUG$ and @DRUG$ block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens;	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, @DRUG$, @DRUG$, and nifedipine.	DDI-false
specific , coadministration with by ( , dapsone disopyramide , , , , cyclosporine , @DRUG$ pimozide , @DRUG$ fentanyl alfentanyl , triazolam have plasma concentrations coadministered with ;	DDI-false
@DRUG$ (e.g., spironolactone, @DRUG$, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
, lidocaine/quinidine , @DRUG$/@DRUG$ phenobarbital/valproic , , valproic acid/phenobarbital	DDI-false
The benzodiazepines are a family of @DRUG$ and @DRUG$.	DDI-false
Drugs Demonstrated to CYP Inhibitors Possible Clinical Significance the Basis of Alprazolam caution recommended with Coadministration @DRUG$ with increased the maximum plasma @DRUG$ 21 , half-life % performance	DDI-false
In view of the long and variable half-life of @DRUG$, potential for drug interactions exists not only with concomitant medication but also with drugs administered after discontinuation of @DRUG$.	DDI-false
@DRUG$: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma @DRUG$ concentrations increased by approximately 20%.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and @DRUG$ (@DRUG$) without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ the effects the @DRUG$ its derivatives .	DDI-effect
Caution should be exercised if an @DRUG$ is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as @DRUG$, spironolactone, and cimetidine.	DDI-advise
been reports of prolongation with TdP in taking amiodarone when @DRUG$ , @DRUG$ were administered	DDI-false
Although this effect was noted even when @DRUG$ was given 4 hours prior to @DRUG$, this regimen did not result in diminished efficacy.	DDI-effect
Both have been compared to triple with the @DRUG$ over weeks as initial therapy responses being with @DRUG$ and with efavirenz	DDI-false
These results suggest that both dexamethasone and @DRUG$, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and @DRUG$.	DDI-effect
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for @DRUG$ therapy and concerns regarding @DRUG$ (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, @DRUG$, amiodarone, @DRUG$, and nifedipine.	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
In general , these more pharmacologic similar to @DRUG$ , anti-arrhythmic agents such as @DRUG$ , and tricyclic anti-depressants	DDI-false
Although specific studies not been performed , coadministration with drugs mainly metabolized by blockers , , quinine amiodarone , cyclosporine derivatives pimozide , @DRUG$ , , , alprazolam and @DRUG$ ) concentrations saquinavir ;	DDI-false
@DRUG$ @DRUG$ ) observed by measuring and stereotyped behavior .	DDI-false
@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Antihypertensives @DRUG$ should be caution in receiving   e.g. , propranolol , CYP3A4 inhibitor antagonists ( verapamil @DRUG$ and diltiazem , CYP3A4 ) because of possible of sinus arrest and block	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, @DRUG$, and @DRUG$.	DDI-false
@DRUG$ increases enterohepatic elimination of @DRUG$ and may reduce its serum levels and t1/2.	DDI-false
Other reported interactions @DRUG$ Fentanyl ( @DRUG$ substrate ) combination with amiodarone , bradycardia , and .	DDI-false
Oral @DRUG$: Pharmacokinetic drug-drug interactions between @DRUG$ and warfarin (7.5 mg single oral dose) have not been demonstrated.	DDI-false
Anticoagulants: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) @DRUG$ response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	DDI-false
@DRUG$ will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-@DRUG$, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).	DDI-mechanism
Administration of rifampin concomitantly with oral @DRUG$ has been shown to result in decreases in serum concentrations of amiodarone and @DRUG$.	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
Concomitant @DRUG$, doxorubicin, vincristine, and prednisone chemotherapy plus @DRUG$ therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, @DRUG$, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
The intensity time course @DRUG$ by @DRUG$ , chloral hydrate and were systematically investigated patients receiving therapy .	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Aspirin/@DRUG$ have been between ( mg given 26 2 hours to initiation @DRUG$   over ) or given , 6 hours prior and initiation of 1.5   . 18 hours	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, @DRUG$, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$ reported to blunt the hypotensive of systemic @DRUG$.It known whether the of these in humans lead interference with IOP effect	DDI-effect
specific studies have performed , that mainly CYP3A4 ( eg , calcium blockers @DRUG$ , quinine quinidine , cyclosporine , ergot pimozide , carbamazepine @DRUG$ , alprazolam , triazolam ) have plasma concentrations with saquinavir ;	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
have shown effects renal insufficiency hyperbilirubinemia , dyspnea concomitant of agents antitumor effectiveness thus should be avoided other @DRUG$ may potentiate the PROLEUKIN .	DDI-false
Concomitantly given @DRUG$ did not the of a tablet @DRUG$.	DDI-false
Co-administration of @DRUG$ and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the toxin may be potentiated.	DDI-advise
Cation-Containing Products including , @DRUG$ @DRUG$ antacids , , VIDEX chewable/buffered tablets or pediatric powder or products , or may decrease the absorption , resulting in serum urine lower than desired	DDI-false
therefore to well the and pattern of and to discriminate magnesium deficiency an insufficient @DRUG$ requires oral depletion related to of the of @DRUG$ which requires more specific of causal dysregulation	DDI-false
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with @DRUG$ and @DRUG$.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
Beta-blocking : @DRUG$ @DRUG$ has been in patients stable .	DDI-false
concomitantly with @DRUG$ @DRUG$ serum 33 % two	DDI-false
HMG-CoA Reductase Inhibitors: Simvastatin (@DRUG$ substrate) in combination with @DRUG$ has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
In a clinical pharmacology study, @DRUG$ or @DRUG$ was administered to hypertensive patients receiving VASOTEC.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some @DRUG$.	DDI-false
Antihypertensives Amiodarone should used -receptor agents propranolol , CYP3A4 inhibitor channel antagonists e.g. , a CYP3A4 substrate and @DRUG$ , @DRUG$ ) because possible of sinus arrest AV	DDI-false
Suppression by @DRUG$ of @DRUG$-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.	DDI-effect
Potassium-sparing diuretics (e.g., spironolactone, @DRUG$, or amiloride), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Sedatives/@DRUG$ : @DRUG$ potential for serious and/or reactions such as prolonged or increased sedation	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, @DRUG$, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, @DRUG$, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	DDI-advise
@DRUG$ : if is concomitantly @DRUG$.	DDI-false
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$: Co- administration of warfarin and @DRUG$ to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.	DDI-false
clinical studies with Fondaparinux , concomitant use ( warfarin , @DRUG$ acetylsalicylic acid NSAIDs , digoxin not significantly affect the @DRUG$.	DDI-false
Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and @DRUG$.	DDI-int
Antihypertensives : should used receiving   -receptor ( e.g. , @DRUG$ , a ) or calcium channel antagonists ( verapamil a CYP3A4 substrate , and diltiazem , @DRUG$ because of possible potentiation , arrest , and AV block	DDI-false
specific studies not been performed , coadministration with drugs mainly by ( calcium channel , @DRUG$ , , amiodarone , tacrolimus @DRUG$ , pimozide , fentanyl , alfentanyl triazolam ) may when coadministered with	DDI-false
Corticosteroids , Diuretics : treatment with @DRUG$ steroids , or @DRUG$ may potentiate a possible effect of  	DDI-false
To evaluate the course patients with , systemic non-Hodgkin ( ) authors a of HIV-NHL who were with , doxorubicin @DRUG$ , prednisone CHOP chemotherapy regimen plus HAART with 80 patients who treated with CHOP or a CHOP-like ( i.e. , cyclophosphamide , doxorubicin and prednisone with receiving @DRUG$	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
While @DRUG$ and ibogaine affinities for kappa opioid possibly nicotinic , @DRUG$ much lower ibogaine for and , channels transporter	DDI-false
Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and @DRUG$ resulted in significantly increased plasma levels of @DRUG$.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
Multivalent Cation-Containing a quinolone , including , cation-containing such aluminum @DRUG$ , chewable/buffered tablets or , calcium @DRUG$ zinc the , and urine considerably lower	DDI-false
Ergot Derivatives: Dihydroergotamine, @DRUG$, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Digoxin: When multiple doses of @DRUG$ and digoxin were coadministered, steady-state plasma @DRUG$ concentrations increased by approximately 20%.	DDI-false
@DRUG$: Plasma digoxin levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg @DRUG$.	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-effect
@DRUG$: Atorvastatin plasma concentrations and LDL-C reduction were not altered by coadministration of @DRUG$.	DDI-false
Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of @DRUG$ and @DRUG$.	DDI-false
Agents Causing Renin Release: The antihypertensive effect of @DRUG$ and enalapril IV is augmented by @DRUG$ that cause renin release (e.g., diuretics).	DDI-effect
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
: pharmacodynamic drug-drug not been concomitantly administered aspirin mg given 26 hours prior to initiation @DRUG$ 1   . over @DRUG$ 1000 mg given 6 and 0 prior , and 6 and 12 hours subsequent to , of 1.5   g/kg/min . 18 hours )	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Concurrent administration of @DRUG$ and androgens may result in elevated serum levels of @DRUG$.	DDI-false
Co-administration: Concomitant use of @DRUG$ with antiplatelet agents, thrombolytics, and other @DRUG$ may increase the risk of bleeding.	DDI-effect
While @DRUG$ and @DRUG$ have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, @DRUG$, and @DRUG$.	DDI-false
Co-administration of BOTOX and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the toxin may be potentiated.	DDI-false
The availability of reverse (NNRTI)-based for @DRUG$ therapy concerns disturbances have significant shifts in treatment in HIV	DDI-false
Although neither @DRUG$ affected of epithelium in RPMI1640 containing alone they modify mitogenic of @DRUG$.	DDI-effect
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-effect
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, @DRUG$, niacin (nicotinic acid), erythromycin, azole antifungals.	DDI-false
BACKGROUND: The effects of combined administration of @DRUG$ and verapamil hydrochloride (@DRUG$), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including @DRUG$ such as @DRUG$ and procainamide, cardiac glycosides and tricyclic anti-depressants.	DDI-false
data clinical trials currently the 3 approved @DRUG$ , @DRUG$ )	DDI-false
, , acid , , and valproic	DDI-false
Both @DRUG$ and 18-MC block @DRUG$-induced and nicotine-induced dopamine release in the nucleus accumbens;	DDI-effect
effects @DRUG$ and were additive @DRUG$ was but basal conditions .	DDI-false
Multivalent Cation-Containing Products Concurrent , , with as @DRUG$ or , sucralfate @DRUG$ or , or calcium iron , zinc may the of ciprofloxacin , resulting levels desired	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
of @DRUG$ and @DRUG$ the absorption vitamin K.	DDI-mechanism
Anticoagulants of ( ) @DRUG$ is almost in @DRUG$ and result serious fatal .	DDI-false
Antiarrhythmics: Other @DRUG$ drugs, such as quinidine, @DRUG$, disopyramide, and phenytoin, have been used concurrently with amiodarone.	DDI-false
is patients understand use @DRUG$ ( @DRUG$ ) capsules supplied inhalation it used in other asthma or COPD	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
@DRUG$ could exaggerate the depression of AV nodal conduction observed with @DRUG$.	DDI-effect
Although studies have not performed , coadministration with drugs by CYP3A4 ( @DRUG$ , @DRUG$ , disopyramide , quinine , amiodarone , quinidine warfarin , tacrolimus cyclosporine ergot pimozide , , , , alprazolam and triazolam may elevated saquinavir ;	DDI-false
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and @DRUG$.	DDI-int
of @DRUG$ and K reduce	DDI-false
of a quinolone including ciprofloxacin , with cation-containing products @DRUG$ @DRUG$ chewable/buffered tablets or powder , containing calcium , iron , zinc substantially decrease the serum and lower desired .	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
have not been , are by CYP3A4 ( eg calcium channel blockers , dapsone @DRUG$ amiodarone , quinidine , warfarin cyclosporine , pimozide , @DRUG$ , , and triazolam may have elevated plasma when coadministered	DDI-false
Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-@DRUG$, @DRUG$, certain HMG-CoA reductase inhibitors, etc.).	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Prostatic proliferates defined medium transferrin ( @DRUG$ ( 10 ng/ml ) , and @DRUG$ ( micrograms/ml IU/ml .	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, @DRUG$, piroxicam, and @DRUG$, nor the pharmacokinetics of digoxin at steady state.	DDI-false
determine injection of thiosulfate permit doses of @DRUG$ to be administered a 9.9-g/m2 dose intravenously three hours concurrently with doses @DRUG$.	DDI-false
Drugs Demonstrated Clinical the Basis Clinical Studies Involving @DRUG$ Coadministration fluoxetine with alprazolam plasma of @DRUG$ 46 decreased by 21 % , increased 17 % , and decreased psychomotor .	DDI-false
@DRUG$ the effects alcohol , , and	DDI-effect
@DRUG$/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/@DRUG$ , and acid/phenobarbital .	DDI-false
Additive effects resulting blockade may @DRUG$ administered with , @DRUG$ haloperidol , , oxidase ) tricyclic antidepressants .	DDI-effect
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
@DRUG$/theophylline , , phenobarbital/acetaminophen , acid quinidine/lidocaine and valproic	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	DDI-false
@DRUG$ and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
from in vitro of @DRUG$ other than possible drug for following : @DRUG$ , , , and nifedipine	DDI-int
Withdrawal @DRUG$ decreased @DRUG$ requirement by 50 .	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The concomitant use of @DRUG$ tablets and other @DRUG$ is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.	DDI-effect
High-dose @DRUG$ with @DRUG$ protection.	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Concomitant @DRUG$, doxorubicin, vincristine, and @DRUG$ chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
In general , are drugs that more pharmacologic bepridil hydrochloride , @DRUG$ quinidine and @DRUG$.	DDI-false
While @DRUG$ and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
@DRUG$ derivatives derivatives , platelet inhibitors such as nonsteroidal ) and the risk bleeding administered concomitantly @DRUG$.	DDI-effect
increase slightly effect of @DRUG$ e.g. , guanethidine , @DRUG$ , reserpine	DDI-false
@DRUG$ @DRUG$ ocular renal effects humans .	DDI-false
: As other @DRUG$ administration of ciprofloxacin with @DRUG$ may lead elevated serum theophylline prolongation of its elimination half-life	DDI-mechanism
Although specific studies have not performed , drugs that are metabolized by CYP3A4 , blockers , @DRUG$ quinine , amiodarone @DRUG$ tacrolimus derivatives , alprazolam and ) plasma coadministered ;	DDI-false
@DRUG$: Probenecid interferes with renal tubular secretion of @DRUG$ and produces an increase in the level of ciprofloxacin in serum.	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
@DRUG$ including tranylcypromine sulfate, @DRUG$, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
In the study , administration @DRUG$ and 12 g cholestyramine resulted decreases of more than % for AUC and 40 when dosing @DRUG$ .	DDI-false
effects of administration of bombesin and @DRUG$ @DRUG$ ) channel blocker , on the peritoneal of intestinal adenocarcinomas azoxymethane AOM ) and intestinal cancers investigated male Wistar	DDI-false
are inducers of ( eg , @DRUG$ @DRUG$ may in decreased levels of	DDI-false
should be @DRUG$ are given	DDI-advise
acetaminophen/@DRUG$ lidocaine/quinidine , phenobarbital/valproic , , and acid/phenobarbital .	DDI-false
Both @DRUG$ and to therapy with the @DRUG$ over 48 as , with similar responses being observed with regimens observed .	DDI-false
been shown effects insufficiency , hyperbilirubinemia , dyspnea of agents with reduce the effectiveness of and thus @DRUG$ and other with @DRUG$.	DDI-effect
@DRUG$ , Methylxanthines Diuretics Concomitant derivatives @DRUG$ or potentiate possible .	DDI-false
@DRUG$ , @DRUG$ for serious .	DDI-false
Although neither @DRUG$ nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and @DRUG$.	DDI-effect
: Flupenthixol may interact with some drugs , like Monoamine oxidase ( @DRUG$ could flupenthixol Arecoline - Eproxindine - : @DRUG$ additive depression - : the of	DDI-false
Drug interact with some drugs , like oxidase inhibitors ( ): could affect flupenthixol pharmacodynamics - Arecoline and Ethanol antidepressants : @DRUG$ the of @DRUG$	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
potent reverse (@DRUG$)-based for @DRUG$ therapy concerns inhibitor disturbances to significant shifts practices in infection	DDI-false
Clinical implications of @DRUG$ interactions with five @DRUG$.	DDI-int
Causing effect @DRUG$ @DRUG$ is by agents that renin ( e.g. .	DDI-false
@DRUG$/@DRUG$ : , to serious life-threatening reactions as prolonged or or depression	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
studies have not been performed coadministration with drugs that are mainly metabolized CYP3A4 eg , @DRUG$ dapsone disopyramide , @DRUG$ , cyclosporine , , fentanyl , may have elevated plasma concentrations when saquinavir ;	DDI-false
@DRUG$/theophylline , lidocaine/quinidine , @DRUG$/acetaminophen phenobarbital/valproic acid , theophylline/acetaminophen ,	DDI-false
, , procainamide , @DRUG$ , have been concurrently with @DRUG$.	DDI-false
Here we show combination of @DRUG$ or 3,7-dihydroxyflavone with @DRUG$ used resistant Enterococcus and level of vancomycin-sensitive strains	DDI-false
interactions between @DRUG$ and warfarin	DDI-false
Antipyrine: Because atorvastatin does not affect the pharmacokinetics of @DRUG$, interactions with other @DRUG$ metabolized via the same cytochrome isozymes are not expected.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Drugs such as disopyramide , @DRUG$ antihistamines , and @DRUG$ may be associated QT-interval prolongation and an increased risk of arrhythmia .	DDI-false
Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving @DRUG$ decreased the renal clearance and significantly increased the plasma levels of @DRUG$.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
@DRUG$ have been reported to decrease the tubular secretion of @DRUG$ and to potentiate its toxicity.	DDI-mechanism
In studies performed with Fondaparinux , the concomitant use of anticoagulants platelet acetylsalicylic , NSAIDs @DRUG$ ) , and digoxin did not significantly affect	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (@DRUG$), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
Barbiturates and @DRUG$ should not patients @DRUG$.	DDI-advise
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
acetaminophen/theophylline lidocaine/quinidine , phenobarbital/valproic , theophylline/@DRUG$ , and .	DDI-false
@DRUG$ , phenobarbital quinidine , @DRUG$ acid serum	DDI-false
Since the concomitant administration of @DRUG$ with amiodarone increases the prothrombin time by 100% after 3 to 4 days, the dose of the @DRUG$ should be reduced by one-third to one-half, and prothrombin times should be monitored closely.	DDI-false
Multivalent Cation-Containing Products : administration of @DRUG$ , including ciprofloxacin , multivalent cation-containing products such as @DRUG$ or aluminum antacids , VIDEX chewable/buffered tablets or , or , substantially decrease the of ciprofloxacin , serum urine levels desired .	DDI-mechanism
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
: be with in patients -receptor agents ( e.g. , , a inhibitor @DRUG$ ( e.g. , @DRUG$ , inhibitor because of of arrest , block	DDI-false
Oral Contraceptives : Coadministration @DRUG$ an @DRUG$ increased AUC values for norethindrone and estradiol approximately 30 and 20 %	DDI-mechanism
Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$ and @DRUG$.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Anticoagulants: Potentiation of @DRUG$-type (CYP2C9 and @DRUG$ substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
dialyzed were phenobarbital @DRUG$ and @DRUG$ both alone therapeutic concentrations serum and ethanol at concentrations in .	DDI-false
acetaminophen/theophylline , , phenobarbital/acetaminophen phenobarbital/valproic acid , @DRUG$/lidocaine , and acid/@DRUG$.	DDI-false
Little has been studied of the adverse effects of the exposure of the liver to the interaction of @DRUG$ with its congeners and @DRUG$, coexisting in the contents of alcoholic beverages.	DDI-false
@DRUG$ or other medications with anticholinergic activity - anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$;	DDI-false
Based on these studies it that @DRUG$ may be coadministered with both @DRUG$ .	DDI-false
@DRUG$ - prior ingestion of diphenidol may decrease the emetic response to @DRUG$ in the treatment of poisoning.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Nephrotoxicity has been reported following concomitant administration of @DRUG$ and @DRUG$.	DDI-effect
Corticosteroids, @DRUG$ and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-false
1 hour after starting the @DRUG$ or @DRUG$ 500 mg p.o.	DDI-false
of glucose and @DRUG$ @DRUG$ co-administered conditions	DDI-false
@DRUG$ decreased the hyperuricemic effect of @DRUG$.	DDI-effect
Administration of @DRUG$ concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of @DRUG$ and desethylamiodarone.	DDI-false
Concomitant cyclophosphamide @DRUG$ @DRUG$ , chemotherapy plus highly antiretroviral in with immunodeficiency virus-related , .	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
interactions following concomitant of ( e.g. @DRUG$ , analgesics , @DRUG$ )	DDI-false
ibogaine ( 40 ) 40 mg/kg intravenous self-administration and @DRUG$ oral self-administration @DRUG$ and in	DDI-false
addition , Fondaparinux @DRUG$ @DRUG$ , and nor the pharmacokinetics digoxin at steady state .	DDI-false
The effects of ruthenium red (RR) on @DRUG$ (@DRUG$)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
specific have not drugs ( , @DRUG$ , dapsone , , amiodarone , @DRUG$ , , tacrolimus cyclosporine , derivatives pimozide , , fentanyl alfentanyl , , and may elevated plasma when coadministered with saquinavir ;	DDI-false
Concurrent administration of @DRUG$ and @DRUG$ may result in elevated serum levels of oxyphenbutazone.	DDI-mechanism
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, secobarbital, @DRUG$, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Additive adverse effects may occur when LEVSIN is administered concomitantly other @DRUG$ , haloperidol , ( ) inhibitors @DRUG$ or .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
acetaminophen/@DRUG$ , , , acid/phenobarbital	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Glyburide: The concomitant administration of @DRUG$ with the sulfonylurea @DRUG$ has, on rare occasions, resulted in severe hypoglycemia.	DDI-effect
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, @DRUG$, disopyramide, and @DRUG$, have been used concurrently with amiodarone.	DDI-false
Oxidase Tricyclic @DRUG$ should administered with extreme in patients being treated oxidase antidepressants because action of @DRUG$ on the cardiovascular may be potentiated these agents	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
during treatment this class is concurrent administration of @DRUG$ , fibric acid , niacin nicotinic ) , @DRUG$	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Antihypertensives @DRUG$ with caution patients agents @DRUG$ a channel antagonists , , a substrate diltiazem potentiation of , arrest , and AV	DDI-false
Although have reduce PROLEUKIN-induced including renal insufficiency hyperbilirubinemia and dyspnea , agents @DRUG$ may effectiveness @DRUG$ should . 12 and other antihypertensives potentiate PROLEUKIN	DDI-false
Multivalent Cation-Containing Products : Concurrent of a quinolone , including ciprofloxacin , with such as aluminum @DRUG$ , @DRUG$ chewable/buffered pediatric products calcium iron may substantially absorption of ciprofloxacin in urine considerably than desired .	DDI-false
The possibility effects with @DRUG$ or enalaprilat by the @DRUG$ or increasing the intake to of treatment .	DDI-effect
No data are available for the coadministration of INVIRASE/@DRUG$ or @DRUG$/ritonavir and garlic capsules.	DDI-false
Therefore it that a cerivastatin bedtime and @DRUG$ evening meal not result in decrease in the of @DRUG$.	DDI-false
FLEXERIL may enhance the effects of @DRUG$, barbiturates, and other @DRUG$.	DDI-false
Multivalent Cation-Containing : Concurrent of including ciprofloxacin , with cation-containing products such as magnesium @DRUG$ , VIDEX tablets or powder or containing , or @DRUG$ may decrease the absorption ciprofloxacin resulting in serum urine levels lower .	DDI-false
Cation-Containing Products : Concurrent a @DRUG$ including , with products as aluminum antacids tablets or powder or @DRUG$ , or may substantially decrease absorption of , in serum .	DDI-mechanism
Ergot Derivatives : @DRUG$ , ergonovine , ergotamine , @DRUG$ to for and such as acute toxicity characterized peripheral the other tissues	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other @DRUG$ and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
@DRUG$ has been shown to have neuromuscular blocking properties that may enhance the action of other @DRUG$.	DDI-effect
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, @DRUG$, @DRUG$ (nicotinic acid), erythromycin, azole antifungals.	DDI-false
concomitant : In clinical the safety profile in subjects treated Acamprosate anxiolytics hypnotics and @DRUG$ or @DRUG$ was subjects with these concomitant medications	DDI-false
such as @DRUG$ , @DRUG$ and nifedipine , platelet activation in , platelet intravascularly	DDI-false
not been with drugs that are mainly ( eg , channel , disopyramide , quinine , , , warfarin , , @DRUG$ , @DRUG$ , carbamazepine , and triazolam plasma concentrations coadministered with ;	DDI-false
of @DRUG$-type ( CYP2C9 and substrate @DRUG$ is seen amiodarone in serious or	DDI-false
@DRUG$ patients @DRUG$ and , no effects were seen plasma levels or blood glucose .	DDI-false
Acetaminophen lidocaine , @DRUG$ , , theophylline @DRUG$ were to pooled serum at concentrations	DDI-false
Moreover, the mechanisms underlying the development of dependence may be similar for @DRUG$ and @DRUG$.	DDI-false
Multivalent Products administration a , including ciprofloxacin , with multivalent cation-containing such @DRUG$ aluminum antacids , , tablets powder , or containing calcium @DRUG$ , decrease absorption of in serum urine levels considerably than desired .	DDI-false
with for plasma concentrations of @DRUG$ n-acetyl @DRUG$ by % , respectively	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, @DRUG$, carbamazepine) may result in decreased plasma levels of @DRUG$.	DDI-mechanism
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, ritonavir, @DRUG$, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
@DRUG$ have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with @DRUG$ in humans can lead to resulting interference with the IOP lowering effect.	DDI-false
Coingestion of @DRUG$ with theophylline, phenobarbital with acetaminophen, and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
, , phenobarbital/valproic acid quinidine/lidocaine theophylline/acetaminophen and @DRUG$/phenobarbital	DDI-false
Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-@DRUG$, dihydropyridine calcium channel blockers, certain @DRUG$, etc.).	DDI-false
Corticosteroids, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, phenothiazines, @DRUG$, tricyclic antidepressants or some antihistamines.	DDI-false
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
@DRUG$ @DRUG$	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, @DRUG$, and CYP3A4.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, @DRUG$, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
specific studies not been with drugs are metabolized , blockers disopyramide @DRUG$ , , , cyclosporine , derivatives , , fentanyl @DRUG$ , and triazolam have plasma concentrations when saquinavir	DDI-false
Combination of @DRUG$ with other antiarrhythmic therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to @DRUG$.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with @DRUG$, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ : @DRUG$ with renal secretion of and produces increase the ciprofloxacin in	DDI-false
@DRUG$-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics, hypnotics and sedatives (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Antacids: Concomitant administration of @DRUG$ may reduce plasma levels of @DRUG$.	DDI-mechanism
@DRUG$: Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic @DRUG$ treatment.	DDI-false
addition to the interactions above , 2 weeks ) oral Cordarone administration phenytoin , @DRUG$ ,	DDI-false
Monoamine @DRUG$ : @DRUG$ should administered caution patients treated or tricyclic antidepressants because of on potentiated these .	DDI-false
In a clinical pharmacology study, @DRUG$ or sulindac was administered to hypertensive patients receiving @DRUG$.	DDI-false
@DRUG$-Concomitant intake @DRUG$ may reduce absorption of vitamin	DDI-false
: antiarrhythmic drugs , as quinidine , @DRUG$ , @DRUG$ have been amiodarone .	DDI-false
@DRUG$-@DRUG$ can antagonize the effect of warfarin	DDI-false
Coingestion of @DRUG$ with @DRUG$, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-effect
Longitudinal assessment of @DRUG$ in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on @DRUG$.	DDI-false
: The rate extent absorption ciprofloxacin was bioequivalent Proquin XR given when @DRUG$ @DRUG$ maximally acid secretion	DDI-false
suggest a interaction @DRUG$ the following :	DDI-int
Aspirin/@DRUG$ : pharmacodynamic drug-drug interactions have been demonstrated between @DRUG$ mg given 26 hours initiation of Argatroban 1 . 4 hours or mg given and 0 hours prior , 6 subsequent to of over ) .	DDI-false
Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., @DRUG$, fluoxetine, and @DRUG$.	DDI-false
The pharmacokinetics of naltrexone and its major metabolite @DRUG$ were unaffected following co-administration with @DRUG$.	DDI-false
@DRUG$ : and extent absorption of ciprofloxacin was bioequivalent when @DRUG$ was given or Proquin XR was at the maximally gastric acid secretion .	DDI-false
Further, no effects on either @DRUG$ levels or prothrombin times were observed in a study involving concomitant administration of warfarin and @DRUG$.	DDI-false
: diabetic @DRUG$ and @DRUG$ no significant or .	DDI-false
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., narcotics, analgesics, antiemetics, sedatives, @DRUG$).	DDI-false
Drug Flupenthixol may some , like oxidase inhibitors ( ): MAOI theoretically @DRUG$ pharmacodynamics - Arecoline - Ethanol : @DRUG$ and Ethanol cause CNS Tricyclic increases the effect of	DDI-false
Since @DRUG$ does markedly CYP450s ( , CYP2A6 , CYP2C19 , CYP2D6 or CYP3A4 @DRUG$ expected to with drugs vivo by these isozymes	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, @DRUG$, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	DDI-advise
@DRUG$ administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of @DRUG$ on drug metabolism in MS patients is unknown.	DDI-false
Tolbutamide : In diabetic receiving @DRUG$ and tolbutamide , significant seen on @DRUG$ levels blood	DDI-false
the mechanisms development be similar @DRUG$ @DRUG$.	DDI-false
and (ii) the effects of @DRUG$ were more efficiently inhibited by added cholesterol, the major membrane sterol in human cells, whereas the effects of @DRUG$ were more efficiently inhibited by ergosterol, the major membrane sterol in yeast.	DDI-false
@DRUG$ no significant on @DRUG$	DDI-false
The effects of DCG-IV and L-CCG-1 upon @DRUG$ (@DRUG$)-induced locomotion and behavioral changes in mice.	DDI-false
@DRUG$ and retinyl acetate similarly inhibit and stimulate EGF- or @DRUG$-induced proliferation of prostatic epithelium.	DDI-effect
, lidocaine/quinidine phenobarbital/acetaminophen @DRUG$/valproic acid quinidine/lidocaine @DRUG$/acetaminophen , valproic acid/phenobarbital	DDI-false
with of this increased with administration @DRUG$ , fibric derivatives @DRUG$ , , azole	DDI-false
not been , are by CYP3A4 ( eg , calcium channel blockers , , @DRUG$ quinine , , , , @DRUG$ alfentanyl may elevated concentrations when coadministered with saquinavir	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$: In healthy individuals, plasma concentrations of @DRUG$ increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.	DDI-false
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole ( @DRUG$ , cefamandole latamoxef ( ) cause vitamin K and .	DDI-false
The effects of @DRUG$ (RR) on @DRUG$ (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
Cardiovasculars: @DRUG$: In patients receiving @DRUG$ therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., @DRUG$, analgesics, antiemetics, sedatives, @DRUG$).	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
HMG-CoA Reductase Inhibitors: @DRUG$ (@DRUG$ substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
@DRUG$ could exaggerate depression of AV conduction observed with @DRUG$.	DDI-effect
The effects of concomitant @DRUG$ administration on the steady-state pharmacokinetics of @DRUG$.	DDI-false
drug studies have been completed both @DRUG$ @DRUG$.	DDI-false
@DRUG$ may interfere with the absorption of @DRUG$.	DDI-mechanism
@DRUG$ Lithium toxicity has reported in lithium with which elimination @DRUG$.	DDI-false
Both @DRUG$ and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only @DRUG$ increases extracellular levels of serotonin in the nucleus accumbens.	DDI-false
Although studies designed to examine drug interactions have not been done, it was noted that @DRUG$ or ACTH treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving @DRUG$.	DDI-false
Acetaminophen , @DRUG$ @DRUG$ added at concentrations .	DDI-false
@DRUG$ @DRUG$ inhibit stimulate of prostatic epithelium	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with enalapril or @DRUG$.	DDI-false
Additional drugs that are not recommended for coadministration with @DRUG$ and @DRUG$ are included below.	DDI-false
Drug : interact with some , like Monoamine inhibitors ( MAOI ): MAOI could flupenthixol pharmacodynamics - @DRUG$ Eproxindine : cause CNS @DRUG$ : increases effect of antidepressants	DDI-false
lidocaine/@DRUG$ , phenobarbital/@DRUG$ , quinidine/lidocaine , and	DDI-false
No data from prospective clinical trials currently exist comparing the 3 approved agents (efavirenz, @DRUG$ or @DRUG$).	DDI-false
Haemodynamic effects of glucose and @DRUG$ were additive when @DRUG$ was co-administered but not under basal conditions.	DDI-false
@DRUG$ diminished @DRUG$ by % increase FDF , at 1732 micromol/L.	DDI-mechanism
to be antagonistic to @DRUG$ , including @DRUG$ , based on vitro time kill curves enteric gram-negative	DDI-false
No data are available for the coadministration of @DRUG$/ritonavir or FORTOVASE/@DRUG$ and garlic capsules.	DDI-false
has reported oral amiodarone lidocaine ( @DRUG$ ) given for	DDI-false
@DRUG$-based regimens may several @DRUG$-based prolonged , tablet , drug interactions , central nervous system	DDI-false
Both efavirenz and nevirapine have been compared to triple therapy with the @DRUG$ indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with @DRUG$.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Acetaminophen, lidocaine, @DRUG$, quinidine, @DRUG$, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Careful observation is required when @DRUG$ is administered concurrently with @DRUG$.	DDI-advise
Additive adverse effects cholinergic occur concomitantly with , amantadine , @DRUG$ , monoamine oxidase ( ) inhibitors , @DRUG$ antihistamines	DDI-false
Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, @DRUG$, CYP2D6, and @DRUG$.	DDI-false
on effect between @DRUG$ @DRUG$ or tuftsin	DDI-effect
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
adjustment @DRUG$ may when with CYP2D6 inhibitors , paroxetine @DRUG$ , .	DDI-advise
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Although neither @DRUG$ nor @DRUG$ affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin.	DDI-false
Interactions : Flupenthixol , Monoamine oxidase inhibitors ( @DRUG$ could theoretically flupenthixol - - : @DRUG$ additive antidepressants Flupenthixol effect Tricyclic antidepressants	DDI-false
: Pharmacokinetic drug-drug not been demonstrated Argatroban @DRUG$ ( orally 26 and 2 hours initiation of Argatroban 1   . ) or acetaminophen 1000 mg orally , 6 and prior to and hours subsequent of @DRUG$ g/kg/min . hours )	DDI-false
there was no significant change in prothrombin test results during the trials of @DRUG$ and @DRUG$.	DDI-false
chemotherapy HAART clinical course of systemic , non-Hodgkin lymphoma ( HIV-NHL , the authors retrospectively a of 24 patients with HIV-NHL who were with the doxorubicin @DRUG$ ( ) plus with group of with a , doxorubicin , prednisone with plus ) receiving @DRUG$	DDI-false
Co-medications induce CYP3A4 dexamethasone , @DRUG$ , @DRUG$ , phenobarbital or St.	DDI-false
@DRUG$ is a substrate for both CYP2D6 and @DRUG$.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).	DDI-false
Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, @DRUG$, rifampin, @DRUG$ or St.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
Plasma levels of @DRUG$ have been reported to increase in the presence of oral @DRUG$;	DDI-false
No data from prospective clinical trials currently exist comparing the 3 approved agents (@DRUG$, nevirapine or @DRUG$).	DDI-false
Reductase Inhibitors : @DRUG$ ( @DRUG$ substrate ) with amiodarone has been with	DDI-false
@DRUG$ has been reported to increase the @DRUG$ requirements in human subjects ingesting these agents simultaneously.	DDI-mechanism
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: @DRUG$, cyclosporine, amiodarone, @DRUG$, and nifedipine.	DDI-false
Similarly dialyzed were phenobarbital, @DRUG$, and theophylline, both alone at therapeutic concentrations in serum and with @DRUG$ at three different concentrations in serum.	DDI-false
Cardiovasculars: @DRUG$: In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum @DRUG$ concentration that may reach toxic levels with resultant clinical toxicity.	DDI-false
Antipyrine : does affect the pharmacokinetics @DRUG$ , interactions @DRUG$ via same isozymes	DDI-false
interaction , report describes a novel chemical @DRUG$ ( benzodiazepine ) @DRUG$ under conditions similar those , resulting a	DDI-mechanism
This effect is small with occasional doses of @DRUG$, but may be clinically significant when @DRUG$ are used on a continuous schedule.	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, @DRUG$, higher alcohols and @DRUG$ in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
Capsules Garlic should be used while taking @DRUG$ ( ) the sole @DRUG$ due to the risk of decreased saquinavir .	DDI-false
Higher concentrations of @DRUG$ (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of @DRUG$.	DDI-effect
Pretreatment of healthy volunteers with multiple doses of @DRUG$ followed by a single dose of @DRUG$, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).	DDI-mechanism
effects resulting blockade occur is administered with other antimuscarinics amantadine , @DRUG$ , , monoamine oxidase ) inhibitors tricyclic or some @DRUG$.	DDI-false
The effects and @DRUG$ (@DRUG$)-induced locomotion and behavioral in	DDI-false
healthy volunteers with @DRUG$ followed a single @DRUG$ , increased oral-dose , which p mean and AUC(0 - .	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Data vitro than @DRUG$ suggest a possible interaction the : ergotamine , , , nicardipine and	DDI-int
Therefore, when @DRUG$ is given to a patient receiving warfarin, the dosage of @DRUG$ should be reduced to prevent excessive prolongation of the prothrombin time.	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
reports increased levels of @DRUG$ , , therapy with	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, erythromycin, clarithromycin).	DDI-advise
acetaminophen/theophylline , @DRUG$/acetaminophen acid , quinidine/lidocaine , and valproic acid/phenobarbital	DDI-false
Drugs such @DRUG$ , @DRUG$ tricyclic may associated and an risk ventricular arrhythmia	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of @DRUG$ and non-selective @DRUG$ may cause hypertension.	DDI-effect
@DRUG$ concomitant use of @DRUG$ been safely tolerated with angina .	DDI-false
In general , these are that have one similar @DRUG$ , @DRUG$ such as quinidine procainamide and tricyclic anti-depressants	DDI-false
may alter imatinib plasma concentrations imatinib plasma is when administering Gleevec family @DRUG$ , erythromycin , @DRUG$ ) .	DDI-false
Cation-Containing Products : of @DRUG$ , cation-containing as magnesium or @DRUG$ VIDEX chewable/buffered pediatric or substantially ciprofloxacin , resulting in serum urine levels	DDI-mechanism
In studies performed with Fondaparinux , the concomitant use oral @DRUG$ ) inhibitors ( acetylsalicylic ( @DRUG$ ) of	DDI-false
may some inhibitors ( ): theoretically Arecoline - Eproxindine - Ethanol @DRUG$ cause CNS depression Tricyclic antidepressants : @DRUG$ increases the effect Tricyclic	DDI-false
Lithium: @DRUG$ toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including @DRUG$.	DDI-false
@DRUG$ and major co-administration with @DRUG$.	DDI-false
Other concomitant : clinical , the profile subjects treated with @DRUG$ with anxiolytics , @DRUG$ sedatives ( including benzodiazepines , or non-opioid analgesics was that of taking with concomitant medications	DDI-false
Glyburide: The concomitant administration of @DRUG$ with the @DRUG$ glyburide has, on rare occasions, resulted in severe hypoglycemia.	DDI-effect
Antihypertensives : be used with receiving   blocking agents e.g. , @DRUG$ ) or channel antagonists verapamil a substrate , , a CYP3A4 ) because of the bradycardia , arrest , AV ;	DDI-false
been combination containing high and antineoplastic , specifically @DRUG$ , @DRUG$ , tamoxifen and interferon-alfa	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and @DRUG$, @DRUG$ and tricyclic anti-depressants.	DDI-false
study a randomized study patients assigned 1:1:1 doses of mg 1 , or twice with @DRUG$	DDI-false
@DRUG$/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
from studies than alprazolam possible @DRUG$ cyclosporine , @DRUG$ , nicardipine , .	DDI-false
To the impact chemotherapy plus HAART on the clinical course of patients HIV-related non-Hodgkin ) the compared retrospectively of patients treated the , @DRUG$ , prednisone CHOP chemotherapy regimen plus a of 80 patients treated with CHOP CHOP-like , doxorubicin , teniposide and prednisone plus @DRUG$ ) without	DDI-false
Cation-Containing , with multivalent products as magnesium or @DRUG$ sucralfate VIDEX chewable/buffered tablets or powder or products containing iron , or @DRUG$ may absorption resulting and lower than desired	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$: As with some other @DRUG$, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	DDI-false
Accordingly, when @DRUG$ is administered with oral @DRUG$, the prothrombin time should be closely monitored during and for several days after concomitant drug administration.	DDI-advise
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
In concomitant @DRUG$ and @DRUG$ an 50 increase levels .	DDI-mechanism
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, fibric acid derivatives, @DRUG$ (nicotinic acid), erythromycin, azole antifungals.	DDI-false
@DRUG$ : Amiodarone , bepridil , @DRUG$ , propafenone due to potential for reactions	DDI-false
@DRUG$ : normal concomitant and @DRUG$ approximate 50 increase in plasma levels of	DDI-false
the study of and 12 g @DRUG$ decreases % AUC and 40 Cmax @DRUG$ alone .	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, @DRUG$, @DRUG$, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Drugs Demonstrated to be 3A Inhibitors of Possible Clinical Significance on Basis Clinical Studies Involving Alprazolam ( is recommended coadministration alprazolam Coadministration with @DRUG$ the maximum plasma concentration @DRUG$ decreased clearance 21 % increased by 17 , decreased psychomotor performance .	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
only @DRUG$ @DRUG$-induced accumbal .	DDI-effect
Acid-catalyzed ethanolysis @DRUG$ in @DRUG$	DDI-mechanism
Monoamine Tricyclic Antidepressants : FORADIL should administered in with @DRUG$ or @DRUG$ because of on the cardiovascular may potentiated by agents .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
by @DRUG$ metastasis intestinal induced in wistar	DDI-effect
Antiarrhythmics: Amiodarone, @DRUG$, flecainide, propafenone, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
effects resulting from may @DRUG$ concomitantly with @DRUG$ , amantadine , haloperidol monoamine ( ) inhibitors or some antihistamines .	DDI-effect
was that oral @DRUG$ and @DRUG$ can significant in Cmax or tmax .	DDI-false
of @DRUG$ and may its and @DRUG$/2 .	DDI-false
The of ruthenium RR ) @DRUG$ (@DRUG$)-induced were studied rat marrow the patch-clamp recording technique fura-2	DDI-false
@DRUG$ : of @DRUG$ and of plasma levels active approximately .	DDI-false
Corticosteroids @DRUG$ Diuretics : Concomitant treatment with xanthine derivatives @DRUG$ , diuretics may possible hypokalemic effect of beta2-agonists	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
with some drugs , like @DRUG$ ): affect Arecoline - Eproxindine @DRUG$ : cause depression - Tricyclic	DDI-false
Agents Causing Renin Release: The antihypertensive effect of @DRUG$ and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., @DRUG$).	DDI-effect
The possibility of hypotensive effects with @DRUG$ or @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.	DDI-false
Additive resulting from cholinergic blockade may occur is administered with other @DRUG$ , haloperidol , @DRUG$ oxidase MAO tricyclic or some antihistamines	DDI-false
Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and @DRUG$ in rats;	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving @DRUG$, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
acetaminophen/theophylline phenobarbital/@DRUG$ phenobarbital/valproic quinidine/lidocaine @DRUG$/acetaminophen and valproic acid/phenobarbital	DDI-false
Drug Interactions : Flupenthixol some drugs like oxidase ( ): MAOI could @DRUG$ - @DRUG$ and Ethanol depression - antidepressants Tricyclic antidepressants	DDI-false
Although specific studies not been performed , with drugs are by eg calcium channel blockers , , amiodarone , , , @DRUG$ , , , @DRUG$ , fentanyl , alfentanyl , triazolam have elevated plasma concentrations when with saquinavir	DDI-false
Data in studies of @DRUG$ a possible for following : @DRUG$ and .	DDI-false
Administration of @DRUG$ concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of amiodarone and @DRUG$.	DDI-false
Azithromycin no impact on the and AUC of zidovudine , although significantly the @DRUG$ tmax % and increased @DRUG$ %	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient @DRUG$ intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/@DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
of , dosage of @DRUG$ be @DRUG$ are	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Therefore , following psychotropic drugs e.g. , @DRUG$ @DRUG$ , antiemetics , .	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
These results suggest that the of @DRUG$ alcoholic beverages by with its congeners and @DRUG$ ;	DDI-effect
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$: Concurrent administration of @DRUG$ may lower meclofenamate sodium plasma levels, possibly by competing for protein-binding sites.	DDI-false
@DRUG$: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of @DRUG$ and aspirin were administered concomitantly.	DDI-false
To impact chemotherapy HAART on the HIV-related systemic non-Hodgkin HIV-NHL ) , the authors group patients with HIV-NHL who with the doxorubicin , and @DRUG$ ( ) regimen group who with CHOP chemotherapy a CHOP-like and vincristine @DRUG$ ) receiving antiretroviral therapy .	DDI-false
and electrophysiologic been observed concomitant @DRUG$ , @DRUG$ , and	DDI-false
The immediate release, but not the coat-core formulation of @DRUG$ increased plasma @DRUG$ concentrations by about 20%.	DDI-mechanism
, , phenobarbital/valproic acid , , acid/phenobarbital .	DDI-false
@DRUG$ : of @DRUG$ and in normal effect of naproxen but urinary naproxen and its metabolite	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Pharmacokinetic pharmacodynamic Argatroban concomitantly administered ( 162.5 mg orally given and prior of @DRUG$   over 4 hours ( 1000 given 12 , 0 prior and 12 subsequent Argatroban 1.5 g/kg/min over hours	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, @DRUG$, saquinavir, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between @DRUG$ deficiency due to an insufficient @DRUG$ intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Coadministration compounds are potent inducers of ( eg phenobarbital , @DRUG$ , ) in plasma levels @DRUG$.	DDI-mechanism
Although studies been with drugs that are mainly metabolized eg calcium channel blockers dapsone quinine @DRUG$ , quinidine , cyclosporine @DRUG$ fentanyl , alfentanyl may have elevated plasma concentrations when coadministered ;	DDI-false
@DRUG$ may increase slightly the effect of antihypertensive drugs, e.g., @DRUG$, methyldopa, reserpine.	DDI-effect
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, @DRUG$, clarithromycin).	DDI-false
induce CYP3A4 ( e.g. , , , carbamazepine @DRUG$ @DRUG$ St.	DDI-false
Concomitant oral administration of @DRUG$ (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral @DRUG$.	DDI-mechanism
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving @DRUG$, tricyclic antidepressants or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-false
Haemodynamic effects of @DRUG$ and @DRUG$ were additive when somatostatin was co-administered but not under basal conditions.	DDI-false
acetaminophen/theophylline , , phenobarbital/valproic , , theophylline/acetaminophen , .	DDI-false
Interactions may drugs Monoamine oxidase inhibitors @DRUG$ could affect pharmacodynamics Arecoline - - Ethanol : @DRUG$ cause additive CNS - Tricyclic antidepressants : Flupenthixol the of	DDI-false
@DRUG$: The concomitant administration of @DRUG$ and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, @DRUG$ (nicotinic acid), erythromycin, @DRUG$.	DDI-false
Administration concomitantly with oral @DRUG$ serum of and	DDI-false
@DRUG$: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and @DRUG$, a known inhibitor of cytochrome P450 3A4.	DDI-false
@DRUG$ displace acidic @DRUG$ or from binding sites .	DDI-mechanism
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	DDI-false
Delayed Adverse Reactions to @DRUG$: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various @DRUG$ containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
anti-inflammatory drugs but not @DRUG$ ): with high @DRUG$ have to	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Garlic should be FORTOVASE ) as sole @DRUG$ due the risk @DRUG$ plasma .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with @DRUG$): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of @DRUG$ by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
studies not been performed coadministration with drugs that are CYP3A4 ( , calcium channel disopyramide quinine , warfarin @DRUG$ cyclosporine , ergot pimozide fentanyl , @DRUG$ , , triazolam ) may elevated plasma concentrations when coadministered saquinavir	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
have been prolongation , without in @DRUG$ when @DRUG$ , , or azoles	DDI-false
Monitoring for amiodarone toxicity and serial measurement of @DRUG$ serum concentration during concomitant @DRUG$ therapy should be considered.	DDI-advise
, , phenobarbital/valproic , valproic	DDI-false
Drugs that alter @DRUG$ @DRUG$ concentrations Gleevec with of ( , itraconazole , , ) .	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with @DRUG$ increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
: Flupenthixol interact like oxidase ( @DRUG$ MAOI affect @DRUG$ Ethanol and Ethanol antidepressants : Flupenthixol increases the	DDI-false
The data suggest that @DRUG$ has a narrower spectrum of actions and will have a substantially greater therapeutic index than @DRUG$.	DDI-false
treated @DRUG$ the AUC atomoxetine to 8-fold and max is about to 4-fold than @DRUG$ alone	DDI-false
@DRUG$ and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
@DRUG$ : Other , procainamide , disopyramide @DRUG$ , been with	DDI-false
@DRUG$ may block the antihypertensive action @DRUG$ acting compounds	DDI-effect
Antagonism between @DRUG$ @DRUG$ has demonstrated .	DDI-effect
interaction @DRUG$ not be for @DRUG$.	DDI-false
The , and time anticoagulant @DRUG$ , glutethimide chloral hydrate and methaqualone investigated in receiving @DRUG$ therapy	DDI-false
Theophylline : @DRUG$ concurrent administration @DRUG$ lead elevated concentrations and its elimination half-life	DDI-false
containing side of N-methylthiotetrazole ( cefamandole @DRUG$ or ( cefazolin cause deficiency and hypoprothrombinemia .	DDI-false
availability (NNRTI)-based @DRUG$ and concerns regarding @DRUG$ (PI)-related have led to shifts in treatment practices in infection .	DDI-false
Chloral hydrate and @DRUG$ interact pharmacologically with orally administered @DRUG$, but the effect is not clinically significant.	DDI-int
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/@DRUG$, and valproic acid/phenobarbital.	DDI-false
Hypotension: Patients on Diuretic Therapy: Patients on @DRUG$ and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with @DRUG$ or enalaprilat.	DDI-effect
@DRUG$-@DRUG$ in large doses may inhibit vitamin K epoxide reductase resulting in vitamin K deficiency.	DDI-false
Atromid-S may displace acidic drugs such as @DRUG$ or @DRUG$ from their binding sites.	DDI-false
target were : @DRUG$/@DRUG$.	DDI-false
In the present study , the @DRUG$ was in combination with an of @DRUG$ in two-lever drug discrimination and signalled-unsignalled differential-reinforcement-of-low-rates )	DDI-false
Drug : may interact with , like @DRUG$ MAOI ): could pharmacodynamics - - Eproxindine - Ethanol : @DRUG$ and additive depression - Tricyclic the effect of antidepressants	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
THERAPY specific studies were in used with converting enzyme ACE ) inhibitors betablockers calcium-channel blockers @DRUG$ @DRUG$ ) evidence of clinically adverse .	DDI-false
effect of @DRUG$ on warfarin requirement to be maximal 5 7 days the of @DRUG$ and length of time after rifampin withdrawal	DDI-false
Interactions some , Monoamine oxidase inhibitors MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine Ethanol : and @DRUG$ cause depression : Flupenthixol increases effect of antidepressants	DDI-false
However, in the second study, administration of 12 g @DRUG$ 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the @DRUG$ AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.	DDI-false
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
Other Drugs:Drugs such as quinidine, @DRUG$, procainamide, phenothiazines, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
efavirenz have triple the @DRUG$ over 48 as initial , with @DRUG$ with efavirenz	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as @DRUG$ and procainamide, cardiac glycosides and @DRUG$.	DDI-false
@DRUG$ shown PROLEUKIN-induced side effects including , insufficiency hyperbilirubinemia , , these with PROLEUKIN effectiveness @DRUG$ avoided antihypertensives with PROLEUKIN	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin (@DRUG$), erythromycin, @DRUG$.	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and @DRUG$.	DDI-false
Slow-channel calcium , @DRUG$ and @DRUG$ , activation in vitro intravascularly .	DDI-false
Therefore , interactions could occur administration @DRUG$ , , analgesics @DRUG$ , ) .	DDI-false
In studies performed with @DRUG$ use oral ( ) NSAIDs ( did not pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
BACKGROUND of and verapamil ( @DRUG$ a @DRUG$ , on of induced ( of intestinal investigated in male rats .	DDI-false
acetaminophen/@DRUG$ , phenobarbital/valproic acid , theophylline/acetaminophen , and valproic .	DDI-false
In addition , have that @DRUG$ is useful tool with @DRUG$-mediated responses .	DDI-false
@DRUG$: Administration of nonsteroial anti-inflammatory drugs concomitantly with @DRUG$ has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	DDI-false
Although specific performed , coadministration with drugs that are by CYP3A4 , channel @DRUG$ disopyramide , amiodarone quinidine , @DRUG$ , tacrolimus , derivatives pimozide carbamazepine , , alfentanyl , and triazolam concentrations when coadministered with ;	DDI-false
In , @DRUG$ pharmacodynamics of warfarin @DRUG$ piroxicam , and the pharmacokinetics of digoxin at steady state .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
studies have not been coadministration with drugs that mainly ( eg , calcium , dapsone disopyramide amiodarone quinidine @DRUG$ @DRUG$ , ergot , , carbamazepine , alfentanyl , alprazolam and ) may plasma with saquinavir ;	DDI-false
DIGOXIN @DRUG$ and @DRUG$ clearance at by of cerivastatin	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Probenecid : @DRUG$ interferes with renal tubular secretion and an in level @DRUG$ serum .	DDI-mechanism
Although specific studies have not performed coadministration with that are metabolized eg calcium , quinidine @DRUG$ tacrolimus cyclosporine ergot , , , alfentanyl , and @DRUG$ may have concentrations	DDI-false
Anticoagulant inhibition was observed during the administration of phenobarbital, @DRUG$ and @DRUG$;	DDI-false
Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole @DRUG$ due to the risk of decreased @DRUG$ plasma concentrations.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
, in second , of 12 cholestyramine hour before the mg @DRUG$ after same evening in the less % , decrease Cmax of about 30 % when @DRUG$ .	DDI-false
Delayed Adverse to @DRUG$ review revealed that 12.6 11 28 % 501 @DRUG$ containing regimens subsequently iodinated experienced atypical adverse reactions	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as @DRUG$ and @DRUG$, cardiac glycosides and tricyclic anti-depressants.	DDI-false
No data are available for the coadministration of @DRUG$/@DRUG$ or FORTOVASE/ritonavir and garlic capsules.	DDI-false
Nonsteroidal Anti-Inflammatory Drugs: The administration of @DRUG$ to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of @DRUG$.	DDI-false
: Amiodarone should be caution in -receptor agents , @DRUG$ , a ) or verapamil , a CYP3A4 substrate and @DRUG$ , CYP3A4 inhibitor potentiation of sinus arrest ,	DDI-false
@DRUG$: Dihydroergotamine, ergonovine, @DRUG$, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
: @DRUG$ : In digoxin therapy , administration oral amiodarone regularly an increase serum @DRUG$ that toxic levels resultant clinical	DDI-false
These results suggest that both dexamethasone and @DRUG$, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF.	DDI-effect
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of ethanol and @DRUG$ in rats;	DDI-false
To impact chemotherapy on the course of with HIV-related , systemic non-Hodgkin lymphoma HIV-NHL ) , the authors compared retrospectively HIV-NHL with cyclophosphamide , vincristine , plus HAART with a group of 80 were with or CHOP-like regimen , @DRUG$ , teniposide , @DRUG$ plus bleomycin ) receiving antiretroviral therapy .	DDI-false
Co-administration @DRUG$ @DRUG$ not the pharmacokinetics of	DDI-false
Combination @DRUG$ other @DRUG$ therapy should be patients who are incompletely to a single incompletely amiodarone .	DDI-false
, derivatives and @DRUG$ as nonsteroidal drugs @DRUG$ ) , and aspirin increase the risk when with ardeparin	DDI-false
Cardiovascular Agents : and have been agents @DRUG$ nitrates calcium-blocking agents , , @DRUG$ and evidence significant interactions	DDI-false
Although neither dexamethasone nor @DRUG$ affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and @DRUG$.	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
However, if @DRUG$ is to be initiated after cessation of @DRUG$ therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of Argatroban therapy.	DDI-false
@DRUG$ ( but not @DRUG$ in combination with high have been shown to provoke studies .	DDI-false
Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, carbamazepine, @DRUG$, @DRUG$ or St.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
The concomitant intake of alcohol and @DRUG$ does not affect the pharmacokinetics of either alcohol or @DRUG$.	DDI-false
, , quinidine/lidocaine theophylline/acetaminophen valproic acid/phenobarbital .	DDI-false
Concomitant cyclophosphamide, doxorubicin, vincristine, and @DRUG$ chemotherapy plus @DRUG$ therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
Corticosteroids Methylxanthines Diuretics xanthine @DRUG$ or diuretics may hypokalemic of   @DRUG$	DDI-effect
Although specific studies have not performed that mainly metabolized CYP3A4 , @DRUG$ disopyramide , warfarin , tacrolimus derivatives carbamazepine , fentanyl alfentanyl @DRUG$ may elevated plasma with saquinavir ;	DDI-false
@DRUG$: Other antiarrhythmic drugs, such as quinidine, @DRUG$, disopyramide, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Colestipol: Plasma concentrations of atorvastatin decreased approximately 25% when @DRUG$ and @DRUG$ were coadministered.	DDI-mechanism
@DRUG$ and methaqualone interact pharmacologically with orally administered @DRUG$, but the effect is not clinically significant.	DDI-int
been with in combination with @DRUG$ CYP3A4	DDI-false
are for coadministration @DRUG$/@DRUG$ and .	DDI-false
Flupenthixol interact with some inhibitors MAOI could theoretically affect pharmacodynamics Arecoline - @DRUG$ : Ethanol additive depression @DRUG$ Flupenthixol Tricyclic	DDI-false
Theophylline: As with some other quinolones, concurrent administration of @DRUG$ with @DRUG$ may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	DDI-mechanism
The of effects @DRUG$ or @DRUG$ can minimized by the or the salt intake to of treatment or enalaprilat .	DDI-false
because of this, the dosage of @DRUG$ should be adjusted when these @DRUG$ are administered concomitantly.	DDI-false
Additive adverse effects resulting cholinergic may when LEVSIN administered concomitantly with antimuscarinics , amantadine , phenothiazines , @DRUG$ , @DRUG$ some antihistamines	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Agents @DRUG$ coadministration of with an reduces the of	DDI-false
Quetiapine fumarate ('@DRUG$') is a newly introduced @DRUG$ with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia.	DDI-false
@DRUG$ similarly stimulate or @DRUG$-induced proliferation of prostatic .	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
acetaminophen/@DRUG$, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ - prior ingestion of @DRUG$ may decrease the emetic response to apomorphine in the treatment of poisoning.	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Antihypertensives : should used with in patients -receptor blocking ( e.g. , a inhibitor ) @DRUG$ antagonists e.g. substrate , @DRUG$ inhibitor because the potentiation of and	DDI-false
Lack of an effect of @DRUG$ on the disposition of zidovudine and @DRUG$ in HIV-infected patients.	DDI-false
@DRUG$ the effect	DDI-effect
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, @DRUG$, cis-platinum, tamoxifen and @DRUG$.	DDI-false
Therefore interactions concomitant psychotropic e.g. narcotics , @DRUG$ @DRUG$ , .	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Some drugs/substances are known to accelerate the metabolism of @DRUG$ by stimulating the synthesis of @DRUG$ (enzyme induction).	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
, additional interaction studies niacin and not any on @DRUG$ plasma levels administration to digoxin resulted no the extent of of @DRUG$ to data	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Ergot Derivatives : @DRUG$ , , ergotamine methylergonovine CONTRAINDICATED to potential life-threatening such as acute @DRUG$ vasospasm and of and other tissues .	DDI-false
Nephrotoxicity has been reported following concomitant administration of @DRUG$ with aminoglycoside antibiotics or potent diuretics such as @DRUG$.	DDI-effect
Coingestion of @DRUG$ with @DRUG$ , and valproic acid with at high to concentrations decreases of target drug	DDI-effect
@DRUG$ (e.g., @DRUG$, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., narcotics, analgesics, antiemetics, @DRUG$, tranquilizers).	DDI-false
Antihypertensives : Amiodarone be patients receiving   -receptor e.g. propranolol , CYP3A4 or channel , a @DRUG$ substrate and @DRUG$ a CYP3A4 because the of arrest , AV block	DDI-false
: @DRUG$ CONTRAINDICATED since the coadministration this an @DRUG$ regimen reduces the saquinavir .	DDI-false
@DRUG$: Plasma concentrations of @DRUG$ decreased approximately 25% when colestipol and atorvastatin were coadministered.	DDI-false
Acetaminophen lidocaine , , @DRUG$ , @DRUG$ valproic added to serum at concentrations	DDI-false
The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with @DRUG$ or enalaprilat.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
suggest both @DRUG$ , other glucocorticoids retinoids , regulate the proliferation of epithelium by a dose-dependent modification of activity @DRUG$ and EGF	DDI-effect
@DRUG$ and glutethimide should not be administered to patients receiving @DRUG$.	DDI-advise
Therefore , interactions following concomitant administration of @DRUG$ , narcotics @DRUG$ , tranquilizers )	DDI-false
@DRUG$ : volunteers administration of @DRUG$ and acetaminophen resulted 50 % plasma of acetaminophen .	DDI-false
Although dexamethasone retinyl acetate proliferation @DRUG$ alone they modify the of EGF	DDI-false
@DRUG$: rifampin CONTRAINDICATED since the coadministration of this product with @DRUG$ in an antiretroviral regimen reduces the plasma concentrations of saquinavir.	DDI-false
Co-administration: Concomitant use of @DRUG$ with antiplatelet agents, @DRUG$, and other anticoagulants may increase the risk of bleeding.	DDI-effect
@DRUG$ : @DRUG$ appear to have no significant the ciprofloxacin .	DDI-false
@DRUG$ prior ingestion may decrease @DRUG$ response to apomorphine treatment of poisoning	DDI-false
The of rifampin on the @DRUG$ of appeared be to rifampin length of time after @DRUG$ withdrawal	DDI-false
Garlic Capsules Garlic capsules should not be used while taking saquinavir (@DRUG$) as the sole @DRUG$ due to the risk of decreased saquinavir plasma concentrations.	DDI-false
Oral @DRUG$: Pharmacokinetic drug-drug interactions between Argatroban and @DRUG$ (7.5 mg single oral dose) have not been demonstrated.	DDI-false
Antiarrhythmics : , such as @DRUG$ procainamide , @DRUG$ , used .	DDI-false
Caution exercised if @DRUG$ administered that may decrease activity of endogenous steroid @DRUG$ and cimetidine .	DDI-advise
The monoamine oxidase inhibitory effects of @DRUG$ may persist for a substantial period after discontinuation of the drug, and this should be borne in mind when another drug is prescribed following @DRUG$.	DDI-false
, additional studies niacin @DRUG$ have demonstrated effect on levels , administration a population @DRUG$ resulted in no difference in the extent relative control	DDI-false
The pressure effect @DRUG$ greater in on than in on @DRUG$	DDI-false
, studies and have demonstrated effect plasma levels , and administration a patient chronically @DRUG$ no in the extent of bioavailability of @DRUG$ control data	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
ANTACID @DRUG$ plasma concentrations were by co-administration of @DRUG$.	DDI-false
neither nor @DRUG$ the of in RPMI1640 containing @DRUG$ the mitogenic effect EGF and insulin .	DDI-false
Multivalent : administration @DRUG$ ciprofloxacin , with or aluminum @DRUG$ VIDEX tablets products containing substantially decrease of , in levels lower .	DDI-mechanism
treatment with inhibitors of activity as intraconazole , @DRUG$ @DRUG$ etc . reduction the be .	DDI-false
Colestipol: Plasma concentrations of @DRUG$ decreased approximately 25% when @DRUG$ and atorvastatin were coadministered.	DDI-false
data for coadministration INVIRASE/@DRUG$ @DRUG$/ritonavir capsules .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other @DRUG$ and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and @DRUG$.	DDI-effect
If treatment inhibitors CYP3A4 activity such as ketoconazole , intraconazole ritonavir , @DRUG$ , @DRUG$ , etc , the dose considered .	DDI-false
: of @DRUG$-type ( CYP2C9 and @DRUG$ is always patients amiodarone and can or fatal bleeding .	DDI-false
Agents : In some patients compromised renal function are treated @DRUG$ co-administration of @DRUG$ further of renal	DDI-effect
BACKGROUND: The effects of combined administration of @DRUG$ and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (@DRUG$) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Drug-drug @DRUG$ @DRUG$ or	DDI-false
The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume @DRUG$ and @DRUG$ on a regular basis.	DDI-mechanism
The , time course of @DRUG$ phenobarbital secobarbital glutethimide , chloral and @DRUG$ 16 patients	DDI-false
Drugs that Drugs may @DRUG$ Caution is when administering Gleevec inhibitors the CYP3A4 family ketoconazole erythromycin , @DRUG$ .	DDI-false
The effects of DCG-IV and @DRUG$ upon phencyclidine (@DRUG$)-induced locomotion and behavioral changes in mice.	DDI-false
@DRUG$: @DRUG$ (CYP3A4 substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
Phenytoin: Altered serum levels of @DRUG$ (increased and decreased) have been reported in patients receiving concomitant @DRUG$.	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
acetaminophen/@DRUG$ , lidocaine/quinidine , phenobarbital/acetaminophen phenobarbital/@DRUG$ , , , and valproic .	DDI-false
: @DRUG$ enalapril IV used with , nitrates , @DRUG$ , hydralazine evidence of clinically adverse interactions .	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, @DRUG$, and digoxin, nor the pharmacokinetics of @DRUG$ at steady state.	DDI-false
have significant the oral bioavailability @DRUG$ and ciprofloxacin when concomitantly with	DDI-mechanism
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, @DRUG$) may result in decreased plasma levels of @DRUG$.	DDI-mechanism
Dihydroergotamine , @DRUG$ @DRUG$ due potential for serious and life-threatening such as acute ergot toxicity characterized by the and .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ taken concomitantly with @DRUG$ for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively.	DDI-false
@DRUG$-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of vitamin K.	DDI-false
@DRUG$ should with patients   -receptor blocking agents a inhibitor or calcium antagonists ( , a CYP3A4 substrate @DRUG$ because of the possible potentiation of bradycardia , sinus arrest AV block ;	DDI-false
drugs/substances of @DRUG$ stimulating synthesis @DRUG$	DDI-false
Other Cardiovascular : have agents @DRUG$ , , @DRUG$ , hydralazine , prazosin without of clinically significant adverse .	DDI-false
Pretreatment of healthy multiple doses a dose of @DRUG$ , increased @DRUG$ oral-dose clearance by ( 0.05 decreased mean and - 8)	DDI-false
OTHER THERAPY : Although interaction not studies sodium angiotensin- ( ACE inhibitors , betablockers , @DRUG$ , diuretics @DRUG$ ) without adverse interactions	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, @DRUG$, @DRUG$, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
Drug-drug interactions have not been observed between Argatroban and @DRUG$ or @DRUG$.	DDI-false
Amiodarone be with patients   blocking ( , propranolol , CYP3A4 inhibitor ) or @DRUG$ antagonists @DRUG$ and , CYP3A4 inhibitor ) of the possible potentiation of sinus arrest , and AV	DDI-false
Lithium : @DRUG$ been reported receiving @DRUG$ with drugs cause of sodium , inhibitors	DDI-false
effects of @DRUG$ @DRUG$ locomotion changes in	DDI-false
The aim of this paper was to study the interaction between @DRUG$ and both @DRUG$ or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection.	DDI-false
: multiple of @DRUG$ and @DRUG$ steady-state plasma digoxin approximately %	DDI-mechanism
Other Drugs : Drugs such as quinidine @DRUG$ , @DRUG$ , tricyclic be with and risk of arrhythmia	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
: of administration @DRUG$ @DRUG$ ( , calcium channel , on the incidence of peritoneal of intestinal induced and labeling index of intestinal investigated male .	DDI-false
@DRUG$ volunteers concomitant of and hydrochlorothiazide in significantly plasma levels	DDI-false
Although have not been , coadministration with drugs that CYP3A4 channel , @DRUG$ , disopyramide , , amiodarone , quinidine , warfarin , cyclosporine derivatives carbamazepine , , , @DRUG$ , and triazolam elevated when with saquinavir ;	DDI-false
Additive resulting LEVSIN is administered concomitantly with other antimuscarinics amantadine , haloperidol @DRUG$ MAO ) inhibitors tricyclic antidepressants	DDI-false
@DRUG$    @DRUG$ antagonism	DDI-false
Interactions : Flupenthixol may interact with drugs like @DRUG$ MAOI could affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol Ethanol cause additive CNS depression Tricyclic : Flupenthixol the @DRUG$	DDI-false
Mineral Oil-Concomitant intake @DRUG$ vitamin may absorption of	DDI-false
@DRUG$-@DRUG$ may decrease the absorption of vitamin K.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and @DRUG$, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.	DDI-effect
Concurrent administration of possessing ( e.g. @DRUG$ indomethacin , e.g. , cytotoxic chemotherapy ) , ( , @DRUG$ or hepatotoxic , ) with may in .	DDI-false
Although specific studies have , coadministration with drugs are mainly metabolized by CYP3A4 ( channel blockers , , disopyramide , amiodarone , @DRUG$ , tacrolimus , cyclosporine , ergot derivatives @DRUG$ , , fentanyl alfentanyl , and triazolam may have elevated ;	DDI-false
The risk during with drugs of this class increased with concurrent , @DRUG$ , niacin , ,	DDI-false
@DRUG$ , and @DRUG$ alone in serum and with ethanol concentrations in serum	DDI-false
To the impact chemotherapy clinical course patients HIV-related ( HIV-NHL ) , the compared group of patients who were @DRUG$ , vincristine , and ( CHOP ) regimen plus HAART with treated with CHOP-like regimen ( i.e. cyclophosphamide @DRUG$ prednisone with vincristine plus receiving antiretroviral	DDI-false
@DRUG$ block @DRUG$-induced dopamine the accumbens ;	DDI-effect
including coumarin , indandione derivatives such anti-inflammatory drugs ( @DRUG$ , may the bleeding when with @DRUG$.	DDI-effect
Effects of @DRUG$ on Drug Metabolizing Enzymes and Drug Transport Systems @DRUG$ inhibits CYP3A4 and CYP2C8 in vitro at clinically relevant concentrations.	DDI-false
@DRUG$: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant @DRUG$.	DDI-false
Therefore, when @DRUG$ is given to a patient receiving @DRUG$, the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.	DDI-advise
@DRUG$ enhance the in patients @DRUG$	DDI-effect
@DRUG$   known interact with conventional of	DDI-false
The combined administration @DRUG$ ( verapamil , of metastasis intestinal @DRUG$ ) the index of cancers Wistar .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$ @DRUG$ n = ) ( later changed mg/day n 5 ) for 8 of course mg , five times/day .	DDI-false
Like ( 40 ) @DRUG$ 40 the intravenous morphine and cocaine self-administration of ethanol @DRUG$ rats	DDI-false
Combinations of @DRUG$ and @DRUG$: effects on drug discrimination and behavioral inhibition in rats.	DDI-false
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive @DRUG$ tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and @DRUG$.	DDI-false
Cation-Containing Concurrent administration of including ciprofloxacin cation-containing magnesium @DRUG$ antacids , , @DRUG$ chewable/buffered pediatric zinc may decrease the absorption of , in serum lower	DDI-false
@DRUG$ Dihydroergotamine , , , @DRUG$ to for serious life-threatening reactions such ergot toxicity peripheral vasospasm ischemia other tissues .	DDI-false
Moreover, additional interaction studies with @DRUG$ and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data.	DDI-false
Cholestyramine-Concomitant of @DRUG$ and reduce the	DDI-false
@DRUG$: The concomitant use of @DRUG$ and beta-blocking agents has been well tolerated in patients with stable angina.	DDI-false
@DRUG$ phenobarbital , @DRUG$ , theophylline , and were added pooled human at therapeutic concentrations .	DDI-false
Although specific have been performed , coadministration mainly metabolized CYP3A4 ( eg calcium @DRUG$ disopyramide , quinine amiodarone warfarin , , , , @DRUG$ , alfentanyl , alprazolam and ) have elevated plasma coadministered saquinavir	DDI-false
: Our objective was the pharmacokinetics @DRUG$ and cyclosporine , @DRUG$ in novo kidney recipients during after transplantation .	DDI-false
nephrotoxic , aminoglycosides indomethacin ) , myelotoxic e.g. ) , ( e.g. , @DRUG$ ) , , ) with @DRUG$ may increase	DDI-effect
BACKGROUND effects of of bombesin and ( @DRUG$ , a calcium the of peritoneal of intestinal by @DRUG$ AOM ) index intestinal investigated in male rats .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Antiarrhythmics Other drugs , such , @DRUG$ @DRUG$ , , have concurrently with amiodarone	DDI-false
@DRUG$, @DRUG$, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
To evaluate impact plus on the clinical of with , , non-Hodgkin ( , the authors compared retrospectively of with HIV-NHL who treated with the cyclophosphamide , , , and @DRUG$ ( CHOP ) chemotherapy with a of with or a ( , , doxorubicin , and @DRUG$ bleomycin without antiretroviral therapy .	DDI-false
To evaluate the impact of clinical of patients systemic ( HIV-NHL ) the compared retrospectively a group , doxorubicin , vincristine , and ( regimen HAART with of were CHOP or CHOP-like i.e. , @DRUG$ and prednisone with @DRUG$ plus bleomycin receiving antiretroviral	DDI-false
Hydroxide ): @DRUG$ plasma concentrations affected @DRUG$.	DDI-false
@DRUG$ concomitantly with oral @DRUG$ shown to serum concentrations of amiodarone and desethylamiodarone	DDI-false
@DRUG$ @DRUG$ 5 followed 2.5 - orally 6 - days the time ( ) and Normalized ( INR .	DDI-effect
@DRUG$ of diflunisal @DRUG$ no on the of , but significantly decreased the urinary excretion naproxen and its	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
, lidocaine/quinidine phenobarbital/acetaminophen , quinidine/lidocaine , .	DDI-false
, acid , quinidine/lidocaine theophylline/@DRUG$ acid/@DRUG$.	DDI-false
Amiodarone may suppress certain CYP450 enzymes, including @DRUG$, CYP2C9, @DRUG$, and CYP3A4.	DDI-false
Anticoagulants: Potentiation of warfarin-type (CYP2C9 and @DRUG$ substrate) anticoagulant response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	DDI-false
that @DRUG$ acetate and other glucocorticoids and retinoids regulate proliferation by a dose-dependent of the of insulin @DRUG$.	DDI-effect
Acetaminophen, @DRUG$, phenobarbital, quinidine, @DRUG$, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Drugs imatinib that may plasma concentrations when Gleevec with inhibitors of the e.g. @DRUG$ @DRUG$ .	DDI-false
Concurrent administration of @DRUG$ (for the treatment of hypotension related to obstetric blocks) and @DRUG$ may cause severe, persistent hypertension or cerebrovascular accidents.	DDI-effect
Drug : @DRUG$ may interact with , like oxidase ( MAOI could theoretically pharmacodynamics - Arecoline - - @DRUG$ Flupenthixol and cause CNS - increases effect of	DDI-false
@DRUG$ had no significant effect on @DRUG$ pharmacokinetics.	DDI-false
and have concomitant @DRUG$ @DRUG$.	DDI-false
of @DRUG$ @DRUG$ produced in and a increase in of .	DDI-mechanism
@DRUG$-Cephalosporins containing side of cefmenoxime , @DRUG$ , latamoxef ) or methylthiadiazole ( can K deficiency and .	DDI-false
Theophylline: As with some other @DRUG$, concurrent administration of @DRUG$ with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., @DRUG$, analgesics, @DRUG$, sedatives, tranquilizers).	DDI-false
Antiarrhythmics: Other @DRUG$ drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with @DRUG$.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of @DRUG$	DDI-effect
@DRUG$ , @DRUG$ does responding water )	DDI-false
Similarly dialyzed were phenobarbital, quinidine, and @DRUG$, both alone at therapeutic concentrations in serum and with @DRUG$ at three different concentrations in serum.	DDI-false
drug of HUMORSOL with @DRUG$ or with other @DRUG$.	DDI-false
in the , 12 @DRUG$ before evening meal and mg @DRUG$ approximately after the same evening resulted decrease than 8 % decrease of about 30 % when dosing cerivastatin sodium alone .	DDI-mechanism
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
adverse resulting from cholinergic blockade may @DRUG$ is administered concomitantly with other , , phenothiazines @DRUG$ antidepressants or some antihistamines .	DDI-effect
Acid-catalyzed ethanolysis of @DRUG$ in anhydrous and aqueous @DRUG$ solutions.	DDI-mechanism
Cyclosporine: Administration of @DRUG$ concomitantly with cyclosporine has been associated with an increase in @DRUG$-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Delayed Adverse Reactions to Iodinated Contrast Media: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various @DRUG$ containing regimens who were subsequently administered @DRUG$ experienced acute, atypical adverse reactions.	DDI-effect
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Acetaminophen, @DRUG$, phenobarbital, quinidine, theophylline, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
Multivalent Cation-Containing Products of including multivalent cation-containing products as or aluminum antacids sucralfate , chewable/buffered containing @DRUG$ iron or @DRUG$ may the absorption ciprofloxacin serum urine levels lower	DDI-false
vitro studies have that occurs when @DRUG$ mixed	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, secobarbital, glutethimide, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, @DRUG$, @DRUG$, nicardipine, and nifedipine.	DDI-false
If @DRUG$ with that inhibit Pgp concentrations of @DRUG$ are , and caution should exercised .	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, hypnotics and sedatives (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including anti-arrhythmic agents such as @DRUG$ and procainamide, cardiac glycosides and tricyclic anti-depressants.	DDI-false
@DRUG$ : normal resulted in an approximate % increase levels	DDI-false
@DRUG$, @DRUG$, and azoles are known to cause QTc prolongation.	DDI-false
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ (@DRUG$) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
DIGOXIN: Plasma digoxin levels and @DRUG$ clearance at steady-state were not affected by co-administration of 0.2 mg @DRUG$.	DDI-false
@DRUG$ and @DRUG$ exert additive ocular and renal vasodilator effects on healthy humans.	DDI-false
No data are available for the coadministration of @DRUG$/ritonavir or @DRUG$/ritonavir and garlic capsules.	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
Additive from is other antimuscarinics , @DRUG$ , haloperidol oxidase ) inhibitors , @DRUG$ or .	DDI-false
Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with @DRUG$ in an antiretroviral regimen reduces the plasma concentrations of @DRUG$.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Concomitant cyclophosphamide , doxorubicin , vincristine , @DRUG$ chemotherapy @DRUG$ in virus-related , lymphoma	DDI-false
This interaction should be given consideration in patients taking @DRUG$ concomitantly with @DRUG$.	DDI-advise
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
derivatives , aggregation inhibitors @DRUG$ ( @DRUG$ aspirin risk of bleeding when .	DDI-false
Additive adverse from cholinergic blockade occur LEVSIN is concomitantly with @DRUG$ @DRUG$ ( MAO inhibitors tricyclic or antihistamines .	DDI-false
@DRUG$ may effect e.g. guanethidine @DRUG$ ,	DDI-effect
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Although @DRUG$ have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-effect
Derivatives : , @DRUG$ , due for serious and as @DRUG$ characterized and ischemia the extremities and other .	DDI-false
@DRUG$ and @DRUG$ interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant.	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF.	DDI-effect
Cardiovascular Agents : @DRUG$ have , methyldopa nitrates , agents , @DRUG$ prazosin digoxin evidence of significant interactions	DDI-false
Nephrotoxicity has been reported following concomitant administration of @DRUG$ and @DRUG$.	DDI-effect
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and @DRUG$ (including benzodiazepines), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Azithromycin had no significant impact on the Cmax and AUC of @DRUG$, although it significantly decreased the @DRUG$ tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.	DDI-false
@DRUG$ is a neutralizing agent for @DRUG$ that protects against renal damage.	DDI-effect
Previous studies have demonstrated a significant reduction in the oral bioavailability of @DRUG$ and @DRUG$ when administered concomitantly with an intravenous opiate such as morphine.	DDI-false
@DRUG$, lidocaine, phenobarbital, @DRUG$, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
@DRUG$ @DRUG$ block nicotine-induced dopamine the	DDI-false
There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for @DRUG$ versus levofloxacin/@DRUG$ regimens.	DDI-false
Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of @DRUG$ and nicotine in rats;	DDI-false
in patients receiving sequential high and @DRUG$ specifically , , cis-platinum , tamoxifen @DRUG$.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
@DRUG$ @DRUG$ ( CYP3A4 ) in combination with amiodarone has been with of myopathy/rhabdomyolysis	DDI-false
@DRUG$ (e.g., spironolactone, triamterene, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
@DRUG$ : Meclofenamate enhances effect of	DDI-false
Co-medications e.g. , phenytoin @DRUG$ , @DRUG$ , St.	DDI-false
administration possessing ( e.g. , ( e.g. @DRUG$ ) cardiotoxic ( e.g. @DRUG$ ) hepatotoxic ( e.g. , asparaginase PROLEUKIN may these	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
been @DRUG$ lidocaine @DRUG$ given for local .	DDI-false
@DRUG$: Simvastatin (@DRUG$ substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of @DRUG$ and ciprofloxacin when administered concomitantly with an intravenous @DRUG$ such as morphine.	DDI-mechanism
Multivalent Products of a , ciprofloxacin , multivalent cation-containing products as @DRUG$ aluminum sucralfate , chewable/buffered or pediatric , products @DRUG$ iron or decrease of in and urine levels lower than desired	DDI-false
The safety and efficacy @DRUG$ in combination with @DRUG$ have been established .	DDI-false
Dosage adjustment of @DRUG$ may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and @DRUG$.	DDI-advise
phenobarbital/acetaminophen , , quinidine/lidocaine , and @DRUG$/phenobarbital	DDI-false
Drugs that @DRUG$ plasma Drugs that may increase concentrations Caution is recommended Gleevec of the CYP3A4 family e.g. @DRUG$ , erythromycin clarithromycin	DDI-false
@DRUG$: Concurrent administration of aspirin may lower @DRUG$ plasma levels, possibly by competing for protein-binding sites.	DDI-false
, lidocaine/@DRUG$ , phenobarbital/acetaminophen phenobarbital/valproic , valproic acid/phenobarbital .	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
The possibility of hypotensive effects with @DRUG$ or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$ or enalaprilat.	DDI-false
@DRUG$ should be used with caution in patients taking @DRUG$, and renal function should be carefully monitored.	DDI-advise
In , Fondaparinux neither influenced the @DRUG$ acetylsalicylic , piroxicam , and , nor @DRUG$ state	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
by @DRUG$ bombesin-enhanced of induced by @DRUG$	DDI-false
@DRUG$ and @DRUG$ have similar kappa opioid and possibly nicotinic , lower affinities than ibogaine for and sigma-2 , sodium , transporter	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Although specific studies been performed , drugs are metabolized by CYP3A4 eg calcium channel dapsone quinine , @DRUG$ , @DRUG$ pimozide carbamazepine , , alprazolam , triazolam ) may when with	DDI-false
the of chemotherapy plus HAART clinical course of , non-Hodgkin ( ) the retrospectively a 24 patients with cyclophosphamide doxorubicin vincristine , and @DRUG$ ) chemotherapy regimen with of patients CHOP chemotherapy or a regimen ( i.e. , @DRUG$ , and prednisone plus bleomycin without receiving .	DDI-false
The risk of drugs of this is with acid niacin @DRUG$ ) @DRUG$ , azole	DDI-false
have reported in combination regimens containing high @DRUG$ , , @DRUG$ , tamoxifen and	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
only @DRUG$ enhances @DRUG$-induced increases in accumbal dopamine.	DDI-effect
efavirenz and nevirapine have been to triple therapy with @DRUG$ @DRUG$ 48 weeks as initial with responses and superiority efavirenz .	DDI-false
@DRUG$ : Amiodarone should be in patients receiving ( , propranolol CYP3A4 inhibitor ) or ( e.g. , , a CYP3A4 substrate , @DRUG$ a CYP3A4 ) because of , and AV block ;	DDI-false
Both ibogaine and @DRUG$ levels of dopamine the nucleus but only @DRUG$ increases extracellular of serotonin the nucleus	DDI-false
rate absorption ciprofloxacin was bioequivalent @DRUG$ or when @DRUG$ hours after omeprazole the that suppresses	DDI-false
Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent @DRUG$ such as @DRUG$.	DDI-false
Cardiovascular Agents and IV have been concomitantly adrenergic-blocking , methyldopa , calcium-blocking , hydralazine , @DRUG$ and @DRUG$ evidence of significant adverse interactions	DDI-false
: Pharmacokinetic interactions not been demonstrated @DRUG$ and aspirin mg orally given 26 and hours prior initiation Argatroban g/kg/min . over hours @DRUG$ mg 12 , and hours and subsequent , initiation of   g/kg/min . 18 hours ) .	DDI-false
Cholestyramine-Concomitant intake of @DRUG$ and @DRUG$ may reduce the absorption of vitamin K.	DDI-mechanism
In clinical trials , the safety in concomitantly with @DRUG$ sedatives @DRUG$ to that subjects placebo with these concomitant medications .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Cation-Containing Concurrent administration a @DRUG$ including ciprofloxacin with as magnesium aluminum , tablets pediatric or containing @DRUG$ may decrease of , serum levels	DDI-mechanism
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Corticosteroids, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
ANTACID (@DRUG$): @DRUG$ plasma concentrations were not affected by co-administration of antacid.	DDI-false
be CYP 3A Inhibitors of Basis of Clinical Involving Alprazolam recommended alprazolam of @DRUG$ with @DRUG$ increased of decreased clearance by 21 % half-life 17 % and decreased measured .	DDI-mechanism
of @DRUG$-enhanced peritoneal intestinal by @DRUG$ wistar	DDI-false
Although specific performed coadministration drugs metabolized ( eg calcium channel blockers , amiodarone , , tacrolimus cyclosporine , derivatives , carbamazepine , @DRUG$ , @DRUG$ ) may elevated concentrations ;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Monitoring for @DRUG$ toxicity and serial measurement of @DRUG$ serum concentration during concomitant protease inhibitor therapy should be considered.	DDI-false
Antihypertensives : Amiodarone should with caution patients receiving blocking , propranolol CYP3A4 or @DRUG$ verapamil , a CYP3A4 and , CYP3A4 the of bradycardia sinus arrest	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Although specific not been performed with are mainly by calcium , , @DRUG$ , quinine @DRUG$ quinidine cyclosporine , ergot derivatives , pimozide carbamazepine , fentanyl alfentanyl , ) may plasma concentrations coadministered with ;	DDI-false
, lidocaine @DRUG$ @DRUG$ theophylline , and valproic acid were to human serum at	DDI-false
, of metabotropic receptor mGluR agonists , @DRUG$ and the above induced by @DRUG$ were	DDI-false
Both the toxicity of @DRUG$ and the therapeutic value of @DRUG$ can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells;	DDI-false
has been reported following administration of @DRUG$ with aminoglycoside antibiotics potent such as	DDI-effect
However, @DRUG$ stimulated, but did not significantly inhibit, proliferation in the presence of @DRUG$.	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
to of on the of Clinical Involving @DRUG$ is recommended during coadministration with alprazolam of fluoxetine with alprazolam increased maximum plasma concentration @DRUG$ by 46 , by , half-life by % , performance	DDI-false
Sedatives/Hypnotics @DRUG$ , @DRUG$ to potential serious reactions such as prolonged or respiratory	DDI-false
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Concurrent of possessing nephrotoxic e.g. aminoglycosides indomethacin ) , e.g. @DRUG$ e.g. , ) hepatotoxic e.g. , asparaginase @DRUG$ may in these organ .	DDI-effect
The availability of potent non-nucleoside reverse transcriptase inhibitor (@DRUG$)-based regimens for antiretroviral therapy and concerns regarding @DRUG$ (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
Corticosteroids , Methylxanthines @DRUG$ : with derivatives , steroids may potentiate a hypokalemic of @DRUG$	DDI-false
@DRUG$ has been shown to be antagonistic to @DRUG$, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.	DDI-effect
@DRUG$ : Altered @DRUG$ increased and decreased ) have been reported in patients receiving concomitant ciprofloxacin	DDI-false
specific studies not performed , coadministration that mainly metabolized CYP3A4 @DRUG$ dapsone disopyramide , quinine , quinidine warfarin , , @DRUG$ ergot derivatives pimozide carbamazepine , , alfentanyl , alprazolam and elevated concentrations when saquinavir	DDI-false
Nephrotoxicity been concomitant of with @DRUG$ or potent @DRUG$ such as	DDI-false
containing side of N-methylthiotetrazole ( @DRUG$ cefotetan , @DRUG$ ) can vitamin K deficiency hypoprothrombinemia .	DDI-false
However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg @DRUG$ approximately 4 hours after the same evening meal resulted in a decrease in the @DRUG$ AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.	DDI-false
Other Drugs:Drugs such as @DRUG$, disopyramide, procainamide, phenothiazines, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, @DRUG$ or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
, @DRUG$/quinidine , phenobarbital/valproic acid , theophylline/acetaminophen , and valproic .	DDI-false
@DRUG$: The concomitant administration of diflunisal and @DRUG$ in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.	DDI-false
both and retinyl acetate and possibly and @DRUG$ , regulate proliferation of prostate by dose-dependent the of @DRUG$ and	DDI-effect
@DRUG$ lidocaine , @DRUG$ quinidine , and valproic acid were added to pooled human serum concentrations .	DDI-false
Other Agents : Enalapril been used concomitantly @DRUG$ @DRUG$ nitrates , calcium-blocking , , prazosin digoxin clinically significant	DDI-false
CYP2D6 inhibitors - @DRUG$ is primarily metabolized by the CYP2D6 pathway to @DRUG$.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Both the toxicity of @DRUG$ and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these @DRUG$ showed differential effects on cells;	DDI-false
treatment with CYP3A4 ( as @DRUG$ , , indinavir saquinavir , is indicated reduction @DRUG$ should be .	DDI-advise
Co-medications that induce CYP3A4 (e.g., dexamethasone, @DRUG$, @DRUG$, rifampin, phenobarbital or St.	DDI-false
BACKGROUND: The effects of combined administration of @DRUG$ and verapamil hydrochloride (verapamil), a @DRUG$, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Co-administration : Concomitant use of @DRUG$ , @DRUG$ other may risk of bleeding	DDI-false
Prostatic in basal medium containing @DRUG$ ( 1 microgram/ml , @DRUG$ ng/ml ) , and insulin 3.7 or 0.1 .	DDI-false
administration of @DRUG$ @DRUG$ to patients inhibitors , tricyclic phenothiazines produce ,	DDI-false
These results suggest that both @DRUG$ and @DRUG$, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
Cardiovascular Agents : @DRUG$ IV been concomitantly agents , @DRUG$ , calcium-blocking agents , , digoxin of clinically adverse interactions .	DDI-false
Hypersensitivity been in receiving regimens sequential high dose agents specifically dacarbazine , cis-platinum , @DRUG$ and	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Co-administration of warfarin and @DRUG$ did not alter the pharmacokinetics of @DRUG$.	DDI-false
@DRUG$ , a in lowering the and extent of @DRUG$ bioavailability .	DDI-mechanism
@DRUG$ : Dihydroergotamine , @DRUG$ , ergotamine , methylergonovine due to for serious life-threatening reactions as acute toxicity characterized by vasospasm and ischemia of the and tissues	DDI-false
Multivalent Cation-Containing : of quinolone with cation-containing such magnesium aluminum @DRUG$ , VIDEX or powder products calcium iron , or substantially the of @DRUG$ resulting in serum considerably lower desired	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, phenothiazines, @DRUG$, tricyclic antidepressants or some antihistamines.	DDI-false
Additive adverse effects resulting from occur is other , @DRUG$ haloperidol @DRUG$ , monoamine ( MAO ) , antidepressants	DDI-false
or presentation a number has observed concurrent @DRUG$ and @DRUG$ , including oculo-bulbar myasthenia gravis , inflammatory arthritis thyroiditis pemphigoid Stevens-Johnson syndrome .	DDI-effect
METHOD : This study was multicenter randomized double-blind of 101 were to receive @DRUG$ at doses of 0.5 mg 1 , or 2 twice @DRUG$ prednisone .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Other Chemotherapy Agents In a separate study, concomitant administration of @DRUG$ with @DRUG$ did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine).	DDI-false
Cephalosporins-Cephalosporins containing side chains of , @DRUG$ , , @DRUG$ methylthiadiazole ( ) can cause vitamin K deficiency .	DDI-false
: as @DRUG$ , and @DRUG$ associated with QT-interval risk of ventricular arrhythmia	DDI-false
@DRUG$/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, @DRUG$, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ Dihydroergotamine ergonovine , @DRUG$ methylergonovine CONTRAINDICATED due to potential for serious and life-threatening such acute ergot toxicity characterized by peripheral vasospasm ischemia of the extremities and other .	DDI-false
from in than a possible interaction following : @DRUG$ amiodarone , @DRUG$.	DDI-false
@DRUG$ , plasma concentrations % @DRUG$ , a P450 3A4	DDI-false
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the @DRUG$ tmax by 44% and increased the intracellular exposure to phosphorylated @DRUG$ by 110%.	DDI-false
@DRUG$ and nevirapine have been triple therapy with PI over with similar being observed nevirapine regimens superiority observed	DDI-false
Oral Contraceptives of @DRUG$ and increased AUC values for norethindrone @DRUG$ by approximately 30 % and 20	DDI-mechanism
However absolute of @DRUG$-related is far than the number in amphetamine @DRUG$ .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
@DRUG$ and the therapeutic amphotericin B at cellular and ( @DRUG$ showed cells	DDI-false
intake of @DRUG$ vitamin K the absorption of vitamin	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Data in studies of drug following : ergotamine , @DRUG$ , @DRUG$ nifedipine	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ : Concomitant administration @DRUG$ may reduce diflunisal .	DDI-false
ANTACID (Magnesium-Aluminum Hydroxide): @DRUG$ plasma concentrations were not affected by co-administration of @DRUG$.	DDI-false
, phenobarbital/valproic acid , @DRUG$/@DRUG$ , theophylline/acetaminophen , valproic acid/phenobarbital .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving @DRUG$, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Additive adverse effects blockade occur when is administered antimuscarinics amantadine , haloperidol , @DRUG$ @DRUG$ some	DDI-false
@DRUG$ : Altered serum levels ( increased and decreased have been receiving @DRUG$.	DDI-false
@DRUG$ of CYP3A4 drugs ( e.g. , triazolo-@DRUG$ dihydropyridine calcium blockers certain HMG-CoA , . .	DDI-mechanism
@DRUG$ taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl @DRUG$ by 55% and 33%, respectively.	DDI-false
It was concluded that oral @DRUG$ and @DRUG$ can be administered concomitantly without a significant decrease in AUC, Cmax, or tmax.	DDI-false
@DRUG$ substrate and	DDI-false
Cation-Containing Products administration quinolone , including , with cation-containing or aluminum VIDEX tablets or powder or @DRUG$ , zinc decrease absorption @DRUG$ in levels considerably than desired	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
The uniformity and course of interference , secobarbital , , @DRUG$ and were systematically receiving @DRUG$ therapy	DDI-false
ANTACID (@DRUG$): Cerivastatin plasma concentrations were not affected by co-administration of @DRUG$.	DDI-false
Five days of @DRUG$ treatment did not significantly affect steady-state pharmacokinetic variables of @DRUG$ compared with placebo;	DDI-false
FLEXERIL may enhance the effects of alcohol, @DRUG$, and other @DRUG$.	DDI-false
effects @DRUG$ @DRUG$ were additive was co-administered not basal .	DDI-false
@DRUG$ The @DRUG$ with the , on occasions , hypoglycemia	DDI-false
Amiodarone may suppress certain CYP450 enzymes, including @DRUG$, CYP2C9, CYP2D6, and @DRUG$.	DDI-false
increased interaction and high affinity @DRUG$ dopamine2- and serotonin2-receptors antipsychotic @DRUG$ after	DDI-false
Although specific studies have been , coadministration with that are mainly metabolized by CYP3A4 ( eg , calcium channel dapsone , , amiodarone , quinidine , @DRUG$ @DRUG$ ergot , , fentanyl , , alprazolam , and elevated coadministered with ;	DDI-false
Cardiovascular and IV have with adrenergic-blocking , nitrates , @DRUG$ hydralazine , @DRUG$ and digoxin of clinically significant interactions .	DDI-false
@DRUG$ including sulfate @DRUG$ , : Concomitant and non-selective MAO may hypertension	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
Coingestion of acetaminophen with theophylline, @DRUG$ with @DRUG$, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-effect
adverse effects cholinergic may when is concomitantly with other amantadine , @DRUG$ , @DRUG$ antidepressants or some antihistamines .	DDI-false
Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of ethanol and nicotine in rats;	DDI-false
Fenfluramine slightly e.g. , guanethidine @DRUG$ , @DRUG$.	DDI-false
Although not coadministration that mainly metabolized CYP3A4 blockers disopyramide , , @DRUG$ , tacrolimus , ergot , , , @DRUG$ alfentanyl , and triazolam ) have plasma when ;	DDI-false
Antihypertensives be with -receptor blocking propranolol , a @DRUG$ or @DRUG$ antagonists , verapamil , CYP3A4 , diltiazem CYP3A4 ) because of the possible potentiation of , sinus AV block ;	DDI-false
Potassium-sparing diuretics (e.g., spironolactone, triamterene, or @DRUG$), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-effect
Since @DRUG$ is a substrate for @DRUG$, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced amiodarone levels.	DDI-false
Possible drug interactions of @DRUG$ with succinylcholine or with other @DRUG$.	DDI-int
neither @DRUG$ nor retinyl acetate affected proliferation of RPMI1640 @DRUG$ alone modify mitogenic of insulin	DDI-false
Glyburide The of @DRUG$ with the @DRUG$ rare resulted	DDI-effect
Although @DRUG$ have to reduce @DRUG$-induced effects including fever confusion and dyspnea concomitant administration of these agents with may reduce the antitumor and . 12 Beta-blockers and other may potentiate the hypotension PROLEUKIN	DDI-effect
@DRUG$ and Tricyclic Antidepressants FORADIL with extreme caution in patients treated monoamine inhibitors the @DRUG$ system may be agents	DDI-false
In some patients the combined use of @DRUG$ and @DRUG$ has been associated with fatal gastrointestinal hemorrhage.	DDI-effect
Amiodarone be used blocking ( e.g. , propranolol @DRUG$ ) ( , verapamil @DRUG$ substrate diltiazem CYP3A4 inhibitor ) because of the of AV ;	DDI-false
CONCOMITANT THERAPY : Although specific interaction studies not performed , in clinical studies @DRUG$ was used with @DRUG$ , betablockers , calcium-channel , and nonsteroidal drugs ( NSAIDs evidence clinically interactions .	DDI-false
hour starting @DRUG$ or @DRUG$ mg p.o .	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
interactions following concomitant of psychotropic drugs ( , , @DRUG$ sedatives @DRUG$ )	DDI-false
necessary to well with and of @DRUG$ and to discriminate due to an @DRUG$ intake which physiological supplementation and depletion to dysregulation of the control of magnesium requires more or less specific of its dysregulation	DDI-false
There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus @DRUG$/@DRUG$ regimens.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, dacarbazine, @DRUG$, tamoxifen and interferon-alfa.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, fibric acid derivatives, niacin (nicotinic acid), @DRUG$, azole antifungals.	DDI-false
To determine whether injection of @DRUG$ would permit larger doses of @DRUG$ to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin.	DDI-false
that @DRUG$ concentrations Drugs increase imatinib plasma : Caution is recommended when administering @DRUG$ the family , ketoconazole , , clarithromycin ) .	DDI-false
Agents Causing Renin Release: The antihypertensive effect of @DRUG$ and @DRUG$ IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).	DDI-false
Other reported interactions with @DRUG$: @DRUG$ (CYP3A4 substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ bepridil flecainide , @DRUG$ quinidine due potential for reactions	DDI-false
Other Agents @DRUG$ have been used @DRUG$ , methyldopa , nitrates calcium-blocking without .	DDI-false
The of @DRUG$ and Acamprosate not the either @DRUG$ acamprosate	DDI-false
@DRUG$ (@DRUG$) produces psychotomimetic effects in humans that resemble schizophrenia symptoms.	DDI-false
Although studies have been , with drugs are mainly metabolized CYP3A4 ( eg calcium channel blockers , dapsone , amiodarone warfarin , , ergot , @DRUG$ , alprazolam and @DRUG$ plasma concentrations coadministered saquinavir ;	DDI-false
In studies performed with Fondaparinux , the of @DRUG$ ( warfarin ) , ( acetylsalicylic , @DRUG$ ( piroxicam ) did	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing @DRUG$, @DRUG$, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
reactions been in receiving dose PROLEUKIN @DRUG$ specifically @DRUG$ , , tamoxifen	DDI-false
uniformity time of phenobarbital , secobarbital , @DRUG$ , @DRUG$ systematically patients therapy	DDI-false
and ibogaine for possibly , @DRUG$ lower affinities @DRUG$ for receptors , the 5-HT .	DDI-false
Two groups SH/DA ; SH/FA submitted daily synthetic hydroalcoholic solutions containing @DRUG$ , alcohols @DRUG$ the same proportions as those most common	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ Probenecid with renal tubular secretion of an in level of @DRUG$ .	DDI-false
Suppression by verapamil of @DRUG$-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ in wistar rats.	DDI-false
Ergot Derivatives : @DRUG$ @DRUG$ , ergotamine , methylergonovine CONTRAINDICATED potential for serious and ergot toxicity characterized peripheral and and other .	DDI-false
@DRUG$ had significant impact on Cmax AUC @DRUG$ although decreased the zidovudine intracellular exposure to phosphorylated % .	DDI-false
@DRUG$ and ibogaine have affinities for possibly nicotinic receptors , 18-MC than @DRUG$ NMDA sodium the 5-HT .	DDI-false
@DRUG$ Other antiarrhythmic drugs such as quinidine , procainamide , , used concurrently @DRUG$.	DDI-false
: @DRUG$ with caution blocking agents , propranolol , CYP3A4 inhibitor ) or calcium antagonists ( , , and , @DRUG$ ) because of the of , and AV block	DDI-false
Data from in vitro studies of @DRUG$ other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.	DDI-false
@DRUG$: Amiodarone, bepridil, @DRUG$, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
@DRUG$ is substrate for @DRUG$ CYP3A4 .	DDI-false
: be used caution receiving e.g. , @DRUG$ , a CYP3A4 inhibitor ) ( substrate and a inhibitor the potentiation bradycardia sinus , and block ;	DDI-false
Warfarin-@DRUG$ can antagonize the effect of @DRUG$	DDI-effect
intensity and time of interference phenobarbital @DRUG$ @DRUG$ systematically receiving coumarin .	DDI-false
@DRUG$ Amiodarone , bepridil , flecainide propafenone @DRUG$ CONTRAINDICATED to potential serious	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ : * @DRUG$ * due to for serious cardiac	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, @DRUG$ and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
The during is with concurrent administration , @DRUG$ , @DRUG$ ( ) antifungals	DDI-false
Co-medications that induce CYP3A4 (e.g., @DRUG$, phenytoin, carbamazepine, @DRUG$, phenobarbital or St.	DDI-false
Moreover, additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
increase slightly effect @DRUG$ , guanethidine , , @DRUG$.	DDI-false
Azithromycin had no significant impact on the Cmax and AUC of @DRUG$, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated @DRUG$ by 110%.	DDI-false
inhibitors tranylcypromine sulfate , phenelzine sulfate : use @DRUG$ @DRUG$ may cause hypertension	DDI-effect
@DRUG$ patients , @DRUG$ Cmax approximately 50 respectively after with known inhibitor cytochrome P450 .	DDI-false
Naproxen: The concomitant administration of @DRUG$ and naproxen in normal volunteers had no effect on the plasma levels of @DRUG$, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	DDI-false
@DRUG$/@DRUG$ , , , , valproic acid/phenobarbital .	DDI-false
@DRUG$ : As with some quinolones , administration of ciprofloxacin with theophylline may serum of @DRUG$ and prolongation its elimination half-life .	DDI-false
To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of @DRUG$ was given intravenously over three hours concurrently with escalating doses of @DRUG$.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, @DRUG$, @DRUG$, tricyclic antidepressants or some antihistamines.	DDI-false
, lidocaine/@DRUG$ acid , quinidine/lidocaine valproic acid/phenobarbital .	DDI-false
: @DRUG$ drugs , as quinidine , @DRUG$ , and , have been used concurrently	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
have not with that mainly CYP3A4 ( , channel dapsone @DRUG$ , amiodarone warfarin @DRUG$ , cyclosporine , ergot carbamazepine , and ) elevated when with ;	DDI-false
glucocorticoids have to reduce @DRUG$-induced side fever , renal insufficiency administration of these reduce effectiveness and be avoided 12 Beta-blockers and other may potentiate the hypotension seen	DDI-false
acetaminophen/@DRUG$ lidocaine/quinidine , , phenobarbital/valproic , quinidine/lidocaine , theophylline/@DRUG$ , and valproic .	DDI-false
The of local @DRUG$ epinephrine or receiving oxidase inhibitors @DRUG$ , prolonged hypotension hypertension .	DDI-effect
Reported examples include the following: @DRUG$: @DRUG$ are known to inhibit CYP3A4 to varying degrees.	DDI-false
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ and extended a similar length of time after @DRUG$ withdrawal.	DDI-false
Concomitant cyclophosphamide, @DRUG$, vincristine, and prednisone chemotherapy plus @DRUG$ therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
such quinidine , @DRUG$ phenothiazines , @DRUG$ , tricyclic may QT-interval prolongation and an increased risk of ventricular	DDI-false
studies demonstrated a oral bioavailability of @DRUG$ administered with intravenous @DRUG$ morphine	DDI-mechanism
@DRUG$ : receiving diflunisal @DRUG$ , were seen tolbutamide levels or fasting	DDI-false
@DRUG$ CONTRAINDICATED since the of product in an regimen reduces the concentrations of	DDI-false
The intensity , and time course anticoagulant @DRUG$ , glutethimide , chloral hydrate and @DRUG$ were therapy .	DDI-false
Cation-Containing Products Concurrent of @DRUG$ , @DRUG$ with multivalent cation-containing products such magnesium or sucralfate VIDEX tablets pediatric powder products , iron , substantially absorption of ciprofloxacin resulting in urine levels considerably lower desired .	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: @DRUG$, @DRUG$, amiodarone, nicardipine, and nifedipine.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
should exercised inhibitor is concomitantly drugs decrease or activity of steroid hormones such as ketoconazole @DRUG$ @DRUG$.	DDI-false
Multivalent Cation-Containing administration of a quinolone with cation-containing products @DRUG$ @DRUG$ , , VIDEX tablets pediatric powder or products calcium , , or zinc may substantially decrease the absorption of in serum levels lower than .	DDI-false
Potassium-sparing diuretics (e.g., spironolactone, triamterene, or @DRUG$), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
@DRUG$ may enhance the effects of alcohol, barbiturates, and other @DRUG$.	DDI-effect
It is important that patients understand how to use @DRUG$  (@DRUG$) capsules with the supplied AerolizerTM inhalation device and how it should be used in relation to other asthma or COPD medications they are taking.	DDI-false
To evaluate impact of on the clinical of with systemic ) , the compared retrospectively group of 24 patients HIV-NHL who @DRUG$ , @DRUG$ , and CHOP regimen plus a of 80 treated CHOP CHOP-like regimen i.e. , doxorubicin , , and ) receiving therapy	DDI-false
Although specific studies been with drugs by CYP3A4 eg channel , @DRUG$ , amiodarone warfarin @DRUG$ cyclosporine , ergot pimozide , carbamazepine fentanyl , alfentanyl and ) may have plasma ;	DDI-false
The possibility of effects enalapril can minimized by either or the salt prior to initiation of treatment @DRUG$ or @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either @DRUG$ or @DRUG$.	DDI-false
@DRUG$ should used with in patients receiving   e.g. a inhibitor ) channel antagonists @DRUG$ , substrate , inhibitor ) of bradycardia sinus and AV	DDI-false
acetaminophen/theophylline , , acid quinidine/lidocaine , and valproic	DDI-false
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
clinical with of @DRUG$ ( warfarin , platelet inhibitors ( piroxicam @DRUG$ did affect the of fondaparinux	DDI-false
@DRUG$ does affect serum @DRUG$ levels .	DDI-false
Drug-drug observed between @DRUG$ digoxin @DRUG$.	DDI-false
The of enalapril and enalapril is augmented by @DRUG$ renin , @DRUG$ .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
@DRUG$ and @DRUG$ could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.	DDI-false
or pharmacodynamic have not demonstrated @DRUG$ and concomitantly administered ( 162.5 given and hours prior to initiation 1   g/kg/min . over or 1000 mg orally 12 6 0 to and and subsequent of 1.5 g/kg/min . .	DDI-false
The monoamine inhibitory @DRUG$ a period after of drug and this should be borne in drug is following	DDI-false
Potassium-sparing @DRUG$ , or @DRUG$ , potassium , potassium-containing substitutes may lead to increases serum potassium .	DDI-false
Slow-channel calcium blockers, such as @DRUG$, diltiazem and @DRUG$, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, @DRUG$ has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
Other , @DRUG$ @DRUG$ , disopyramide been used concurrently amiodarone .	DDI-false
It was shown that @DRUG$ antagonized evidently the antinociceptive effect of @DRUG$ and their analogue.	DDI-effect
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-effect
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
